PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 28830790-2 2017 The potent anticancer agent topotecan is a substrate of efflux transporters BCRP and P-gp, which are expressed at the BRB to restrict vitreous and retinal distribution of xenobiotics. Topotecan 28-37 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 76-80 29993250-0 2018 Small Molecule Inhibition of MicroRNA miR-21 Rescues Chemosensitivity of Renal-Cell Carcinoma to Topotecan. Topotecan 97-106 microRNA 21 Homo sapiens 38-44 29993250-5 2018 In a chemoresistant-RCC cell line, inhibition of miR-21 via small molecule treatment rescued the expression of tumor-suppressor proteins and sensitized cells to topotecan-induced apoptosis. Topotecan 161-170 microRNA 21 Homo sapiens 49-55 29723616-10 2018 A co-localised enhancement of topotecan fluorescence emission was also observed immediately after application of FUS indicating rapid triggered drug release. Topotecan 30-39 fused in sarcoma Mus musculus 113-116 29391350-4 2018 In cancer cells not expressing SLFN11, transfection of SLFN11 sensitized the cells to camptothecin, topotecan, hydroxyurea, and cisplatin but not to paclitaxel. Topotecan 100-109 schlafen family member 11 Homo sapiens 55-61 29246888-5 2018 The EC50 of 7-ethyl-10-hydroxycamptothecin (SN-38), topotecan, and mitoxantrone decreased in the presence of a BCRP inhibitor in PANC-1 and AsPC-1 cells, which exhibit high BCRP expression. Topotecan 52-61 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 111-115 29458405-17 2018 Importantly, dacomitinib significantly enhanced the efficacy of topotecan in ABCG2-overexpressing H460/MX20 cell xenografts in nude mice without incurring additional toxicity. Topotecan 64-73 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 77-82 29098282-0 2017 Intracameral Topotecan Hydrochloride for Anterior Chamber Seeding of Retinoblastoma. Topotecan 13-36 RB transcriptional corepressor 1 Homo sapiens 69-83 27667581-4 2017 The stability of the complexes of COX-1, COX-2, Topo I, Topo IIbeta and aromatase with the most potent inhibitor curcumin and those of the respective drugs, namely ibuprofen, aspirin, topotecan, etoposide, and exemestane were also analyzed through MD simulation analyses which revealed better stability of curcumin complexes than those of respective drugs. Topotecan 184-193 mitochondrially encoded cytochrome c oxidase I Homo sapiens 34-39 29518481-3 2018 The efficacy of SN-38, topotecan, and mitoxantrone (MX) were significantly increased by PD153035, PD153035 significantly reversed ABCG2-mediated MDR by attenuating the efflux activity of this transporter. Topotecan 23-32 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 130-135 29518481-6 2018 These results, provided that they can be extrapolated to humans, suggest that the combination of topotecan and PD153035 could be a promising therapeutic strategy to attenuate the resistance to topotecan, as well as other anticancer drugs, mediated by the overexpression of ABCG2. Topotecan 97-106 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 273-278 29485043-9 2018 Furthermore, immunohistochemistry results revealed that expression levels of vascular endothelial growth factor, CXC chemokine ligand 12, CD68, CD3, and tumor necrosis factor alpha in the lesion area were significantly lower in treated (topotecan or AMD3100) brains versus control brains, while ionized calcium-binding adapter molecule 1 (Iba1) and HIF-1alpha expression was similar, though somewhat reduced. Topotecan 237-246 tumor necrosis factor Mus musculus 153-180 29485043-9 2018 Furthermore, immunohistochemistry results revealed that expression levels of vascular endothelial growth factor, CXC chemokine ligand 12, CD68, CD3, and tumor necrosis factor alpha in the lesion area were significantly lower in treated (topotecan or AMD3100) brains versus control brains, while ionized calcium-binding adapter molecule 1 (Iba1) and HIF-1alpha expression was similar, though somewhat reduced. Topotecan 237-246 allograft inflammatory factor 1 Mus musculus 295-337 29485043-9 2018 Furthermore, immunohistochemistry results revealed that expression levels of vascular endothelial growth factor, CXC chemokine ligand 12, CD68, CD3, and tumor necrosis factor alpha in the lesion area were significantly lower in treated (topotecan or AMD3100) brains versus control brains, while ionized calcium-binding adapter molecule 1 (Iba1) and HIF-1alpha expression was similar, though somewhat reduced. Topotecan 237-246 allograft inflammatory factor 1 Mus musculus 339-343 29485043-9 2018 Furthermore, immunohistochemistry results revealed that expression levels of vascular endothelial growth factor, CXC chemokine ligand 12, CD68, CD3, and tumor necrosis factor alpha in the lesion area were significantly lower in treated (topotecan or AMD3100) brains versus control brains, while ionized calcium-binding adapter molecule 1 (Iba1) and HIF-1alpha expression was similar, though somewhat reduced. Topotecan 237-246 hypoxia inducible factor 1, alpha subunit Mus musculus 349-359 29485043-10 2018 CXCR4 expression was reduced only in topotecan-treated mice, while interleukin 6 expression was unaffected by either topotecan or AMD3100. Topotecan 37-46 chemokine (C-X-C motif) receptor 4 Mus musculus 0-5 28987798-0 2018 Exploration of G-quadruplex function in c-Myb gene and its transcriptional regulation by topotecan. Topotecan 89-98 MYB proto-oncogene, transcription factor Homo sapiens 40-45 28987798-4 2018 Attentions were being paid to the development of G-quadruplex binders for selective recognition, and topotecan was found to have high binding affinity in vitro and could effectively affect the c-Myb transcription activities in cells. Topotecan 101-110 MYB proto-oncogene, transcription factor Homo sapiens 193-198 28985478-6 2018 We confirmed that topotecan disrupts the interaction between NHP2L1 and U4 by binding to U4 and inhibits RNA splicing. Topotecan 18-27 small nuclear ribonucleoprotein 13 Homo sapiens 61-67 30104007-0 2018 Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status. Topotecan 14-23 BRCA1 DNA repair associated Homo sapiens 135-139 28830790-2 2017 The potent anticancer agent topotecan is a substrate of efflux transporters BCRP and P-gp, which are expressed at the BRB to restrict vitreous and retinal distribution of xenobiotics. Topotecan 28-37 phosphoglycolate phosphatase Mus musculus 85-89 28830790-3 2017 In this work we have studied vitreous and retinal distribution, tumor accumulation and antitumor activity of topotecan, using pantoprazole as inhibitor of BCRP and P-gp. Topotecan 109-118 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 155-159 28830790-3 2017 In this work we have studied vitreous and retinal distribution, tumor accumulation and antitumor activity of topotecan, using pantoprazole as inhibitor of BCRP and P-gp. Topotecan 109-118 phosphoglycolate phosphatase Mus musculus 164-168 28206967-6 2017 Treatment of neuroblastoma cells with increasing concentrations of CDDP (0.1-10 muM) or TOPO (0.1 nM-1 muM) induced cytotoxicity and increased apoptosis in a concentration- and time-dependent manner. Topotecan 88-92 latexin Homo sapiens 103-106 29212189-6 2017 Importantly, quizartinib at 30 mg/kg strongly enhanced the effect of topotecan (3 mg/kg) in ABCG2-overexpressing (H460/MX20) xenografts in athymic nude mice. Topotecan 69-78 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 92-97 28785061-6 2017 We also provide evidence that inhibition of SUMOylation by topotecan is associated with reduced levels of CDK6 and HIF-1alpha, as well as pronounced changes in cell cycle progression and cellular metabolism, thereby highlighting its putative role as an adjuvant therapy in defined GBM patient populations. Topotecan 59-68 cyclin dependent kinase 6 Homo sapiens 106-110 28785061-6 2017 We also provide evidence that inhibition of SUMOylation by topotecan is associated with reduced levels of CDK6 and HIF-1alpha, as well as pronounced changes in cell cycle progression and cellular metabolism, thereby highlighting its putative role as an adjuvant therapy in defined GBM patient populations. Topotecan 59-68 hypoxia inducible factor 1 subunit alpha Homo sapiens 115-125 28092395-7 2017 Mean IOP 1 to 30 seconds after intravitreal topotecan (second injection) was 44.5 +- 11.0 mm Hg, which decreased to 31.0 +- 5.0 mm Hg by 150 seconds after injection. Topotecan 44-53 cytosolic iron-sulfur assembly component 3 Homo sapiens 5-10 28373423-7 2017 In all topotecan-resistant cell lines an overexpression of ABCG2, IFIH1 and SAMD4 genes was observed. Topotecan 7-16 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 59-64 28373423-7 2017 In all topotecan-resistant cell lines an overexpression of ABCG2, IFIH1 and SAMD4 genes was observed. Topotecan 7-16 interferon induced with helicase C domain 1 Homo sapiens 66-71 28373423-7 2017 In all topotecan-resistant cell lines an overexpression of ABCG2, IFIH1 and SAMD4 genes was observed. Topotecan 7-16 sterile alpha motif domain containing 4A Homo sapiens 76-81 28373423-11 2017 CONCLUSION: Expression of ABCG2 and ABCB1 genes plays the most important role in topotecan resistance. Topotecan 81-90 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 26-31 28373423-11 2017 CONCLUSION: Expression of ABCG2 and ABCB1 genes plays the most important role in topotecan resistance. Topotecan 81-90 ATP binding cassette subfamily B member 1 Homo sapiens 36-41 28131876-5 2017 Cabozantinib, at non-toxic concentrations (3 or 5muM), sensitized the ABCG2-overexpressing cells to mitoxantrone, SN-38, and topotecan. Topotecan 125-134 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 70-75 28059154-4 2017 Importantly, xH460/MX20 cells exhibited high levels of resistance to ABCG2 substrates such as mitoxantrone and topotecan as H460/MX20 cells did. Topotecan 111-120 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 69-74 28007908-5 2017 Interestingly, topotecan treatment also significantly reduced insoluble mutant huntingtin load in the HD mouse brain. Topotecan 15-24 huntingtin Mus musculus 79-89 28007908-6 2017 Finally, we show that topotecan treatment to HD mouse not only inhibits the expression of transgenic mutant huntingtin, but also at the same time induces the expression of Ube3a, an ubiquitin ligase linked to the clearance of mutant huntingtin. Topotecan 22-31 huntingtin Mus musculus 108-118 28007908-6 2017 Finally, we show that topotecan treatment to HD mouse not only inhibits the expression of transgenic mutant huntingtin, but also at the same time induces the expression of Ube3a, an ubiquitin ligase linked to the clearance of mutant huntingtin. Topotecan 22-31 ubiquitin protein ligase E3A Mus musculus 172-177 28007908-6 2017 Finally, we show that topotecan treatment to HD mouse not only inhibits the expression of transgenic mutant huntingtin, but also at the same time induces the expression of Ube3a, an ubiquitin ligase linked to the clearance of mutant huntingtin. Topotecan 22-31 huntingtin Mus musculus 233-243 28059154-5 2017 Furthermore, lapatinib, the inhibitor of ABCG2, potently reversed mitoxantrone- and topotecan-resistance of xH460/MX20 cells. Topotecan 84-93 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 41-46 27444351-5 2016 The effect of MHP-1 against topotecan-resistant MCF-7 cells that developed an EMT-like phenotype was also examined. Topotecan 28-37 calcium voltage-gated channel subunit alpha1 A Homo sapiens 14-19 27893431-11 2016 Co-treatment of Tdp1mutant with topotecan shows more than additive cytotoxicity. Topotecan 32-41 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 16-20 28477120-6 2017 Examples of ATM activation and H2AX phosphorylation in response to DNA damage in leukemic HL-60 cells by DNA topoisomerase I inhibitor topotecan, and in lung carcinoma A549 cells by hydrogen peroxide, are presented. Topotecan 135-144 ATM serine/threonine kinase Homo sapiens 12-15 28477120-6 2017 Examples of ATM activation and H2AX phosphorylation in response to DNA damage in leukemic HL-60 cells by DNA topoisomerase I inhibitor topotecan, and in lung carcinoma A549 cells by hydrogen peroxide, are presented. Topotecan 135-144 H2A.X variant histone Homo sapiens 31-35 27671528-0 2016 Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts. Topotecan 32-41 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 6-11 27671528-3 2016 The ATP-binding cassette family G member 2 (ABCG2) efflux protein has been described as one mechanism that confers multiple-drug resistance to solid tumors and contributes to topotecan resistance in ovarian carcinoma. Topotecan 175-184 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 4-42 27671528-3 2016 The ATP-binding cassette family G member 2 (ABCG2) efflux protein has been described as one mechanism that confers multiple-drug resistance to solid tumors and contributes to topotecan resistance in ovarian carcinoma. Topotecan 175-184 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 44-49 27444351-15 2016 We further showed that MHP-1 restored sensitivity in topotecan (TPT)-resistant MCF-7 cells that developed an EMT-like phenotype. Topotecan 53-62 calcium voltage-gated channel subunit alpha1 A Homo sapiens 23-28 27444351-15 2016 We further showed that MHP-1 restored sensitivity in topotecan (TPT)-resistant MCF-7 cells that developed an EMT-like phenotype. Topotecan 64-67 calcium voltage-gated channel subunit alpha1 A Homo sapiens 23-28 27444351-16 2016 Similarly, the effect of TPT on resistant MCF-7 cells was also increased either by ALK5 (TGFbetaRI) siRNA or by a small molecular inhibitor of ALK5, SB-431542. Topotecan 25-28 transforming growth factor beta receptor 1 Homo sapiens 83-87 27444351-16 2016 Similarly, the effect of TPT on resistant MCF-7 cells was also increased either by ALK5 (TGFbetaRI) siRNA or by a small molecular inhibitor of ALK5, SB-431542. Topotecan 25-28 transforming growth factor beta receptor 1 Homo sapiens 143-147 27444351-18 2016 CONCLUSION: MHP-1 significantly inhibited breast cancer metastasis and restored drug sensitivity in TPT-resistant cells via down-regulation of TGF-beta signaling and EMT program. Topotecan 100-103 calcium voltage-gated channel subunit alpha1 A Homo sapiens 12-17 27444351-18 2016 CONCLUSION: MHP-1 significantly inhibited breast cancer metastasis and restored drug sensitivity in TPT-resistant cells via down-regulation of TGF-beta signaling and EMT program. Topotecan 100-103 transforming growth factor beta 1 Homo sapiens 143-151 27443528-8 2016 The most abundant expression of ALDH1A1 was noted in paclitaxel- and topotecan-resistant cell lines where two populations of ALDH-positive and ALDH-negative cells could be observed. Topotecan 69-78 aldehyde dehydrogenase 1 family member A1 Homo sapiens 32-39 27456539-2 2016 Topotecan is an approved second-line chemotherapy for small cell lung cancer (SCLC). Topotecan 0-9 SCLC1 Homo sapiens 78-82 27443528-8 2016 The most abundant expression of ALDH1A1 was noted in paclitaxel- and topotecan-resistant cell lines where two populations of ALDH-positive and ALDH-negative cells could be observed. Topotecan 69-78 aldehyde dehydrogenase 1 family member A1 Homo sapiens 32-36 27443528-8 2016 The most abundant expression of ALDH1A1 was noted in paclitaxel- and topotecan-resistant cell lines where two populations of ALDH-positive and ALDH-negative cells could be observed. Topotecan 69-78 aldehyde dehydrogenase 1 family member A1 Homo sapiens 125-129 27247353-10 2016 Associating drug response with micro-RNA expression indicated that lines most sensitive to etoposide and topotecan expressed high miR-200c-3p and low miR-140-5p and miR-9-5p. Topotecan 105-114 microRNA 95 Homo sapiens 165-173 27052877-0 2016 Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. Topotecan 36-45 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 122-127 27052877-9 2016 These results demonstrate a possible role for the ABCG2 rs4148157 allele in the pharmacokinetics of oral topotecan in infants and very young children, and warrants further investigation. Topotecan 105-114 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 50-55 27105508-0 2016 Synergistic combination of DT-13 and topotecan inhibits human gastric cancer via myosin IIA-induced endocytosis of EGF receptor in vitro and in vivo. Topotecan 37-46 epidermal growth factor receptor Homo sapiens 115-127 27105508-3 2016 We found that the combination of the saponin monomer 13 from the dwarf lilyturf tuber (DT-13), performing anti-metastasis and anti-angiogenesis effects, with TPT synergistically induced apoptotic cytotoxicity in GCs with high EGF receptor (EGFR) expression, which was dependent on DT-13-induced endocytosis of EGFR. Topotecan 158-161 epidermal growth factor receptor Homo sapiens 226-238 27105508-3 2016 We found that the combination of the saponin monomer 13 from the dwarf lilyturf tuber (DT-13), performing anti-metastasis and anti-angiogenesis effects, with TPT synergistically induced apoptotic cytotoxicity in GCs with high EGF receptor (EGFR) expression, which was dependent on DT-13-induced endocytosis of EGFR. Topotecan 158-161 epidermal growth factor receptor Homo sapiens 240-244 27105508-3 2016 We found that the combination of the saponin monomer 13 from the dwarf lilyturf tuber (DT-13), performing anti-metastasis and anti-angiogenesis effects, with TPT synergistically induced apoptotic cytotoxicity in GCs with high EGF receptor (EGFR) expression, which was dependent on DT-13-induced endocytosis of EGFR. Topotecan 158-161 epidermal growth factor receptor Homo sapiens 310-314 27105508-5 2016 Moreover, the synergistic pro-apoptotic efficacy of DT-13 and TPT in GCs with high EGFR expression was eliminated by both the NM II inhibitor (-)-blebbistatin and MYH-9 shRNA. Topotecan 62-65 epidermal growth factor receptor Homo sapiens 83-87 27105508-5 2016 Moreover, the synergistic pro-apoptotic efficacy of DT-13 and TPT in GCs with high EGFR expression was eliminated by both the NM II inhibitor (-)-blebbistatin and MYH-9 shRNA. Topotecan 62-65 myosin heavy chain 9 Homo sapiens 163-168 26728137-0 2016 All-trans retinoic acid synergizes with topotecan to suppress AML cells via promoting RARalpha-mediated DNA damage. Topotecan 40-49 retinoic acid receptor, alpha Mus musculus 86-94 26657295-0 2016 Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence. Topotecan 11-20 MYCN proto-oncogene, bHLH transcription factor Homo sapiens 45-49 26657295-6 2016 Low-dose topotecan (TPT) was identified as an inducer of a favorable SASP while lacking NFKB1/p50 activation. Topotecan 9-18 aspartic peptidase retroviral like 1 Homo sapiens 69-73 26657295-6 2016 Low-dose topotecan (TPT) was identified as an inducer of a favorable SASP while lacking NFKB1/p50 activation. Topotecan 20-23 aspartic peptidase retroviral like 1 Homo sapiens 69-73 26657295-8 2016 Importantly, TPT-treated senescent tumor cells act growth-inhibitory in a dose-dependent manner on non-senescent tumor cells and MYCN expression is significantly reduced in vitro and in vivo. Topotecan 13-16 MYCN proto-oncogene, bHLH transcription factor Homo sapiens 129-133 26657295-9 2016 Furthermore, in a mouse xenotransplant-model for MYCN-amplified NB metronomic TPT leads to senescence selectively in tumor cells, complete or partial remission, prolonged survival and a favorable SASP.This new mode-of-action of metronomic TPT treatment, i.e. promoting a tumor-inhibiting type of senescence in MYCN-amplified tumors, is clinically relevant as metronomic regimens are increasingly implemented in therapy protocols of various cancer entities and are considered as a feasible maintenance treatment option with moderate adverse event profiles. Topotecan 78-81 v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived Mus musculus 49-53 26657295-9 2016 Furthermore, in a mouse xenotransplant-model for MYCN-amplified NB metronomic TPT leads to senescence selectively in tumor cells, complete or partial remission, prolonged survival and a favorable SASP.This new mode-of-action of metronomic TPT treatment, i.e. promoting a tumor-inhibiting type of senescence in MYCN-amplified tumors, is clinically relevant as metronomic regimens are increasingly implemented in therapy protocols of various cancer entities and are considered as a feasible maintenance treatment option with moderate adverse event profiles. Topotecan 78-81 aspartic peptidase, retroviral-like 1 Mus musculus 196-200 26657295-9 2016 Furthermore, in a mouse xenotransplant-model for MYCN-amplified NB metronomic TPT leads to senescence selectively in tumor cells, complete or partial remission, prolonged survival and a favorable SASP.This new mode-of-action of metronomic TPT treatment, i.e. promoting a tumor-inhibiting type of senescence in MYCN-amplified tumors, is clinically relevant as metronomic regimens are increasingly implemented in therapy protocols of various cancer entities and are considered as a feasible maintenance treatment option with moderate adverse event profiles. Topotecan 78-81 v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived Mus musculus 310-314 26657295-9 2016 Furthermore, in a mouse xenotransplant-model for MYCN-amplified NB metronomic TPT leads to senescence selectively in tumor cells, complete or partial remission, prolonged survival and a favorable SASP.This new mode-of-action of metronomic TPT treatment, i.e. promoting a tumor-inhibiting type of senescence in MYCN-amplified tumors, is clinically relevant as metronomic regimens are increasingly implemented in therapy protocols of various cancer entities and are considered as a feasible maintenance treatment option with moderate adverse event profiles. Topotecan 239-242 v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived Mus musculus 49-53 27231886-2 2016 We previously found that topotecan reduces the expression of long (>100 kb) genes and unsilences the paternal allele of Ube3a in neurons. Topotecan 25-34 ubiquitin protein ligase E3A Mus musculus 123-128 27231886-5 2016 We found that topotecan treatment significantly alters the expression of many more genes, including long neuronal genes, immediate early genes, and paternal Ube3a, when compared to Top1 deletion. Topotecan 14-23 ubiquitin protein ligase E3A Mus musculus 157-162 26848703-14 2016 In conclusion, thymoquinone increased the effectiveness of the chemotherapeutic reagent topotecan by inhibiting proliferation and lowering toxicity through p53- and Bax/Bcl2-independent mechanisms. Topotecan 88-97 tumor protein p53 Homo sapiens 156-159 26848703-14 2016 In conclusion, thymoquinone increased the effectiveness of the chemotherapeutic reagent topotecan by inhibiting proliferation and lowering toxicity through p53- and Bax/Bcl2-independent mechanisms. Topotecan 88-97 BCL2 associated X, apoptosis regulator Homo sapiens 165-168 26848703-14 2016 In conclusion, thymoquinone increased the effectiveness of the chemotherapeutic reagent topotecan by inhibiting proliferation and lowering toxicity through p53- and Bax/Bcl2-independent mechanisms. Topotecan 88-97 BCL2 apoptosis regulator Homo sapiens 169-173 26515463-2 2015 The diverse range of substrates of ABCG2 includes many antineoplastic agents such as topotecan, doxorubicin and mitoxantrone. Topotecan 85-94 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 35-40 26623560-6 2015 Notably, the pazopanib and metronomic topotecan combination treatment inhibited expression of HIF1alpha and ABCG2 genes in cells grown under hypoxic conditions, and this was associated with an increased intracellular concentration of the active form of topotecan. Topotecan 38-47 hypoxia inducible factor 1 subunit alpha Homo sapiens 94-103 26623560-6 2015 Notably, the pazopanib and metronomic topotecan combination treatment inhibited expression of HIF1alpha and ABCG2 genes in cells grown under hypoxic conditions, and this was associated with an increased intracellular concentration of the active form of topotecan. Topotecan 38-47 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 108-113 26623560-6 2015 Notably, the pazopanib and metronomic topotecan combination treatment inhibited expression of HIF1alpha and ABCG2 genes in cells grown under hypoxic conditions, and this was associated with an increased intracellular concentration of the active form of topotecan. Topotecan 253-262 hypoxia inducible factor 1 subunit alpha Homo sapiens 94-103 26637880-11 2015 Drug screening revealed a marked sensitivity of FH(-/-) cells to mitoxantrone, epirubicin, topotecan and a high sensitivity to bortezomib. Topotecan 91-100 fumarate hydratase Homo sapiens 48-50 26515463-10 2015 In a murine model system, combination treatment of A-803467 (35 mg/kg) and topotecan (3 mg/kg) significantly inhibited the tumor growth in mice xenografted with ABCG2-overexpressing cancer cells. Topotecan 75-84 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 161-166 26692923-5 2015 Consistent with our previous studies on irinotecan, FL118 exhibited >=25 fold more effectiveness than topotecan at inhibiting cancer cell growth and colony formation; we further showed that although topotecan can inhibit the expression of survivin, Mcl-1, XIAP or cIAP2, its effectiveness is about 10-100 fold weaker than FL118. Topotecan 202-211 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 252-257 26692923-5 2015 Consistent with our previous studies on irinotecan, FL118 exhibited >=25 fold more effectiveness than topotecan at inhibiting cancer cell growth and colony formation; we further showed that although topotecan can inhibit the expression of survivin, Mcl-1, XIAP or cIAP2, its effectiveness is about 10-100 fold weaker than FL118. Topotecan 202-211 X-linked inhibitor of apoptosis Homo sapiens 259-263 26692923-5 2015 Consistent with our previous studies on irinotecan, FL118 exhibited >=25 fold more effectiveness than topotecan at inhibiting cancer cell growth and colony formation; we further showed that although topotecan can inhibit the expression of survivin, Mcl-1, XIAP or cIAP2, its effectiveness is about 10-100 fold weaker than FL118. Topotecan 202-211 baculoviral IAP repeat containing 3 Homo sapiens 267-272 26692923-6 2015 Lastly, in contrast to both SN-38 (active metabolite of irinotecan) and topotecan are substrates of the efflux pump proteins P-gp/MDR1 and ABCG2/BCRP, FL118 is not a substrate of P-gp and ABCG2. Topotecan 72-81 phosphoglycolate phosphatase Homo sapiens 125-129 26692923-6 2015 Lastly, in contrast to both SN-38 (active metabolite of irinotecan) and topotecan are substrates of the efflux pump proteins P-gp/MDR1 and ABCG2/BCRP, FL118 is not a substrate of P-gp and ABCG2. Topotecan 72-81 ATP binding cassette subfamily B member 1 Homo sapiens 130-134 26692923-6 2015 Lastly, in contrast to both SN-38 (active metabolite of irinotecan) and topotecan are substrates of the efflux pump proteins P-gp/MDR1 and ABCG2/BCRP, FL118 is not a substrate of P-gp and ABCG2. Topotecan 72-81 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 139-144 26692923-6 2015 Lastly, in contrast to both SN-38 (active metabolite of irinotecan) and topotecan are substrates of the efflux pump proteins P-gp/MDR1 and ABCG2/BCRP, FL118 is not a substrate of P-gp and ABCG2. Topotecan 72-81 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 145-149 26079886-0 2015 Camptothecin and topotecan inhibit adipocyte differentiation by inducing degradation of PPARgamma. Topotecan 17-26 peroxisome proliferator activated receptor gamma Mus musculus 88-97 26351135-8 2015 RESULTS: The two Pim1 inhibitors increased the potency of flavopiridol, mitoxantrone, topotecan and doxorubicin, specifically in ABCG2-expressing cells. Topotecan 86-95 Pim-1 proto-oncogene, serine/threonine kinase Homo sapiens 17-21 26351135-8 2015 RESULTS: The two Pim1 inhibitors increased the potency of flavopiridol, mitoxantrone, topotecan and doxorubicin, specifically in ABCG2-expressing cells. Topotecan 86-95 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 129-134 26199091-4 2015 By screening ABC substrates against mouse G3 medulloblastoma tumorspheres in vitro, we found that Abcg2 inhibition could potentiate responses to the clinically used drug topotecan, producing a more than 9-fold suppression of cell proliferation. Topotecan 170-179 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 98-103 26199091-5 2015 Extended studies in vivo in this model confirmed that Abcg2 inhibition was sufficient to enhance antiproliferative responses to topotecan, producing a significant survival advantage compared with subjects treated with topotecan alone. Topotecan 128-137 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 54-59 26199091-5 2015 Extended studies in vivo in this model confirmed that Abcg2 inhibition was sufficient to enhance antiproliferative responses to topotecan, producing a significant survival advantage compared with subjects treated with topotecan alone. Topotecan 218-227 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 54-59 25301452-4 2015 Treatment with topotecan, etoposide and cisplatin caused significant changes in the expression patterns of OATP4A1, OATP5A1, OATP6A1, chromogranin and synaptophysin. Topotecan 15-24 solute carrier organic anion transporter family member 4A1 Homo sapiens 107-114 25933544-3 2015 The fine targeting efficiency of HA-PAMAM/TPT was confirmed by the CD44 receptor-mediated high cellular uptake efficiency and low cytotoxicity in HCT-116 cells, and the in vivo higher tumor distribution percentage than in other tissues in mice bearing an S-180 tumor. Topotecan 42-45 CD44 molecule (Indian blood group) Homo sapiens 67-71 26017759-1 2015 Using DOSY NMR and MALDI-TOF MS techniques, we present evidence that quaternary trimethylammonium salts of topotecan, [TPT-NMe3 ](+) X(-) (X = CF3SO3, HCOO), bind covalently the natural DNA oligomer upon near UV irradiation in water under physiological conditions. Topotecan 107-116 NME/NM23 nucleoside diphosphate kinase 3 Homo sapiens 123-127 25878333-7 2015 Topotecan showed the greatest synergistic effect with XPO1 inhibitor. Topotecan 0-9 exportin 1 Mus musculus 54-58 25878333-10 2015 Significant antitumor effects were observed with XPO1 inhibitor monotherapy in orthotopic ovarian (P < 0.001) and breast (P < 0.001) cancer mouse models, with a further decrease in tumor burden observed in combination with topotecan or paclitaxel (P < 0.05). Topotecan 229-238 exportin 1 Mus musculus 49-53 25986678-9 2015 Both flavopiridol and SNS-032 showed synergistic antiproliferative effects in combination with relevant ABC transporter substrates such as daunorubicin and topotecan in cancer cells. Topotecan 156-165 ATP binding cassette subfamily B member 6 (Langereis blood group) Homo sapiens 104-107 25896494-6 2015 The topotecan drug sensor shows a low detectable concentration of 0.1 muM with a good selectivity over other anticancer drug molecules and interfering reagents. Topotecan 4-13 latexin Homo sapiens 70-73 25667043-6 2015 In MCF7 cells, we found that PJ34 addition reverts TPT-dependent PARP-1 auto-modification and triggers caspase-dependent PARP-1 proteolysis. Topotecan 51-54 poly(ADP-ribose) polymerase 1 Homo sapiens 65-71 25667043-7 2015 Moreover, TPT as single agent stimulates p53(ser15) phosphorylation, p53 PARylation and occupancy of the p21WAF promoter by p53 resulting in an increase of p21WAF expression. Topotecan 10-13 tumor protein p53 Homo sapiens 41-44 25667043-7 2015 Moreover, TPT as single agent stimulates p53(ser15) phosphorylation, p53 PARylation and occupancy of the p21WAF promoter by p53 resulting in an increase of p21WAF expression. Topotecan 10-13 tumor protein p53 Homo sapiens 69-72 25667043-7 2015 Moreover, TPT as single agent stimulates p53(ser15) phosphorylation, p53 PARylation and occupancy of the p21WAF promoter by p53 resulting in an increase of p21WAF expression. Topotecan 10-13 tumor protein p53 Homo sapiens 69-72 25667043-8 2015 Interestingly, PJ34 in combination with TPT enhances p53 occupancy at the BAX promoter and is associated with increased BAX protein level. Topotecan 40-43 tumor protein p53 Homo sapiens 53-56 25667043-8 2015 Interestingly, PJ34 in combination with TPT enhances p53 occupancy at the BAX promoter and is associated with increased BAX protein level. Topotecan 40-43 BCL2 associated X, apoptosis regulator Homo sapiens 74-77 25667043-8 2015 Interestingly, PJ34 in combination with TPT enhances p53 occupancy at the BAX promoter and is associated with increased BAX protein level. Topotecan 40-43 BCL2 associated X, apoptosis regulator Homo sapiens 120-123 25870839-3 2015 We used a picogreen and colonogenic assay to appraise the DNA damage and cell death in a spheroid culture of GBM cells caused by iodine-131 (I-131) beta radiation in the presence of topotecan (TPT). Topotecan 182-191 limb development membrane protein 1 Homo sapiens 193-196 25892097-0 2015 Topotecan-induced ABCG2 expression in MCF-7 cells is associated with decreased CD24 and EpCAM expression and a loss of tumorigenicity. Topotecan 0-9 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 18-23 25892097-0 2015 Topotecan-induced ABCG2 expression in MCF-7 cells is associated with decreased CD24 and EpCAM expression and a loss of tumorigenicity. Topotecan 0-9 CD24 molecule Homo sapiens 79-83 25892097-0 2015 Topotecan-induced ABCG2 expression in MCF-7 cells is associated with decreased CD24 and EpCAM expression and a loss of tumorigenicity. Topotecan 0-9 epithelial cell adhesion molecule Homo sapiens 88-93 25892097-8 2015 We found an elevated ABCG2 expression in MCF-7 cells in the presence of 500 nM topotecan. Topotecan 79-88 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 21-26 25892097-9 2015 Compared with untreated MCF-7 cells, the application of topotecan induced a subpopulation with decreased CD24/EpCAM expression, whereas CD44 expression remained largely unchanged. Topotecan 56-65 CD24 molecule Homo sapiens 105-109 25892097-9 2015 Compared with untreated MCF-7 cells, the application of topotecan induced a subpopulation with decreased CD24/EpCAM expression, whereas CD44 expression remained largely unchanged. Topotecan 56-65 epithelial cell adhesion molecule Homo sapiens 110-115 26199910-12 2015 DNA damage was significantly increased when GBM cells treated with TPT ceased at S phase due to the inhibition of topoisomerase enzyme and phosphorylation of Chk1 enzyme. Topotecan 67-70 checkpoint kinase 1 Homo sapiens 158-162 25854646-3 2015 The overexpression of BCRP contributes to the resistance of several chemotherapeutic drugs, such as topotecan, methotrexate, mitoxantrone, doxorubicin and daunorubicin. Topotecan 100-109 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 22-26 25884494-0 2015 Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells. Topotecan 0-9 checkpoint kinase 1 Homo sapiens 26-31 25884494-0 2015 Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells. Topotecan 0-9 checkpoint kinase 1 Homo sapiens 33-37 25884494-11 2015 When combined with CHEK1 inhibitor, TPT potently and synergistically inhibited the proliferation of HGS ovarian cancer cells. Topotecan 36-39 checkpoint kinase 1 Homo sapiens 19-24 25884494-13 2015 CONCLUSIONS: Our findings suggest that the addition of CHEK1 inhibitor increases the response of ovarian cancer cells to TPT. Topotecan 121-124 checkpoint kinase 1 Homo sapiens 55-60 25594147-1 2015 PURPOSE: The aim of this study was to evaluate the tolerability and efficacy of poly(ADP-ribose) polymerase (PARP) inhibition by veliparib during cytotoxic topotecan administration with filgrastim or pegfilgrastim neutrophil support in women with persistent or recurrent uterine cervix cancer. Topotecan 156-165 poly(ADP-ribose) polymerase 1 Homo sapiens 80-107 25594147-1 2015 PURPOSE: The aim of this study was to evaluate the tolerability and efficacy of poly(ADP-ribose) polymerase (PARP) inhibition by veliparib during cytotoxic topotecan administration with filgrastim or pegfilgrastim neutrophil support in women with persistent or recurrent uterine cervix cancer. Topotecan 156-165 poly(ADP-ribose) polymerase 1 Homo sapiens 109-113 25594147-9 2015 Patients with low immunohistochemical expression (0-1+) of PARP-1 in their primary uterine cervix cancer were more likely to have a longer progression-free interval (hazard ratio, 0.25; P = 0.02) and survival (hazard ratio, 0.12; P = 0.005) after veliparib-topotecan therapy. Topotecan 257-266 poly(ADP-ribose) polymerase 1 Homo sapiens 59-65 25301452-4 2015 Treatment with topotecan, etoposide and cisplatin caused significant changes in the expression patterns of OATP4A1, OATP5A1, OATP6A1, chromogranin and synaptophysin. Topotecan 15-24 solute carrier organic anion transporter family member 5A1 Homo sapiens 116-123 25301452-4 2015 Treatment with topotecan, etoposide and cisplatin caused significant changes in the expression patterns of OATP4A1, OATP5A1, OATP6A1, chromogranin and synaptophysin. Topotecan 15-24 solute carrier organic anion transporter family member 6A1 Homo sapiens 125-132 25301452-4 2015 Treatment with topotecan, etoposide and cisplatin caused significant changes in the expression patterns of OATP4A1, OATP5A1, OATP6A1, chromogranin and synaptophysin. Topotecan 15-24 synaptophysin Homo sapiens 151-164 26284262-7 2015 Additionally, we aimed to measure effects of doxorubicin and topotecan (TPT) and 14G2a on expression of a novel human NDUFAF2 gene encoding for mimitin protein (MYC-induced mitochondrial protein) and correlate it with expression of the MYCN gene. Topotecan 61-70 NADH:ubiquinone oxidoreductase complex assembly factor 2 Homo sapiens 118-125 26284262-7 2015 Additionally, we aimed to measure effects of doxorubicin and topotecan (TPT) and 14G2a on expression of a novel human NDUFAF2 gene encoding for mimitin protein (MYC-induced mitochondrial protein) and correlate it with expression of the MYCN gene. Topotecan 61-70 NADH:ubiquinone oxidoreductase complex assembly factor 2 Homo sapiens 144-151 26284262-7 2015 Additionally, we aimed to measure effects of doxorubicin and topotecan (TPT) and 14G2a on expression of a novel human NDUFAF2 gene encoding for mimitin protein (MYC-induced mitochondrial protein) and correlate it with expression of the MYCN gene. Topotecan 61-70 NADH:ubiquinone oxidoreductase complex assembly factor 2 Homo sapiens 161-194 26284262-7 2015 Additionally, we aimed to measure effects of doxorubicin and topotecan (TPT) and 14G2a on expression of a novel human NDUFAF2 gene encoding for mimitin protein (MYC-induced mitochondrial protein) and correlate it with expression of the MYCN gene. Topotecan 61-70 MYCN proto-oncogene, bHLH transcription factor Homo sapiens 236-240 26284262-7 2015 Additionally, we aimed to measure effects of doxorubicin and topotecan (TPT) and 14G2a on expression of a novel human NDUFAF2 gene encoding for mimitin protein (MYC-induced mitochondrial protein) and correlate it with expression of the MYCN gene. Topotecan 72-75 NADH:ubiquinone oxidoreductase complex assembly factor 2 Homo sapiens 118-125 26284262-7 2015 Additionally, we aimed to measure effects of doxorubicin and topotecan (TPT) and 14G2a on expression of a novel human NDUFAF2 gene encoding for mimitin protein (MYC-induced mitochondrial protein) and correlate it with expression of the MYCN gene. Topotecan 72-75 NADH:ubiquinone oxidoreductase complex assembly factor 2 Homo sapiens 144-151 26284262-7 2015 Additionally, we aimed to measure effects of doxorubicin and topotecan (TPT) and 14G2a on expression of a novel human NDUFAF2 gene encoding for mimitin protein (MYC-induced mitochondrial protein) and correlate it with expression of the MYCN gene. Topotecan 72-75 NADH:ubiquinone oxidoreductase complex assembly factor 2 Homo sapiens 161-194 26284262-7 2015 Additionally, we aimed to measure effects of doxorubicin and topotecan (TPT) and 14G2a on expression of a novel human NDUFAF2 gene encoding for mimitin protein (MYC-induced mitochondrial protein) and correlate it with expression of the MYCN gene. Topotecan 72-75 MYCN proto-oncogene, bHLH transcription factor Homo sapiens 236-240 26536450-7 2015 RESULTS: A 48 hours exposure of human erythrocytes to topotecan significantly increased the percentage of annexin-V-binding cells and significantly decreased forward scatter. Topotecan 54-63 annexin A5 Homo sapiens 106-115 25701194-5 2015 The results indicate that TPT or CDDP activates ATM (ATM serine/threonine kinase), which phosphorylates PTEN at serine 113 and further regulates PTEN nuclear translocation in A549 and HeLa cells. Topotecan 26-29 ATM serine/threonine kinase Homo sapiens 48-51 25701194-5 2015 The results indicate that TPT or CDDP activates ATM (ATM serine/threonine kinase), which phosphorylates PTEN at serine 113 and further regulates PTEN nuclear translocation in A549 and HeLa cells. Topotecan 26-29 ATM serine/threonine kinase Homo sapiens 53-56 25701194-5 2015 The results indicate that TPT or CDDP activates ATM (ATM serine/threonine kinase), which phosphorylates PTEN at serine 113 and further regulates PTEN nuclear translocation in A549 and HeLa cells. Topotecan 26-29 phosphatase and tensin homolog Homo sapiens 104-108 25701194-5 2015 The results indicate that TPT or CDDP activates ATM (ATM serine/threonine kinase), which phosphorylates PTEN at serine 113 and further regulates PTEN nuclear translocation in A549 and HeLa cells. Topotecan 26-29 phosphatase and tensin homolog Homo sapiens 145-149 25701194-6 2015 After nuclear translocation, PTEN induces autophagy, in association with the activation of the p-JUN-SESN2/AMPK pathway, in response to TPT. Topotecan 136-139 phosphatase and tensin homolog Homo sapiens 29-33 25701194-6 2015 After nuclear translocation, PTEN induces autophagy, in association with the activation of the p-JUN-SESN2/AMPK pathway, in response to TPT. Topotecan 136-139 sestrin 2 Homo sapiens 101-106 25481395-3 2015 The configuration of 19 was determined by (1)H NMR and NOESY spectra as syn-isomers, suggesting that the cycloaddition of topotecan with alkyl vinyl ethers could undergo a hetero Diels-Alder reaction. Topotecan 122-131 synemin Homo sapiens 72-75 26536450-9 2015 The effect of topotecan on annexin-V-binding was significantly blunted, but not abolished by removal of extracellular Ca2+. Topotecan 14-23 annexin A5 Homo sapiens 27-36 24959385-14 2014 Furthermore, both irinotecan and topotecan are the efflux pump ABCG2 substrates; cancer cells with high expression of ABCG2 showed strong irinotecan and topotecan resistance. Topotecan 33-42 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 63-68 26278147-1 2015 The present study aimed to investigate the antitumor efficacy of combination of topotecan with rapamycin, a mTOR inhibitor, in cisplatin-resistant ovarian cancer cells A2780cis and COC1/DDP. Topotecan 80-89 mechanistic target of rapamycin kinase Homo sapiens 108-112 26278147-1 2015 The present study aimed to investigate the antitumor efficacy of combination of topotecan with rapamycin, a mTOR inhibitor, in cisplatin-resistant ovarian cancer cells A2780cis and COC1/DDP. Topotecan 80-89 translocase of inner mitochondrial membrane 8A Homo sapiens 186-189 26278147-6 2015 Pretreatment with rapamycin significantly enhanced the effects of topotecan in suppressing cell proliferation and soliciting cell apoptosis in A2780cis and COC1/DDP cells. Topotecan 66-75 translocase of inner mitochondrial membrane 8A Homo sapiens 161-164 26278147-7 2015 Cells that were sequentially exposed to rapamycin and topotecan had significantly higher levels of cleaved caspase-8, -3, and PARP compared to those treated with topotecan alone. Topotecan 54-63 caspase 8 Homo sapiens 107-116 26278147-7 2015 Cells that were sequentially exposed to rapamycin and topotecan had significantly higher levels of cleaved caspase-8, -3, and PARP compared to those treated with topotecan alone. Topotecan 54-63 poly(ADP-ribose) polymerase 1 Homo sapiens 126-130 26278147-9 2015 The results suggested that rapamycin sensitized A2780cis and COC1/DDP cells to topotecan-induced apoptosis and rapamycin-topotecan combination might have a value in treatment of cisplatin-resistant ovarian cancer. Topotecan 79-88 translocase of inner mitochondrial membrane 8A Homo sapiens 66-69 25436978-4 2014 In addition, afatinib, in combination with topotecan, significantly inhibited the growth of ABCG2- overexpressing cell xenograft tumors in vivo. Topotecan 43-52 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 92-97 25404338-4 2014 Here we report that in primary cortical neurons, topotecan depleted synaptic proteins that are encoded by extremely long genes, including Neurexin-1, Neuroligin-1, Cntnap2, and GABA(A)beta3. Topotecan 49-58 neurexin 1 Homo sapiens 138-148 25404338-4 2014 Here we report that in primary cortical neurons, topotecan depleted synaptic proteins that are encoded by extremely long genes, including Neurexin-1, Neuroligin-1, Cntnap2, and GABA(A)beta3. Topotecan 49-58 neuroligin 1 Homo sapiens 150-162 25404338-4 2014 Here we report that in primary cortical neurons, topotecan depleted synaptic proteins that are encoded by extremely long genes, including Neurexin-1, Neuroligin-1, Cntnap2, and GABA(A)beta3. Topotecan 49-58 contactin associated protein 2 Homo sapiens 164-171 25232464-0 2014 TDP1/TOP1 Ratio as a Promising Indicator for the Response of Small Cell Lung Cancer to Topotecan. Topotecan 87-96 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 0-4 25232464-10 2014 CONCLUSION: This study provides the first cellular analyses of TDP1 and TOP1 in SCLC and suggests the potential utility of TDP1/TOP1 ratio to assess the response of SCLC to topotecan. Topotecan 173-182 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 63-67 25232464-10 2014 CONCLUSION: This study provides the first cellular analyses of TDP1 and TOP1 in SCLC and suggests the potential utility of TDP1/TOP1 ratio to assess the response of SCLC to topotecan. Topotecan 173-182 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 123-127 24694948-7 2014 In addition, TAI-95 increased the potency of cytotoxic Pgp substrates, including doxorubicin and topotecan. Topotecan 97-106 ATP binding cassette subfamily B member 1 Homo sapiens 55-58 26696754-5 2015 In addition, IL-1beta-induced cell migration in hypoxia was not affected when HIF-1alpha was inhibited by either siRNA or Topotecan, well known for its inhibitory effect on HIF-1alpha. Topotecan 122-131 interleukin 1 beta Homo sapiens 13-21 26696754-5 2015 In addition, IL-1beta-induced cell migration in hypoxia was not affected when HIF-1alpha was inhibited by either siRNA or Topotecan, well known for its inhibitory effect on HIF-1alpha. Topotecan 122-131 hypoxia inducible factor 1 subunit alpha Homo sapiens 78-88 25128152-4 2014 Several anticancer drugs have been identified as ABCG2 substrates including mitoxantrone, etoposide and topotecan. Topotecan 104-113 ATP binding cassette subfamily G member 2 Canis lupus familiaris 49-54 25182801-8 2014 These effects were influenced by the p53 activity: cells carrying an active p53 were more sensitive to the combination of PARP inhibitor and RT, while cells carrying an inactive p53 displayed a higher sensitivity to the combination of PARP inhibitor and TPT. Topotecan 254-257 tumor protein p53 Homo sapiens 37-40 25182801-8 2014 These effects were influenced by the p53 activity: cells carrying an active p53 were more sensitive to the combination of PARP inhibitor and RT, while cells carrying an inactive p53 displayed a higher sensitivity to the combination of PARP inhibitor and TPT. Topotecan 254-257 tumor protein p53 Homo sapiens 76-79 25182801-8 2014 These effects were influenced by the p53 activity: cells carrying an active p53 were more sensitive to the combination of PARP inhibitor and RT, while cells carrying an inactive p53 displayed a higher sensitivity to the combination of PARP inhibitor and TPT. Topotecan 254-257 poly(ADP-ribose) polymerase 1 Homo sapiens 122-126 25182801-8 2014 These effects were influenced by the p53 activity: cells carrying an active p53 were more sensitive to the combination of PARP inhibitor and RT, while cells carrying an inactive p53 displayed a higher sensitivity to the combination of PARP inhibitor and TPT. Topotecan 254-257 tumor protein p53 Homo sapiens 76-79 25182801-9 2014 Our study suggests that p53 activity influences the differential sensitivity of GBM cells to combined treatments of TPT, RT, and PARP inhibitors. Topotecan 116-119 tumor protein p53 Homo sapiens 24-27 24853185-3 2014 METHODS: Migration of triple-negative MDA-231 breast cancer cells and its modulation by IGFs, the IGF-1R inhibitor NVP-AEW541 and the IGF-2-sequestering monoclonal antibody MAB292 were assessed by the scratch wound healing and Boyden chamber assays; the effect of topotecan (inhibiting hypoxia-inducible factor-1 (HIF-1)) under hypoxia was also evaluated. Topotecan 264-273 insulin like growth factor 2 Homo sapiens 134-139 24853185-6 2014 Under hypoxia, topotecan was also effective, likely by reducing HIF-1-induced IGF-2 release. Topotecan 15-24 hypoxia inducible factor 1 subunit alpha Homo sapiens 64-69 24853185-6 2014 Under hypoxia, topotecan was also effective, likely by reducing HIF-1-induced IGF-2 release. Topotecan 15-24 insulin like growth factor 2 Homo sapiens 78-83 23929729-7 2014 CSF concentration of topotecan closed lactone ranged from 3.73 to 312 ng/mL (median = 131 ng/mL) and plasma topotecan closed lactone ranged from 0.44 to 1.78 ng/mL (median = 0.92 ng/mL). Topotecan 21-30 colony stimulating factor 2 Homo sapiens 0-3 23929729-8 2014 The median CSF topotecan concentration was greater than the median serum topotecan concentration by a 44-fold magnitude when samples were obtained at the same time point. Topotecan 15-24 colony stimulating factor 2 Homo sapiens 11-14 24959385-14 2014 Furthermore, both irinotecan and topotecan are the efflux pump ABCG2 substrates; cancer cells with high expression of ABCG2 showed strong irinotecan and topotecan resistance. Topotecan 33-42 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 118-123 24959385-14 2014 Furthermore, both irinotecan and topotecan are the efflux pump ABCG2 substrates; cancer cells with high expression of ABCG2 showed strong irinotecan and topotecan resistance. Topotecan 153-162 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 63-68 24959385-14 2014 Furthermore, both irinotecan and topotecan are the efflux pump ABCG2 substrates; cancer cells with high expression of ABCG2 showed strong irinotecan and topotecan resistance. Topotecan 153-162 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 118-123 24448640-1 2014 PURPOSE: Topotecan is widely used for refractory solid tumors but multi-drug resistance may occur due to tumor expression of ATP-binding cassette (ABC) transporters. Topotecan 9-18 ATP binding cassette subfamily B member 6 (Langereis blood group) Homo sapiens 125-145 24448640-1 2014 PURPOSE: Topotecan is widely used for refractory solid tumors but multi-drug resistance may occur due to tumor expression of ATP-binding cassette (ABC) transporters. Topotecan 9-18 ATP binding cassette subfamily B member 6 (Langereis blood group) Homo sapiens 147-150 24465398-7 2014 RESULTS: By univariate analysis, both melphalan and topotecan appear to be associated with changes in ERG amplitude at both 3 and 12 months; but for the most part, these changes are minimal and likely clinically insignificant. Topotecan 52-61 ETS transcription factor ERG Homo sapiens 102-105 24557436-1 2014 OBJECTIVES: Preclinical data suggest that mammalian target of rapamycin inhibitors may potentiate the efficacy of topotecan. Topotecan 114-123 mechanistic target of rapamycin kinase Homo sapiens 42-71 24587832-7 2014 Topotecan alone was the first approved therapy for second-line treatment for relapsed SCLC. Topotecan 0-9 SCLC1 Homo sapiens 86-90 24457564-7 2014 By contrast, treatment with taxanes (with or without platinum) or topotecan led to similar PFS in BRCA mutation carriers and in patients with NH disease. Topotecan 66-75 BRCA1 DNA repair associated Homo sapiens 98-102 24563078-10 2014 Four or more CA-125 responses in 30 patients would justify further study of this regimen in prior topotecan treatment failures. Topotecan 98-107 mucin 16, cell surface associated Homo sapiens 13-19 24563078-20 2014 CONCLUSION: Continuous-infusion topotecan with erlotinib was found safe in six pretreated ovarian cancer patients; one met CA-125 criteria for partial response. Topotecan 32-41 mucin 16, cell surface associated Homo sapiens 123-129 24407585-7 2014 The combination of dasatinib and docetaxel, gemcitabine, or topotecan had a synergistic antiproliferative effect (CI, 0.49-0.68), whereas dasatinib combined with doxorubicin had an additive effect (CI, 1.08).In SKOV3 cells, dasatinib resulted in less pronounced reductions of phospho-SRC/total SRC (49%) and p-paxillin/t-paxillin (62%). Topotecan 60-69 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 284-287 24407585-7 2014 The combination of dasatinib and docetaxel, gemcitabine, or topotecan had a synergistic antiproliferative effect (CI, 0.49-0.68), whereas dasatinib combined with doxorubicin had an additive effect (CI, 1.08).In SKOV3 cells, dasatinib resulted in less pronounced reductions of phospho-SRC/total SRC (49%) and p-paxillin/t-paxillin (62%). Topotecan 60-69 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 294-297 24407585-7 2014 The combination of dasatinib and docetaxel, gemcitabine, or topotecan had a synergistic antiproliferative effect (CI, 0.49-0.68), whereas dasatinib combined with doxorubicin had an additive effect (CI, 1.08).In SKOV3 cells, dasatinib resulted in less pronounced reductions of phospho-SRC/total SRC (49%) and p-paxillin/t-paxillin (62%). Topotecan 60-69 paxillin Homo sapiens 310-318 24407585-7 2014 The combination of dasatinib and docetaxel, gemcitabine, or topotecan had a synergistic antiproliferative effect (CI, 0.49-0.68), whereas dasatinib combined with doxorubicin had an additive effect (CI, 1.08).In SKOV3 cells, dasatinib resulted in less pronounced reductions of phospho-SRC/total SRC (49%) and p-paxillin/t-paxillin (62%). Topotecan 60-69 paxillin Homo sapiens 321-329 25479544-8 2014 Finally, the selective BCRP transport inhibitor Ko143 did not increase erlotinib sensitivity, but did decrease the transport activity of BCRP in A549 and H1650 cells as it induced the accumulation of its transport substrate topotecan. Topotecan 224-233 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 23-27 24603438-4 2014 The effect of 14-3-3zeta siRNA on topotecan (TPT)-induced apoptosis was evaluated by several assays. Topotecan 34-43 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta Homo sapiens 14-24 24603438-4 2014 The effect of 14-3-3zeta siRNA on topotecan (TPT)-induced apoptosis was evaluated by several assays. Topotecan 45-48 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta Homo sapiens 14-24 24603438-10 2014 CONCLUSIONS: Silencing of 14-3-3zeta increased the sensitivity of both sensitive and resistant HL-60 cells to TPT-induced apoptosis, possibly through altering the expression of apoptosis-associated proteins, suggesting that it may be a potential target for MDR AML. Topotecan 110-113 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta Homo sapiens 26-36 25479544-8 2014 Finally, the selective BCRP transport inhibitor Ko143 did not increase erlotinib sensitivity, but did decrease the transport activity of BCRP in A549 and H1650 cells as it induced the accumulation of its transport substrate topotecan. Topotecan 224-233 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 137-141 23666509-4 2013 Here, we show that TPT at a therapeutically relevant dose partially activated monocyte-derived DCs as reflected by enhanced migratory activity, elevated expression of HLA-DR and costimulatory/maturation markers, and accordingly an increased allogenic CD4(+) T cell stimulation. Topotecan 19-22 CD4 molecule Homo sapiens 251-254 24074809-0 2013 Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers. Topotecan 5-14 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 64-69 23906928-3 2013 Chronomodulated radiosensitization of TPT was investigated by analysis of tumor regrowth delay (TGD), pimonidazole hydrochloride, histone H2AX phosphorylation, (gamma-H2AX) topoisomerase I (Top I), cell cycle, and apoptosis after treatment with (1) TPT (10 mg/kg) alone; (2) radiation therapy alone (RT); and (3) TPT+RT at 3, 9, 15, and 21 HALO. Topotecan 38-41 DNA topoisomerase I Homo sapiens 173-188 23906928-3 2013 Chronomodulated radiosensitization of TPT was investigated by analysis of tumor regrowth delay (TGD), pimonidazole hydrochloride, histone H2AX phosphorylation, (gamma-H2AX) topoisomerase I (Top I), cell cycle, and apoptosis after treatment with (1) TPT (10 mg/kg) alone; (2) radiation therapy alone (RT); and (3) TPT+RT at 3, 9, 15, and 21 HALO. Topotecan 38-41 DNA topoisomerase I Homo sapiens 190-195 23906928-9 2013 The expression of Top I in the TPT+RT group was also significantly different from the control tumors at 15 HALO (P<.05). Topotecan 31-34 DNA topoisomerase I Homo sapiens 18-23 23650219-2 2013 Our objective was to describe the outcomes and toxicities for a topotecan and cyclophosphamide (TOPO/CTX) regimen for first relapse or progression of high-risk neuroblastoma. Topotecan 64-73 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 101-104 23928469-0 2013 ATM is required for the repair of Topotecan-induced replication-associated double-strand breaks. Topotecan 34-43 ATM serine/threonine kinase Homo sapiens 0-3 23928469-10 2013 RESULTS: ATM-deficiency leads to enhanced numbers of residual DSBs, resulting in a pronounced S/G2-block and decreased survival upon TPT-treatment. Topotecan 133-136 ATM serine/threonine kinase Homo sapiens 9-12 23928469-11 2013 In common with IR, persisting Rad51 foci were detected following TPT-treatment. Topotecan 65-68 RAD51 recombinase Homo sapiens 30-35 23928469-12 2013 CONCLUSIONS: These results demonstrate that ATM is essentially required for the completion of HR-mediated repair of TPT-induced DSBs formed indirectly at replication forks. Topotecan 116-119 ATM serine/threonine kinase Homo sapiens 44-47 23686319-2 2013 Three model drugs-fexofenadine (FEX), sulfasalazine (SASP), and topotecan (TPT)-were selected as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and P-gp and BCRP substrates, respectively. Topotecan 64-73 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 97-111 23686319-2 2013 Three model drugs-fexofenadine (FEX), sulfasalazine (SASP), and topotecan (TPT)-were selected as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and P-gp and BCRP substrates, respectively. Topotecan 75-78 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 97-111 23788247-1 2013 Topotecan (TPT) is an important anti-cancer drug that inhibits topoisomerase I. Topotecan 0-9 DNA topoisomerase I Canis lupus familiaris 63-78 23788247-1 2013 Topotecan (TPT) is an important anti-cancer drug that inhibits topoisomerase I. Topotecan 11-14 DNA topoisomerase I Canis lupus familiaris 63-78 23816875-3 2013 Available tumor specimens were analyzed for ISG15 gene expression as a biomarker of response to topotecan. Topotecan 96-105 ISG15 ubiquitin like modifier Homo sapiens 44-49 22488590-6 2013 In addition, clinical PI3K/mTOR inhibitors, PI-103, and BEZ235, showed anti-proliferative effects on BRCA1 mutant breast cancer cell lines and synergism in combination with chemotherapeutic drugs, cisplatin, doxorubicin, topotecan, and gemcitabine. Topotecan 221-230 mechanistic target of rapamycin kinase Homo sapiens 27-31 23918391-0 2013 R-loop formation at Snord116 mediates topotecan inhibition of Ube3a-antisense and allele-specific chromatin decondensation. Topotecan 38-47 predicted gene, 26504 Mus musculus 20-28 23918391-0 2013 R-loop formation at Snord116 mediates topotecan inhibition of Ube3a-antisense and allele-specific chromatin decondensation. Topotecan 38-47 ubiquitin protein ligase E3A Mus musculus 62-67 23918391-5 2013 Interestingly, topoisomerase inhibitors, including topotecan, were recently identified in an unbiased drug screen for compounds that could reverse the silent paternal allele of Ube3a in neurons, but the mechanism of topotecan action on the PWS/AS locus is unknown. Topotecan 51-60 ubiquitin protein ligase E3A Mus musculus 177-182 23918391-6 2013 Here, we demonstrate that topotecan treatment stabilizes the formation of RNA:DNA hybrids (R loops) at G-skewed repeat elements within paternal Snord116, corresponding to increased chromatin decondensation and inhibition of Ube3a-ATS expression. Topotecan 26-35 predicted gene, 26504 Mus musculus 144-152 23918391-6 2013 Here, we demonstrate that topotecan treatment stabilizes the formation of RNA:DNA hybrids (R loops) at G-skewed repeat elements within paternal Snord116, corresponding to increased chromatin decondensation and inhibition of Ube3a-ATS expression. Topotecan 26-35 ubiquitin protein ligase E3A Mus musculus 224-229 23918391-7 2013 Neural precursor cells from paternal Snord116 deletion mice exhibit increased Ube3a-ATS levels in differentiated neurons and show a reduced effect of topotecan compared with wild-type neurons. Topotecan 150-159 predicted gene, 26504 Mus musculus 37-45 23918391-8 2013 These results demonstrate that the AS candidate drug topotecan acts predominantly through stabilizing R loops and chromatin decondensation at the paternally expressed PWS Snord116 locus. Topotecan 53-62 predicted gene, 26504 Mus musculus 171-179 23578789-6 2013 Induction of TREX1 was found following treatment with the crosslinking alkylating agents nimustine, carmustine, fotemustine and the topoisomerase I inhibitor topotecan, but not following temozolomide, etoposide and ionizing radiation. Topotecan 158-167 three prime repair exonuclease 1 Homo sapiens 13-18 23578789-9 2013 TREX1 knockdown resulted in enhanced cell death following nimustine, fotemustine and topotecan and to a reduced recovery from the anticancer drug induced block to replication. Topotecan 85-94 three prime repair exonuclease 1 Homo sapiens 0-5 23666509-5 2013 In marked contrast, TPT prevented full maturation of DCs stimulated with a cocktail of proinflammatory mediators, accompanied by somewhat lower upregulation of NF-kappaB factors p65 and RelB. Topotecan 20-23 RELA proto-oncogene, NF-kB subunit Homo sapiens 178-181 23666509-5 2013 In marked contrast, TPT prevented full maturation of DCs stimulated with a cocktail of proinflammatory mediators, accompanied by somewhat lower upregulation of NF-kappaB factors p65 and RelB. Topotecan 20-23 RELB proto-oncogene, NF-kB subunit Homo sapiens 186-190 23406775-13 2013 CONCLUSION: Our study established a novel TP53-associated pediatric ACC xenograft and identified topotecan as a potentially effective agent for treating children with this disease. Topotecan 97-106 tumor protein p53 Homo sapiens 42-46 23548269-4 2013 In contrast, while cisplatin, topotecan, and gemcitabine each activated Chk1, RNAi-mediated depletion or inhibition of this kinase in cells sensitized them only to gemcitabine. Topotecan 30-39 checkpoint kinase 1 Homo sapiens 72-76 23548269-7 2013 In addition, we also found that VE-821 could further sensitize BRCA1-depleted cells to cisplatin, topotecan, and veliparib beyond the potent sensitization already caused by their deficiency in homologous recombination. Topotecan 98-107 BRCA1 DNA repair associated Homo sapiens 63-68 23729661-5 2013 Axitinib showed incomplete inhibition of P-gp-mediated transport of digoxin in Caco-2 cells and BCRP transport of topotecan in BCRP-transfected MDCK cells with IC50 values of 3 muM and 4.4 muM, respectively. Topotecan 114-123 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 96-100 23729661-5 2013 Axitinib showed incomplete inhibition of P-gp-mediated transport of digoxin in Caco-2 cells and BCRP transport of topotecan in BCRP-transfected MDCK cells with IC50 values of 3 muM and 4.4 muM, respectively. Topotecan 114-123 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 127-131 23635651-5 2013 Similarly, the Abcc2;Abcb1(-/-) strain also had elevated renal elimination and reduced fecal excretion of topotecan lactone. Topotecan 106-123 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Mus musculus 15-20 23635651-5 2013 Similarly, the Abcc2;Abcb1(-/-) strain also had elevated renal elimination and reduced fecal excretion of topotecan lactone. Topotecan 106-123 ATP-binding cassette, sub-family B (MDR/TAP), member 1B Mus musculus 21-26 23635651-8 2013 It is concluded that Abcg2 has the most significant effect on topotecan elimination, whereas both Abcb1 and Abcc2 have overlapping functions with Abcg2. Topotecan 62-71 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 21-26 23376119-2 2013 Our previous findings showed that the hydrophilic PARP inhibitor PJ34 enhances the sensitivity of p53 proficient MCF7 breast carcinoma cells to topotecan, a DNA Topoisomerase I (TOP 1) inhibitor. Topotecan 144-153 poly(ADP-ribose) polymerase 1 Homo sapiens 50-54 23376119-2 2013 Our previous findings showed that the hydrophilic PARP inhibitor PJ34 enhances the sensitivity of p53 proficient MCF7 breast carcinoma cells to topotecan, a DNA Topoisomerase I (TOP 1) inhibitor. Topotecan 144-153 tumor protein p53 Homo sapiens 98-101 23324287-0 2013 Effect of topotecan on retinocytoma cell apoptosis and expression of Livin and PTEN. Topotecan 10-19 baculoviral IAP repeat containing 7 Homo sapiens 69-74 23324287-0 2013 Effect of topotecan on retinocytoma cell apoptosis and expression of Livin and PTEN. Topotecan 10-19 phosphatase and tensin homolog Homo sapiens 79-83 23462296-4 2013 This study demonstrates alterations in ABC and SLC gene expression levels in methotrexate, cisplatin, doxorubicin, vincristine, topotecan and paclitaxel-resistant variant of W1 ovarian cancer cell line. Topotecan 128-137 ATP binding cassette subfamily B member 6 (Langereis blood group) Homo sapiens 39-42 23462296-4 2013 This study demonstrates alterations in ABC and SLC gene expression levels in methotrexate, cisplatin, doxorubicin, vincristine, topotecan and paclitaxel-resistant variant of W1 ovarian cancer cell line. Topotecan 128-137 C-C motif chemokine ligand 21 Homo sapiens 47-50 23305320-4 2013 Topotecan inhibited 5-HT-gated current through homomeric 5-HT3A receptors. Topotecan 0-9 5-hydroxytryptamine receptor 3A Homo sapiens 57-63 23305320-5 2013 Interestingly, however, additional expression of the 5-HT3B subunit changed the response to topotecan dramatically from an inhibitory to a potentiatory one. Topotecan 92-101 5-hydroxytryptamine receptor 3B Homo sapiens 53-59 23002039-9 2013 Results of simulation studies showed that at the dose levels evaluated, >99.9% of patients are expected to achieve CSF topotecan lactone concentrations >1 ng/ml for at least 8 hours. Topotecan 122-139 colony stimulating factor 2 Homo sapiens 118-121 23324287-17 2013 TPT could induce human RB cell strain HXO-Rb44 cell apoptosis, and its mechanism is associated with the inhibition of Livin and PTEN expressions. Topotecan 0-3 baculoviral IAP repeat containing 7 Homo sapiens 118-123 23324287-17 2013 TPT could induce human RB cell strain HXO-Rb44 cell apoptosis, and its mechanism is associated with the inhibition of Livin and PTEN expressions. Topotecan 0-3 phosphatase and tensin homolog Homo sapiens 128-132 23027040-1 2012 OBJECTIVE: Lapatinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), also inhibits breast cancer resistance protein (BCRP) involved in resistance to topotecan. Topotecan 233-242 erb-b2 receptor tyrosine kinase 2 Homo sapiens 146-150 23331791-10 2013 Suppressing HIF-1alpha with low-dose topotecan potentiates the effects of the antiangiogenic drugs in a mouse model. Topotecan 37-46 hypoxia inducible factor 1, alpha subunit Mus musculus 12-22 23316441-3 2013 In this study, we focused on camptothecin and its derivatives, topotecan and irinotecan, which are type I topoisomerase inhibitors that create DNA double-strand breaks in rapidly dividing cells. Topotecan 63-72 Topoisomerase 1 Drosophila melanogaster 99-119 23316441-4 2013 Here, we describe two polymorphisms in Drosophila Cyp6d2 that result in extreme sensitivity to camptothecin but not topotecan or irinotecan. Topotecan 116-125 Cyp6d2 Drosophila melanogaster 50-56 20301284-8 1993 Agents/circumstances to avoid: Because TDP1 codes for a DNA repair enzyme, genotoxic anti-cancer drugs such as camptothecins (e.g., irinotecan and topotecan) and bleomycin are likely to be extremely harmful and possibly fatal; exposure to radiation is likely to be extremely harmful and possibly fatal. Topotecan 147-156 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 39-43 23134462-10 2012 with the lower dose of TPT can induce apoptosis through generation of ROS and activation of caspases. Topotecan 23-26 caspase 9 Homo sapiens 92-100 23027040-1 2012 OBJECTIVE: Lapatinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), also inhibits breast cancer resistance protein (BCRP) involved in resistance to topotecan. Topotecan 233-242 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 201-205 22344449-5 2012 Topotecan is the standard treatment as second-line therapy and it is an inhibitor of topoisomerase I (TOP I). Topotecan 0-9 DNA topoisomerase I Homo sapiens 126-131 22452992-8 2012 The overall data indicated that (i) both genistein and topotecan induce cellular death in LNCaP cells, (ii) genistein-topotecan combination was significantly more efficacious in reducing LNCaP cell viability compared with either genistein or topotecan alone, (iii) in all cases, cell death was primarily through apoptosis, via the activation of caspase-3 and -9, which are involved in the intrinsic pathway, (iv) ROS generation levels increased significantly with the genistein-topotecan combination treatment. Topotecan 118-127 caspase 3 Homo sapiens 345-361 22452992-8 2012 The overall data indicated that (i) both genistein and topotecan induce cellular death in LNCaP cells, (ii) genistein-topotecan combination was significantly more efficacious in reducing LNCaP cell viability compared with either genistein or topotecan alone, (iii) in all cases, cell death was primarily through apoptosis, via the activation of caspase-3 and -9, which are involved in the intrinsic pathway, (iv) ROS generation levels increased significantly with the genistein-topotecan combination treatment. Topotecan 118-127 caspase 3 Homo sapiens 345-361 22452992-8 2012 The overall data indicated that (i) both genistein and topotecan induce cellular death in LNCaP cells, (ii) genistein-topotecan combination was significantly more efficacious in reducing LNCaP cell viability compared with either genistein or topotecan alone, (iii) in all cases, cell death was primarily through apoptosis, via the activation of caspase-3 and -9, which are involved in the intrinsic pathway, (iv) ROS generation levels increased significantly with the genistein-topotecan combination treatment. Topotecan 118-127 caspase 3 Homo sapiens 345-361 22895574-3 2012 E2-EPF knockdown also increases the chemosensitivity to topoisomerase I inhibitor (topotecan) and II (etoposide and doxorubicin). Topotecan 95-104 ubiquitin conjugating enzyme E2 S Homo sapiens 0-6 22158045-8 2012 Topotecan, a soluble analog of CPT and FDA-approved anticancer drug, dramatically arrested the growth of SULF2M-ISG15H, but not SULF2U-ISG15L lung tumors in nude mice (P<0.002). Topotecan 0-9 sulfatase 2 Homo sapiens 105-111 22158045-8 2012 Topotecan, a soluble analog of CPT and FDA-approved anticancer drug, dramatically arrested the growth of SULF2M-ISG15H, but not SULF2U-ISG15L lung tumors in nude mice (P<0.002). Topotecan 0-9 sulfatase 2 Mus musculus 105-110 22158045-9 2012 Similarly, high ISG15 expression that is comparable to the topotecan (TPT)-sensitive NSCLC cell lines was found in tumors from 25% of NSCLC patients compared with normal lung, indicating a potential to identify and target the most sensitive NSCLC subpopulation for personalized TPT therapy. Topotecan 278-281 ISG15 ubiquitin like modifier Homo sapiens 16-21 22689924-0 2012 Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter. Topotecan 96-105 poly(ADP-ribose) polymerase 1 Homo sapiens 14-41 22689924-0 2012 Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter. Topotecan 96-105 solute carrier family 6 member 2 Homo sapiens 167-192 22689924-2 2012 We previously reported that combining (131)I-MIBG with the topoisomerase I inhibitor topotecan induced long-term DNA damage and supraadditive toxicity to noradrenaline transporter (NAT)-expressing cells and xenografts. Topotecan 85-94 solute carrier family 6 member 2 Homo sapiens 154-179 22689924-2 2012 We previously reported that combining (131)I-MIBG with the topoisomerase I inhibitor topotecan induced long-term DNA damage and supraadditive toxicity to noradrenaline transporter (NAT)-expressing cells and xenografts. Topotecan 85-94 solute carrier family 6 member 2 Homo sapiens 181-184 22689924-4 2012 This present study investigated the potential of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP-1) inhibition, in vitro and in vivo, to further enhance (131)I-MIBG/topotecan efficacy. Topotecan 175-184 poly(ADP-ribose) polymerase 1 Homo sapiens 102-108 22689924-11 2012 All scheduled combinations of PJ34 and (131)I-MIBG/topotecan induced supraadditive toxicity and increased DNA damage in SK-N-BE(2c) cells, but only simultaneous administration induced enhanced efficacy in UVW/NAT cells. Topotecan 51-60 solute carrier family 6 member 2 Homo sapiens 209-212 22689924-13 2012 In vivo, simultaneous administration of PJ34 and (131)I-MIBG/topotecan significantly delayed the growth of SK-N-BE(2c) and UVW/NAT xenografts, compared with (131)I-MIBG/topotecan therapy. Topotecan 61-70 solute carrier family 6 member 2 Homo sapiens 127-130 22689924-14 2012 CONCLUSION: The antitumor efficacy of topotecan, (131)I-MIBG, and (131)I-MIBG/topotecan combination treatment was increased by PARP-1 inhibition in vitro and in vivo. Topotecan 38-47 poly(ADP-ribose) polymerase 1 Homo sapiens 127-133 22689924-14 2012 CONCLUSION: The antitumor efficacy of topotecan, (131)I-MIBG, and (131)I-MIBG/topotecan combination treatment was increased by PARP-1 inhibition in vitro and in vivo. Topotecan 78-87 poly(ADP-ribose) polymerase 1 Homo sapiens 127-133 22904680-5 2012 In vitro, p53-72P was less effective than p53-72R in inducing apoptosis and inhibiting survival of p53-null LAN-1 cells treated with etoposide, topotecan, or ionizing radiation but not taxol. Topotecan 144-153 tumor protein p53 Homo sapiens 10-13 22764771-5 2012 Important examples include ketoconazole inhibition of hepatic CYP3A4 in order to increase systemic exposure to docetaxel, irinotecan and etoposide, and cyclosporine inhibition of intestinal ATP-binding cassette transporters in order to decrease the toxicity of irinotecan and increase the bioavailability of oral docetaxel, paclitaxel and topotecan. Topotecan 339-348 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 62-68 22360854-5 2012 Furthermore, the specific ABCG2 inhibitor Ko143 potently sensitized xS1-M1-80 cells to mitoxantrone and topotecan. Topotecan 104-113 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 26-31 22619121-8 2012 We found that neuroblastoma cells with amplification of MYCN are more sensitive than MYCN negative cells to camptothecin and topotecan killing. Topotecan 125-134 MYCN proto-oncogene, bHLH transcription factor Homo sapiens 56-60 22619121-8 2012 We found that neuroblastoma cells with amplification of MYCN are more sensitive than MYCN negative cells to camptothecin and topotecan killing. Topotecan 125-134 MYCN proto-oncogene, bHLH transcription factor Homo sapiens 85-89 22619121-9 2012 Campothecin and topotecan caused selective down-regulation of B-Myb and MycN expression in neuroblastoma cells. Topotecan 16-25 MYB proto-oncogene like 2 Homo sapiens 62-67 22619121-9 2012 Campothecin and topotecan caused selective down-regulation of B-Myb and MycN expression in neuroblastoma cells. Topotecan 16-25 MYCN proto-oncogene, bHLH transcription factor Homo sapiens 72-76 22619121-10 2012 Notably, forced overexpression of B-Myb could antagonize the killing effect of topotecan and camptothecin, demonstrating that the transcription factor is a key target of the drugs. Topotecan 79-88 MYB proto-oncogene like 2 Homo sapiens 34-39 22426819-3 2012 Breast cancer resistance protein (BCRP)/ABCG2, a drug efflux pump, confers resistance to multiple anticancer agents such as SN-38 and topotecan. Topotecan 158-167 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-32 22426819-3 2012 Breast cancer resistance protein (BCRP)/ABCG2, a drug efflux pump, confers resistance to multiple anticancer agents such as SN-38 and topotecan. Topotecan 158-167 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 34-38 22426819-3 2012 Breast cancer resistance protein (BCRP)/ABCG2, a drug efflux pump, confers resistance to multiple anticancer agents such as SN-38 and topotecan. Topotecan 158-167 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 40-45 22426819-6 2012 LY294002, but not wortmannin, reversed the BCRP-mediated SN-38 and topotecan resistance. Topotecan 79-88 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 43-47 22426819-7 2012 LY294002 treatment did not affect total or cell surface BCRP levels as determined by western blotting and flow cytometry but blocked BCRP-mediated topotecan efflux in a dose-dependent manner. Topotecan 171-180 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 157-161 22619121-0 2012 A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. Topotecan 55-64 MYB proto-oncogene like 2 Homo sapiens 96-101 22619121-0 2012 A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. Topotecan 55-64 MYCN proto-oncogene, bHLH transcription factor Homo sapiens 102-106 22436457-0 2012 Synthetic lethal screen identifies NF-kappaB as a target for combination therapy with topotecan for patients with neuroblastoma. Topotecan 86-95 nuclear factor kappa B subunit 1 Homo sapiens 35-44 22436457-6 2012 RESULTS: We found that there were nine genes whose suppression synergized with topotecan to enhance cell death, and the NF-kappaB signaling pathway was significantly enriched. Topotecan 79-88 nuclear factor kappa B subunit 1 Homo sapiens 120-129 22436457-7 2012 Microarray analysis of cells treated with topotecan revealed a significant enrichment of NF-kappaB target genes among the differentially altered genes, suggesting that NF-kappaB pathway was activated in the treated cells. Topotecan 42-51 nuclear factor kappa B subunit 1 Homo sapiens 89-98 22436457-7 2012 Microarray analysis of cells treated with topotecan revealed a significant enrichment of NF-kappaB target genes among the differentially altered genes, suggesting that NF-kappaB pathway was activated in the treated cells. Topotecan 42-51 nuclear factor kappa B subunit 1 Homo sapiens 168-177 22436457-8 2012 Combination of topotecan and known NF-kappaB inhibitors (NSC 676914 or bortezomib) significantly reduced cell growth and induced caspase 3 activity in vitro. Topotecan 15-24 caspase 3 Homo sapiens 129-138 22665973-9 2012 Intravitreal injection of Topotecan (TPT), a compound that inhibits HIF-1alpha expression, partially eliminated HVS defects in Cited2(CKO) lenses. Topotecan 26-35 hypoxia inducible factor 1, alpha subunit Mus musculus 68-78 21765463-11 2012 Nutlin-3, RITA and Topotecan lead to comparable p53 activation and growth inhibition under normoxia and hypoxia. Topotecan 19-28 tumor protein p53 Homo sapiens 48-51 21765463-13 2012 Also Topotecan, alone or in combination with Nutlin-3, reduced HIF-1alpha protein levels, suggesting that a certain level of DNA damage response is required for p53-mediated downregulation of HIF-1alpha. Topotecan 5-14 hypoxia inducible factor 1 subunit alpha Homo sapiens 63-73 21765463-13 2012 Also Topotecan, alone or in combination with Nutlin-3, reduced HIF-1alpha protein levels, suggesting that a certain level of DNA damage response is required for p53-mediated downregulation of HIF-1alpha. Topotecan 5-14 tumor protein p53 Homo sapiens 161-164 21765463-13 2012 Also Topotecan, alone or in combination with Nutlin-3, reduced HIF-1alpha protein levels, suggesting that a certain level of DNA damage response is required for p53-mediated downregulation of HIF-1alpha. Topotecan 5-14 hypoxia inducible factor 1 subunit alpha Homo sapiens 192-202 22158865-3 2012 In this study we evaluated the ability of the PARP inhibitor veliparib to enhance the cytotoxicity of the topoisomerase I poisons topotecan and camptothecin (CPT). Topotecan 130-139 poly (ADP-ribose) polymerase family, member 1 Mus musculus 46-50 22138446-4 2012 Lack of p53 is associated with an increase in sensitivity to the combination treatment; p53+/+ cells treated with the topoisomerase I poison topotecan (TPT) arrest at G2, whereas in p53-/- cells the additional presence of the Hsp90 inhibitor geldanamycin (GA) selectively abrogates the G2M checkpoint. Topotecan 141-150 tumor protein p53 Homo sapiens 8-11 22138446-4 2012 Lack of p53 is associated with an increase in sensitivity to the combination treatment; p53+/+ cells treated with the topoisomerase I poison topotecan (TPT) arrest at G2, whereas in p53-/- cells the additional presence of the Hsp90 inhibitor geldanamycin (GA) selectively abrogates the G2M checkpoint. Topotecan 141-150 tumor protein p53 Homo sapiens 88-91 22138446-4 2012 Lack of p53 is associated with an increase in sensitivity to the combination treatment; p53+/+ cells treated with the topoisomerase I poison topotecan (TPT) arrest at G2, whereas in p53-/- cells the additional presence of the Hsp90 inhibitor geldanamycin (GA) selectively abrogates the G2M checkpoint. Topotecan 141-150 tumor protein p53 Homo sapiens 88-91 22138446-4 2012 Lack of p53 is associated with an increase in sensitivity to the combination treatment; p53+/+ cells treated with the topoisomerase I poison topotecan (TPT) arrest at G2, whereas in p53-/- cells the additional presence of the Hsp90 inhibitor geldanamycin (GA) selectively abrogates the G2M checkpoint. Topotecan 141-150 heat shock protein 90 alpha family class A member 1 Homo sapiens 226-231 22665973-9 2012 Intravitreal injection of Topotecan (TPT), a compound that inhibits HIF-1alpha expression, partially eliminated HVS defects in Cited2(CKO) lenses. Topotecan 26-35 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 Mus musculus 127-133 22665973-9 2012 Intravitreal injection of Topotecan (TPT), a compound that inhibits HIF-1alpha expression, partially eliminated HVS defects in Cited2(CKO) lenses. Topotecan 26-35 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 Mus musculus 134-137 22665973-9 2012 Intravitreal injection of Topotecan (TPT), a compound that inhibits HIF-1alpha expression, partially eliminated HVS defects in Cited2(CKO) lenses. Topotecan 37-40 hypoxia inducible factor 1, alpha subunit Mus musculus 68-78 22665973-9 2012 Intravitreal injection of Topotecan (TPT), a compound that inhibits HIF-1alpha expression, partially eliminated HVS defects in Cited2(CKO) lenses. Topotecan 37-40 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 Mus musculus 127-133 22665973-9 2012 Intravitreal injection of Topotecan (TPT), a compound that inhibits HIF-1alpha expression, partially eliminated HVS defects in Cited2(CKO) lenses. Topotecan 37-40 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 Mus musculus 134-137 23024792-2 2012 In this study, sensitising topotecan to colon cancer cells with different P53 status via modulation of autophagy was examined. Topotecan 27-36 tumor protein p53 Homo sapiens 74-77 23024792-3 2012 METHODOLOGY/PRINCIPAL FINDINGS: The DNA damage induced by topotecan treatment resulted in cytoprotective autophagy in colon cancer cells with wild-type p53. Topotecan 58-67 tumor protein p53 Homo sapiens 152-155 23024792-4 2012 However, in cells with mutant p53 or p53 knockout, treatment with topotecan induced autophagy-associated cell death. Topotecan 66-75 tumor protein p53 Homo sapiens 30-33 23024792-4 2012 However, in cells with mutant p53 or p53 knockout, treatment with topotecan induced autophagy-associated cell death. Topotecan 66-75 tumor protein p53 Homo sapiens 37-40 23024792-5 2012 In wild-type p53 colon cancer cells, topotecan treatment activated p53, upregulated the expression of sestrin 2, induced the phosphorylation of the AMPKalpha subunit at Thr172, and inhibited the mTORC1 pathway. Topotecan 37-46 tumor protein p53 Homo sapiens 13-16 23024792-5 2012 In wild-type p53 colon cancer cells, topotecan treatment activated p53, upregulated the expression of sestrin 2, induced the phosphorylation of the AMPKalpha subunit at Thr172, and inhibited the mTORC1 pathway. Topotecan 37-46 tumor protein p53 Homo sapiens 67-70 23024792-5 2012 In wild-type p53 colon cancer cells, topotecan treatment activated p53, upregulated the expression of sestrin 2, induced the phosphorylation of the AMPKalpha subunit at Thr172, and inhibited the mTORC1 pathway. Topotecan 37-46 sestrin 2 Homo sapiens 102-111 23024792-5 2012 In wild-type p53 colon cancer cells, topotecan treatment activated p53, upregulated the expression of sestrin 2, induced the phosphorylation of the AMPKalpha subunit at Thr172, and inhibited the mTORC1 pathway. Topotecan 37-46 CREB regulated transcription coactivator 1 Mus musculus 195-201 23024792-6 2012 Furthermore, the inhibition of autophagy enhanced the anti-tumour effect of topotecan treatment in wild-type p53 colon cancer cells but alleviated the anti-tumour effect of topotecan treatment in p53 knockout cells in vivo. Topotecan 76-85 tumor protein p53 Homo sapiens 109-112 23028879-0 2012 EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. Topotecan 45-54 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 30-35 23028879-2 2012 Using our conditional K14cre;Brca1(F/F);p53(F/F) mouse model, we showed previously that BRCA1;p53-deficient mammary tumors initially respond to topotecan, but frequently acquire resistance by overexpression of the efflux transporter ABCG2. Topotecan 144-153 breast cancer 1, early onset Mus musculus 88-93 23028879-2 2012 Using our conditional K14cre;Brca1(F/F);p53(F/F) mouse model, we showed previously that BRCA1;p53-deficient mammary tumors initially respond to topotecan, but frequently acquire resistance by overexpression of the efflux transporter ABCG2. Topotecan 144-153 transformation related protein 53, pseudogene Mus musculus 94-97 23028879-5 2012 We also evaluated tumor-specific ABCG2 inhibition by Ko143 in Abcg2(-/-) host animals that carried tumors with topotecan-induced ABCG2 expression. Topotecan 111-120 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 129-134 23024792-6 2012 Furthermore, the inhibition of autophagy enhanced the anti-tumour effect of topotecan treatment in wild-type p53 colon cancer cells but alleviated the anti-tumour effect of topotecan treatment in p53 knockout cells in vivo. Topotecan 173-182 tumor protein p53 Homo sapiens 196-199 23024792-7 2012 CONCLUSIONS/SIGNIFICANCE: These results imply that the wild-type p53-dependent induction of cytoprotective autophagy is one of the cellular responses that determines the cellular sensitivity to the DNA-damaging drug topotecan. Topotecan 216-225 tumor protein p53 Homo sapiens 65-68 22530032-9 2012 In contrast, topotecan, a bona fide transport substrate of ABCG2, accumulated exclusively in EVs of MDR cells but was neither detected in lysosomes of normal breast epithelial cells nor in non-MDR breast cancer cells. Topotecan 13-22 ATP binding cassette subfamily G member 2 Equus caballus 59-64 22851904-2 2012 The combination of topotecan and cyclophosphamide (TC) has activity in pediatric patients with recurrent sarcoma, especially Ewing"s sarcoma (EWS). Topotecan 19-28 EWS RNA binding protein 1 Homo sapiens 142-145 22396773-3 2012 In the current studies, we demonstrate that topotecan (TPT), a topoisomerase I-targeting drug with a well-defined mechanism of action, stimulates major histocompatibility complex class I (MHC I) expression in breast cancer cells through elevated expression/secretion of interferon-beta (IFN-beta) and activation of type I IFN signaling. Topotecan 44-53 interferon beta 1 Homo sapiens 270-285 22396773-3 2012 In the current studies, we demonstrate that topotecan (TPT), a topoisomerase I-targeting drug with a well-defined mechanism of action, stimulates major histocompatibility complex class I (MHC I) expression in breast cancer cells through elevated expression/secretion of interferon-beta (IFN-beta) and activation of type I IFN signaling. Topotecan 44-53 interferon beta 1 Homo sapiens 287-295 22396773-3 2012 In the current studies, we demonstrate that topotecan (TPT), a topoisomerase I-targeting drug with a well-defined mechanism of action, stimulates major histocompatibility complex class I (MHC I) expression in breast cancer cells through elevated expression/secretion of interferon-beta (IFN-beta) and activation of type I IFN signaling. Topotecan 55-58 interferon beta 1 Homo sapiens 270-285 22396773-3 2012 In the current studies, we demonstrate that topotecan (TPT), a topoisomerase I-targeting drug with a well-defined mechanism of action, stimulates major histocompatibility complex class I (MHC I) expression in breast cancer cells through elevated expression/secretion of interferon-beta (IFN-beta) and activation of type I IFN signaling. Topotecan 55-58 interferon beta 1 Homo sapiens 287-295 22396773-6 2012 Consistently, TPT-treated cells exhibit elevated expression of multiple cytokines such as IFN-beta, TNF-alpha, IL-6 and IL-8. Topotecan 14-17 interferon beta 1 Homo sapiens 90-98 22396773-6 2012 Consistently, TPT-treated cells exhibit elevated expression of multiple cytokines such as IFN-beta, TNF-alpha, IL-6 and IL-8. Topotecan 14-17 tumor necrosis factor Homo sapiens 100-109 22396773-6 2012 Consistently, TPT-treated cells exhibit elevated expression of multiple cytokines such as IFN-beta, TNF-alpha, IL-6 and IL-8. Topotecan 14-17 interleukin 6 Homo sapiens 111-115 22396773-6 2012 Consistently, TPT-treated cells exhibit elevated expression of multiple cytokines such as IFN-beta, TNF-alpha, IL-6 and IL-8. Topotecan 14-17 C-X-C motif chemokine ligand 8 Homo sapiens 120-124 22396773-7 2012 Third, either knocking down the type I interferon receptor subunit 1 (IFNAR1) or addition of neutralizing antibody against IFN-beta results in reduced MHC I expression in TPT-treated cells. Topotecan 171-174 interferon alpha and beta receptor subunit 1 Homo sapiens 70-76 22396773-7 2012 Third, either knocking down the type I interferon receptor subunit 1 (IFNAR1) or addition of neutralizing antibody against IFN-beta results in reduced MHC I expression in TPT-treated cells. Topotecan 171-174 interferon beta 1 Homo sapiens 123-131 22396773-8 2012 Together, these results suggest that TPT induces increased IFN-beta autocrine/paracrine signaling through type I IFN receptor, resulting in the elevated MHC I expression in tumor cells. Topotecan 37-40 interferon beta 1 Homo sapiens 59-67 22101337-3 2011 Using gene expression microarray analysis, we find that DNA damage response (DDR) pathways elicited by veliparib (ABT-888), a PARP inhibitor, plus topotecan comprise the G1/S checkpoint, ATM, and p53 signaling pathways in p53-wildtype cancer cell lines and BRCA1, BRCA2 and ATR pathway in p53-mutant lines. Topotecan 147-156 tumor protein p53 Homo sapiens 196-199 22190039-5 2011 At nanomolar concentrations, topotecan upregulated catalytically active UBE3A in neurons from maternal Ube3a-null mice. Topotecan 29-38 ubiquitin protein ligase E3A Mus musculus 72-77 22190039-5 2011 At nanomolar concentrations, topotecan upregulated catalytically active UBE3A in neurons from maternal Ube3a-null mice. Topotecan 29-38 ubiquitin protein ligase E3A Mus musculus 103-108 22190039-6 2011 Topotecan concomitantly downregulated expression of the Ube3a antisense transcript that overlaps the paternal copy of Ube3a. Topotecan 0-9 ubiquitin protein ligase E3A Mus musculus 56-61 22190039-6 2011 Topotecan concomitantly downregulated expression of the Ube3a antisense transcript that overlaps the paternal copy of Ube3a. Topotecan 0-9 ubiquitin protein ligase E3A Mus musculus 118-123 22190039-7 2011 These results indicate that topotecan unsilences Ube3a in cis by reducing transcription of an imprinted antisense RNA. Topotecan 28-37 ubiquitin protein ligase E3A Mus musculus 49-54 22190039-8 2011 When administered in vivo, topotecan unsilenced the paternal Ube3a allele in several regions of the nervous system, including neurons in the hippocampus, neocortex, striatum, cerebellum and spinal cord. Topotecan 27-36 ubiquitin protein ligase E3A Mus musculus 61-66 22190039-9 2011 Paternal expression of Ube3a remained elevated in a subset of spinal cord neurons for at least 12 weeks after cessation of topotecan treatment, indicating that transient topoisomerase inhibition can have enduring effects on gene expression. Topotecan 124-133 ubiquitin protein ligase E3A Mus musculus 23-28 22101337-3 2011 Using gene expression microarray analysis, we find that DNA damage response (DDR) pathways elicited by veliparib (ABT-888), a PARP inhibitor, plus topotecan comprise the G1/S checkpoint, ATM, and p53 signaling pathways in p53-wildtype cancer cell lines and BRCA1, BRCA2 and ATR pathway in p53-mutant lines. Topotecan 147-156 tumor protein p53 Homo sapiens 222-225 22101337-3 2011 Using gene expression microarray analysis, we find that DNA damage response (DDR) pathways elicited by veliparib (ABT-888), a PARP inhibitor, plus topotecan comprise the G1/S checkpoint, ATM, and p53 signaling pathways in p53-wildtype cancer cell lines and BRCA1, BRCA2 and ATR pathway in p53-mutant lines. Topotecan 147-156 BRCA1 DNA repair associated Homo sapiens 257-262 22101337-3 2011 Using gene expression microarray analysis, we find that DNA damage response (DDR) pathways elicited by veliparib (ABT-888), a PARP inhibitor, plus topotecan comprise the G1/S checkpoint, ATM, and p53 signaling pathways in p53-wildtype cancer cell lines and BRCA1, BRCA2 and ATR pathway in p53-mutant lines. Topotecan 147-156 BRCA2 DNA repair associated Homo sapiens 264-269 22101337-3 2011 Using gene expression microarray analysis, we find that DNA damage response (DDR) pathways elicited by veliparib (ABT-888), a PARP inhibitor, plus topotecan comprise the G1/S checkpoint, ATM, and p53 signaling pathways in p53-wildtype cancer cell lines and BRCA1, BRCA2 and ATR pathway in p53-mutant lines. Topotecan 147-156 ATR serine/threonine kinase Homo sapiens 274-277 22101337-3 2011 Using gene expression microarray analysis, we find that DNA damage response (DDR) pathways elicited by veliparib (ABT-888), a PARP inhibitor, plus topotecan comprise the G1/S checkpoint, ATM, and p53 signaling pathways in p53-wildtype cancer cell lines and BRCA1, BRCA2 and ATR pathway in p53-mutant lines. Topotecan 147-156 tumor protein p53 Homo sapiens 222-225 22101337-4 2011 In contrast, topotecan alone induces the G1/S checkpoint pathway in p53-wildtype lines and not in p53-mutant cells. Topotecan 13-22 tumor protein p53 Homo sapiens 68-71 21855118-0 2011 Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Topotecan 0-9 BRCA1 DNA repair associated Homo sapiens 27-31 21855118-1 2011 OBJECTIVE: To evaluate the efficacy of topoisomerase I inhibitor, topotecan, in patients with recurrent BRCA+ versus BRCA- ovarian, fallopian tube, and primary peritoneal carcinomas. Topotecan 66-75 BRCA1 DNA repair associated Homo sapiens 104-108 21855118-1 2011 OBJECTIVE: To evaluate the efficacy of topoisomerase I inhibitor, topotecan, in patients with recurrent BRCA+ versus BRCA- ovarian, fallopian tube, and primary peritoneal carcinomas. Topotecan 66-75 BRCA1 DNA repair associated Homo sapiens 117-121 21855118-5 2011 RESULTS: A total of 50 patients (9 BRCA+, 41 BRCA-) were treated with topotecan. Topotecan 70-79 BRCA1 DNA repair associated Homo sapiens 35-39 21855118-5 2011 RESULTS: A total of 50 patients (9 BRCA+, 41 BRCA-) were treated with topotecan. Topotecan 70-79 BRCA1 DNA repair associated Homo sapiens 45-49 21210765-2 2011 Irinotecan and topotecan are currently used to treat various types of cancers and many CPT derivatives are being developed. Topotecan 15-24 choline phosphotransferase 1 Homo sapiens 87-90 21555147-1 2011 OBJECTIVES: To evaluate the feasibility, toxicity and activity of neoadjuvant chemotherapy (NACT) using cisplatin and topotecan in patients affected by locally advanced cervical cancer (IB2-IIIB). Topotecan 118-127 mitogen-activated protein kinase 8 interacting protein 2 Homo sapiens 186-189 21709443-8 2011 METHODS: The cytotoxicity of topotecan after conventional or metronomic dosing was determined by examining cellular morphology, mitochondrial enzymatic activity (MTT), total cellular protein (SRB), annexin V and propidium iodine (PI) staining, cell cycle and western blot analysis in human prostate cancer cell lines (PC-3 and LNCaP) and the effects metronomic or continuous infusion on tumor growth in an in vivo tumor xenograft model. Topotecan 29-38 chaperonin containing TCP1 subunit 4 Homo sapiens 192-195 21709443-8 2011 METHODS: The cytotoxicity of topotecan after conventional or metronomic dosing was determined by examining cellular morphology, mitochondrial enzymatic activity (MTT), total cellular protein (SRB), annexin V and propidium iodine (PI) staining, cell cycle and western blot analysis in human prostate cancer cell lines (PC-3 and LNCaP) and the effects metronomic or continuous infusion on tumor growth in an in vivo tumor xenograft model. Topotecan 29-38 annexin A5 Homo sapiens 198-207 21709443-10 2011 These data also suggest the novel finding that the enhanced antitumor activity of topotecan following low-dose exposure correlates to alterations in cell cycle and increased p21 expression. Topotecan 82-91 H3 histone pseudogene 16 Homo sapiens 174-177 21673063-0 2011 Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1alpha in advanced solid tumors. Topotecan 50-59 hypoxia inducible factor 1 subunit alpha Homo sapiens 79-110 21673063-2 2011 Topotecan, a topoisomerase I inhibitor, has been shown to inhibit HIF-1alpha expression in preclinical models. Topotecan 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 66-76 21673063-3 2011 We designed a pilot trial to measure HIF-1alpha inhibition in tumor biopsies from patients with advanced solid tumors overexpressing HIF-1alpha, after treatment with oral topotecan. Topotecan 171-180 hypoxia inducible factor 1 subunit alpha Homo sapiens 37-47 21673063-14 2011 CONCLUSIONS: This multihistology, target assessment trial of a small molecule inhibitor of HIF-1alpha showed that topotecan could decrease HIF-1alpha expression in advanced solid tumors. Topotecan 114-123 hypoxia inducible factor 1 subunit alpha Homo sapiens 91-101 21673063-14 2011 CONCLUSIONS: This multihistology, target assessment trial of a small molecule inhibitor of HIF-1alpha showed that topotecan could decrease HIF-1alpha expression in advanced solid tumors. Topotecan 114-123 hypoxia inducible factor 1 subunit alpha Homo sapiens 139-149 21795476-11 2011 We show a mechanistic interaction of a PARP inhibitor, ABT-888, with a topoisomerase I inhibitor, topotecan, in PBMCs, tumor, and CTCs. Topotecan 98-107 collagen type XI alpha 2 chain Homo sapiens 39-43 21514634-2 2011 One purported mechanism of topotecan resistance is the breast cancer resistance protein (BCRP) and P-glycoprotein (Pgp). Topotecan 27-36 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 55-87 21514634-2 2011 One purported mechanism of topotecan resistance is the breast cancer resistance protein (BCRP) and P-glycoprotein (Pgp). Topotecan 27-36 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 89-93 21514634-2 2011 One purported mechanism of topotecan resistance is the breast cancer resistance protein (BCRP) and P-glycoprotein (Pgp). Topotecan 27-36 ATP binding cassette subfamily B member 1 Homo sapiens 99-113 21514634-2 2011 One purported mechanism of topotecan resistance is the breast cancer resistance protein (BCRP) and P-glycoprotein (Pgp). Topotecan 27-36 ATP binding cassette subfamily B member 1 Homo sapiens 115-118 21514634-3 2011 We designed a phase II clinical trial evaluating the efficacy and adverse event profile of concomitant topotecan and lapatinib, a small molecule pan-erbB inhibitor that can block BCRP/Pgp efflux of topotecan. Topotecan 103-112 epidermal growth factor receptor Homo sapiens 149-153 21514634-3 2011 We designed a phase II clinical trial evaluating the efficacy and adverse event profile of concomitant topotecan and lapatinib, a small molecule pan-erbB inhibitor that can block BCRP/Pgp efflux of topotecan. Topotecan 103-112 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 179-183 21514634-3 2011 We designed a phase II clinical trial evaluating the efficacy and adverse event profile of concomitant topotecan and lapatinib, a small molecule pan-erbB inhibitor that can block BCRP/Pgp efflux of topotecan. Topotecan 103-112 ATP binding cassette subfamily B member 1 Homo sapiens 184-187 21514634-3 2011 We designed a phase II clinical trial evaluating the efficacy and adverse event profile of concomitant topotecan and lapatinib, a small molecule pan-erbB inhibitor that can block BCRP/Pgp efflux of topotecan. Topotecan 198-207 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 179-183 21514634-3 2011 We designed a phase II clinical trial evaluating the efficacy and adverse event profile of concomitant topotecan and lapatinib, a small molecule pan-erbB inhibitor that can block BCRP/Pgp efflux of topotecan. Topotecan 198-207 ATP binding cassette subfamily B member 1 Homo sapiens 184-187 20580163-5 2011 At present, topotecan is the only drug approved by the US Food and Drug Administration for relapsed SCLC, and is considered the standard second-line chemotherapy in many countries. Topotecan 12-21 SCLC1 Homo sapiens 100-104 21718946-0 2011 Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography. Topotecan 113-122 phosphoglycolate phosphatase Mus musculus 18-32 21718946-0 2011 Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography. Topotecan 113-122 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 38-70 21718946-7 2011 RESULTS: The transport of [(11)C]TPT to the extracellular side was determined in MES-SA/Dx5 cells exhibiting the expressions of Pgp and BCRP at high levels. Topotecan 33-36 phosphoglycolate phosphatase Homo sapiens 128-131 21718946-7 2011 RESULTS: The transport of [(11)C]TPT to the extracellular side was determined in MES-SA/Dx5 cells exhibiting the expressions of Pgp and BCRP at high levels. Topotecan 33-36 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 136-140 21309545-1 2011 P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) combination knockout mice display disproportionately increased brain penetration of shared substrates, including topotecan and several tyrosine kinase inhibitors, compared to mice deficient for only one transporter. Topotecan 191-200 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 21309545-1 2011 P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) combination knockout mice display disproportionately increased brain penetration of shared substrates, including topotecan and several tyrosine kinase inhibitors, compared to mice deficient for only one transporter. Topotecan 191-200 phosphoglycolate phosphatase Mus musculus 16-20 21309545-1 2011 P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) combination knockout mice display disproportionately increased brain penetration of shared substrates, including topotecan and several tyrosine kinase inhibitors, compared to mice deficient for only one transporter. Topotecan 191-200 ATP-binding cassette, sub-family B (MDR/TAP), member 1B Mus musculus 21-26 21309545-1 2011 P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) combination knockout mice display disproportionately increased brain penetration of shared substrates, including topotecan and several tyrosine kinase inhibitors, compared to mice deficient for only one transporter. Topotecan 191-200 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 32-64 21309545-1 2011 P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) combination knockout mice display disproportionately increased brain penetration of shared substrates, including topotecan and several tyrosine kinase inhibitors, compared to mice deficient for only one transporter. Topotecan 191-200 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 66-70 21309545-5 2011 ABCB1 and ABCG2 contributed to similar extents to topotecan transport, which was only partly saturable. Topotecan 50-59 ATP-binding cassette, sub-family B (MDR/TAP), member 1B Mus musculus 0-5 21309545-5 2011 ABCB1 and ABCG2 contributed to similar extents to topotecan transport, which was only partly saturable. Topotecan 50-59 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 10-15 21566063-1 2011 Breast cancer resistance protein (BCRP/ABCG2) confers resistance to anticancer drugs such as 7-ethyl-10-hydroxycamptothecin (SN-38, an active metabolite of irinotecan), mitoxantrone, and topotecan. Topotecan 187-196 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-32 21566063-1 2011 Breast cancer resistance protein (BCRP/ABCG2) confers resistance to anticancer drugs such as 7-ethyl-10-hydroxycamptothecin (SN-38, an active metabolite of irinotecan), mitoxantrone, and topotecan. Topotecan 187-196 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 34-38 21566063-1 2011 Breast cancer resistance protein (BCRP/ABCG2) confers resistance to anticancer drugs such as 7-ethyl-10-hydroxycamptothecin (SN-38, an active metabolite of irinotecan), mitoxantrone, and topotecan. Topotecan 187-196 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 39-44 21566063-3 2011 YHO-13177 potentiated the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells and SN-38-resistant human lung cancer A549 (A549/SN4) cells that express BCRP, but had little effect in the parental cells. Topotecan 67-76 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 85-89 21566063-3 2011 YHO-13177 potentiated the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells and SN-38-resistant human lung cancer A549 (A549/SN4) cells that express BCRP, but had little effect in the parental cells. Topotecan 67-76 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 135-139 21566063-3 2011 YHO-13177 potentiated the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells and SN-38-resistant human lung cancer A549 (A549/SN4) cells that express BCRP, but had little effect in the parental cells. Topotecan 67-76 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 135-139 20960503-0 2011 The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan. Topotecan 157-166 neurotrophic receptor tyrosine kinase 1 Homo sapiens 14-17 21059829-6 2011 miR-21 knock-down in cell-line models has been associated with increased sensitivity to topotecan and taxol in vitro and the limitation of lung metastasis in vivo. Topotecan 88-97 microRNA 21 Homo sapiens 0-6 20875401-7 2011 Furthermore, TPT-dependent induction of p53, p21 and apoptosis were found 24-72h after treatment and were increased by PJ34 both in PARP-1 proficient and silenced cells. Topotecan 13-16 tumor protein p53 Homo sapiens 40-43 20875401-7 2011 Furthermore, TPT-dependent induction of p53, p21 and apoptosis were found 24-72h after treatment and were increased by PJ34 both in PARP-1 proficient and silenced cells. Topotecan 13-16 H3 histone pseudogene 16 Homo sapiens 45-48 20875401-7 2011 Furthermore, TPT-dependent induction of p53, p21 and apoptosis were found 24-72h after treatment and were increased by PJ34 both in PARP-1 proficient and silenced cells. Topotecan 13-16 poly(ADP-ribose) polymerase 1 Homo sapiens 132-138 21542457-6 2011 In the present study, we found that the combination of SAHA and topotecan effectively inhibited the growth of renal cancer cells by suppressing the expression of cyclin-dependent kinase (CDK) 4 and cyclin D1, and promoting retinoblastoma protein (Rb) dephosphorylation. Topotecan 64-73 cyclin dependent kinase 4 Homo sapiens 162-193 21542457-6 2011 In the present study, we found that the combination of SAHA and topotecan effectively inhibited the growth of renal cancer cells by suppressing the expression of cyclin-dependent kinase (CDK) 4 and cyclin D1, and promoting retinoblastoma protein (Rb) dephosphorylation. Topotecan 64-73 cyclin D1 Homo sapiens 198-207 20935474-8 2010 RESULTS: Topotecan significantly inhibited Cisplatin-induced Akt activation in Caov-3 cells, but not in A2780 cells. Topotecan 9-18 AKT serine/threonine kinase 1 Homo sapiens 61-64 20935474-10 2010 Topotecan inhibited not only Cisplatin-induced Akt activation but also VEGF and HIF-1alpha expression. Topotecan 0-9 AKT serine/threonine kinase 1 Homo sapiens 47-50 20935474-0 2010 Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers. Topotecan 0-9 AKT serine/threonine kinase 1 Homo sapiens 58-61 20935474-10 2010 Topotecan inhibited not only Cisplatin-induced Akt activation but also VEGF and HIF-1alpha expression. Topotecan 0-9 vascular endothelial growth factor A Homo sapiens 71-75 20935474-0 2010 Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers. Topotecan 0-9 vascular endothelial growth factor A Homo sapiens 66-70 20935474-10 2010 Topotecan inhibited not only Cisplatin-induced Akt activation but also VEGF and HIF-1alpha expression. Topotecan 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 80-90 20935474-12 2010 CONCLUSION: We herein demonstrated that Topotecan inhibits Akt kinase activity and VEGF transcriptional activation after Cisplatin treatment in platinum-resistant ovarian cancers. Topotecan 40-49 AKT serine/threonine kinase 1 Homo sapiens 59-62 20935474-12 2010 CONCLUSION: We herein demonstrated that Topotecan inhibits Akt kinase activity and VEGF transcriptional activation after Cisplatin treatment in platinum-resistant ovarian cancers. Topotecan 40-49 vascular endothelial growth factor A Homo sapiens 83-87 20655304-8 2010 Finally, cytotoxicity assays using mitoxantrone and topotecan as substrates revealed that the EC(90) values for FTC were always significantly lower in human BCRP-transduced cells. Topotecan 52-61 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 157-161 20924131-3 2010 EXPERIMENTAL DESIGN: The gammaH2AX immunofluorescence assay uses a novel data quantitation and image processing algorithm to determine the extent of nuclear-specific gammaH2AX staining in tumor needle biopsies and hair follicles collected from mice bearing topotecan-responsive A375 xenografts. Topotecan 257-266 H2A.X variant histone Mus musculus 25-34 20924131-3 2010 EXPERIMENTAL DESIGN: The gammaH2AX immunofluorescence assay uses a novel data quantitation and image processing algorithm to determine the extent of nuclear-specific gammaH2AX staining in tumor needle biopsies and hair follicles collected from mice bearing topotecan-responsive A375 xenografts. Topotecan 257-266 H2A.X variant histone Mus musculus 166-175 20924131-5 2010 RESULTS: gammaH2AX response to topotecan was quantified over a 60-fold dose range (0.016-1.0 times the murine single-dose maximum tolerated dose), and significant pharmacodynamic response was measured at the mouse equivalent of the 1.5 mg/m(2) clinical dose as well as the lowest dose tested. Topotecan 31-40 H2A.X variant histone Mus musculus 9-18 19967559-1 2010 Breast cancer resistance protein (BCRP/ABCG2), an ATP-binding cassette half transporter, confers multidrug resistance (MDR) to a series of antitumor agents such as mitoxantrone, daunorubicin, SN-38, and topotecan, and often limits the efficacy of chemotherapy. Topotecan 203-212 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-32 19967559-1 2010 Breast cancer resistance protein (BCRP/ABCG2), an ATP-binding cassette half transporter, confers multidrug resistance (MDR) to a series of antitumor agents such as mitoxantrone, daunorubicin, SN-38, and topotecan, and often limits the efficacy of chemotherapy. Topotecan 203-212 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 34-38 19967559-1 2010 Breast cancer resistance protein (BCRP/ABCG2), an ATP-binding cassette half transporter, confers multidrug resistance (MDR) to a series of antitumor agents such as mitoxantrone, daunorubicin, SN-38, and topotecan, and often limits the efficacy of chemotherapy. Topotecan 203-212 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 39-44 20716361-16 2010 Indirect evidence showed that oral topotecan was at least as good as or better than CAV on all outcomes (survival, response rates, toxicities, and symptoms) that allowed indirect comparisons, with the only exception being grade four thrombocytopenia which occurred less often on CAV treatment. Topotecan 35-44 caveolin 2 Homo sapiens 279-282 20563626-8 2010 Topotecan was shown by MTS assay to have an IC(50) for human pancreatic adenocarcinoma cells (PSN-1) of 0.22 and 0.27 microM compared to 28.1 and 19.2 microM for irinotecan at 48 and 72 h, respectively. Topotecan 0-9 5'-nucleotidase, cytosolic IIIA Homo sapiens 94-99 20812902-2 2010 BCRP was initially discovered in multidrug resistant breast cancer cell lines where it confers resistance to chemotherapeutic agents such as mitoxantrone, topotecan and methotrexate by extruding these compounds out of the cell. Topotecan 155-164 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-4 20662736-8 2010 Although mitoxantrone, ellipticine, camptothecin, and topotecan all exhibited concentration-dependent disruption of the p53-hDM2 PPIB, they were much less potent than Nutlin-3. Topotecan 54-63 tumor protein p53 Homo sapiens 120-123 20416282-3 2010 To understand the genesis of chemotherapeutic resistance to the CPT family of anticancer drugs, we examined by gene expression profiling the pharmacological response to topotecan in the human hepatoma HepG2 cells and found a striking induction of the phospholipid transfer protein (PLTP) gene expression by topotecan. Topotecan 169-178 phospholipid transfer protein Homo sapiens 282-286 20457140-6 2010 Suggested transport-independent apoptosis inhibiting activities of ATP-binding cassette (ABC)-transporters, such as the inhibition of caspases, were shown to be necessary for the inhibition of topotecan-induced apoptosis and were found to be associated with stabilization of beta-catenin especially in the cytosol. Topotecan 193-202 catenin beta 1 Homo sapiens 275-287 20662736-7 2010 Anthracycline (topoisomerase II inhibitors such as mitoxantrone and ellipticine) and camptothecin (topoisomerase I inhibitor) derivatives including topotecan induce DNA double strand breaks, which activate the p53 pathway through the ataxia telangiectasia mutated-checkpoint kinase 2 (ATM-CHK2) DNA damage response pathway. Topotecan 148-157 tumor protein p53 Homo sapiens 210-213 20662736-8 2010 Although mitoxantrone, ellipticine, camptothecin, and topotecan all exhibited concentration-dependent disruption of the p53-hDM2 PPIB, they were much less potent than Nutlin-3. Topotecan 54-63 immunoglobulin heavy diversity 1-14 (non-functional) Homo sapiens 124-128 20662736-7 2010 Anthracycline (topoisomerase II inhibitors such as mitoxantrone and ellipticine) and camptothecin (topoisomerase I inhibitor) derivatives including topotecan induce DNA double strand breaks, which activate the p53 pathway through the ataxia telangiectasia mutated-checkpoint kinase 2 (ATM-CHK2) DNA damage response pathway. Topotecan 148-157 ATM serine/threonine kinase Homo sapiens 285-293 20515774-4 2010 In vitro, two cell lines exhibiting a similar sensitivity towards Topotecan-induced cell death revealed a similar induction of p53 target genes but strongly differed in their extent of apoptosis. Topotecan 66-75 tumor protein p53 Homo sapiens 127-130 20682644-8 2010 Moreover, depleted levels of ABCG2 in these Nrf2 knockdown cells sensitized them to mitoxantrone and topotecan, two chemotherapy drugs detoxified mainly by ABCG2. Topotecan 101-110 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 29-34 20682644-8 2010 Moreover, depleted levels of ABCG2 in these Nrf2 knockdown cells sensitized them to mitoxantrone and topotecan, two chemotherapy drugs detoxified mainly by ABCG2. Topotecan 101-110 NFE2 like bZIP transcription factor 2 Homo sapiens 44-48 20682644-8 2010 Moreover, depleted levels of ABCG2 in these Nrf2 knockdown cells sensitized them to mitoxantrone and topotecan, two chemotherapy drugs detoxified mainly by ABCG2. Topotecan 101-110 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 156-161 20460504-0 2010 Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. Topotecan 45-54 TXK tyrosine kinase Homo sapiens 0-15 20460504-1 2010 Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, increases brain parenchymal extracellular fluid (ECF) accumulation of topotecan, a substrate of the ATP-binding cassette (ABC) transporters P-glycoprotein (Pgp/MDR-1) and breast cancer resistance protein (BCRP/ABCG2). Topotecan 144-153 TXK tyrosine kinase Homo sapiens 47-62 20460504-1 2010 Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, increases brain parenchymal extracellular fluid (ECF) accumulation of topotecan, a substrate of the ATP-binding cassette (ABC) transporters P-glycoprotein (Pgp/MDR-1) and breast cancer resistance protein (BCRP/ABCG2). Topotecan 144-153 phosphoglycolate phosphatase Homo sapiens 230-233 20460504-1 2010 Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, increases brain parenchymal extracellular fluid (ECF) accumulation of topotecan, a substrate of the ATP-binding cassette (ABC) transporters P-glycoprotein (Pgp/MDR-1) and breast cancer resistance protein (BCRP/ABCG2). Topotecan 144-153 ATP binding cassette subfamily B member 1 Homo sapiens 234-239 20460504-1 2010 Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, increases brain parenchymal extracellular fluid (ECF) accumulation of topotecan, a substrate of the ATP-binding cassette (ABC) transporters P-glycoprotein (Pgp/MDR-1) and breast cancer resistance protein (BCRP/ABCG2). Topotecan 144-153 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 245-277 20460504-1 2010 Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, increases brain parenchymal extracellular fluid (ECF) accumulation of topotecan, a substrate of the ATP-binding cassette (ABC) transporters P-glycoprotein (Pgp/MDR-1) and breast cancer resistance protein (BCRP/ABCG2). Topotecan 144-153 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 279-283 20460504-1 2010 Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, increases brain parenchymal extracellular fluid (ECF) accumulation of topotecan, a substrate of the ATP-binding cassette (ABC) transporters P-glycoprotein (Pgp/MDR-1) and breast cancer resistance protein (BCRP/ABCG2). Topotecan 144-153 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 284-289 20304538-5 2010 Several of these trifluoromethylated hCPT derivatives (such as 6a, 6b and 6c) possessed higher in vitro antitumor activity than topotecan (TPT). Topotecan 128-137 choline phosphotransferase 1 Homo sapiens 37-41 20304538-5 2010 Several of these trifluoromethylated hCPT derivatives (such as 6a, 6b and 6c) possessed higher in vitro antitumor activity than topotecan (TPT). Topotecan 139-142 choline phosphotransferase 1 Homo sapiens 37-41 20145144-0 2010 Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Topotecan 113-122 breast cancer 1, early onset Mus musculus 39-44 20371722-9 2010 In conclusion, oral topotecan may be an ideal agent to consider for clinical trial assessment of metronomic chemotherapy for ovarian cancer, especially when combined with an antiangiogenic drug targeting the vascular endothelial growth factor pathway, such as pazopanib. Topotecan 20-29 vascular endothelial growth factor A Homo sapiens 208-242 20038611-7 2010 Finally, we show that the combination of L-asparaginase (by specifically down-regulating Mcl-1 protein levels), topotecan (by activating p53 via DNA damage), and ABT-737 (by inhibiting antiapoptotic Bcl-2 family members) caused profound synergistic antileukemic efficacy both in vitro and in vivo. Topotecan 112-121 tumor protein p53 Homo sapiens 137-140 20145144-0 2010 Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Topotecan 113-122 transformation related protein 53, pseudogene Mus musculus 45-48 20145144-8 2010 Tumor-specific genetic ablation of Abcg2 significantly increased overall survival of topotecan-treated animals (P < 0.001), confirming the in vivo relevance of ABCG2 for topotecan resistance in a novel approach. Topotecan 85-94 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 35-40 20145144-8 2010 Tumor-specific genetic ablation of Abcg2 significantly increased overall survival of topotecan-treated animals (P < 0.001), confirming the in vivo relevance of ABCG2 for topotecan resistance in a novel approach. Topotecan 173-182 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 35-40 20208132-8 2010 In vitro, caspase-2 activation in RCC cell lines coincidenced with sensitivity of tumour cells towards Topotecan-induced apoptosis. Topotecan 103-112 caspase 2 Homo sapiens 10-19 19686789-4 2010 Anti-EGFR and anti-HER2-immunoliposomal formulations dramatically increased uptake of topotecan compared to nontargeted nanoliposomal topotecan and poorly permeable free topotecan in receptor-overexpressing cancer cell lines, with a corresponding increase in cytotoxicity in multiple breast cancer cell lines and improved antitumor activity against HER2-overexpressing human breast cancer (BT474) xenografts. Topotecan 86-95 epidermal growth factor receptor Homo sapiens 5-9 19686789-4 2010 Anti-EGFR and anti-HER2-immunoliposomal formulations dramatically increased uptake of topotecan compared to nontargeted nanoliposomal topotecan and poorly permeable free topotecan in receptor-overexpressing cancer cell lines, with a corresponding increase in cytotoxicity in multiple breast cancer cell lines and improved antitumor activity against HER2-overexpressing human breast cancer (BT474) xenografts. Topotecan 86-95 erb-b2 receptor tyrosine kinase 2 Homo sapiens 19-23 19686789-4 2010 Anti-EGFR and anti-HER2-immunoliposomal formulations dramatically increased uptake of topotecan compared to nontargeted nanoliposomal topotecan and poorly permeable free topotecan in receptor-overexpressing cancer cell lines, with a corresponding increase in cytotoxicity in multiple breast cancer cell lines and improved antitumor activity against HER2-overexpressing human breast cancer (BT474) xenografts. Topotecan 86-95 erb-b2 receptor tyrosine kinase 2 Homo sapiens 349-353 19802874-0 2009 ABCG2-associated resistance to Hoechst 33342 and topotecan in a murine cell model with constitutive expression of side population characteristics. Topotecan 49-58 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 0-5 20019844-5 2009 Furthermore, drug selection with sulfasalazine and topotecan induced a complete demethylation of the ABCG2 promoter in the T-ALL and ovarian carcinoma model cell lines CCRF-CEM and IGROV1, respectively. Topotecan 51-60 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 101-106 19812371-0 2010 Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage. Topotecan 0-9 tumor protein p53 Homo sapiens 32-35 19812371-0 2010 Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage. Topotecan 0-9 X-linked inhibitor of apoptosis Homo sapiens 78-82 19812371-0 2010 Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage. Topotecan 0-9 caspase 3 Homo sapiens 115-124 19812371-0 2010 Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage. Topotecan 0-9 BH3 interacting domain death agonist Homo sapiens 134-137 19812371-2 2010 We previously showed that TPT-induced apoptosis depends on p53 with p53 wild-type (wt) cells being more resistant because of p53-controlled degradation of topoisomerase I. Topotecan 26-29 tumor protein p53 Homo sapiens 59-62 19812371-2 2010 We previously showed that TPT-induced apoptosis depends on p53 with p53 wild-type (wt) cells being more resistant because of p53-controlled degradation of topoisomerase I. Topotecan 26-29 tumor protein p53 Homo sapiens 68-71 19812371-2 2010 We previously showed that TPT-induced apoptosis depends on p53 with p53 wild-type (wt) cells being more resistant because of p53-controlled degradation of topoisomerase I. Topotecan 26-29 tumor protein p53 Homo sapiens 68-71 19812371-8 2010 Accordingly, TPT-induced apoptosis in wt cells was increased after XIAP/survivin knockdown. Topotecan 13-16 X-linked inhibitor of apoptosis Homo sapiens 67-71 19812371-9 2010 Silencing of Bid led to reduction of TPT-triggered apoptosis. Topotecan 37-40 BH3 interacting domain death agonist Homo sapiens 13-16 19812371-12 2010 Furthermore, the knockdown of XIAP and survivin led to increased TPT-triggered apoptosis. Topotecan 65-68 X-linked inhibitor of apoptosis Homo sapiens 30-34 19812371-13 2010 Overall, the data show that p53-deficient/depleted cells are hypersensitive to TPT because they down-regulate XIAP and survivin, and thus amplify the intrinsic apoptotic pathway via caspase-3-mediated Bid cleavage. Topotecan 79-82 tumor protein p53 Homo sapiens 28-31 19812371-13 2010 Overall, the data show that p53-deficient/depleted cells are hypersensitive to TPT because they down-regulate XIAP and survivin, and thus amplify the intrinsic apoptotic pathway via caspase-3-mediated Bid cleavage. Topotecan 79-82 X-linked inhibitor of apoptosis Homo sapiens 110-114 19812371-13 2010 Overall, the data show that p53-deficient/depleted cells are hypersensitive to TPT because they down-regulate XIAP and survivin, and thus amplify the intrinsic apoptotic pathway via caspase-3-mediated Bid cleavage. Topotecan 79-82 caspase 3 Homo sapiens 182-191 19812371-13 2010 Overall, the data show that p53-deficient/depleted cells are hypersensitive to TPT because they down-regulate XIAP and survivin, and thus amplify the intrinsic apoptotic pathway via caspase-3-mediated Bid cleavage. Topotecan 79-82 BH3 interacting domain death agonist Homo sapiens 201-204 19812371-14 2010 Therefore, in gliomas harboring wild-type p53, TPT-based therapy might be improved by targeted down-regulation of XIAP and survivin. Topotecan 47-50 tumor protein p53 Homo sapiens 42-45 19812371-14 2010 Therefore, in gliomas harboring wild-type p53, TPT-based therapy might be improved by targeted down-regulation of XIAP and survivin. Topotecan 47-50 X-linked inhibitor of apoptosis Homo sapiens 114-118 19883083-4 2009 Tdp1 inhibitors have been regarded as potential therapeutics in combination with Top1 inhibitors, such as the camptothecin derivatives, topotecan, and irinotecan, which are used to treat human cancers. Topotecan 136-145 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 0-4 19796956-3 2009 Results have also shown that 2,9-bis(3-(dimethylamino)propoxy)-6-(4-(3-(dimethylamino)propoxy)phenyl)-11H-indeno[1,2-c]quinolin-11-one (17), which exhibited GI(50) of 0.60 and 0.68 microM against the growth of Hep G2 and A549, respectively, was more active than the positive topotecan and irinotecan. Topotecan 275-284 DNL-type zinc finger Homo sapiens 210-213 19802874-2 2009 Side-population cells have predicted resistance to minor groove ligands, including the DNA topoisomerase I poison topotecan. Topotecan 114-123 topoisomerase (DNA) I Mus musculus 87-106 19802874-7 2009 Hoechst 33342-resistant murine cells showed lower but significant crossresistance to topotecan, again attributable to enhanced ABCG2 expression, enabling cells to evade S-phase arrest. Topotecan 85-94 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 127-132 19148680-1 2009 PURPOSE: This study was to investigate whether the topoisomerase (Top) I inhibitor topotecan and the Top II inhibitor etoposide could modulate the hypoxia-induced HIF-1alpha expression in non-small cell lung cancer (NSCLC) cell lines. Topotecan 83-92 hypoxia inducible factor 1 subunit alpha Homo sapiens 163-173 19664333-0 2009 [Effect of topotecan on expression of aquaporin protein 5 and nuclear factor-kappaB in ovarian cancer SKOV3 cells]. Topotecan 11-20 aquaporin 5 Homo sapiens 38-57 19664333-2 2009 This study was to explore the effects of topotecan (TPT) on the expression of AQP5, nuclear factor-kappaB (NF-kappaB) and its receptor IkappaBalpha in ovarian cancer SKOV3 cells. Topotecan 41-50 aquaporin 5 Homo sapiens 78-105 19664333-2 2009 This study was to explore the effects of topotecan (TPT) on the expression of AQP5, nuclear factor-kappaB (NF-kappaB) and its receptor IkappaBalpha in ovarian cancer SKOV3 cells. Topotecan 41-50 NFKB inhibitor alpha Homo sapiens 135-147 19738426-10 2009 Pro-angiogenic regulators Hif-1alpha and VEGF levels were reduced in vitro (HeyA8 and SKOV3ip1) with topotecan independent of proteasome degradation and topoisomerase I. Topotecan 101-110 vascular endothelial growth factor A Homo sapiens 41-45 19664333-2 2009 This study was to explore the effects of topotecan (TPT) on the expression of AQP5, nuclear factor-kappaB (NF-kappaB) and its receptor IkappaBalpha in ovarian cancer SKOV3 cells. Topotecan 52-55 aquaporin 5 Homo sapiens 78-105 19664333-2 2009 This study was to explore the effects of topotecan (TPT) on the expression of AQP5, nuclear factor-kappaB (NF-kappaB) and its receptor IkappaBalpha in ovarian cancer SKOV3 cells. Topotecan 52-55 NFKB inhibitor alpha Homo sapiens 135-147 19664333-7 2009 AQP5 expression was negatively correlated to the proliferation inhibition rate of SKOV3 cells induced by TPT (r=-0.965, P<0.05), and positively correlated to NF-kappaB p65 and IkappaBalpha expression (r=0.903, 0.896, P<0.05). Topotecan 105-108 aquaporin 5 Homo sapiens 0-4 19567673-1 2009 Topotecan is a substrate of the ATP-binding cassette transporters P-glycoprotein (P-gp/MDR1) and breast cancer resistance protein (BCRP). Topotecan 0-9 phosphoglycolate phosphatase Mus musculus 82-86 19567673-1 2009 Topotecan is a substrate of the ATP-binding cassette transporters P-glycoprotein (P-gp/MDR1) and breast cancer resistance protein (BCRP). Topotecan 0-9 ATP-binding cassette, sub-family B (MDR/TAP), member 1B Mus musculus 87-91 19567673-1 2009 Topotecan is a substrate of the ATP-binding cassette transporters P-glycoprotein (P-gp/MDR1) and breast cancer resistance protein (BCRP). Topotecan 0-9 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 97-129 19567673-1 2009 Topotecan is a substrate of the ATP-binding cassette transporters P-glycoprotein (P-gp/MDR1) and breast cancer resistance protein (BCRP). Topotecan 0-9 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 131-135 19567673-6 2009 Topotecan lactone was below detectable limits in the ECF of Mdr1a/b(-/-) mice. Topotecan 0-17 ATP-binding cassette, sub-family B (MDR/TAP), member 1A Mus musculus 60-65 19567673-8 2009 Preferential active transport of topotecan lactone over topotecan carboxylate was shown in vivo by vCSF lactone-to-carboxylate area under the curve ratios for wild-type, Mdr1a/b(-/-), Bcrp1(-/-), and Mdr1a/b(-/-)Bcrp1(-/-) mice of 5.69 +/- 0.83, 3.85 +/- 0.64, 3.61 +/- 0.46, and 0.78 +/- 0.19, respectively. Topotecan 33-50 ATP-binding cassette, sub-family B (MDR/TAP), member 1A Mus musculus 170-175 19567673-8 2009 Preferential active transport of topotecan lactone over topotecan carboxylate was shown in vivo by vCSF lactone-to-carboxylate area under the curve ratios for wild-type, Mdr1a/b(-/-), Bcrp1(-/-), and Mdr1a/b(-/-)Bcrp1(-/-) mice of 5.69 +/- 0.83, 3.85 +/- 0.64, 3.61 +/- 0.46, and 0.78 +/- 0.19, respectively. Topotecan 33-50 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 184-189 19567673-8 2009 Preferential active transport of topotecan lactone over topotecan carboxylate was shown in vivo by vCSF lactone-to-carboxylate area under the curve ratios for wild-type, Mdr1a/b(-/-), Bcrp1(-/-), and Mdr1a/b(-/-)Bcrp1(-/-) mice of 5.69 +/- 0.83, 3.85 +/- 0.64, 3.61 +/- 0.46, and 0.78 +/- 0.19, respectively. Topotecan 33-50 ATP-binding cassette, sub-family B (MDR/TAP), member 1A Mus musculus 200-205 19567673-8 2009 Preferential active transport of topotecan lactone over topotecan carboxylate was shown in vivo by vCSF lactone-to-carboxylate area under the curve ratios for wild-type, Mdr1a/b(-/-), Bcrp1(-/-), and Mdr1a/b(-/-)Bcrp1(-/-) mice of 5.69 +/- 0.83, 3.85 +/- 0.64, 3.61 +/- 0.46, and 0.78 +/- 0.19, respectively. Topotecan 33-50 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 212-217 19567673-9 2009 Our results suggest that Bcrp1 and P-gp transport topotecan into vCSF and out of brain parenchyma through the blood-brain barrier. Topotecan 50-59 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 25-30 19567673-9 2009 Our results suggest that Bcrp1 and P-gp transport topotecan into vCSF and out of brain parenchyma through the blood-brain barrier. Topotecan 50-59 phosphoglycolate phosphatase Mus musculus 35-39 19363519-0 2009 Topotecan inhibits cancer cell migration by down-regulation of chemokine CC motif receptor 7 and matrix metalloproteinases. Topotecan 0-9 C-C motif chemokine receptor 7 Homo sapiens 63-92 19584228-4 2009 The activity of bevacizumab, either alone or in combination with the HIF-1alpha inhibitor topotecan, was evaluated in U251-HRE xenografts. Topotecan 90-99 hypoxia inducible factor 1, alpha subunit Mus musculus 69-79 19363519-3 2009 To verify the effect of TPT on the chemokine receptors CXCR4 and CCR7, quantitative PCR, semi-quantitative PCR and Western blot analysis were performed. Topotecan 24-27 C-X-C motif chemokine receptor 4 Homo sapiens 55-60 19363519-3 2009 To verify the effect of TPT on the chemokine receptors CXCR4 and CCR7, quantitative PCR, semi-quantitative PCR and Western blot analysis were performed. Topotecan 24-27 C-C motif chemokine receptor 7 Homo sapiens 65-69 19363519-7 2009 Additionally, TPT significantly decreased the expression of CCR7 in both MDA-MB-435 and MDA-MB-231 cells and moderately reduced the expression of CXCR4 in MDA-MB-435 cells. Topotecan 14-17 C-C motif chemokine receptor 7 Homo sapiens 60-64 19363519-7 2009 Additionally, TPT significantly decreased the expression of CCR7 in both MDA-MB-435 and MDA-MB-231 cells and moderately reduced the expression of CXCR4 in MDA-MB-435 cells. Topotecan 14-17 C-X-C motif chemokine receptor 4 Homo sapiens 146-151 19363519-8 2009 The secretion of MMPs (MMP-2, MMP-9) was also inhibited by TPT. Topotecan 59-62 matrix metallopeptidase 2 Homo sapiens 17-21 19363519-8 2009 The secretion of MMPs (MMP-2, MMP-9) was also inhibited by TPT. Topotecan 59-62 matrix metallopeptidase 2 Homo sapiens 23-28 19363519-8 2009 The secretion of MMPs (MMP-2, MMP-9) was also inhibited by TPT. Topotecan 59-62 matrix metallopeptidase 9 Homo sapiens 30-35 19363519-10 2009 CONCLUSION: TPT inhibited cancer cell migration by down-regulation of CCR7 and MMPs (MMP-2 and MMP-9). Topotecan 12-15 C-C motif chemokine receptor 7 Homo sapiens 70-74 19363519-10 2009 CONCLUSION: TPT inhibited cancer cell migration by down-regulation of CCR7 and MMPs (MMP-2 and MMP-9). Topotecan 12-15 matrix metallopeptidase 2 Homo sapiens 79-83 19363519-10 2009 CONCLUSION: TPT inhibited cancer cell migration by down-regulation of CCR7 and MMPs (MMP-2 and MMP-9). Topotecan 12-15 matrix metallopeptidase 2 Homo sapiens 85-90 19363519-10 2009 CONCLUSION: TPT inhibited cancer cell migration by down-regulation of CCR7 and MMPs (MMP-2 and MMP-9). Topotecan 12-15 matrix metallopeptidase 9 Homo sapiens 95-100 19170519-5 2009 Chemosensitivity assays against MCF-7/Topo cells revealed that the nontoxic inhibitor 6 completely reverted ABCG2-mediated topotecan resistance at concentrations >100 nM, whereas 5 showed ABCG2 independent cytotoxicity. Topotecan 123-132 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 108-113 19233938-5 2009 Pharmacokinetic studies performed using the A2780 xenograft tumor model showed that animals receiving combined intraperitoneal topotecan and an anti-vascular endothelial growth factor (VEGF) monoclonal antibody had approximately 6.5-fold higher (p = 0.0015) tumor topotecan concentrations compared with animals receiving intraperitoneal topotecan alone, whereas there was no significant (p = 0.16) difference for systemic topotecan. Topotecan 264-273 vascular endothelial growth factor A Homo sapiens 144-183 19233938-5 2009 Pharmacokinetic studies performed using the A2780 xenograft tumor model showed that animals receiving combined intraperitoneal topotecan and an anti-vascular endothelial growth factor (VEGF) monoclonal antibody had approximately 6.5-fold higher (p = 0.0015) tumor topotecan concentrations compared with animals receiving intraperitoneal topotecan alone, whereas there was no significant (p = 0.16) difference for systemic topotecan. Topotecan 264-273 vascular endothelial growth factor A Homo sapiens 185-189 19233938-5 2009 Pharmacokinetic studies performed using the A2780 xenograft tumor model showed that animals receiving combined intraperitoneal topotecan and an anti-vascular endothelial growth factor (VEGF) monoclonal antibody had approximately 6.5-fold higher (p = 0.0015) tumor topotecan concentrations compared with animals receiving intraperitoneal topotecan alone, whereas there was no significant (p = 0.16) difference for systemic topotecan. Topotecan 264-273 vascular endothelial growth factor A Homo sapiens 144-183 19233938-5 2009 Pharmacokinetic studies performed using the A2780 xenograft tumor model showed that animals receiving combined intraperitoneal topotecan and an anti-vascular endothelial growth factor (VEGF) monoclonal antibody had approximately 6.5-fold higher (p = 0.0015) tumor topotecan concentrations compared with animals receiving intraperitoneal topotecan alone, whereas there was no significant (p = 0.16) difference for systemic topotecan. Topotecan 264-273 vascular endothelial growth factor A Homo sapiens 185-189 19233938-5 2009 Pharmacokinetic studies performed using the A2780 xenograft tumor model showed that animals receiving combined intraperitoneal topotecan and an anti-vascular endothelial growth factor (VEGF) monoclonal antibody had approximately 6.5-fold higher (p = 0.0015) tumor topotecan concentrations compared with animals receiving intraperitoneal topotecan alone, whereas there was no significant (p = 0.16) difference for systemic topotecan. Topotecan 264-273 vascular endothelial growth factor A Homo sapiens 144-183 19233938-5 2009 Pharmacokinetic studies performed using the A2780 xenograft tumor model showed that animals receiving combined intraperitoneal topotecan and an anti-vascular endothelial growth factor (VEGF) monoclonal antibody had approximately 6.5-fold higher (p = 0.0015) tumor topotecan concentrations compared with animals receiving intraperitoneal topotecan alone, whereas there was no significant (p = 0.16) difference for systemic topotecan. Topotecan 264-273 vascular endothelial growth factor A Homo sapiens 185-189 19233938-6 2009 Therapeutic studies conducted with two different drugs, topotecan and cisplatin, showed that animals receiving combined intraperitoneal chemotherapy and anti-VEGF therapy displayed superior survival relative to animals treated with chemotherapy alone (i.e., cisplatin or topotecan), anti-VEGF alone, or intravenous chemotherapy with concomitant anti-VEGF therapy. Topotecan 56-65 vascular endothelial growth factor A Homo sapiens 158-162 19060920-13 2009 JNK-mediated Beclin 1 expression was also observed in topotecan-induced autophagy. Topotecan 54-63 mitogen-activated protein kinase 8 Homo sapiens 0-3 19174487-0 2009 Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Topotecan 70-79 poly(ADP-ribose) polymerase 1 Homo sapiens 14-43 19174487-5 2009 RESULTS: Addition of PARP-inhibitory concentrations of AG014699 significantly potentiated growth inhibition by both topotecan (1.5- to 2.3-fold) and temozolomide (3- to 10-fold) in vitro, with equivalent effects confirmed in clonogenic assays. Topotecan 116-125 poly(ADP-ribose) polymerase 1 Homo sapiens 21-25 19174487-10 2009 CONCLUSIONS: These data show enhancement of temozolomide and topotecan efficacy by PARP inhibition in neuroblastoma. Topotecan 61-70 poly(ADP-ribose) polymerase 1 Homo sapiens 83-87 19060920-13 2009 JNK-mediated Beclin 1 expression was also observed in topotecan-induced autophagy. Topotecan 54-63 beclin 1 Homo sapiens 13-21 19111841-1 2009 The breast cancer resistance protein, BCRP/ABCG2, is a half-molecule ATP-binding cassette transporter that facilitates the efflux of various anticancer agents from the cell, including 7-ethyl-10-hydroxycamptothecin, topotecan and mitoxantrone. Topotecan 216-225 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 4-36 18594817-12 2009 Furthermore, the CD3(+) T cells co-cultured with topotecan treated U-87 and autologous GBM tumor cells showed a significant increase in expression in IFN-gamma, a key cytokine produced by activated T cells, and accordingly enhanced tumor cytotoxicity. Topotecan 49-58 interferon gamma Homo sapiens 150-159 19111841-1 2009 The breast cancer resistance protein, BCRP/ABCG2, is a half-molecule ATP-binding cassette transporter that facilitates the efflux of various anticancer agents from the cell, including 7-ethyl-10-hydroxycamptothecin, topotecan and mitoxantrone. Topotecan 216-225 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 38-42 19111841-1 2009 The breast cancer resistance protein, BCRP/ABCG2, is a half-molecule ATP-binding cassette transporter that facilitates the efflux of various anticancer agents from the cell, including 7-ethyl-10-hydroxycamptothecin, topotecan and mitoxantrone. Topotecan 216-225 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 43-48 18805512-3 2008 We show that cells not expressing WRN are hypersensitive to the toxic effect of the topoisomerase I inhibitor topotecan, but not to the topoisomerase II inhibitor etoposide. Topotecan 110-119 WRN RecQ like helicase Homo sapiens 34-37 19032367-1 2008 ATP-binding cassette transporter G2 (ABCG2) is the most recently described transporter of the multidrug-resistance pump and it promotes resistance to anticancer drugs such as doxorubicin, mitoxantrone, topotecan, and SN-38. Topotecan 202-211 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-35 19032367-1 2008 ATP-binding cassette transporter G2 (ABCG2) is the most recently described transporter of the multidrug-resistance pump and it promotes resistance to anticancer drugs such as doxorubicin, mitoxantrone, topotecan, and SN-38. Topotecan 202-211 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 37-42 19047120-1 2008 PURPOSE: Topotecan resistance can result from drug efflux by P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) as well as survival signals initiated by epidermal growth factor receptor family members. Topotecan 9-18 phosphoglycolate phosphatase Mus musculus 61-75 19047120-1 2008 PURPOSE: Topotecan resistance can result from drug efflux by P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) as well as survival signals initiated by epidermal growth factor receptor family members. Topotecan 9-18 phosphoglycolate phosphatase Mus musculus 77-80 19047120-1 2008 PURPOSE: Topotecan resistance can result from drug efflux by P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) as well as survival signals initiated by epidermal growth factor receptor family members. Topotecan 9-18 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 86-118 19047120-1 2008 PURPOSE: Topotecan resistance can result from drug efflux by P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) as well as survival signals initiated by epidermal growth factor receptor family members. Topotecan 9-18 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 120-124 19047120-1 2008 PURPOSE: Topotecan resistance can result from drug efflux by P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) as well as survival signals initiated by epidermal growth factor receptor family members. Topotecan 9-18 epidermal growth factor receptor Mus musculus 167-199 19047120-6 2008 RESULTS: Lapatinib increased topotecan accumulation in BCRP- or Pgp-expressing cells in vitro, and the combination showed enhanced efficacy in HER2+ BT474 xenografts. Topotecan 29-38 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 55-59 18805512-5 2008 Upon topotecan treatment WRN deficient cells showed enhanced DNA replication inhibition and S-phase arrest, whereas after treatment with etoposide they showed the same cell cycle response as the wild-type. Topotecan 5-14 WRN RecQ like helicase Homo sapiens 25-28 18805512-6 2008 A considerable difference between WRN and wild-type cells was observed for DNA single- and double-strand break formation in response to topotecan. Topotecan 136-145 WRN RecQ like helicase Homo sapiens 34-37 18654741-0 2008 Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. Topotecan 133-142 ATP binding cassette subfamily B member 1 Homo sapiens 15-29 18273617-0 2008 Topotecan distribution in an anephric infant with therapy-resistant bilateral Wilms tumor with a novel germline WT1 gene mutation. Topotecan 0-9 WT1 transcription factor Homo sapiens 112-115 18654741-0 2008 Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. Topotecan 133-142 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 66-98 18654741-6 2008 CONCLUSION: The involvement of secretory transporters P-gp, MRP2 and BCRP, particularly for belotecan, as well as a low passive permeability, appears to be responsible for the low bioavailability of belotecan and topotecan. Topotecan 213-222 PGP Canis lupus familiaris 54-58 18654741-6 2008 CONCLUSION: The involvement of secretory transporters P-gp, MRP2 and BCRP, particularly for belotecan, as well as a low passive permeability, appears to be responsible for the low bioavailability of belotecan and topotecan. Topotecan 213-222 ATP binding cassette subfamily C member 2 Canis lupus familiaris 60-64 18654741-6 2008 CONCLUSION: The involvement of secretory transporters P-gp, MRP2 and BCRP, particularly for belotecan, as well as a low passive permeability, appears to be responsible for the low bioavailability of belotecan and topotecan. Topotecan 213-222 ATP binding cassette subfamily G member 2 Canis lupus familiaris 69-73 18703021-7 2008 A number of Pgp substrates (quinidine, amprenavir, irinotecan, topotecan, atorvastatin and erythromycin) induced net digoxin secretion, as did the non-Pgp substrate artemisinin. Topotecan 63-72 ATP binding cassette subfamily B member 1 Homo sapiens 12-15 18703021-9 2008 Of the compounds that increased Pgp secretion, quinidine, topotecan, atorvastatin and amprenavir pre-exposure also elevated MDR1 mRNA levels, whereas erythromycin, irinotecan and artemisinin displayed no change in transcript levels. Topotecan 58-67 ATP binding cassette subfamily B member 1 Homo sapiens 124-128 18568767-0 2008 The expression of Bcl-XL, Bcl-XS and p27Kip1 in topotecan-induced apoptosis in hepatoblastoma HepG2 cell line. Topotecan 48-57 BCL2 like 1 Homo sapiens 18-24 17922272-9 2008 MTD was reached at topotecan 0.75 mg/m(2) and carboplatin AUC5. Topotecan 19-28 metallothionein 1E Homo sapiens 0-3 18645007-0 2008 Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha. Topotecan 0-9 vascular endothelial growth factor A Homo sapiens 19-53 18645007-0 2008 Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha. Topotecan 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 144-187 18645007-4 2008 We investigated the effects of the topoisomerase I inhibitor, topotecan, on vascular endothelial growth factor (VEGF) induction by hypoxia in advanced-stage human neuroblastoma cells. Topotecan 62-71 vascular endothelial growth factor A Homo sapiens 76-110 18645007-4 2008 We investigated the effects of the topoisomerase I inhibitor, topotecan, on vascular endothelial growth factor (VEGF) induction by hypoxia in advanced-stage human neuroblastoma cells. Topotecan 62-71 vascular endothelial growth factor A Homo sapiens 112-116 18645007-5 2008 Topotecan counteracted hypoxic induction of VEGF and decreased angiogenic activity of conditioned medium from hypoxic cultures in vivo in the chick chorioallantoic membrane. Topotecan 0-9 vascular endothelial growth factor A Gallus gallus 44-48 18645007-7 2008 Topotecan-inhibitory effects on VEGF induction by hypoxia were mediated through suppression of both HIF-1alpha and HIF-2alpha protein accumulation and transactivation properties, which was specific and required ongoing RNA transcription. Topotecan 0-9 vascular endothelial growth factor A Homo sapiens 32-36 18645007-9 2008 These data provide the first evidence that topotecan is a potent inhibitor of HIF-1alpha and HIF-2alpha subunits in hypoxic neuroblastoma cells, leading to decreased VEGF expression and angiogenic activity. Topotecan 43-52 hypoxia inducible factor 1 subunit alpha Homo sapiens 78-88 18645007-9 2008 These data provide the first evidence that topotecan is a potent inhibitor of HIF-1alpha and HIF-2alpha subunits in hypoxic neuroblastoma cells, leading to decreased VEGF expression and angiogenic activity. Topotecan 43-52 endothelial PAS domain protein 1 Homo sapiens 93-103 18645007-9 2008 These data provide the first evidence that topotecan is a potent inhibitor of HIF-1alpha and HIF-2alpha subunits in hypoxic neuroblastoma cells, leading to decreased VEGF expression and angiogenic activity. Topotecan 43-52 vascular endothelial growth factor A Homo sapiens 166-170 18802408-6 2008 In the nuclei of cells treated with TPT or MXT, the expression of p53-Ser15(P) appeared as closely packed foci of intense IF. Topotecan 36-39 tumor protein p53 Homo sapiens 66-69 18802408-7 2008 Following TPT treatment, the induction of p53-Ser15(P) was most pronounced in S-phase cells while no significant cell cycle phase differences were seen in cells treated with MXT. Topotecan 10-13 tumor protein p53 Homo sapiens 42-45 18802408-8 2008 The maximal increase in p53-Ser15(P) expression, rising up to 2.5-fold above the level of its constitutive expression, was observed in cells treated with TPT or MXT for 4-6 h. This maximum expression of p53-Ser15(P) coincided in time with the peak of Chk2 activation but not with ATM activation and H2AX phosphorylation, both of which crested 1-2 h after the treatment with TPT or MXT. Topotecan 154-157 tumor protein p53 Homo sapiens 24-27 18802408-8 2008 The maximal increase in p53-Ser15(P) expression, rising up to 2.5-fold above the level of its constitutive expression, was observed in cells treated with TPT or MXT for 4-6 h. This maximum expression of p53-Ser15(P) coincided in time with the peak of Chk2 activation but not with ATM activation and H2AX phosphorylation, both of which crested 1-2 h after the treatment with TPT or MXT. Topotecan 154-157 tumor protein p53 Homo sapiens 203-206 18802408-8 2008 The maximal increase in p53-Ser15(P) expression, rising up to 2.5-fold above the level of its constitutive expression, was observed in cells treated with TPT or MXT for 4-6 h. This maximum expression of p53-Ser15(P) coincided in time with the peak of Chk2 activation but not with ATM activation and H2AX phosphorylation, both of which crested 1-2 h after the treatment with TPT or MXT. Topotecan 154-157 checkpoint kinase 2 Homo sapiens 251-255 18802408-8 2008 The maximal increase in p53-Ser15(P) expression, rising up to 2.5-fold above the level of its constitutive expression, was observed in cells treated with TPT or MXT for 4-6 h. This maximum expression of p53-Ser15(P) coincided in time with the peak of Chk2 activation but not with ATM activation and H2AX phosphorylation, both of which crested 1-2 h after the treatment with TPT or MXT. Topotecan 154-157 ATM serine/threonine kinase Homo sapiens 280-283 18802408-8 2008 The maximal increase in p53-Ser15(P) expression, rising up to 2.5-fold above the level of its constitutive expression, was observed in cells treated with TPT or MXT for 4-6 h. This maximum expression of p53-Ser15(P) coincided in time with the peak of Chk2 activation but not with ATM activation and H2AX phosphorylation, both of which crested 1-2 h after the treatment with TPT or MXT. Topotecan 154-157 H2A.X variant histone Homo sapiens 299-303 18802408-8 2008 The maximal increase in p53-Ser15(P) expression, rising up to 2.5-fold above the level of its constitutive expression, was observed in cells treated with TPT or MXT for 4-6 h. This maximum expression of p53-Ser15(P) coincided in time with the peak of Chk2 activation but not with ATM activation and H2AX phosphorylation, both of which crested 1-2 h after the treatment with TPT or MXT. Topotecan 374-377 tumor protein p53 Homo sapiens 24-27 18802408-8 2008 The maximal increase in p53-Ser15(P) expression, rising up to 2.5-fold above the level of its constitutive expression, was observed in cells treated with TPT or MXT for 4-6 h. This maximum expression of p53-Ser15(P) coincided in time with the peak of Chk2 activation but not with ATM activation and H2AX phosphorylation, both of which crested 1-2 h after the treatment with TPT or MXT. Topotecan 374-377 tumor protein p53 Homo sapiens 203-206 18802408-8 2008 The maximal increase in p53-Ser15(P) expression, rising up to 2.5-fold above the level of its constitutive expression, was observed in cells treated with TPT or MXT for 4-6 h. This maximum expression of p53-Ser15(P) coincided in time with the peak of Chk2 activation but not with ATM activation and H2AX phosphorylation, both of which crested 1-2 h after the treatment with TPT or MXT. Topotecan 374-377 checkpoint kinase 2 Homo sapiens 251-255 18802408-8 2008 The maximal increase in p53-Ser15(P) expression, rising up to 2.5-fold above the level of its constitutive expression, was observed in cells treated with TPT or MXT for 4-6 h. This maximum expression of p53-Ser15(P) coincided in time with the peak of Chk2 activation but not with ATM activation and H2AX phosphorylation, both of which crested 1-2 h after the treatment with TPT or MXT. Topotecan 374-377 ATM serine/threonine kinase Homo sapiens 280-283 18802408-8 2008 The maximal increase in p53-Ser15(P) expression, rising up to 2.5-fold above the level of its constitutive expression, was observed in cells treated with TPT or MXT for 4-6 h. This maximum expression of p53-Ser15(P) coincided in time with the peak of Chk2 activation but not with ATM activation and H2AX phosphorylation, both of which crested 1-2 h after the treatment with TPT or MXT. Topotecan 374-377 H2A.X variant histone Homo sapiens 299-303 18523872-5 2008 RESULTS: The Bcrp inhibitor Ko143 blocked topotecan and ABZSO transport in a concentration-dependent manner. Topotecan 42-51 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 13-17 18794444-3 2008 Recent studies show that imatinib reverses ABCG2-mediated drug resistance to topotecan hydrochloride and SN-38. Topotecan 77-100 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 43-48 18568767-0 2008 The expression of Bcl-XL, Bcl-XS and p27Kip1 in topotecan-induced apoptosis in hepatoblastoma HepG2 cell line. Topotecan 48-57 cyclin dependent kinase inhibitor 1B Homo sapiens 37-44 18568767-5 2008 It was shown that the expression of Bcl-XL was simultaneously down-regulated with the up-regulation of Bcl-XS in cytoplasm, which was possibly a key downstream event following the topotecan-induced DNA damage in nucleus. Topotecan 180-189 BCL2 like 1 Homo sapiens 36-42 18568767-8 2008 CONCLUSION: Topotecan had potent cytotoxicity against HepG2 cells by triggering an interphase apoptosis possibly mediated by increasing the ratio of Bcl-XS/Bcl-XL. Topotecan 12-21 BCL2 like 1 Homo sapiens 156-162 17943230-1 2008 Clinically relevant resistance to the currently approved camptothecins, irinotecan and topotecan, is poorly understood but may involve increased expression of ATP-dependent drug transporters such as ABCG2 (breast cancer resistant protein, BCRP). Topotecan 87-96 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 199-204 18459160-0 2008 Kinetics of histone H2AX phosphorylation and Chk2 activation in A549 cells treated with topotecan and mitoxantrone in relation to the cell cycle phase. Topotecan 88-97 H2A.X variant histone Homo sapiens 20-24 18459160-0 2008 Kinetics of histone H2AX phosphorylation and Chk2 activation in A549 cells treated with topotecan and mitoxantrone in relation to the cell cycle phase. Topotecan 88-97 checkpoint kinase 2 Homo sapiens 45-49 18459160-5 2008 In the present study we explored a relationship between H2AX phosphorylation and activation of checkpoint kinase 2 (Chk2) in human lung carcinoma A549 cells treated with TPT or with MXT. Topotecan 170-173 H2A.X variant histone Homo sapiens 56-60 18459160-5 2008 In the present study we explored a relationship between H2AX phosphorylation and activation of checkpoint kinase 2 (Chk2) in human lung carcinoma A549 cells treated with TPT or with MXT. Topotecan 170-173 checkpoint kinase 2 Homo sapiens 95-114 18459160-5 2008 In the present study we explored a relationship between H2AX phosphorylation and activation of checkpoint kinase 2 (Chk2) in human lung carcinoma A549 cells treated with TPT or with MXT. Topotecan 170-173 checkpoint kinase 2 Homo sapiens 116-120 18459160-8 2008 Upon treatment with TPT or MTX, the activated Chk2 presented itself in form of either minute or large IF foci in the cell"s nucleoplasm. Topotecan 20-23 checkpoint kinase 2 Homo sapiens 46-50 18459160-9 2008 H2AX phosphorylation whether induced by TPT or MXT was rapid, with the maximal rate occurring during the initial 2 h and peaking at 2 h of treatment. Topotecan 40-43 H2A.X variant histone Homo sapiens 0-4 18459160-10 2008 TPT or MXT induced Chk2 activation occurred at a distinctly slower pace, peaking at 4 h. While TPT-induced H2AX phosphorylation and Chk2 activation were maximal in S-phase cells, Chk2 activation was also much pronounced in G(2)M cells; the least affected by TPT were G(1) cells. Topotecan 0-3 checkpoint kinase 2 Homo sapiens 19-23 18459160-10 2008 TPT or MXT induced Chk2 activation occurred at a distinctly slower pace, peaking at 4 h. While TPT-induced H2AX phosphorylation and Chk2 activation were maximal in S-phase cells, Chk2 activation was also much pronounced in G(2)M cells; the least affected by TPT were G(1) cells. Topotecan 0-3 H2A.X variant histone Homo sapiens 107-111 18459160-10 2008 TPT or MXT induced Chk2 activation occurred at a distinctly slower pace, peaking at 4 h. While TPT-induced H2AX phosphorylation and Chk2 activation were maximal in S-phase cells, Chk2 activation was also much pronounced in G(2)M cells; the least affected by TPT were G(1) cells. Topotecan 0-3 checkpoint kinase 2 Homo sapiens 132-136 18459160-10 2008 TPT or MXT induced Chk2 activation occurred at a distinctly slower pace, peaking at 4 h. While TPT-induced H2AX phosphorylation and Chk2 activation were maximal in S-phase cells, Chk2 activation was also much pronounced in G(2)M cells; the least affected by TPT were G(1) cells. Topotecan 0-3 checkpoint kinase 2 Homo sapiens 132-136 18459160-10 2008 TPT or MXT induced Chk2 activation occurred at a distinctly slower pace, peaking at 4 h. While TPT-induced H2AX phosphorylation and Chk2 activation were maximal in S-phase cells, Chk2 activation was also much pronounced in G(2)M cells; the least affected by TPT were G(1) cells. Topotecan 95-98 checkpoint kinase 2 Homo sapiens 19-23 18459160-10 2008 TPT or MXT induced Chk2 activation occurred at a distinctly slower pace, peaking at 4 h. While TPT-induced H2AX phosphorylation and Chk2 activation were maximal in S-phase cells, Chk2 activation was also much pronounced in G(2)M cells; the least affected by TPT were G(1) cells. Topotecan 95-98 H2A.X variant histone Homo sapiens 107-111 18459160-10 2008 TPT or MXT induced Chk2 activation occurred at a distinctly slower pace, peaking at 4 h. While TPT-induced H2AX phosphorylation and Chk2 activation were maximal in S-phase cells, Chk2 activation was also much pronounced in G(2)M cells; the least affected by TPT were G(1) cells. Topotecan 95-98 checkpoint kinase 2 Homo sapiens 19-23 18459160-10 2008 TPT or MXT induced Chk2 activation occurred at a distinctly slower pace, peaking at 4 h. While TPT-induced H2AX phosphorylation and Chk2 activation were maximal in S-phase cells, Chk2 activation was also much pronounced in G(2)M cells; the least affected by TPT were G(1) cells. Topotecan 95-98 H2A.X variant histone Homo sapiens 107-111 17943230-1 2008 Clinically relevant resistance to the currently approved camptothecins, irinotecan and topotecan, is poorly understood but may involve increased expression of ATP-dependent drug transporters such as ABCG2 (breast cancer resistant protein, BCRP). Topotecan 87-96 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 239-243 17943230-5 2008 Expression of wild-type or mutant ABCG2 in human cell lines conferred resistance to topotecan but not to gimatecan. Topotecan 84-93 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 34-39 18086804-4 2008 BCRP substrates include numerous drugs (topotecan, nitrofurantoin, cimetidine) as well as food carcinogens (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and the vitamins riboflavin and folic acid. Topotecan 40-49 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-4 18349103-5 2008 In the presence of camptothecin or its derivative topotecan, ATP (at up to 2 mM) inhibited PARP-1/NAD-facilitated TLD religation in a dose-dependent manner. Topotecan 50-59 poly(ADP-ribose) polymerase 1 Homo sapiens 91-97 18089722-5 2007 In spite of this, we observed that NSC73306 is a transport substrate for ABCG2 that can effectively inhibit ABCG2-mediated drug transport and reverse resistance to both mitoxantrone and topotecan in ABCG2-expressing cells. Topotecan 186-195 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 73-78 18187809-4 2008 Using this approach, we discovered that semaphorin 6A (SEMA6A) is down-regulated not only in IDN5390-resistant cells but also in cells made resistant to cisplatin, topotecan, and doxorubicin, whereas no changes were noticed in paclitaxel- and gemcitabine-resistant cells. Topotecan 164-173 semaphorin 6A Homo sapiens 40-53 18187809-4 2008 Using this approach, we discovered that semaphorin 6A (SEMA6A) is down-regulated not only in IDN5390-resistant cells but also in cells made resistant to cisplatin, topotecan, and doxorubicin, whereas no changes were noticed in paclitaxel- and gemcitabine-resistant cells. Topotecan 164-173 semaphorin 6A Homo sapiens 55-61 18319332-7 2008 We showed that scFv-targeted immunoliposomes were efficiently and specifically taken up by both epithelioid and sarcomatous mesothelioma cells, but not control cells, and immunoliposomes encapsulating the small-molecule drug topotecan caused targeted killing of both types of mesothelioma cells in vitro. Topotecan 225-234 immunglobulin heavy chain variable region Homo sapiens 15-19 17506844-2 2008 Oral topotecan was given at a starting dose of 0.4 mg/m(2)/dose, twice a day (BID) for 21 consecutive days out of 28 days. Topotecan 5-14 BH3 interacting domain death agonist Homo sapiens 78-81 17914460-6 2007 Tdp1-/- mice treated with topotecan, a drug that increases levels of Top1-DNA complexes, also demonstrated significant loss of intestinal and hematopoietic progenitor cells. Topotecan 26-35 tyrosyl-DNA phosphodiesterase 1 Mus musculus 0-4 17518356-7 2007 Ketoconazole and itraconazole also effectively reversed BCRP-mediated resistance of HEK cells to topotecan. Topotecan 97-106 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 56-60 17936093-5 2007 The present method was successfully applied for demonstrating P-gp mediated transport of topotecan and its inhibition using verapamil in Caco-2 cell monolayer. Topotecan 89-98 phosphoglycolate phosphatase Homo sapiens 62-66 17936093-6 2007 The method can be used in identification of novel P-gp inhibitors for topotecan and estimating the contribution of P-gp in affecting oral bioavailability of topotecan. Topotecan 70-79 phosphoglycolate phosphatase Homo sapiens 50-54 17936093-6 2007 The method can be used in identification of novel P-gp inhibitors for topotecan and estimating the contribution of P-gp in affecting oral bioavailability of topotecan. Topotecan 157-166 phosphoglycolate phosphatase Homo sapiens 115-119 17345086-7 2007 The reversal of BCRP activity was tested by measuring the fluorescence of intracellular topotecan. Topotecan 88-97 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 16-20 17938267-5 2007 Immunoliposomal formulations of topotecan, vinorelbine, and doxorubicin each showed efficient and targeted uptake by three prostate cancer cell lines (Du-145, PC3, and LNCaP). Topotecan 32-41 chromobox 8 Homo sapiens 159-162 17975156-0 2007 P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Topotecan 133-142 phosphoglycolate phosphatase Mus musculus 0-14 17975156-0 2007 P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Topotecan 133-142 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 19-51 17975156-5 2007 RESULTS: The area under the plasma and tissue concentration-time curve (AUC) of topotecan in brains of Mdr1a/b(-/-) and Bcrp1(-/-) mice was only 1.5-fold higher compared with WT mice, but in Mdr1a/b(-/-)Bcrp1(-/-) mice, where both transporters are absent, the AUC increased by 12-fold. Topotecan 80-89 ATP-binding cassette, sub-family B (MDR/TAP), member 1A Mus musculus 103-108 17975156-5 2007 RESULTS: The area under the plasma and tissue concentration-time curve (AUC) of topotecan in brains of Mdr1a/b(-/-) and Bcrp1(-/-) mice was only 1.5-fold higher compared with WT mice, but in Mdr1a/b(-/-)Bcrp1(-/-) mice, where both transporters are absent, the AUC increased by 12-fold. Topotecan 80-89 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 120-125 17975156-5 2007 RESULTS: The area under the plasma and tissue concentration-time curve (AUC) of topotecan in brains of Mdr1a/b(-/-) and Bcrp1(-/-) mice was only 1.5-fold higher compared with WT mice, but in Mdr1a/b(-/-)Bcrp1(-/-) mice, where both transporters are absent, the AUC increased by 12-fold. Topotecan 80-89 ATP-binding cassette, sub-family B (MDR/TAP), member 1A Mus musculus 191-196 17975156-5 2007 RESULTS: The area under the plasma and tissue concentration-time curve (AUC) of topotecan in brains of Mdr1a/b(-/-) and Bcrp1(-/-) mice was only 1.5-fold higher compared with WT mice, but in Mdr1a/b(-/-)Bcrp1(-/-) mice, where both transporters are absent, the AUC increased by 12-fold. Topotecan 80-89 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 203-208 17975156-8 2007 The P-gp/BCRP inhibitor elacridar fully inhibited P-gp-mediated transport of topotecan, whereas inhibition of Bcrp1-mediated transport by elacridar was minimal. Topotecan 77-86 phosphoglycolate phosphatase Mus musculus 4-8 17975156-8 2007 The P-gp/BCRP inhibitor elacridar fully inhibited P-gp-mediated transport of topotecan, whereas inhibition of Bcrp1-mediated transport by elacridar was minimal. Topotecan 77-86 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 9-13 17975156-8 2007 The P-gp/BCRP inhibitor elacridar fully inhibited P-gp-mediated transport of topotecan, whereas inhibition of Bcrp1-mediated transport by elacridar was minimal. Topotecan 77-86 phosphoglycolate phosphatase Mus musculus 50-54 17975156-9 2007 CONCLUSIONS: Our results using Mdr1a/b(-/-)Bcrp1(-/-) mice clearly show the effect of Bcrp1 at the BBB and also show how two drug transporters act in concert to limit the brain penetration of topotecan. Topotecan 192-201 ATP-binding cassette, sub-family B (MDR/TAP), member 1A Mus musculus 31-36 17975156-9 2007 CONCLUSIONS: Our results using Mdr1a/b(-/-)Bcrp1(-/-) mice clearly show the effect of Bcrp1 at the BBB and also show how two drug transporters act in concert to limit the brain penetration of topotecan. Topotecan 192-201 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 86-91 17496931-5 2007 We demonstrate that in addition to topotecan (TPT), a known inhibitor of HIF-1alpha, UVC, but not other DNA damaging agents (cisplatin, ionizing radiation and doxorubicin), inhibited HIF-1alpha protein accumulation in a dose-dependent, p53-independent fashion. Topotecan 35-44 hypoxia inducible factor 1 subunit alpha Homo sapiens 73-83 17496931-5 2007 We demonstrate that in addition to topotecan (TPT), a known inhibitor of HIF-1alpha, UVC, but not other DNA damaging agents (cisplatin, ionizing radiation and doxorubicin), inhibited HIF-1alpha protein accumulation in a dose-dependent, p53-independent fashion. Topotecan 46-49 hypoxia inducible factor 1 subunit alpha Homo sapiens 73-83 17496931-5 2007 We demonstrate that in addition to topotecan (TPT), a known inhibitor of HIF-1alpha, UVC, but not other DNA damaging agents (cisplatin, ionizing radiation and doxorubicin), inhibited HIF-1alpha protein accumulation in a dose-dependent, p53-independent fashion. Topotecan 46-49 hypoxia inducible factor 1 subunit alpha Homo sapiens 183-193 17496931-5 2007 We demonstrate that in addition to topotecan (TPT), a known inhibitor of HIF-1alpha, UVC, but not other DNA damaging agents (cisplatin, ionizing radiation and doxorubicin), inhibited HIF-1alpha protein accumulation in a dose-dependent, p53-independent fashion. Topotecan 46-49 tumor protein p53 Homo sapiens 236-239 17556638-0 2007 Involvement of rat and human organic anion transporter 3 in the renal tubular secretion of topotecan [(S)-9-dimethylaminomethyl-10-hydroxy-camptothecin hydrochloride]. Topotecan 91-100 solute carrier family 22 member 8 Homo sapiens 29-56 17636258-5 2007 Topotecan- and paclitaxel-resistant prostate cancer lines were as sensitive to p53p-Ant-induced targeted necrosis as parental lines. Topotecan 0-9 tumor protein p53 Homo sapiens 79-83 17636258-5 2007 Topotecan- and paclitaxel-resistant prostate cancer lines were as sensitive to p53p-Ant-induced targeted necrosis as parental lines. Topotecan 0-9 solute carrier family 25 member 6 Homo sapiens 84-87 17610067-5 2007 In the sensitive cell line an upregulation of multiple E2F1- and p53-inducible proapaptotic and cell-cycle regulating target genes by Topotecan as well as TRAIL was observed. Topotecan 134-143 E2F transcription factor 1 Homo sapiens 55-59 17610067-5 2007 In the sensitive cell line an upregulation of multiple E2F1- and p53-inducible proapaptotic and cell-cycle regulating target genes by Topotecan as well as TRAIL was observed. Topotecan 134-143 tumor protein p53 Homo sapiens 65-68 17556638-8 2007 These results suggest that the urinary excretion of topotecan hydroxyl acid is accounted for by transport via OAT3, as well as glomerular filtration, in both rats and humans; therefore, drug-drug interactions involving OAT3 may cause a change in clearance of topotecan. Topotecan 52-61 solute carrier family 22 member 8 Rattus norvegicus 110-114 17556638-8 2007 These results suggest that the urinary excretion of topotecan hydroxyl acid is accounted for by transport via OAT3, as well as glomerular filtration, in both rats and humans; therefore, drug-drug interactions involving OAT3 may cause a change in clearance of topotecan. Topotecan 52-61 solute carrier family 22 member 8 Homo sapiens 219-223 17509534-5 2007 Kinetic analyses demonstrated the Michaelis-Menten constants for the hMATE1-mediated transport of tetraethylammonium, 1-methyl-4-phenylpyridinium, cimetidine, metformin, guanidine, procainamide, topotecan, estrone sulfate, acycrovir, and ganciclovir to be (in mM) 0.38, 0.10, 0.17, 0.78, 2.10, 1.23, 0.07, 0.47, 2.64, and 5.12, respectively. Topotecan 195-204 solute carrier family 47 member 1 Homo sapiens 69-75 17347325-8 2007 Basal ABCG2-ATPase activity could be stimulated by sulfasalazine, prazosin, and topotecan, known substrates of ABCG2 in cholesterol-loaded MXR-Sf9 and MXR-M cell membranes. Topotecan 80-89 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 6-11 17718196-0 2007 Antiproliferation in human EA.hy926 endothelial cells and inhibition of VEGF expression in PC-3 cells by topotecan. Topotecan 105-114 vascular endothelial growth factor A Homo sapiens 72-76 17718196-8 2007 Western blotting results showed that TPT caused an obvious increase of p53 expression and a decline of ERK expression in EA.hy926 cells. Topotecan 37-40 tumor protein p53 Homo sapiens 71-74 17718196-8 2007 Western blotting results showed that TPT caused an obvious increase of p53 expression and a decline of ERK expression in EA.hy926 cells. Topotecan 37-40 mitogen-activated protein kinase 1 Homo sapiens 103-106 17718196-9 2007 In addition, the VEGF expression of PC-3 cells is inhibited by TPT in hypoxia. Topotecan 63-66 vascular endothelial growth factor A Homo sapiens 17-21 17718196-10 2007 Altogether, inhibiting proliferation of endothelial cells and down-regulating VEGF expression in cancer cells may involve in the antiangiogenesis mechanism of TPT. Topotecan 159-162 vascular endothelial growth factor A Homo sapiens 78-82 17545533-1 2007 PURPOSE: Breast cancer resistance protein (ABCG2) substantially limits the oral bioavailability of topotecan. Topotecan 99-108 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 9-41 17545533-1 2007 PURPOSE: Breast cancer resistance protein (ABCG2) substantially limits the oral bioavailability of topotecan. Topotecan 99-108 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 43-48 17545533-2 2007 Coadministration with elacridar, an inhibitor of breast cancer resistance protein-mediated drug transport, increases the bioavailability of topotecan. Topotecan 140-149 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 49-81 17347325-8 2007 Basal ABCG2-ATPase activity could be stimulated by sulfasalazine, prazosin, and topotecan, known substrates of ABCG2 in cholesterol-loaded MXR-Sf9 and MXR-M cell membranes. Topotecan 80-89 dynein axonemal heavy chain 8 Homo sapiens 12-18 17347325-8 2007 Basal ABCG2-ATPase activity could be stimulated by sulfasalazine, prazosin, and topotecan, known substrates of ABCG2 in cholesterol-loaded MXR-Sf9 and MXR-M cell membranes. Topotecan 80-89 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 111-116 17347325-8 2007 Basal ABCG2-ATPase activity could be stimulated by sulfasalazine, prazosin, and topotecan, known substrates of ABCG2 in cholesterol-loaded MXR-Sf9 and MXR-M cell membranes. Topotecan 80-89 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 139-142 17347325-8 2007 Basal ABCG2-ATPase activity could be stimulated by sulfasalazine, prazosin, and topotecan, known substrates of ABCG2 in cholesterol-loaded MXR-Sf9 and MXR-M cell membranes. Topotecan 80-89 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 151-154 17300679-6 2007 In cycle 1, CA-125 increases in patients were carboplatin, 4/17 (24%); liposomal doxorubicin, 41/59 (69%); and topotecan, 11/60 (18%). Topotecan 111-120 mucin 16, cell surface associated Homo sapiens 12-18 17513814-1 2007 PURPOSE: Single-agent intravenous (IV) topotecan is an effective treatment for small-cell lung cancer (SCLC) after failure of first-line chemotherapy. Topotecan 39-48 SCLC1 Homo sapiens 103-107 17513814-2 2007 This open-label, randomized, phase III study compared oral and IV topotecan in patients with SCLC sensitive to initial chemotherapy. Topotecan 66-75 SCLC1 Homo sapiens 93-97 17513814-11 2007 CONCLUSION: Oral topotecan demonstrates activity and tolerability similar to IV topotecan in chemotherapy-sensitive SCLC patients and offers patients a convenient alternative to IV therapy. Topotecan 17-26 SCLC1 Homo sapiens 116-120 17375082-6 2007 ABCG2 also appears influential in the inter-patient variation and generally poor oral bioavailability of certain chemotherapeutic drugs such as topotecan. Topotecan 144-153 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-5 17300679-7 2007 In cycle 2, CA-125 increases were carboplatin, 2/16 (13%); liposomal doxorubicin, 19/37 (51%); and topotecan, 9/50 (18%). Topotecan 99-108 mucin 16, cell surface associated Homo sapiens 12-18 17300679-8 2007 In cycle 3, CA-125 increases were carboplatin, 0/12 (0%); liposomal doxorubicin, 7/23 (30%); and topotecan, 6/38 (16%). Topotecan 97-106 mucin 16, cell surface associated Homo sapiens 12-18 17300679-10 2007 The most prominent delay in CA-125 decline was in patients given liposomal doxorubicin compared with those given topotecan or carboplatin. Topotecan 113-122 mucin 16, cell surface associated Homo sapiens 28-34 17208558-0 2007 Interferon beta-mediated vessel stabilization improves delivery and efficacy of systemically administered topotecan in a murine neuroblastoma model. Topotecan 106-115 interferon beta 1, fibroblast Mus musculus 0-15 17390033-2 2007 Gefitinib and imatinib are tyrosine kinase inhibitors which have clinical activities in several malignancies and they are also potent inhibitors of breast cancer resistance protein (BCRP) transporter, which confers the resistance of topoisomerase I inhibitors including SN-38 and topotecan. Topotecan 280-289 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 148-180 17390033-2 2007 Gefitinib and imatinib are tyrosine kinase inhibitors which have clinical activities in several malignancies and they are also potent inhibitors of breast cancer resistance protein (BCRP) transporter, which confers the resistance of topoisomerase I inhibitors including SN-38 and topotecan. Topotecan 280-289 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 182-186 17323127-5 2007 ABCG2 is the most recently described of the three major multidrug-resistance pumps, and its substrates include mitoxantrone, topotecan, irinotecan, flavopiridol, and methotrexate. Topotecan 125-134 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-5 17131346-11 2007 These results suggest that at least 2 different mechanisms--inhibition of ABCG2 and/or PDGFRbeta--are involved in the synergistic interaction between imatinib and TPT, and support the use of this combination for the treatment of high-risk RMS patients. Topotecan 163-166 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 74-79 17131346-11 2007 These results suggest that at least 2 different mechanisms--inhibition of ABCG2 and/or PDGFRbeta--are involved in the synergistic interaction between imatinib and TPT, and support the use of this combination for the treatment of high-risk RMS patients. Topotecan 163-166 platelet derived growth factor receptor beta Homo sapiens 87-96 17351396-10 2007 It has been previously shown that topotecan, a topoisomerase I inhibitor, can also modulate hypoxia-induced hypoxia-inducible factor-1alpha accumulation (Rapisarda et al., Cancer Res 2003; 64:1475-1482). Topotecan 34-43 hypoxia inducible factor 1 subunit alpha Homo sapiens 108-139 17208558-14 2007 CONCLUSION: Interferon beta-mediated vessel stabilization resulted in improved intratumoral delivery of systemically administered TPT, enhancing its antitumor efficacy. Topotecan 130-133 interferon beta 1, fibroblast Mus musculus 12-27 17227902-8 2007 Increases in CA125 were also seen in topotecan-treated patients; however, fewer patients had increases (20% and 8%, respectively). Topotecan 37-46 mucin 16, cell surface associated Homo sapiens 13-18 17227902-9 2007 Overall, 15% of responding patients (CR + PR) receiving PLD and 6% receiving topotecan had elevated CA125 after two cycles of therapy. Topotecan 77-86 mucin 16, cell surface associated Homo sapiens 100-105 17227902-10 2007 For those patients achieving a partial response, 19% of PLD-treated patients and 8% of topotecan-treated patients had CA125 levels above baseline at cycle 2. Topotecan 87-96 mucin 16, cell surface associated Homo sapiens 118-123 17162470-8 2006 In summary, using a pharmacokinetic tool as a surrogate, it has been shown that the pharmacokinetic disposition of TPT improved considerably upon treatment with DPPX, a selective adenosine A1 antagonist. Topotecan 115-118 dipeptidyl peptidase like 6 Rattus norvegicus 161-165 17132110-0 2006 Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Topotecan 0-9 BCL2 apoptosis regulator Homo sapiens 75-79 17132110-0 2006 Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Topotecan 0-9 BCL2 like 12 Homo sapiens 89-96 17132110-4 2006 In the present study we investigated the expression profile of the novel apoptotic gene BCL2L12 in relation to other apoptotic genes in the human leukemic cell line HL-60, after treatment with topotecan or methotrexate. Topotecan 193-202 BCL2 like 12 Homo sapiens 88-95 17132110-7 2006 Downregulation of BCL2L12, BCL2 and FAS was observed after treatment of HL-60 cells with topotecan, while treatment with methotrexate led to downregulation of BCL2 and FAS, with no change in BCL2L12 expression. Topotecan 89-98 BCL2 like 12 Homo sapiens 18-25 17132110-7 2006 Downregulation of BCL2L12, BCL2 and FAS was observed after treatment of HL-60 cells with topotecan, while treatment with methotrexate led to downregulation of BCL2 and FAS, with no change in BCL2L12 expression. Topotecan 89-98 BCL2 apoptosis regulator Homo sapiens 18-22 17132110-7 2006 Downregulation of BCL2L12, BCL2 and FAS was observed after treatment of HL-60 cells with topotecan, while treatment with methotrexate led to downregulation of BCL2 and FAS, with no change in BCL2L12 expression. Topotecan 89-98 BCL2 apoptosis regulator Homo sapiens 27-31 16917872-5 2006 A panel of cytotoxic P-gp substrates comprising doxorubicin, vinblastine, vincristine, paclitaxel, or topotecan (a poor P-gp substrate) was used to evaluate the functional impact of G1199 variations. Topotecan 102-111 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 16917872-7 2006 In contrast, MDR1(G1199T) reduced resistance to (1/4) that of MDR1(wt) for all drugs except topotecan. Topotecan 92-101 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 16917872-7 2006 In contrast, MDR1(G1199T) reduced resistance to (1/4) that of MDR1(wt) for all drugs except topotecan. Topotecan 92-101 ATP binding cassette subfamily B member 1 Homo sapiens 62-66 16917872-8 2006 Expression of MDR1 exhibits some degree of resistance to topotecan, but 1199 variation has no impact. Topotecan 57-66 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 16917002-3 2006 ABCG2 function was determined by measuring topotecan and doxorubicin efflux using flow cytometry, in the presence and absence of the specific ABCG2 inhibitor, tryprostatin A. Topotecan 43-52 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-5 16917002-5 2006 We found that ABCG2 expression in myeloma cell lines increased after exposure to topotecan and doxorubicin, and was greater in logphase cells when compared with quiescent cells. Topotecan 81-90 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 14-19 16917002-6 2006 Myeloma patients treated with topotecan had an increase in ABCG2 mRNA and protein expression after treatment with topotecan, and at relapse. Topotecan 30-39 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 59-64 16917002-6 2006 Myeloma patients treated with topotecan had an increase in ABCG2 mRNA and protein expression after treatment with topotecan, and at relapse. Topotecan 114-123 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 59-64 17145877-10 2006 These results are consistent with the possibility that expression of Bcrp1 and P-glycoprotein at the apical side of the choroid plexus facilitates an influx transport mechanism across the blood-cerebrospinal fluid barrier, resulting in high topotecan CSF penetration. Topotecan 241-250 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 69-74 16520985-8 2006 Also, gefitinib increased intracellular topotecan accumulation in proportion to the BCRP levels. Topotecan 40-49 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 84-88 16404634-0 2006 Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Topotecan 159-168 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 75-107 16404634-7 2006 Cyclosporin A, tacrolimus and sirolimus also effectively reversed resistance of HEK cells to topotecan and mitoxantrone conferred by BCRP. Topotecan 93-102 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 133-137 16404634-0 2006 Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Topotecan 159-168 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 109-114 16714402-6 2006 In HT29/Mit cells, NiK-12192 reverted the pattern of acidification induced by topotecan. Topotecan 78-87 mitogen-activated protein kinase kinase kinase 14 Homo sapiens 19-22 16714402-7 2006 The potentiation of topotecan efficacy by NiK-12192 was documented by an increased efficacy of the combination in both the HT29 tumor xenografts, being more evident in the topotecan-resistant HT29/Mit tumor. Topotecan 20-29 mitogen-activated protein kinase kinase kinase 14 Homo sapiens 42-45 16714402-7 2006 The potentiation of topotecan efficacy by NiK-12192 was documented by an increased efficacy of the combination in both the HT29 tumor xenografts, being more evident in the topotecan-resistant HT29/Mit tumor. Topotecan 172-181 mitogen-activated protein kinase kinase kinase 14 Homo sapiens 42-45 16928820-5 2006 Nontoxic concentration of curcumin I, II, and III sensitized the ABCG2-expressing cells to mitoxantrone, topotecan, SN-38, and doxorubicin. Topotecan 105-114 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 65-70 16760673-5 2006 Unlike MXT, the treatment with TP induced ATM activation and H2AX phosphorylation almost exclusively in S-phase cells and only S phase cells underwent apoptosis. Topotecan 31-33 ATM serine/threonine kinase Homo sapiens 42-45 16760673-5 2006 Unlike MXT, the treatment with TP induced ATM activation and H2AX phosphorylation almost exclusively in S-phase cells and only S phase cells underwent apoptosis. Topotecan 31-33 H2A.X variant histone Homo sapiens 61-65 16821598-2 2006 BACKGROUND: Topotecan is able to cross the blood-brain barrier (BBB) and has been demonstrated to be active in brain metastases from small cell lung cancer (SCLC). Topotecan 12-21 SCLC1 Homo sapiens 157-161 16708050-10 2006 CYP3A4 conferred resistance to taxol, vinblastine and topotecan. Topotecan 54-63 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 16516327-4 2006 The activities of caspase 3 and 7 (marked as caspase 3/7), and caspase 8 were significantly activated by topotecan with amlodipine co-treated as the stealth liposomes. Topotecan 105-114 caspase 3 Homo sapiens 18-33 16516327-4 2006 The activities of caspase 3 and 7 (marked as caspase 3/7), and caspase 8 were significantly activated by topotecan with amlodipine co-treated as the stealth liposomes. Topotecan 105-114 caspase 3 Homo sapiens 18-27 16516327-4 2006 The activities of caspase 3 and 7 (marked as caspase 3/7), and caspase 8 were significantly activated by topotecan with amlodipine co-treated as the stealth liposomes. Topotecan 105-114 caspase 8 Homo sapiens 63-72 16651435-5 2006 In our studies, pretreatment of Abcg2(-/-) and Mdr1(a/b)(-/-) mice with gefitinib increased oral absorption and decreased systemic clearance of topotecan, a model substrate, indicating that additional transporters were inhibited. Topotecan 144-153 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 32-37 16651435-5 2006 In our studies, pretreatment of Abcg2(-/-) and Mdr1(a/b)(-/-) mice with gefitinib increased oral absorption and decreased systemic clearance of topotecan, a model substrate, indicating that additional transporters were inhibited. Topotecan 144-153 ATP-binding cassette, sub-family B (MDR/TAP), member 1B Mus musculus 47-51 16454695-0 2006 Topotecan is a substrate for multidrug resistance associated protein 4. Topotecan 0-9 ATP binding cassette subfamily C member 4 Homo sapiens 29-70 16720854-0 2006 Topotecan continuous infusion: CA-125 responses including patients pretreated with other schedules of topotecan. Topotecan 0-9 mucin 16, cell surface associated Homo sapiens 31-37 16415123-7 2006 This increase resulted in decreased sensitivity to the ABCG2 substrates mitoxantrone and topotecan. Topotecan 89-98 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 55-60 16702730-1 2006 The ATP-binding cassette transporter, ABCG2, which is expressed at high levels in the intestine and liver, functions as an efflux transporter for many drugs, including clinically used anticancer agents such as topotecan and the active metabolite of irinotecan (SN-38). Topotecan 210-219 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 38-43 16438941-3 2006 Topotecan- and gimatecan induced moderate up-regulation of TRAIL-R1 and -R2 which resulted in a different cell response to the combination in androgen-independent cells (DU-145 and PC-3). Topotecan 0-9 TNF receptor superfamily member 10a Homo sapiens 59-75 16542215-5 2006 The cellular accumulation of topotecan in H23/SN-38 cells was decreased compared with that in NCI-H23 and H23/SN-38REV cells, and treatment with reserpine (an inhibitor of ABCG2) increased the cellular accumulation of topotecan in H23/SN-38 cells. Topotecan 218-227 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 172-177 16426422-3 2006 Activation of ATM and/or H2AX phosphorylation in HL-60 or Jurkat cells treated with topotecan (Tpt) was detected immunocytochemically in relation to cell cycle phase, by multiparameter cytometry. Topotecan 84-93 ATM serine/threonine kinase Homo sapiens 14-17 16426422-3 2006 Activation of ATM and/or H2AX phosphorylation in HL-60 or Jurkat cells treated with topotecan (Tpt) was detected immunocytochemically in relation to cell cycle phase, by multiparameter cytometry. Topotecan 84-93 H2A.X variant histone Homo sapiens 25-29 16426422-3 2006 Activation of ATM and/or H2AX phosphorylation in HL-60 or Jurkat cells treated with topotecan (Tpt) was detected immunocytochemically in relation to cell cycle phase, by multiparameter cytometry. Topotecan 95-98 ATM serine/threonine kinase Homo sapiens 14-17 16426422-3 2006 Activation of ATM and/or H2AX phosphorylation in HL-60 or Jurkat cells treated with topotecan (Tpt) was detected immunocytochemically in relation to cell cycle phase, by multiparameter cytometry. Topotecan 95-98 H2A.X variant histone Homo sapiens 25-29 16426422-4 2006 Exposure to Tpt led to concurrent phosphorylation of ATM and H2AX in S-phase cells, whereas G1 cells were unaffected. Topotecan 12-15 ATM serine/threonine kinase Homo sapiens 53-56 16426422-4 2006 Exposure to Tpt led to concurrent phosphorylation of ATM and H2AX in S-phase cells, whereas G1 cells were unaffected. Topotecan 12-15 H2A.X variant histone Homo sapiens 61-65 16303243-1 2006 Breast cancer resistance protein (BCRP) is a half-molecule ATP-binding cassette transporter that pumps out various anticancer agents such as 7-ethyl-10-hydroxycamptothecin, topotecan and mitoxantrone. Topotecan 173-182 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-32 16303243-1 2006 Breast cancer resistance protein (BCRP) is a half-molecule ATP-binding cassette transporter that pumps out various anticancer agents such as 7-ethyl-10-hydroxycamptothecin, topotecan and mitoxantrone. Topotecan 173-182 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 34-38 16542215-5 2006 The cellular accumulation of topotecan in H23/SN-38 cells was decreased compared with that in NCI-H23 and H23/SN-38REV cells, and treatment with reserpine (an inhibitor of ABCG2) increased the cellular accumulation of topotecan in H23/SN-38 cells. Topotecan 29-38 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 172-177 16254058-7 2006 DX-52-1 and topotecan have been previously established as HIF-1 inhibitors. Topotecan 12-21 hypoxia inducible factor 1 subunit alpha Homo sapiens 58-63 16254058-9 2006 Topotecan inhibited HIF-1 activity only at cytotoxic concentrations and was not used in the combination study. Topotecan 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 20-25 17163259-1 2006 OBJECTIVE: To determine the feasibility and maximum tolerated dose of dose-dense topotecan as induction chemotherapy before standard therapy (carboplatin plus etoposide alone or in combination with radiotherapy) in patients with small cell lung cancer (SCLC). Topotecan 81-90 SCLC1 Homo sapiens 253-257 17163259-15 2006 CONCLUSION: The results of this phase I study suggest that a regimen of sequential dose-dense topotecan and carboplatin plus etoposide is feasible, and the preliminary activity observed in patients with SCLC warrants further investigation at a starting dose of topotecan 2.25 mg/m2/day. Topotecan 94-103 SCLC1 Homo sapiens 203-207 17163259-15 2006 CONCLUSION: The results of this phase I study suggest that a regimen of sequential dose-dense topotecan and carboplatin plus etoposide is feasible, and the preliminary activity observed in patients with SCLC warrants further investigation at a starting dose of topotecan 2.25 mg/m2/day. Topotecan 261-270 SCLC1 Homo sapiens 203-207 16454695-8 2006 BSO, MK-571, celecoxib, or diclofenac sensitised MRP4/HepG2 cells to TPT cytotoxicity and partially reversed MRP4-mediated resistance to TPT. Topotecan 137-140 ATP binding cassette subfamily C member 4 Homo sapiens 109-113 16454695-9 2006 In addition, the accumulation of TPT was significantly reduced in MRP4/HepG2 cells compared to V/HepG2 cells, and one-binding site model was found the best fit for the MRP4-mediated efflux of TPT, with an estimated K(m) of 1.66 microM and V(max) of 0.341 ng/min/106 cells. Topotecan 33-36 ATP binding cassette subfamily C member 4 Homo sapiens 66-70 16454695-9 2006 In addition, the accumulation of TPT was significantly reduced in MRP4/HepG2 cells compared to V/HepG2 cells, and one-binding site model was found the best fit for the MRP4-mediated efflux of TPT, with an estimated K(m) of 1.66 microM and V(max) of 0.341 ng/min/106 cells. Topotecan 33-36 ATP binding cassette subfamily C member 4 Homo sapiens 168-172 16454695-9 2006 In addition, the accumulation of TPT was significantly reduced in MRP4/HepG2 cells compared to V/HepG2 cells, and one-binding site model was found the best fit for the MRP4-mediated efflux of TPT, with an estimated K(m) of 1.66 microM and V(max) of 0.341 ng/min/106 cells. Topotecan 192-195 ATP binding cassette subfamily C member 4 Homo sapiens 66-70 16454695-9 2006 In addition, the accumulation of TPT was significantly reduced in MRP4/HepG2 cells compared to V/HepG2 cells, and one-binding site model was found the best fit for the MRP4-mediated efflux of TPT, with an estimated K(m) of 1.66 microM and V(max) of 0.341 ng/min/106 cells. Topotecan 192-195 ATP binding cassette subfamily C member 4 Homo sapiens 168-172 16454695-10 2006 Preincubation of MRP4/HepG2 cells with BSO (200 microM) for 24 hr, celecoxib (50 microM), or MK-571 (100 microM) for 2 hr significantly increased the accumulation of TPT over 10 min in MRP4/HepG2 cells by 28.0%, 37.3% and 32.5% (P < 0.05), respectively. Topotecan 166-169 ATP binding cassette subfamily C member 4 Homo sapiens 17-21 16454695-10 2006 Preincubation of MRP4/HepG2 cells with BSO (200 microM) for 24 hr, celecoxib (50 microM), or MK-571 (100 microM) for 2 hr significantly increased the accumulation of TPT over 10 min in MRP4/HepG2 cells by 28.0%, 37.3% and 32.5% (P < 0.05), respectively. Topotecan 166-169 ATP binding cassette subfamily C member 4 Homo sapiens 185-189 16454695-14 2006 These findings indicate that MRP4 confers resistance to TPT and TPT is the substrate for MRP4. Topotecan 56-59 ATP binding cassette subfamily C member 4 Homo sapiens 29-33 16454695-14 2006 These findings indicate that MRP4 confers resistance to TPT and TPT is the substrate for MRP4. Topotecan 64-67 ATP binding cassette subfamily C member 4 Homo sapiens 29-33 16454695-14 2006 These findings indicate that MRP4 confers resistance to TPT and TPT is the substrate for MRP4. Topotecan 64-67 ATP binding cassette subfamily C member 4 Homo sapiens 89-93 16454695-15 2006 Further studies are needed to explore the role of MRP4 in resistance to, toxicity and pharmacokinetics of TPT in cancer patients. Topotecan 106-109 ATP binding cassette subfamily C member 4 Homo sapiens 50-54 16454695-3 2006 The mechanisms for resistance to TPT are not fully defined, but increased efflux of the drug by multiple drug transporters including P-glycoprotein (PgP), multidrug resistance associated protein 1 (MRP1) and breast cancer resistance protein (BCRP) from tumor cells has been highly implicated. Topotecan 33-36 ATP binding cassette subfamily B member 1 Homo sapiens 149-152 16454695-3 2006 The mechanisms for resistance to TPT are not fully defined, but increased efflux of the drug by multiple drug transporters including P-glycoprotein (PgP), multidrug resistance associated protein 1 (MRP1) and breast cancer resistance protein (BCRP) from tumor cells has been highly implicated. Topotecan 33-36 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 242-246 16454695-4 2006 This study aimed to investigate whether overexpression of human MRP4 rendered resistance to TPT by examining the cytotoxicity profiles using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazonium bromide (MTT) assay and cellular accumulation of TPT in HepG2 cells stably overexpressing MRP4. Topotecan 92-95 ATP binding cassette subfamily C member 4 Homo sapiens 64-68 16454695-4 2006 This study aimed to investigate whether overexpression of human MRP4 rendered resistance to TPT by examining the cytotoxicity profiles using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazonium bromide (MTT) assay and cellular accumulation of TPT in HepG2 cells stably overexpressing MRP4. Topotecan 247-250 ATP binding cassette subfamily C member 4 Homo sapiens 64-68 16454695-6 2006 The intracellular accumulation of TPT and paclitaxel (a PgP substrate) by V/HepG2 and MRP4/HepG2 cells was determined by incubation of TPT with the cells and the amounts of the drug in cells were determined by validated HPLC methods. Topotecan 34-37 ATP binding cassette subfamily B member 1 Homo sapiens 56-59 16454695-6 2006 The intracellular accumulation of TPT and paclitaxel (a PgP substrate) by V/HepG2 and MRP4/HepG2 cells was determined by incubation of TPT with the cells and the amounts of the drug in cells were determined by validated HPLC methods. Topotecan 34-37 ATP binding cassette subfamily C member 4 Homo sapiens 86-90 16454695-7 2006 The study demonstrated that MRP4 conferred a 12.03- and 6.86-fold resistance to TPT in the 4- and 48-hr drug-exposure MTT assay, respectively. Topotecan 80-83 ATP binding cassette subfamily C member 4 Homo sapiens 28-32 16454695-8 2006 BSO, MK-571, celecoxib, or diclofenac sensitised MRP4/HepG2 cells to TPT cytotoxicity and partially reversed MRP4-mediated resistance to TPT. Topotecan 69-72 ATP binding cassette subfamily C member 4 Homo sapiens 49-53 16595064-2 2005 Topotecan may influence docetaxel metabolism by inhibiting the CYP3A4 enzyme. Topotecan 0-9 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 63-69 16533421-2 2006 Expression of Fhit resulted in reduced sensitivity to etoposide, doxorubicin, and topotecan. Topotecan 82-91 fragile histidine triad diadenosine triphosphatase Homo sapiens 14-18 17878748-1 2006 OBJECTIVES: Breast cancer resistance protein (BCRP) confers resistance to certain anticancer drugs such as mitoxantrone, topotecan and SN-38. Topotecan 121-130 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 12-44 17878748-1 2006 OBJECTIVES: Breast cancer resistance protein (BCRP) confers resistance to certain anticancer drugs such as mitoxantrone, topotecan and SN-38. Topotecan 121-130 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 46-50 16322308-3 2005 PARP-1-/- mouse embryonic fibroblasts were 3-fold more sensitive to topotecan than PARP-1+/+ mouse embryonic fibroblasts (GI50, 21 and 65 nmol/L, respectively). Topotecan 68-77 poly (ADP-ribose) polymerase family, member 1 Mus musculus 0-6 16322308-4 2005 AG14361 caused a >3-fold sensitization of PARP-1+/+ cells to topotecan compared with a <1.4-fold sensitization in PARP-1-/- cells. Topotecan 64-73 poly (ADP-ribose) polymerase family, member 1 Mus musculus 45-51 15895231-6 2005 In a parallel series of in vitro experiments, cell cultures were exposed to hypoxia (0.1% or 0.7% O(2)) in a hypoxic chamber or normoxia for 24 h. We found a dose-dependent downregulation of HIF-1alpha by topotecan (30-270 nM). Topotecan 205-214 hypoxia inducible factor 1 subunit alpha Homo sapiens 191-201 15895231-7 2005 The hypoxic upregulation of Glucose transporter-1 and VEGF secretion to the culture medium was inhibited by the addition of topotecan, while doses up to 270 nM had no effect on VEGF under normoxia. Topotecan 124-133 vascular endothelial growth factor A Homo sapiens 54-58 15895231-8 2005 VEGF protein levels in tumors were also reduced by topotecan. Topotecan 51-60 vascular endothelial growth factor A Homo sapiens 0-4 15895231-9 2005 These data show that the effect of topotecan is increased by transient hypoxia, and this may be a direct effect on the ability of cells to survive under hypoxia as well as an antiangiogenic effect, mediated through the HIF-1 inhibitory effect of topotecan. Topotecan 35-44 hypoxia inducible factor 1 subunit alpha Homo sapiens 219-224 15895231-9 2005 These data show that the effect of topotecan is increased by transient hypoxia, and this may be a direct effect on the ability of cells to survive under hypoxia as well as an antiangiogenic effect, mediated through the HIF-1 inhibitory effect of topotecan. Topotecan 246-255 hypoxia inducible factor 1 subunit alpha Homo sapiens 219-224 16184611-3 2005 The aim of the present study was to reveal a possible correlation between activation of ATM vis-a-vis H2AX phosphorylation, cell cycle phase, and apoptosis in cells treated with DNA topoisomerase (topo) I (topotecan; Tpt) or topo2 (mitoxantrone; Mtx) inhibitor. Topotecan 206-215 ATM serine/threonine kinase Homo sapiens 88-91 16184611-3 2005 The aim of the present study was to reveal a possible correlation between activation of ATM vis-a-vis H2AX phosphorylation, cell cycle phase, and apoptosis in cells treated with DNA topoisomerase (topo) I (topotecan; Tpt) or topo2 (mitoxantrone; Mtx) inhibitor. Topotecan 206-215 metaxin 1 Homo sapiens 246-249 16278418-0 2005 [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter. Topotecan 35-44 solute carrier family 6 member 2 Homo sapiens 92-117 16184611-3 2005 The aim of the present study was to reveal a possible correlation between activation of ATM vis-a-vis H2AX phosphorylation, cell cycle phase, and apoptosis in cells treated with DNA topoisomerase (topo) I (topotecan; Tpt) or topo2 (mitoxantrone; Mtx) inhibitor. Topotecan 206-215 H2A.X variant histone Homo sapiens 102-106 16343180-0 2005 Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells. Topotecan 42-51 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-32 16343180-1 2005 Overexpression of breast cancer resistance protein (BCRP) and mitoxantrone (MX) resistance protein can confer resistance to a variety of cytostatic drugs, such as MX, topotecan (TPT), doxorubicin, and daunorubicin. Topotecan 167-176 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 18-50 16343180-1 2005 Overexpression of breast cancer resistance protein (BCRP) and mitoxantrone (MX) resistance protein can confer resistance to a variety of cytostatic drugs, such as MX, topotecan (TPT), doxorubicin, and daunorubicin. Topotecan 167-176 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 52-56 16343180-1 2005 Overexpression of breast cancer resistance protein (BCRP) and mitoxantrone (MX) resistance protein can confer resistance to a variety of cytostatic drugs, such as MX, topotecan (TPT), doxorubicin, and daunorubicin. Topotecan 178-181 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 18-50 16343180-1 2005 Overexpression of breast cancer resistance protein (BCRP) and mitoxantrone (MX) resistance protein can confer resistance to a variety of cytostatic drugs, such as MX, topotecan (TPT), doxorubicin, and daunorubicin. Topotecan 178-181 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 52-56 16343180-2 2005 This study investigates the role of BCRP in resistance of ovarian cancer to TPT treatment. Topotecan 76-79 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 36-40 16343180-8 2005 Introduction of antisense-phosphorothioate oligonucleotide derived from BCRP mRNA into TPT-resistant cells resulted in a significant increase in the concentration of intracellular Rh123. Topotecan 87-90 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 72-76 15998509-1 2005 Human breast cancer resistance protein (BCRP/ABCG2) is an ABC-transporter that is present on the luminal membrane of intestinal epithelial cells and restricts absorption of anticancer drugs such as methotrexate, topotecan, mitoxantrone, and doxorubicin. Topotecan 212-221 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 6-38 16132345-3 2005 P-glycoprotein, breast cancer resistance protein, MRP1, and MRP2 have been implicated in resistance to various CPTs including CPT-11 (irinotecan), SN-38 (the active metabolite of CPT-11), and topotecan. Topotecan 192-201 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 16132345-3 2005 P-glycoprotein, breast cancer resistance protein, MRP1, and MRP2 have been implicated in resistance to various CPTs including CPT-11 (irinotecan), SN-38 (the active metabolite of CPT-11), and topotecan. Topotecan 192-201 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 16-48 15875186-1 2005 Breast cancer resistance protein (BCRP/ABCG2) is an ATP-binding cassette (ABC) multidrug transporter that confers resistance to various anticancer drugs like topotecan and mitoxantrone. Topotecan 158-167 ATP binding cassette subfamily G member 2 Canis lupus familiaris 0-32 15875186-1 2005 Breast cancer resistance protein (BCRP/ABCG2) is an ATP-binding cassette (ABC) multidrug transporter that confers resistance to various anticancer drugs like topotecan and mitoxantrone. Topotecan 158-167 ATP binding cassette subfamily G member 2 Canis lupus familiaris 34-38 15875186-1 2005 Breast cancer resistance protein (BCRP/ABCG2) is an ATP-binding cassette (ABC) multidrug transporter that confers resistance to various anticancer drugs like topotecan and mitoxantrone. Topotecan 158-167 ATP binding cassette subfamily G member 2 Canis lupus familiaris 39-44 16204064-0 2005 Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival. Topotecan 0-9 tumor protein p53 Homo sapiens 54-57 16204064-6 2005 We show that p53-deficient mouse embryonic fibroblasts are significantly more sensitive to topotecan than wild-type cells, displaying a higher frequency of topotecan-induced apoptosis and DNA strand breaks. Topotecan 91-100 transformation related protein 53, pseudogene Mus musculus 13-16 16204064-6 2005 We show that p53-deficient mouse embryonic fibroblasts are significantly more sensitive to topotecan than wild-type cells, displaying a higher frequency of topotecan-induced apoptosis and DNA strand breaks. Topotecan 156-165 transformation related protein 53, pseudogene Mus musculus 13-16 16204064-7 2005 Treatment of p53 wild-type cells with pifithrin-alpha, an inhibitor of the trans-activating activity of p53, caused reversal of the phenotype, making wild-type cells more sensitive to topotecan. Topotecan 184-193 tumor protein p53 Homo sapiens 13-16 16204064-7 2005 Treatment of p53 wild-type cells with pifithrin-alpha, an inhibitor of the trans-activating activity of p53, caused reversal of the phenotype, making wild-type cells more sensitive to topotecan. Topotecan 184-193 tumor protein p53 Homo sapiens 104-107 16204064-11 2005 U138 cells (p53 mutated) were significantly more sensitive to topotecan than U87 cells (p53 wild-type). Topotecan 62-71 tumor protein p53 Homo sapiens 12-15 16204064-14 2005 The data suggests that p53 causes resistance of cells to topo I inhibitors due to stimulation of topotecan-triggered topo I degradation which may impact topotecan-based cancer therapy. Topotecan 97-106 tumor protein p53 Homo sapiens 23-26 16204064-14 2005 The data suggests that p53 causes resistance of cells to topo I inhibitors due to stimulation of topotecan-triggered topo I degradation which may impact topotecan-based cancer therapy. Topotecan 153-162 tumor protein p53 Homo sapiens 23-26 15998509-1 2005 Human breast cancer resistance protein (BCRP/ABCG2) is an ABC-transporter that is present on the luminal membrane of intestinal epithelial cells and restricts absorption of anticancer drugs such as methotrexate, topotecan, mitoxantrone, and doxorubicin. Topotecan 212-221 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 40-44 15998509-1 2005 Human breast cancer resistance protein (BCRP/ABCG2) is an ABC-transporter that is present on the luminal membrane of intestinal epithelial cells and restricts absorption of anticancer drugs such as methotrexate, topotecan, mitoxantrone, and doxorubicin. Topotecan 212-221 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 45-50 15838659-3 2005 In 4-day cytotoxicity assays with mitoxantrone, topotecan, SN-38 or diflomotecan, cells transfected with wild-type R482 ABCG2 showed IC50 values up to 1.2-fold to 5-fold higher than cells expressing comparable levels of Q141K ABCG2, suggesting that the Q141K SNP affects drug transport. Topotecan 48-57 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 120-125 16108826-1 2005 Breast cancer resistance protein (BCRP) is a half-molecule ATP-binding cassette transporter that forms a functional homodimer and pumps out various anticancer agents, such as 7-ethyl-10-hydroxycamptothecin, topotecan, mitoxantrone and flavopiridol, from cells. Topotecan 207-216 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-32 16108826-1 2005 Breast cancer resistance protein (BCRP) is a half-molecule ATP-binding cassette transporter that forms a functional homodimer and pumps out various anticancer agents, such as 7-ethyl-10-hydroxycamptothecin, topotecan, mitoxantrone and flavopiridol, from cells. Topotecan 207-216 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 34-38 16108826-1 2005 Breast cancer resistance protein (BCRP) is a half-molecule ATP-binding cassette transporter that forms a functional homodimer and pumps out various anticancer agents, such as 7-ethyl-10-hydroxycamptothecin, topotecan, mitoxantrone and flavopiridol, from cells. Topotecan 207-216 ATP binding cassette subfamily A member 4 Homo sapiens 59-91 15908473-10 2005 The observed increase of topotecan exposure provides proof-of-concept for in vivo inhibition of BCRP by these agents. Topotecan 25-34 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 96-100 16061679-9 2005 In contrast, these concentrations of gefitinib caused a dose-dependent reversal of resistance to paclitaxel in CL1/Pac cells, to doxorubicin in MCF7/ADR cells, and to topotecan in CL1/Tpt and MCF7/TPT cells. Topotecan 167-176 adhesion G protein-coupled receptor L1 Homo sapiens 180-183 16061679-11 2005 Topotecan efflux was inhibited and accumulation was partially restored in CL1/Tpt and MCF7/TPT cells when cells were incubated simultaneously with gefitinib. Topotecan 0-9 adhesion G protein-coupled receptor L1 Homo sapiens 74-77 15908806-0 2005 Effect of ABCG2 genotype on the oral bioavailability of topotecan. Topotecan 56-65 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 10-15 15930297-0 2005 Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Topotecan 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 17-48 15930297-0 2005 Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Topotecan 0-9 vascular endothelial growth factor A Homo sapiens 53-87 15930297-0 2005 Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Topotecan 0-9 insulin like growth factor 1 Homo sapiens 110-138 15930297-11 2005 Topotecan blocked the IGF-I-stimulated increase in HIF-1alpha but not HIF-1beta, and this resulted in a decrease in VEGF in four neuroblastoma cell lines tested. Topotecan 0-9 insulin like growth factor 1 Homo sapiens 22-27 15930297-11 2005 Topotecan blocked the IGF-I-stimulated increase in HIF-1alpha but not HIF-1beta, and this resulted in a decrease in VEGF in four neuroblastoma cell lines tested. Topotecan 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 51-61 15743976-9 2005 Mitoxantrone and topotecan resistance by I206L and N590Y was approximately 2-fold and 0.3-fold of the wild-type BCRP resistance levels, respectively. Topotecan 17-26 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 112-116 16024616-7 2005 The hypoxia responsiveness of this construct can be blocked by treatment with agents that affect the HIF-1alpha pathways, including topotecan, 1-benzyl-3-(5"-hydroxymethyl-2"-furyl)indazole (YC-1), and flavopiridol. Topotecan 132-141 hypoxia inducible factor 1 subunit alpha Homo sapiens 101-111 15908806-1 2005 ABCG2 (BCRP/MXR/ABCP) functions as an efflux transporter for many agents, including topotecan, and the protein is expressed at high levels in the human intestine. Topotecan 84-93 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-5 15908806-1 2005 ABCG2 (BCRP/MXR/ABCP) functions as an efflux transporter for many agents, including topotecan, and the protein is expressed at high levels in the human intestine. Topotecan 84-93 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 7-11 15908806-1 2005 ABCG2 (BCRP/MXR/ABCP) functions as an efflux transporter for many agents, including topotecan, and the protein is expressed at high levels in the human intestine. Topotecan 84-93 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 12-15 15908806-1 2005 ABCG2 (BCRP/MXR/ABCP) functions as an efflux transporter for many agents, including topotecan, and the protein is expressed at high levels in the human intestine. Topotecan 84-93 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 16-20 15908806-5 2005 It is suggested that the high frequency of the A allele in certain ethnic groups may have therapeutic implications for individuals treated with topotecan or other ABCG2 substrates. Topotecan 144-153 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 163-168 15923621-10 2005 In addition, the results of the present study strongly suggest that inhibition of EGFR expression is a novel mechanism by which topotecan inhibits cell proliferation in cancer therapy. Topotecan 128-137 epidermal growth factor receptor Homo sapiens 82-86 15890420-1 2005 BACKGROUND AND PURPOSE: To elucidate the role of TP53 on differential effects of topoisomerase I inhibitor topotecan (Hycamtin on radiation sensitivity. Topotecan 107-116 tumor protein p53 Homo sapiens 49-53 15923621-5 2005 c-Jun target gene epidermal growth factor receptor (EGFR) was identified as a novel gene whose expression was specifically inhibited by topotecan. Topotecan 136-145 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 0-5 15923621-5 2005 c-Jun target gene epidermal growth factor receptor (EGFR) was identified as a novel gene whose expression was specifically inhibited by topotecan. Topotecan 136-145 epidermal growth factor receptor Homo sapiens 18-50 15923621-5 2005 c-Jun target gene epidermal growth factor receptor (EGFR) was identified as a novel gene whose expression was specifically inhibited by topotecan. Topotecan 136-145 epidermal growth factor receptor Homo sapiens 52-56 15923621-6 2005 Moreover, Topo I overexpression supported c-Jun-mediated reporter gene activation and both genetic and chemical inhibition of c-Jun converted cells resistant to topotecan-elicited EGFR downregulation. Topotecan 161-170 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 126-131 15923621-6 2005 Moreover, Topo I overexpression supported c-Jun-mediated reporter gene activation and both genetic and chemical inhibition of c-Jun converted cells resistant to topotecan-elicited EGFR downregulation. Topotecan 161-170 epidermal growth factor receptor Homo sapiens 180-184 15923621-7 2005 Topotecan-elicited suppression of proliferation was rescued by exogenously expressed EGFR. Topotecan 0-9 epidermal growth factor receptor Homo sapiens 85-89 15890420-1 2005 BACKGROUND AND PURPOSE: To elucidate the role of TP53 on differential effects of topoisomerase I inhibitor topotecan (Hycamtin on radiation sensitivity. Topotecan 118-126 tumor protein p53 Homo sapiens 49-53 15846298-7 2005 Combination of HGS-ETR1 with chemotherapeutic agents (topotecan, 5-fluorouracil, and irinotecan) in three independent colon cancer xenograft models resulted in an enhanced antitumour efficacy compared to either agent alone. Topotecan 54-63 CUGBP Elav-like family member 3 Homo sapiens 19-23 15890420-4 2005 Phosphorylation of TP53 and expression of p21(WAF1/CIP1) was induced by IR and/or topotecan in CCD32 cells, and in U118 cells after topotecan treatment, accompanied by cyclin B degradation. Topotecan 82-91 tumor protein p53 Homo sapiens 19-23 15890420-4 2005 Phosphorylation of TP53 and expression of p21(WAF1/CIP1) was induced by IR and/or topotecan in CCD32 cells, and in U118 cells after topotecan treatment, accompanied by cyclin B degradation. Topotecan 82-91 cyclin dependent kinase inhibitor 1A Homo sapiens 42-45 15890420-4 2005 Phosphorylation of TP53 and expression of p21(WAF1/CIP1) was induced by IR and/or topotecan in CCD32 cells, and in U118 cells after topotecan treatment, accompanied by cyclin B degradation. Topotecan 82-91 cyclin dependent kinase inhibitor 1A Homo sapiens 46-50 15890420-4 2005 Phosphorylation of TP53 and expression of p21(WAF1/CIP1) was induced by IR and/or topotecan in CCD32 cells, and in U118 cells after topotecan treatment, accompanied by cyclin B degradation. Topotecan 82-91 cyclin dependent kinase inhibitor 1A Homo sapiens 51-55 15890420-4 2005 Phosphorylation of TP53 and expression of p21(WAF1/CIP1) was induced by IR and/or topotecan in CCD32 cells, and in U118 cells after topotecan treatment, accompanied by cyclin B degradation. Topotecan 132-141 tumor protein p53 Homo sapiens 19-23 15890420-4 2005 Phosphorylation of TP53 and expression of p21(WAF1/CIP1) was induced by IR and/or topotecan in CCD32 cells, and in U118 cells after topotecan treatment, accompanied by cyclin B degradation. Topotecan 132-141 cyclin dependent kinase inhibitor 1A Homo sapiens 42-45 15890420-4 2005 Phosphorylation of TP53 and expression of p21(WAF1/CIP1) was induced by IR and/or topotecan in CCD32 cells, and in U118 cells after topotecan treatment, accompanied by cyclin B degradation. Topotecan 132-141 cyclin dependent kinase inhibitor 1A Homo sapiens 46-50 15890420-4 2005 Phosphorylation of TP53 and expression of p21(WAF1/CIP1) was induced by IR and/or topotecan in CCD32 cells, and in U118 cells after topotecan treatment, accompanied by cyclin B degradation. Topotecan 132-141 cyclin dependent kinase inhibitor 1A Homo sapiens 51-55 15890420-5 2005 In U87 cells only 1 microM topotecan generated phosphorylation of TP53 and p21(WAF1/CIP1) expression; 0.05 microM caused stabilization of cyclin B. Topotecan 27-36 small nucleolar RNA, C/D box 87 Homo sapiens 3-6 15890420-5 2005 In U87 cells only 1 microM topotecan generated phosphorylation of TP53 and p21(WAF1/CIP1) expression; 0.05 microM caused stabilization of cyclin B. Topotecan 27-36 tumor protein p53 Homo sapiens 66-70 15890420-5 2005 In U87 cells only 1 microM topotecan generated phosphorylation of TP53 and p21(WAF1/CIP1) expression; 0.05 microM caused stabilization of cyclin B. Topotecan 27-36 cyclin dependent kinase inhibitor 1A Homo sapiens 75-78 15890420-5 2005 In U87 cells only 1 microM topotecan generated phosphorylation of TP53 and p21(WAF1/CIP1) expression; 0.05 microM caused stabilization of cyclin B. Topotecan 27-36 cyclin dependent kinase inhibitor 1A Homo sapiens 79-83 15890420-5 2005 In U87 cells only 1 microM topotecan generated phosphorylation of TP53 and p21(WAF1/CIP1) expression; 0.05 microM caused stabilization of cyclin B. Topotecan 27-36 cyclin dependent kinase inhibitor 1A Homo sapiens 84-88 15890420-7 2005 Thus, the impact of TP53 on the topotecan response remains indistinct, and is obviously influenced by other genomic alterations acquired by tumor cells. Topotecan 32-41 tumor protein p53 Homo sapiens 20-24 15735043-6 2005 The topotecan transport study was done using the plasma membrane vesicles of PC-6/SN2-5H cells. Topotecan 4-13 proprotein convertase subtilisin/kexin type 5 Homo sapiens 77-81 15608138-5 2005 Chrysin (50 microM) and BF (5 microM) significantly inhibited the BCRP-mediated transport of topotecan in BCRP-overexpressing MCF-7 MX100 cells (MCF-7 cells selected with mitoxantrone) to a level comparable to that observed with 10 microM fumitremorgin C (a potent BCRP inhibitor). Topotecan 93-102 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 66-70 15608138-5 2005 Chrysin (50 microM) and BF (5 microM) significantly inhibited the BCRP-mediated transport of topotecan in BCRP-overexpressing MCF-7 MX100 cells (MCF-7 cells selected with mitoxantrone) to a level comparable to that observed with 10 microM fumitremorgin C (a potent BCRP inhibitor). Topotecan 93-102 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 106-110 15608138-5 2005 Chrysin (50 microM) and BF (5 microM) significantly inhibited the BCRP-mediated transport of topotecan in BCRP-overexpressing MCF-7 MX100 cells (MCF-7 cells selected with mitoxantrone) to a level comparable to that observed with 10 microM fumitremorgin C (a potent BCRP inhibitor). Topotecan 93-102 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 106-110 15700043-9 2005 Furthermore, topotecan treatment significantly decreased the amount of the activated form of Akt, and enhanced the expression of dCK (+155.0 and +115.3% in A549 and Calu-6 cells, respectively), potentially facilitating gemcitabine activity. Topotecan 13-22 AKT serine/threonine kinase 1 Homo sapiens 93-96 15700043-9 2005 Furthermore, topotecan treatment significantly decreased the amount of the activated form of Akt, and enhanced the expression of dCK (+155.0 and +115.3% in A549 and Calu-6 cells, respectively), potentially facilitating gemcitabine activity. Topotecan 13-22 sticky Drosophila melanogaster 129-132 15700043-11 2005 The gemcitabine --> topotecan sequence is antagonistic while drug synergism is obtained with the simultaneous and the sequential topotecan --> gemcitabine combinations, which are associated with induction of decreased Akt phosphorylation and increased dCK expression. Topotecan 132-141 AKT serine/threonine kinase 1 Homo sapiens 224-227 15837759-0 2005 Serum cystatin C is a better marker of topotecan clearance than serum creatinine. Topotecan 39-48 cystatin C Homo sapiens 6-16 15837759-8 2005 RESULTS: Using the building data set, four covariates significantly decreased the objective function value and interindividual variability on topotecan clearance (CL) when tested individually: ideal body weight (IBW), serum creatinine, age, and cystatin C level. Topotecan 142-151 cystatin C Homo sapiens 245-255 15735043-9 2005 Furthermore, gefitinib inhibited the topotecan transport into the vesicles, and the K(i) value was 1.01 +/- 0.09 micromol/L in the Dixon plot analysis, indicating direct inhibition of BCRP by gefitinib. Topotecan 37-46 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 184-188 15685169-2 2005 Here we show that the multidrug transporter BCRP (encoded by ABCG2) is strongly induced in the mammary gland of mice, cows and humans during lactation and that it is responsible for the active secretion of clinically and toxicologically important substrates such as the dietary carcinogen PhIP, the anticancer drug topotecan and the antiulcerative cimetidine into mouse milk. Topotecan 315-324 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 44-48 15661210-8 2005 We found that Bcl-x(L) expression conferred resistance to chemotherapy-induced apoptosis resulting from treatment with cisplatin, paclitaxel, topotecan, and gemcitabine in vitro. Topotecan 142-151 BCL2 like 1 Homo sapiens 14-22 15661210-9 2005 In a xenograft model, Bcl-x(L) expressing tumors continued to grow following treatment with cisplatin, paclitaxel, topotecan, and gemcitabine, in contrast to control tumors, which disappeared. Topotecan 115-124 BCL2 like 1 Homo sapiens 22-30 15735921-12 2005 CONCLUSION: Paclitaxel and topotecan with G-CSF support exhibits modest activity in adults with recurrent or refractory glioblastoma and anaplastic astrocytoma. Topotecan 27-36 colony stimulating factor 3 Homo sapiens 42-47 15685169-2 2005 Here we show that the multidrug transporter BCRP (encoded by ABCG2) is strongly induced in the mammary gland of mice, cows and humans during lactation and that it is responsible for the active secretion of clinically and toxicologically important substrates such as the dietary carcinogen PhIP, the anticancer drug topotecan and the antiulcerative cimetidine into mouse milk. Topotecan 315-324 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 61-66 15813675-2 2005 Cancer cells overexpressing the ABCG2 gene show multidrug resistance to mitoxantrone-, methotrexate-, doxorubicin-, and camptothecin-based anticancer drugs, such as topotecan and SN-38. Topotecan 165-174 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 32-37 16273129-10 2005 In contrast, there was a slight increase in SOD and a significant increase in GPx and catalase activity in MCF-7 cells incubated with Topotecan compared to the control. Topotecan 134-143 catalase Homo sapiens 86-94 15695404-1 2005 Breast cancer resistance protein (BCRP)/ABCG2 mediates concurrent resistance to chemotherapeutic agents, such as 7-ethyl-10-hydroxycamptothecin (SN-38), mitoxantrone, and topotecan, by pumping them out of cells. Topotecan 171-180 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-32 15695404-1 2005 Breast cancer resistance protein (BCRP)/ABCG2 mediates concurrent resistance to chemotherapeutic agents, such as 7-ethyl-10-hydroxycamptothecin (SN-38), mitoxantrone, and topotecan, by pumping them out of cells. Topotecan 171-180 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 34-38 15695404-1 2005 Breast cancer resistance protein (BCRP)/ABCG2 mediates concurrent resistance to chemotherapeutic agents, such as 7-ethyl-10-hydroxycamptothecin (SN-38), mitoxantrone, and topotecan, by pumping them out of cells. Topotecan 171-180 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 40-45 15611638-5 2005 During apoptosis of carcinoma HeLa cells and leukemic HL-60 or Jurkat cells triggered either by the DNA topoisomerase 1 inhibitor topotecan (TPT) or by oxidative stress (H2O2), the cells become reactive with Ph-F. Their Ph-F derived fluorescence was measured by flow and laser scanning cytometry. Topotecan 130-139 DNA topoisomerase I Homo sapiens 100-119 15719269-0 2005 In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma. Topotecan 20-29 TNF superfamily member 10 Homo sapiens 56-61 15719269-0 2005 In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma. Topotecan 20-29 TNF superfamily member 10 Homo sapiens 62-67 15719269-4 2005 Our data show that gliomas preferentially express TRAIL R2 and that treatment with topotecan, a topoisomerase I inhibitor, significantly up-regulates its expression as detected by flow cytometry and western blotting. Topotecan 83-92 TNF receptor superfamily member 10b Homo sapiens 50-58 15719269-5 2005 Moreover, in most cases, treatment with topotecan resulted in an increased sensitivity to TRAIL-dependent apoptosis, although cyclohexymide had to be added to induce apoptosis. Topotecan 40-49 TNF superfamily member 10 Homo sapiens 90-95 15949127-12 2005 Although there was some decrease in SOD and CAT activities in the topotecan-treated groups, differences from the control group were not significant. Topotecan 66-75 catalase Oryctolagus cuniculus 44-47 16127286-1 2005 OBJECTIVE: Since the p53 gene has been identified as a determinant of response to chemotherapy in ovarian carcinoma in previous studies, we investigated the significance of the p53 status in response to topotecan as second-line therapy. Topotecan 203-212 tumor protein p53 Homo sapiens 177-180 16127286-4 2005 RESULTS: Wild-type p53 tumors responsive to first-line therapy maintained substantial responsiveness to topotecan. Topotecan 104-113 tumor protein p53 Homo sapiens 19-22 16127286-7 2005 This outcome is consistent with the clinical observation that the efficacy of topotecan in the treatment of relapsed ovarian carcinoma patients is dependent on platinum sensitivity, because platinum-sensitive tumors are expected to carry wild-type p53. Topotecan 78-87 tumor protein p53 Homo sapiens 248-251 15569250-9 2004 zVAD-fmk, a caspase inhibitor and brain-derived neurotrophic factor (BDNF), but not MK-801, a non-competitive NMDA receptor antagonist, significantly reduced vincristine- or topotecan-induced cell death. Topotecan 174-183 brain-derived neurotrophic factor Rattus norvegicus 34-67 15604285-5 2004 Surprisingly, the RNase L-deficient cells were also highly resistant to apoptosis by combination treatments with a topoisomerase (Topo) I inhibitor (camptothecin, topotecan, or SN-38) and tumor necrosis factor-related apoptosis-inducing ligand [TRAIL (Apo2L)]. Topotecan 163-172 ribonuclease L Homo sapiens 18-25 15569250-9 2004 zVAD-fmk, a caspase inhibitor and brain-derived neurotrophic factor (BDNF), but not MK-801, a non-competitive NMDA receptor antagonist, significantly reduced vincristine- or topotecan-induced cell death. Topotecan 174-183 brain-derived neurotrophic factor Rattus norvegicus 69-73 15569250-8 2004 In cerebellar granule neurons, vincristine and to a lesser extent topotecan induced caspase 3 and caspase 9 cleavage, and enhanced caspase activity and Akt-dependent expression of phosphorylated BAD. Topotecan 66-75 caspase 3 Rattus norvegicus 84-93 15466170-0 2004 Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Topotecan 121-130 hypoxia inducible factor 1 subunit alpha Homo sapiens 33-64 15569250-8 2004 In cerebellar granule neurons, vincristine and to a lesser extent topotecan induced caspase 3 and caspase 9 cleavage, and enhanced caspase activity and Akt-dependent expression of phosphorylated BAD. Topotecan 66-75 caspase 9 Rattus norvegicus 98-107 15569250-8 2004 In cerebellar granule neurons, vincristine and to a lesser extent topotecan induced caspase 3 and caspase 9 cleavage, and enhanced caspase activity and Akt-dependent expression of phosphorylated BAD. Topotecan 66-75 caspase 9 Rattus norvegicus 84-91 15569250-8 2004 In cerebellar granule neurons, vincristine and to a lesser extent topotecan induced caspase 3 and caspase 9 cleavage, and enhanced caspase activity and Akt-dependent expression of phosphorylated BAD. Topotecan 66-75 AKT serine/threonine kinase 1 Rattus norvegicus 152-155 15634651-5 2004 As a functional consequence, knockdown of BCRP by siRNAs increased the sensitivity of human choriocarcinoma BeWo cells to mitoxantrone and topotecan by 10.5- and 8.2-fold, respectively. Topotecan 139-148 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 42-46 15364966-6 2004 CONCLUSION: The GCIG CA-125 response criteria are a better prognostic tool than RECIST in second-line treatment with topotecan or paclitaxel plus carboplatin in patients with ovarian carcinoma. Topotecan 117-126 mucin 16, cell surface associated Homo sapiens 21-27 15466170-1 2004 We have previously shown that topotecan, a topoisomerase I poison, inhibits hypoxia-inducible factor (HIF)-1alpha protein accumulation by a DNA damage-independent mechanism. Topotecan 30-39 hypoxia inducible factor 1 subunit alpha Homo sapiens 76-113 15466170-2 2004 Here, we report that daily administration of topotecan inhibits HIF-1alpha protein expression in U251-HRE glioblastoma xenografts. Topotecan 45-54 hypoxia inducible factor 1 subunit alpha Homo sapiens 64-74 15466170-3 2004 Concomitant with HIF-1alpha inhibition, topotecan caused a significant tumor growth inhibition associated with a marked decrease of angiogenesis and expression of HIF-1 target genes in tumor tissue. Topotecan 40-49 hypoxia inducible factor 1 subunit alpha Homo sapiens 17-27 15466170-3 2004 Concomitant with HIF-1alpha inhibition, topotecan caused a significant tumor growth inhibition associated with a marked decrease of angiogenesis and expression of HIF-1 target genes in tumor tissue. Topotecan 40-49 hypoxia inducible factor 1 subunit alpha Homo sapiens 17-22 15724841-0 2004 Implications of p53 in growth arrest and apoptosis on combined treatment of human Mammary epithelial cells with topotecan and UCN-01. Topotecan 112-121 tumor protein p53 Homo sapiens 16-19 15367706-7 2004 Gefitinib increased intracellular accumulation of topotecan in K562/BCRP cells and suppressed ATP-dependent transport of estrone 3-sulfate, a substrate of BCRP, in membrane vesicles from K562/BCRP cells. Topotecan 50-59 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 68-72 15314169-0 2004 Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Topotecan 27-36 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 Mus musculus 0-4 15314169-4 2004 Further studies demonstrated that topotecan was an Mrp4 substrate and that cells overexpressing Mrp4 were resistant to its cytotoxic effects. Topotecan 34-43 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 Mus musculus 51-55 15314169-4 2004 Further studies demonstrated that topotecan was an Mrp4 substrate and that cells overexpressing Mrp4 were resistant to its cytotoxic effects. Topotecan 34-43 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 Mus musculus 96-100 15314169-7 2004 The topotecan resistance of cells overexpressing Mrp4 and the polarized expression of Mrp4 in the choroid plexus and brain capillary endothelial cells indicate that Mrp4 has a dual role in protecting the brain from cytotoxins and suggest that the therapeutic efficacy of central nervous system-directed drugs that are Mrp4 substrates may be improved by developing Mrp4 inhibitors. Topotecan 4-13 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 Mus musculus 49-53 15724841-4 2004 In this study, we report the implication of p53 on growth arrest and apoptosis following the combined treatment of human mammary epithelial cells with topotecan, a specific topoisomerase I inhibitor, and UCN-01. Topotecan 151-160 tumor protein p53 Homo sapiens 44-47 15724841-9 2004 Detailed cell-cycle analyses revealed that UCN-01 abrogated S-phase accumulation induced by topotecan treatment in p53 defective MDA231 tumor cells and HMEC/E6 cells. Topotecan 92-101 tumor protein p53 Homo sapiens 115-118 15724841-12 2004 These data indicate that UCN-01 selectively enhances topotecan cytotoxicity in p53 defective cells through the induction of apoptotic signaling pathway(s), although the time course for the induction of cell death is not the same. Topotecan 53-62 tumor protein p53 Homo sapiens 79-82 15724841-13 2004 UCN-01 may, therefore, provide a new modality for topotecan-based therapy, particularly in p53 defective cancer patients. Topotecan 50-59 tumor protein p53 Homo sapiens 91-94 15367706-1 2004 Breast cancer resistance protein (BCRP) is an ATP binding cassette transporter that confers resistance to a series of anticancer agents such as 7-ethyl-10-hydroxycamptothecin (SN-38), topotecan, and mitoxantrone. Topotecan 184-193 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-32 15367706-1 2004 Breast cancer resistance protein (BCRP) is an ATP binding cassette transporter that confers resistance to a series of anticancer agents such as 7-ethyl-10-hydroxycamptothecin (SN-38), topotecan, and mitoxantrone. Topotecan 184-193 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 34-38 15059881-0 2004 Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Topotecan 99-108 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 47-52 15310781-9 2004 The desired CSF topotecan exposure was achieved in seven of eight pharmacokinetic studies when the topotecan plasma AUC was within target range. Topotecan 16-25 colony stimulating factor 2 Homo sapiens 12-15 15310781-9 2004 The desired CSF topotecan exposure was achieved in seven of eight pharmacokinetic studies when the topotecan plasma AUC was within target range. Topotecan 99-108 colony stimulating factor 2 Homo sapiens 12-15 15205350-1 2004 Breast cancer resistance protein (BCRP), also called ABCG2, confers resistance to anticancer agents such as 7-ethyl-10-hydroxycamptothecin (SN-38), mitoxantrone, and topotecan. Topotecan 166-175 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-32 15205350-1 2004 Breast cancer resistance protein (BCRP), also called ABCG2, confers resistance to anticancer agents such as 7-ethyl-10-hydroxycamptothecin (SN-38), mitoxantrone, and topotecan. Topotecan 166-175 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 34-38 15205350-1 2004 Breast cancer resistance protein (BCRP), also called ABCG2, confers resistance to anticancer agents such as 7-ethyl-10-hydroxycamptothecin (SN-38), mitoxantrone, and topotecan. Topotecan 166-175 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 53-58 15087395-2 2004 We have shown previously that Ubc9 is important for sumoylation and nucleolar delocalization of topoisomerase (topo) I in response to topo I inhibitors such as topotecan. Topotecan 160-169 ubiquitin conjugating enzyme E2 I Homo sapiens 30-34 15087395-4 2004 In this study, we found that although MCF7 cells expressing a Ubc9 dominant-negative mutant (Ubc9-DN) display decreased activity of topo I, these cells are more sensitive to the topo I inhibitor topotecan and other anticancer agents such as VM-26 and cisplatin. Topotecan 195-204 ubiquitin conjugating enzyme E2 I Homo sapiens 62-66 15087395-4 2004 In this study, we found that although MCF7 cells expressing a Ubc9 dominant-negative mutant (Ubc9-DN) display decreased activity of topo I, these cells are more sensitive to the topo I inhibitor topotecan and other anticancer agents such as VM-26 and cisplatin. Topotecan 195-204 ubiquitin conjugating enzyme E2 I Homo sapiens 93-97 15057963-0 2004 Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin. Topotecan 92-101 H2A.X variant histone Homo sapiens 22-26 15205350-8 2004 Genistein and naringenin increased cellular accumulation of topotecan in K562/BCRP cells. Topotecan 60-69 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 78-82 15059881-3 2004 Previously, 4-anilinoquinazoline TKIs have been shown to inhibit the function of the breast cancer resistance-associated drug transporter (ABCG2), reversing resistance to camptothecin derivatives topotecan and SN-38. Topotecan 196-205 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 139-144 15059881-5 2004 Here, we show that imatinib mesylate potently reverses ABCG2-mediated resistance to topotecan and SN-38 and significantly increases accumulation of topotecan only in cells expressing functional ABCG2. Topotecan 84-93 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 55-60 15059881-5 2004 Here, we show that imatinib mesylate potently reverses ABCG2-mediated resistance to topotecan and SN-38 and significantly increases accumulation of topotecan only in cells expressing functional ABCG2. Topotecan 148-157 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 194-199 15059881-0 2004 Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Topotecan 99-108 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 54-58 15196431-7 2004 No expression of P-gp was demonstrated, and that of MRP was very weak in the TPT-resistant cells (relative expression value = 0.057). Topotecan 77-80 ATP binding cassette subfamily C member 3 Homo sapiens 52-55 15160952-0 2004 High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma. Topotecan 10-19 STT3 oligosaccharyltransferase complex catalytic subunit A Homo sapiens 53-56 15196431-8 2004 BCRP was overexpressed in the TPT-resistant cells (relative expression = 0.66), but not in the parental cells. Topotecan 30-33 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-4 15196431-10 2004 CONCLUSION: The overexpression of BCRP which mediated drug efflux may play an important role in the induction of TPT-resistance in ovarian cancer. Topotecan 113-116 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 34-38 14735180-6 2004 In conclusion, the GCIG CA125 response criteria seem to overestimate a tumour response by WHO criteria when monitoring the efficacy of second-line chemotherapy with topotecan or paclitaxel-platinum in patients with epithelial ovarian carcinoma. Topotecan 165-174 mucin 16, cell surface associated Homo sapiens 24-29 14973080-9 2004 In 4-day cytotoxicity assays, ABCG2-mediated resistance to SN-38 and topotecan was abrogated in ABCG2-transfected HEK-293 cells treated with 1 micro M tariquidar, and ABCG2-transfected cells were 6-7-fold resistant to UCN-01. Topotecan 69-78 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 30-35 14973080-9 2004 In 4-day cytotoxicity assays, ABCG2-mediated resistance to SN-38 and topotecan was abrogated in ABCG2-transfected HEK-293 cells treated with 1 micro M tariquidar, and ABCG2-transfected cells were 6-7-fold resistant to UCN-01. Topotecan 69-78 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 96-101 14973080-9 2004 In 4-day cytotoxicity assays, ABCG2-mediated resistance to SN-38 and topotecan was abrogated in ABCG2-transfected HEK-293 cells treated with 1 micro M tariquidar, and ABCG2-transfected cells were 6-7-fold resistant to UCN-01. Topotecan 69-78 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 96-101 14973083-1 2004 The breast cancer resistance protein (BCRP) is an ATP-binding cassette half transporter that confers resistance to anticancer drugs such as mitoxantrone, anthracyclines, topotecan, and SN-38. Topotecan 170-179 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 4-36 14973083-1 2004 The breast cancer resistance protein (BCRP) is an ATP-binding cassette half transporter that confers resistance to anticancer drugs such as mitoxantrone, anthracyclines, topotecan, and SN-38. Topotecan 170-179 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 38-42 14973083-1 2004 The breast cancer resistance protein (BCRP) is an ATP-binding cassette half transporter that confers resistance to anticancer drugs such as mitoxantrone, anthracyclines, topotecan, and SN-38. Topotecan 170-179 ATP binding cassette subfamily B member 6 (Langereis blood group) Homo sapiens 50-87 14983893-1 2004 We have shown previously that the camptothecin analogue topotecan (TPT), a topoisomerase I (Top 1) poison, inhibits hypoxia-inducible factor 1 (HIF-1) transcriptional activity and HIF-1alpha protein accumulation in hypoxia-treated U251 human glioma cells. Topotecan 56-65 hypoxia inducible factor 1 subunit alpha Homo sapiens 116-142 14983893-1 2004 We have shown previously that the camptothecin analogue topotecan (TPT), a topoisomerase I (Top 1) poison, inhibits hypoxia-inducible factor 1 (HIF-1) transcriptional activity and HIF-1alpha protein accumulation in hypoxia-treated U251 human glioma cells. Topotecan 56-65 hypoxia inducible factor 1 subunit alpha Homo sapiens 144-149 14983893-1 2004 We have shown previously that the camptothecin analogue topotecan (TPT), a topoisomerase I (Top 1) poison, inhibits hypoxia-inducible factor 1 (HIF-1) transcriptional activity and HIF-1alpha protein accumulation in hypoxia-treated U251 human glioma cells. Topotecan 56-65 hypoxia inducible factor 1 subunit alpha Homo sapiens 180-190 14983893-1 2004 We have shown previously that the camptothecin analogue topotecan (TPT), a topoisomerase I (Top 1) poison, inhibits hypoxia-inducible factor 1 (HIF-1) transcriptional activity and HIF-1alpha protein accumulation in hypoxia-treated U251 human glioma cells. Topotecan 67-70 hypoxia inducible factor 1 subunit alpha Homo sapiens 116-142 14983893-1 2004 We have shown previously that the camptothecin analogue topotecan (TPT), a topoisomerase I (Top 1) poison, inhibits hypoxia-inducible factor 1 (HIF-1) transcriptional activity and HIF-1alpha protein accumulation in hypoxia-treated U251 human glioma cells. Topotecan 67-70 hypoxia inducible factor 1 subunit alpha Homo sapiens 144-149 14983893-1 2004 We have shown previously that the camptothecin analogue topotecan (TPT), a topoisomerase I (Top 1) poison, inhibits hypoxia-inducible factor 1 (HIF-1) transcriptional activity and HIF-1alpha protein accumulation in hypoxia-treated U251 human glioma cells. Topotecan 67-70 hypoxia inducible factor 1 subunit alpha Homo sapiens 180-190 14983893-3 2004 In addition, we demonstrate that Top 1 is required for the inhibition of HIF-1alpha protein accumulation by TPT as shown by experiments performed using camptothecin-resistant cell lines with known Top 1 alterations. Topotecan 108-111 hypoxia inducible factor 1 subunit alpha Homo sapiens 73-83 14983893-4 2004 Experiments performed with aphidicolin indicated that TPT inhibited HIF-1alpha protein accumulation in the absence of DNA replication. Topotecan 54-57 hypoxia inducible factor 1 subunit alpha Homo sapiens 68-78 14983893-8 2004 In addition, our findings dissociate the cytotoxic activity of TPT from the inhibition of the HIF-1 pathway and raise the possibility of novel clinical applications of TPT aimed at targeting HIF-1-dependent responses. Topotecan 63-66 hypoxia inducible factor 1 subunit alpha Homo sapiens 191-196 14983893-8 2004 In addition, our findings dissociate the cytotoxic activity of TPT from the inhibition of the HIF-1 pathway and raise the possibility of novel clinical applications of TPT aimed at targeting HIF-1-dependent responses. Topotecan 168-171 hypoxia inducible factor 1 subunit alpha Homo sapiens 191-196 14639618-12 2004 For example, of the 4 lines, the p53wt transfectant was the most resistant to topotecan and the 143mut was the most resistant to carboplatin. Topotecan 78-87 tumor protein p53 Homo sapiens 33-36 14726661-0 2004 A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer. Topotecan 20-29 colony stimulating factor 3 Homo sapiens 56-61 14754410-4 2004 Over-expression of ABCG2 in cell lines confers resistance on a wide variety of anticancer drugs including mitoxantrone, daunorubicin, doxorubicin, topotecan and epirubicin. Topotecan 147-156 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 19-24 14754410-8 2004 ABCG2 is found to be highly expressed in placenta and the luminal surface of microvessel endothelium blood-brain barrier where it may play a role in limiting the penetration of drugs, such as topotecan from the maternal plasma into the fetus and from blood to brain. Topotecan 192-201 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-5 15047921-3 2004 To investigate the feasibility of topotecan in the treatment of relapsed SCLC patients with PS 2 scores, we retrospectively analyzed data from five clinical trials that included 479 patients who were treated with single-agent topotecan at a dose of 1.5 mg/m2/day on days 1-5 of a 21-day course. Topotecan 34-43 taste 2 receptor member 64 pseudogene Homo sapiens 92-96 14618629-1 2004 Breast cancer resistance protein (BCRP/ABCG2) of an ATP-binding cassette half-transporter confers resistance against mitoxantrone and camptothecin derivatives of topotecan and irinotecan. Topotecan 162-171 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-32 14618629-1 2004 Breast cancer resistance protein (BCRP/ABCG2) of an ATP-binding cassette half-transporter confers resistance against mitoxantrone and camptothecin derivatives of topotecan and irinotecan. Topotecan 162-171 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 34-38 14618629-1 2004 Breast cancer resistance protein (BCRP/ABCG2) of an ATP-binding cassette half-transporter confers resistance against mitoxantrone and camptothecin derivatives of topotecan and irinotecan. Topotecan 162-171 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 39-44 14618629-1 2004 Breast cancer resistance protein (BCRP/ABCG2) of an ATP-binding cassette half-transporter confers resistance against mitoxantrone and camptothecin derivatives of topotecan and irinotecan. Topotecan 162-171 ATP binding cassette subfamily B member 6 (Langereis blood group) Homo sapiens 52-89 14618629-7 2004 Compared to the parental PC-6 cells, PC-6/SN2-5H2 cells were 141-, 173- and 57.2-fold resistant to topotecan, SN-38 and mitoxantrone, respectively. Topotecan 99-108 proprotein convertase subtilisin/kexin type 5 Homo sapiens 37-41 14618629-9 2004 Furthermore, novobiocin increased the intracellular topotecan accumulation in these cells and inhibited the topotecan transport into the membrane vesicles of PC-6/SN2-5H2 cells. Topotecan 108-117 proprotein convertase subtilisin/kexin type 5 Homo sapiens 158-162 14618629-11 2004 The kinetic parameters in the transport study indicated that novobiocin was a inhibitor for BCRP, resulting in competitive inhibition of BCRP-mediated topotecan transport. Topotecan 151-160 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 92-96 14618629-11 2004 The kinetic parameters in the transport study indicated that novobiocin was a inhibitor for BCRP, resulting in competitive inhibition of BCRP-mediated topotecan transport. Topotecan 151-160 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 137-141 15616145-8 2004 The clinical profile of topotecan was established in several phase II studies and confirmed in a randomized, phase III trial versus cyclophosphamide, doxorubicin (Adriamycin; Bedford Laboratories; Bedford, OH), and vincristine (Oncovin; Eli Lilly and Company; Indianapolis, IN)--CAV. Topotecan 24-33 caveolin 2 Homo sapiens 279-282 14566825-2 2003 Expression of wild-type BCRP confers resistance to multiple chemotherapeutic agents such as mitoxantrone, SN-38 and topotecan, but not to doxorubicin. Topotecan 116-125 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 24-28 15616148-5 2004 Topotecan (HYCAMTIN; GlaxoSmithKline; Philadelphia, PA), an established treatment for recurrent SCLC, is being investigated in the first-line setting because of its novel mechanism of action; predictable, noncumulative, and manageable toxicities; and potential synergy with other active agents. Topotecan 0-9 SCLC1 Homo sapiens 96-100 15616148-5 2004 Topotecan (HYCAMTIN; GlaxoSmithKline; Philadelphia, PA), an established treatment for recurrent SCLC, is being investigated in the first-line setting because of its novel mechanism of action; predictable, noncumulative, and manageable toxicities; and potential synergy with other active agents. Topotecan 11-19 SCLC1 Homo sapiens 96-100 15616148-8 2004 Additional clinical trials to investigate topotecan-based combination regimens and confirm their role in the first-line treatment of SCLC are under way. Topotecan 42-51 SCLC1 Homo sapiens 133-137 14693055-1 2003 BACKGROUND & OBJECTIVE: Breast cancer resistance protein (BCRP) was overexpressed in topotecan (TPT)-selected human ovarian cancer cell line A2780/TPT, strongly suggesting BCRP to be responsible for the drug-resistance of ovarian cancer. Topotecan 89-98 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 28-60 14693055-1 2003 BACKGROUND & OBJECTIVE: Breast cancer resistance protein (BCRP) was overexpressed in topotecan (TPT)-selected human ovarian cancer cell line A2780/TPT, strongly suggesting BCRP to be responsible for the drug-resistance of ovarian cancer. Topotecan 89-98 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 62-66 14693055-1 2003 BACKGROUND & OBJECTIVE: Breast cancer resistance protein (BCRP) was overexpressed in topotecan (TPT)-selected human ovarian cancer cell line A2780/TPT, strongly suggesting BCRP to be responsible for the drug-resistance of ovarian cancer. Topotecan 89-98 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 176-180 14693055-1 2003 BACKGROUND & OBJECTIVE: Breast cancer resistance protein (BCRP) was overexpressed in topotecan (TPT)-selected human ovarian cancer cell line A2780/TPT, strongly suggesting BCRP to be responsible for the drug-resistance of ovarian cancer. Topotecan 100-103 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 28-60 14693055-1 2003 BACKGROUND & OBJECTIVE: Breast cancer resistance protein (BCRP) was overexpressed in topotecan (TPT)-selected human ovarian cancer cell line A2780/TPT, strongly suggesting BCRP to be responsible for the drug-resistance of ovarian cancer. Topotecan 100-103 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 62-66 14693055-1 2003 BACKGROUND & OBJECTIVE: Breast cancer resistance protein (BCRP) was overexpressed in topotecan (TPT)-selected human ovarian cancer cell line A2780/TPT, strongly suggesting BCRP to be responsible for the drug-resistance of ovarian cancer. Topotecan 100-103 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 176-180 14693055-2 2003 The current study was designed to investigate the reversal effect of BCRP antisense oligonucleotide (ASODN) on topotecan- resistant A2780/TPT cells. Topotecan 111-120 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 69-73 12811515-0 2003 The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis. Topotecan 30-39 TNF superfamily member 10 Homo sapiens 93-98 14612912-4 2003 In cytotoxicity assays, all ABCG2 proteins conferred high levels of resistance to mitoxantrone, SN-38, and topotecan, while mutant ABCG2 also exhibited a gain of function for mitoxantrone as they conferred a four-fold greater resistance compared to wild type. Topotecan 107-116 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 28-33 14504478-4 2003 caspase-3 activation; and c. apoptosis-associated DNA fragmentation in individual human leukemic HL-60 cells treated with the DNA topoisomerase I (topo1) inhibitors topotecan (TPT) and camptothecin (CPT) or with the topo2 inhibitor mitoxantrone (MTX). Topotecan 165-174 caspase 3 Homo sapiens 0-9 14504478-9 2003 Following treatment with TPT, CPT or MTX the peak of H2AX phosphorylation preceded caspase-3 activation and the appearance of apoptosis-associated DNA fragmentation, both selective to S-phase cells. Topotecan 25-28 H2A.X variant histone Homo sapiens 53-57 14504478-9 2003 Following treatment with TPT, CPT or MTX the peak of H2AX phosphorylation preceded caspase-3 activation and the appearance of apoptosis-associated DNA fragmentation, both selective to S-phase cells. Topotecan 25-28 caspase 3 Homo sapiens 83-92 14613996-1 2003 PURPOSE: Overexpression of the transporter ABCG2, also known as breast cancer resistance protein and mitoxantrone resistance protein, can confer resistance to a variety of cytostatic drugs, such as mitoxantrone, topotecan, doxorubicin, and daunorubicin. Topotecan 212-221 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 43-48 14613996-1 2003 PURPOSE: Overexpression of the transporter ABCG2, also known as breast cancer resistance protein and mitoxantrone resistance protein, can confer resistance to a variety of cytostatic drugs, such as mitoxantrone, topotecan, doxorubicin, and daunorubicin. Topotecan 212-221 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 64-96 12811515-10 2003 Surprisingly, only topotecan, a topoisomerase I inhibitor, when used in combination with rTRAIL/Apo-2L led to significant apoptosis of DU-145 cells, as measured by caspase 8 activation, BID cleavage, and annexin V-FITC/PI staining. Topotecan 19-28 TNF superfamily member 10 Rattus norvegicus 89-95 12811515-10 2003 Surprisingly, only topotecan, a topoisomerase I inhibitor, when used in combination with rTRAIL/Apo-2L led to significant apoptosis of DU-145 cells, as measured by caspase 8 activation, BID cleavage, and annexin V-FITC/PI staining. Topotecan 19-28 TNF superfamily member 10 Homo sapiens 96-102 12811515-10 2003 Surprisingly, only topotecan, a topoisomerase I inhibitor, when used in combination with rTRAIL/Apo-2L led to significant apoptosis of DU-145 cells, as measured by caspase 8 activation, BID cleavage, and annexin V-FITC/PI staining. Topotecan 19-28 caspase 8 Homo sapiens 164-173 12811515-10 2003 Surprisingly, only topotecan, a topoisomerase I inhibitor, when used in combination with rTRAIL/Apo-2L led to significant apoptosis of DU-145 cells, as measured by caspase 8 activation, BID cleavage, and annexin V-FITC/PI staining. Topotecan 19-28 annexin A5 Homo sapiens 204-213 12811515-12 2003 Furthermore, the increase in TRAIL/Apo-2L sensitivity following topotecan treatment correlated with increased expression of TRAIL-R1 and TRAIL-R2 and decreased intracellular levels of the antiapoptotic protein survivin. Topotecan 64-73 TNF superfamily member 10 Homo sapiens 29-34 12811515-12 2003 Furthermore, the increase in TRAIL/Apo-2L sensitivity following topotecan treatment correlated with increased expression of TRAIL-R1 and TRAIL-R2 and decreased intracellular levels of the antiapoptotic protein survivin. Topotecan 64-73 TNF superfamily member 10 Homo sapiens 35-41 12811515-0 2003 The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis. Topotecan 30-39 TNF superfamily member 10 Homo sapiens 99-105 12811515-12 2003 Furthermore, the increase in TRAIL/Apo-2L sensitivity following topotecan treatment correlated with increased expression of TRAIL-R1 and TRAIL-R2 and decreased intracellular levels of the antiapoptotic protein survivin. Topotecan 64-73 TNF receptor superfamily member 10a Homo sapiens 124-132 12811515-12 2003 Furthermore, the increase in TRAIL/Apo-2L sensitivity following topotecan treatment correlated with increased expression of TRAIL-R1 and TRAIL-R2 and decreased intracellular levels of the antiapoptotic protein survivin. Topotecan 64-73 TNF receptor superfamily member 10b Homo sapiens 137-145 12912956-1 2003 PURPOSE: Breast cancer resistance protein (BCRP/ABCG2), an ATP binding cassette half-transporter, confers resistance to mitoxantrone, doxorubicin, and topoisomerase I inhibitors of irinotecan and topotecan. Topotecan 196-205 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 9-41 12811515-14 2003 The sensitivity of DU-145 cells to TRAIL/Apo-2L was dramatically increased when combined with topotecan, suggesting that low-dose topotecan treatment to upregulate TRAIL-R1 and TRAIL-R2 and downregulate survivin, followed by TRAIL/Apo-2L administration, may be a viable therapy for treating cancer of the prostate. Topotecan 94-103 TNF superfamily member 10 Homo sapiens 35-40 12811515-14 2003 The sensitivity of DU-145 cells to TRAIL/Apo-2L was dramatically increased when combined with topotecan, suggesting that low-dose topotecan treatment to upregulate TRAIL-R1 and TRAIL-R2 and downregulate survivin, followed by TRAIL/Apo-2L administration, may be a viable therapy for treating cancer of the prostate. Topotecan 130-139 TNF superfamily member 10 Homo sapiens 35-40 12811515-14 2003 The sensitivity of DU-145 cells to TRAIL/Apo-2L was dramatically increased when combined with topotecan, suggesting that low-dose topotecan treatment to upregulate TRAIL-R1 and TRAIL-R2 and downregulate survivin, followed by TRAIL/Apo-2L administration, may be a viable therapy for treating cancer of the prostate. Topotecan 130-139 TNF superfamily member 10 Homo sapiens 41-47 12811515-14 2003 The sensitivity of DU-145 cells to TRAIL/Apo-2L was dramatically increased when combined with topotecan, suggesting that low-dose topotecan treatment to upregulate TRAIL-R1 and TRAIL-R2 and downregulate survivin, followed by TRAIL/Apo-2L administration, may be a viable therapy for treating cancer of the prostate. Topotecan 130-139 TNF receptor superfamily member 10a Homo sapiens 164-172 12811515-14 2003 The sensitivity of DU-145 cells to TRAIL/Apo-2L was dramatically increased when combined with topotecan, suggesting that low-dose topotecan treatment to upregulate TRAIL-R1 and TRAIL-R2 and downregulate survivin, followed by TRAIL/Apo-2L administration, may be a viable therapy for treating cancer of the prostate. Topotecan 130-139 TNF receptor superfamily member 10b Homo sapiens 177-185 12811515-14 2003 The sensitivity of DU-145 cells to TRAIL/Apo-2L was dramatically increased when combined with topotecan, suggesting that low-dose topotecan treatment to upregulate TRAIL-R1 and TRAIL-R2 and downregulate survivin, followed by TRAIL/Apo-2L administration, may be a viable therapy for treating cancer of the prostate. Topotecan 130-139 TNF superfamily member 10 Homo sapiens 164-169 12811515-14 2003 The sensitivity of DU-145 cells to TRAIL/Apo-2L was dramatically increased when combined with topotecan, suggesting that low-dose topotecan treatment to upregulate TRAIL-R1 and TRAIL-R2 and downregulate survivin, followed by TRAIL/Apo-2L administration, may be a viable therapy for treating cancer of the prostate. Topotecan 130-139 TNF superfamily member 10 Homo sapiens 231-237 12920197-1 2003 Breast cancer resistance protein (BCRP), an ATP-binding cassette transporter, confers resistance to a series of anticancer reagents such as mitoxantrone, 7-ethyl-10-hydroxycamptothecin, and topotecan. Topotecan 190-199 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-32 12920197-1 2003 Breast cancer resistance protein (BCRP), an ATP-binding cassette transporter, confers resistance to a series of anticancer reagents such as mitoxantrone, 7-ethyl-10-hydroxycamptothecin, and topotecan. Topotecan 190-199 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 34-38 12912956-1 2003 PURPOSE: Breast cancer resistance protein (BCRP/ABCG2), an ATP binding cassette half-transporter, confers resistance to mitoxantrone, doxorubicin, and topoisomerase I inhibitors of irinotecan and topotecan. Topotecan 196-205 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 43-47 12912956-1 2003 PURPOSE: Breast cancer resistance protein (BCRP/ABCG2), an ATP binding cassette half-transporter, confers resistance to mitoxantrone, doxorubicin, and topoisomerase I inhibitors of irinotecan and topotecan. Topotecan 196-205 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 48-53 12912956-9 2003 RESULTS: The levels of BCRP mRNA expression in the cell lines were significantly correlated with the BCRP function and the sensitivity to SN-38 and topotecan. Topotecan 148-157 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 23-27 12912956-11 2003 Five (22%) of 23 tissues expressed higher levels of the BCRP mRNA than that in NCI-H441 cells with active BCRP function conferring high resistance to topotecan in vitro. Topotecan 150-159 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 56-60 12912956-11 2003 Five (22%) of 23 tissues expressed higher levels of the BCRP mRNA than that in NCI-H441 cells with active BCRP function conferring high resistance to topotecan in vitro. Topotecan 150-159 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 106-110 12684687-4 2003 We report that Brca1-deficiency in p53-null cells was associated with increased sensitivity to the topoisomerase I poisons camptothecin and topotecan, the topoisomerase II poisons doxorubicin, mitoxantrone and etoposide, and to the platinum compounds carboplatin and oxaliplatin, but not to the antimetabolites 5-fluorouracil and gemcitabine and the taxanes docetaxel and paclitaxel. Topotecan 140-149 tumor protein p53 Homo sapiens 35-38 12819931-6 2003 HSP90 inhibitors and topotecan suppressed AKT activity via indirectly downregulating PDK1 and phosphatidylinositide-3-OH kinase activities. Topotecan 21-30 AKT serine/threonine kinase 1 Homo sapiens 42-45 12819931-6 2003 HSP90 inhibitors and topotecan suppressed AKT activity via indirectly downregulating PDK1 and phosphatidylinositide-3-OH kinase activities. Topotecan 21-30 pyruvate dehydrogenase kinase 1 Homo sapiens 85-89 12855651-6 2003 At a nontoxic concentration (0.4 micro M) the PARP-1 inhibitors potentiated TM-induced growth inhibition 1.0-5.3-fold and TP-induced inhibition from 1.0-2.1-fold. Topotecan 122-124 poly (ADP-ribose) polymerase family, member 1 Mus musculus 46-52 12855658-9 2003 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cytotoxicity analysis of both MAGE2 and MAGE6 transfectants demonstrates a 4-fold increase in resistance to paclitaxel and 2-fold increase in resistance to doxorubicin but not to other drugs, such as topotecan and cisplatin, through a nonmultidrug resistance-1 mechanism. Topotecan 261-270 MAGE family member A2B Homo sapiens 91-96 12855658-9 2003 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cytotoxicity analysis of both MAGE2 and MAGE6 transfectants demonstrates a 4-fold increase in resistance to paclitaxel and 2-fold increase in resistance to doxorubicin but not to other drugs, such as topotecan and cisplatin, through a nonmultidrug resistance-1 mechanism. Topotecan 261-270 MAGE family member A6 Homo sapiens 101-106 12782583-1 2003 To uncover transcriptional stress responses related to p53, we used cDNA microarrays (National Cancer Institute Oncochips comprising 6500 different genes) to characterize the gene expression profiles of wild-type p53 HCT-116 cells and an isogenic p53 knockout counterpart after treatment with topotecan, a specific topoisomerase I inhibitor. Topotecan 293-302 tumor protein p53 Homo sapiens 55-58 12782583-5 2003 Approximately 10% of the transcripts were up- or down-regulated in response to topotecan in the p53+/+ cells, whereas only 1% of the transcripts changed in the p53-/- cells, indicating that p53 has a broad effect on the transcriptional response to this stress. Topotecan 79-88 tumor protein p53 Homo sapiens 96-99 12894535-0 2003 Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone. Topotecan 51-60 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 22-26 12894535-0 2003 Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone. Topotecan 51-60 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 31-35 12894535-0 2003 Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone. Topotecan 103-112 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 22-26 12847914-1 2003 This study shows a strong association between cell attachment to substratum and activation of beta 1-integrin-signaling with resistance to the camptothecin derivative topotecan (TPT) in breast cancer cells. Topotecan 167-176 integrin subunit beta 1 Homo sapiens 94-109 12698201-5 2003 Topotecan caused pan-cycle induction and activation of p53. Topotecan 0-9 tumor protein p53 Homo sapiens 55-58 12847914-1 2003 This study shows a strong association between cell attachment to substratum and activation of beta 1-integrin-signaling with resistance to the camptothecin derivative topotecan (TPT) in breast cancer cells. Topotecan 178-181 integrin subunit beta 1 Homo sapiens 94-109 12847914-5 2003 Moreover, inhibition of FAK gene expression by a phosphorothioated antisense oligodeoxynucleotide targeting the portion of the gene encoding amino acids 262-268, increased the sensitivity of ZR-75-1, MDA-MB-231 and MCF7 breast cancer cells to treatment with TPT or CPT-11. Topotecan 258-261 protein tyrosine kinase 2 Homo sapiens 24-27 12393637-3 2002 First, using transduced clonal cell lines expressing varying levels of ABCG2, we found that ABCG2 expression conferred resistance to mitoxantrone and topotecan, but not to idarubicin. Topotecan 150-159 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 71-76 12533678-1 2003 Breast cancer resistance protein (BCRP), an ATP-binding cassette transporter, confers resistance to a series of anticancer agents such as SN-38, mitoxantrone, and topotecan. Topotecan 163-172 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-32 12533678-1 2003 Breast cancer resistance protein (BCRP), an ATP-binding cassette transporter, confers resistance to a series of anticancer agents such as SN-38, mitoxantrone, and topotecan. Topotecan 163-172 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 34-38 12533678-4 2003 First, compounds were tested for effects on the cellular accumulation of topotecan in BCRP-transduced K562 cells (K562/BCRP). Topotecan 73-82 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 86-90 12533678-7 2003 Diethylstilbestrol increased the cellular accumulation of topotecan and reversed drug resistance in K562/BCRP cells but showed marginal or no effect in parental K562 cells. Topotecan 58-67 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 105-109 12533678-9 2003 Tamoxifen and toremifene were also found to enhance topotecan uptake in K562/BCRP cells. Topotecan 52-61 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 77-81 12704006-4 2003 The BCRP-overexpressing tumor cells are resistant to mitoxantrone, adriamycin, daunorubicin, etoposide, topotecan and irinotecan, but lack resistance to paclitaxel and vincristine. Topotecan 104-113 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 4-8 12393637-3 2002 First, using transduced clonal cell lines expressing varying levels of ABCG2, we found that ABCG2 expression conferred resistance to mitoxantrone and topotecan, but not to idarubicin. Topotecan 150-159 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 92-97 12369998-3 2002 When overexpressed in cell lines, ABCG2 has the ability to confer high levels of resistance to anthracyclines, mitoxantrone, bisantrene, and the camptothecins topotecan and SN-38. Topotecan 159-168 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 34-39 21329605-1 2002 BACKGROUND: To evaluate the effects and toxicities of topotecan combined with cisplatin in the treatment of small cell lung cancer (SCLC). Topotecan 54-63 SCLC1 Homo sapiens 132-136 21329605-2 2002 METHODS: Twenty-six patients with SCLC diagnosed by pathologic or cytologic examination were treated with topotecan 1.25 mg/(m2*d) on days 1-5 and cisplatin 25 mg/(m2*d) on days 1-3. Topotecan 106-115 SCLC1 Homo sapiens 34-38 21329605-9 2002 CONCLUSIONS: Topotecan combined with cisplatin is effective for SCLC and it toxicity is tolerable. Topotecan 13-22 SCLC1 Homo sapiens 64-68 12089223-0 2002 Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. Topotecan 34-43 ATP binding cassette subfamily B member 1 Homo sapiens 105-119 12145683-2 2002 Transfection and enforced expression of BCRP in drug-sensitive cells confers resistance to mitoxantrone, doxorubicin, daunorubicin and topotecan. Topotecan 135-144 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 40-44 12089223-1 2002 PURPOSE: We discovered that breast cancer resistance protein (BCRP), a recently identified adenosine triphosphate-binding cassette drug transporter, substantially limits the oral bioavailability of topotecan in mdr1a/1b(-/-) P-glycoprotein (P-gp) knockout and wild-type mice. Topotecan 198-207 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 62-66 12237778-10 2002 Breast cancer resistance protein, however, results in only minor reduction of antitumour activity of DX-8951f which is an advantage over topotecan and CPT-11/SN-38. Topotecan 137-146 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-32 12151959-0 2002 Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignancies. Topotecan 17-26 colony stimulating factor 3 Homo sapiens 69-74 12089223-1 2002 PURPOSE: We discovered that breast cancer resistance protein (BCRP), a recently identified adenosine triphosphate-binding cassette drug transporter, substantially limits the oral bioavailability of topotecan in mdr1a/1b(-/-) P-glycoprotein (P-gp) knockout and wild-type mice. Topotecan 198-207 phosphoglycolate phosphatase Mus musculus 225-239 12089223-1 2002 PURPOSE: We discovered that breast cancer resistance protein (BCRP), a recently identified adenosine triphosphate-binding cassette drug transporter, substantially limits the oral bioavailability of topotecan in mdr1a/1b(-/-) P-glycoprotein (P-gp) knockout and wild-type mice. Topotecan 198-207 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 28-60 12089223-1 2002 PURPOSE: We discovered that breast cancer resistance protein (BCRP), a recently identified adenosine triphosphate-binding cassette drug transporter, substantially limits the oral bioavailability of topotecan in mdr1a/1b(-/-) P-glycoprotein (P-gp) knockout and wild-type mice. Topotecan 198-207 phosphoglycolate phosphatase Mus musculus 241-245 12089223-11 2002 CONCLUSION: Coadministration of the BCRP and P-gp inhibitor GF120918 resulted in a significant increase of the systemic exposure of oral topotecan. Topotecan 137-146 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 36-40 11857382-0 2002 Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway. Topotecan 0-9 fibroblast growth factor 2 Homo sapiens 29-33 12089223-11 2002 CONCLUSION: Coadministration of the BCRP and P-gp inhibitor GF120918 resulted in a significant increase of the systemic exposure of oral topotecan. Topotecan 137-146 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 11956086-3 2002 Although the mouse Bcrp1 amino acid substitutions (M or S) are distinct from those seen in the human cell lines (G or T), they all have similar consequences: (a) greater resistance to anthracyclines (and bisantrene); (b) relatively lower resistance to topotecan; (c) greatly enhanced efflux of the dye rhodamine 123. Topotecan 252-261 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 19-24 11911840-7 2002 A significant up-regulation of Fas/CD95 expression was detected after exposure to topotecan and CPT83, whereas cisplatin induced a low increase and taxol did not modify Fas/CD95 expression. Topotecan 82-91 Fas cell surface death receptor Homo sapiens 35-39 11857382-0 2002 Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway. Topotecan 0-9 vascular endothelial growth factor A Homo sapiens 19-24 12479221-1 2002 Breast cancer resistance protein (BCRP) confers multidrug resistance to cancer cells against agents such as SN-38 (an active metabolite of irinotecan), mitoxantrone, and topotecan. Topotecan 170-179 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-32 12479221-1 2002 Breast cancer resistance protein (BCRP) confers multidrug resistance to cancer cells against agents such as SN-38 (an active metabolite of irinotecan), mitoxantrone, and topotecan. Topotecan 170-179 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 34-38 11857382-0 2002 Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway. Topotecan 0-9 AKT serine/threonine kinase 1 Homo sapiens 109-112 11857382-5 2002 We found that topotecan inhibited VEGF- and bFGF-induced migration of human umbilical vein endothelial cells (HUVECs) in vitro. Topotecan 14-23 vascular endothelial growth factor A Homo sapiens 34-38 11857382-5 2002 We found that topotecan inhibited VEGF- and bFGF-induced migration of human umbilical vein endothelial cells (HUVECs) in vitro. Topotecan 14-23 fibroblast growth factor 2 Homo sapiens 44-48 11857382-7 2002 Thus, we investigated the possibility that topotecan"s antiangiogenic property might be mediated by its inhibitory effect on VEGF- and bFGF-induced activation of the PI3K-Akt signaling pathway. Topotecan 43-52 vascular endothelial growth factor A Homo sapiens 125-129 11857382-7 2002 Thus, we investigated the possibility that topotecan"s antiangiogenic property might be mediated by its inhibitory effect on VEGF- and bFGF-induced activation of the PI3K-Akt signaling pathway. Topotecan 43-52 fibroblast growth factor 2 Homo sapiens 135-139 11857382-7 2002 Thus, we investigated the possibility that topotecan"s antiangiogenic property might be mediated by its inhibitory effect on VEGF- and bFGF-induced activation of the PI3K-Akt signaling pathway. Topotecan 43-52 AKT serine/threonine kinase 1 Homo sapiens 171-174 11857382-8 2002 We found that topotecan treatment decreased the amount of the phosphorylated (activated) form of Akt, but not the amount of Akt protein, in HUVECs. Topotecan 14-23 AKT serine/threonine kinase 1 Homo sapiens 97-100 11857382-9 2002 Moreover, transient transfection of constitutive active akt cDNA into HUVECs reversed the topotecan-mediated decrease in HUVEC migration. Topotecan 90-99 AKT serine/threonine kinase 1 Homo sapiens 56-59 11857382-10 2002 These results suggest that the antiangiogenic activity of topotecan is mediated in part by downregulating the PI3K-Akt signaling pathway. Topotecan 58-67 AKT serine/threonine kinase 1 Homo sapiens 115-118 11688982-1 2001 Overexpression of breast cancer resistance protein (BCRP) ABCG2 reportedly confers cancer cell resistance to camptothecin-based anticancer drugs, such as topotecan and 7-ethyl-10-hydroxycamptothecin (SN-38: the active metabolite of irinotecan). Topotecan 154-163 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 18-50 11927002-1 2002 Breast cancer resistance protein (BCRP), an adenosine triphosphate-binding cassette transporter, confers resistance to a series of anticancer reagents, including mitoxantrone, SN-38 and topotecan. Topotecan 186-195 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-32 11927002-1 2002 Breast cancer resistance protein (BCRP), an adenosine triphosphate-binding cassette transporter, confers resistance to a series of anticancer reagents, including mitoxantrone, SN-38 and topotecan. Topotecan 186-195 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 34-38 11927002-2 2002 In the present study, we found that estrone and 17beta-estradiol potentiated the cytotoxicity of mitoxantrone, SN-38 and topotecan in BCRP-transduced K562 cells (K562 / BCRP). Topotecan 121-130 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 134-138 11927002-2 2002 In the present study, we found that estrone and 17beta-estradiol potentiated the cytotoxicity of mitoxantrone, SN-38 and topotecan in BCRP-transduced K562 cells (K562 / BCRP). Topotecan 121-130 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 169-173 11927002-4 2002 Estrone and 17beta-estradiol increased the cellular accumulation of topotecan in K562 / BCRP cells, but not in K562 cells, suggesting that these estrogens inhibit the BCRP-mediated drug efflux and overcome drug resistance. Topotecan 68-77 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 88-92 11927002-4 2002 Estrone and 17beta-estradiol increased the cellular accumulation of topotecan in K562 / BCRP cells, but not in K562 cells, suggesting that these estrogens inhibit the BCRP-mediated drug efflux and overcome drug resistance. Topotecan 68-77 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 167-171 11742701-1 2001 In the last years, the main topoisomerase I inhibitors (TP1-I) (i.e. topotecan and irinotecan) have been used in combination chemotherapy in non-small cell lung cancer. Topotecan 69-78 transition protein 1 Homo sapiens 56-59 11688982-1 2001 Overexpression of breast cancer resistance protein (BCRP) ABCG2 reportedly confers cancer cell resistance to camptothecin-based anticancer drugs, such as topotecan and 7-ethyl-10-hydroxycamptothecin (SN-38: the active metabolite of irinotecan). Topotecan 154-163 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 52-56 11688982-1 2001 Overexpression of breast cancer resistance protein (BCRP) ABCG2 reportedly confers cancer cell resistance to camptothecin-based anticancer drugs, such as topotecan and 7-ethyl-10-hydroxycamptothecin (SN-38: the active metabolite of irinotecan). Topotecan 154-163 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 58-63 11557123-5 2001 The MTD was topotecan 0.90 mg/m(2) and epirubicin 40 mg/m(2) with neutropenia being the most common dose-limiting event. Topotecan 12-21 metallothionein 1E Homo sapiens 4-7 11822756-16 2001 The MTD was reached at the doses of 100 mg/m2 topotecan and 75 mg/m2 etoposide. Topotecan 46-55 metallothionein 1E Homo sapiens 4-7 11410862-7 2001 Furthermore, a potentiation in the growth inhibitory effect on GEO cancer cells was observed after treatment with these EGFR antisense MBOs in combination with cytotoxic drugs, including cisplatin, doxorubicin, paclitaxel, or topotecan. Topotecan 226-235 epidermal growth factor receptor Homo sapiens 120-124 11559526-6 2001 Cross-resistance studies suggest that, compared with wild-type MXR/BCRP/ABCP, cells having an R482T mutation have higher anthracycline resistance, whereas an R482G mutation seems to confer relatively less resistance to SN-38 and topotecan. Topotecan 229-238 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 63-66 11607769-5 2001 The median peak and median total yield of CD34+ cells were six-fold higher for the topotecan-filgrastim group (328/microl and 21.5 x 10(6)/kg, respectively) than for the filgrastim group (54/microl and 3.7 x 10(6)/kg, respectively). Topotecan 83-92 CD34 molecule Homo sapiens 42-46 11520135-0 2001 High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Topotecan 10-19 STT3 oligosaccharyltransferase complex catalytic subunit A Homo sapiens 54-57 11520135-1 2001 OBJECTIVE: The goal of this study was to determine the optimal dose of topotecan when used in combination with high-dose melphalan and cyclophosphamide (TMC), and to assess the toxicity and efficacy of the regimen in patients with advanced ovarian cancer. Topotecan 71-80 STT3 oligosaccharyltransferase complex catalytic subunit A Homo sapiens 153-156 11520135-11 2001 CONCLUSION: With a topotecan dose of 4.0 mg/m(2)/day x 5 days, the TMC regimen has acceptable toxicity and produces high response rates. Topotecan 19-28 STT3 oligosaccharyltransferase complex catalytic subunit A Homo sapiens 67-70 11474256-8 2001 Maximum tolerated dosage (MTD) for the topotecan and irinotecan combination was defined as that which permitted 4 weeks of topotecan and irinotecan administration with G-CSF at or near the dose intensity reported for each single agent. Topotecan 39-48 colony stimulating factor 2 Homo sapiens 168-173 11398891-11 2001 G-CSF 5 microg/kg subcutaneously starting day 6 permitted further topotecan dose escalation. Topotecan 66-75 colony stimulating factor 3 Homo sapiens 0-5 11404500-0 2001 Temporary reversal by topotecan of marked insulin resistance in a patient with myelodysplastic syndrome: case report and possible mechanism for tumor necrosis factor alpha (TNF-alpha)-induced insulin resistance. Topotecan 22-31 tumor necrosis factor Homo sapiens 144-171 11404500-0 2001 Temporary reversal by topotecan of marked insulin resistance in a patient with myelodysplastic syndrome: case report and possible mechanism for tumor necrosis factor alpha (TNF-alpha)-induced insulin resistance. Topotecan 22-31 tumor necrosis factor Homo sapiens 173-182 11459199-5 2001 By MTT assay and compared with parental, intermediate-level EGFR-expressing ME180 cells, high EGFR-expressing ME180/TNF cells had a three- to fourfold increased sensitivity to cisplatin, camptothecin (CPT), and topotecan, and low EGFR-expressing ME180/Pt cells had a five- to ninefold reduced sensitivity to the same agents. Topotecan 211-220 epidermal growth factor receptor Homo sapiens 94-98 11459199-5 2001 By MTT assay and compared with parental, intermediate-level EGFR-expressing ME180 cells, high EGFR-expressing ME180/TNF cells had a three- to fourfold increased sensitivity to cisplatin, camptothecin (CPT), and topotecan, and low EGFR-expressing ME180/Pt cells had a five- to ninefold reduced sensitivity to the same agents. Topotecan 211-220 tumor necrosis factor Homo sapiens 116-119 11459199-5 2001 By MTT assay and compared with parental, intermediate-level EGFR-expressing ME180 cells, high EGFR-expressing ME180/TNF cells had a three- to fourfold increased sensitivity to cisplatin, camptothecin (CPT), and topotecan, and low EGFR-expressing ME180/Pt cells had a five- to ninefold reduced sensitivity to the same agents. Topotecan 211-220 epidermal growth factor receptor Homo sapiens 94-98 11358853-10 2001 MCJ expression was associated with enhanced sensitivity to paclitaxel, topotecan, and cisplatin, suggesting that MCJ loss may play a role in de novo chemoresistance in ovarian carcinoma. Topotecan 71-80 DnaJ heat shock protein family (Hsp40) member C15 Homo sapiens 0-3 11336465-0 2001 A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study. Topotecan 46-55 colony stimulating factor 3 Homo sapiens 61-98 11404500-0 2001 Temporary reversal by topotecan of marked insulin resistance in a patient with myelodysplastic syndrome: case report and possible mechanism for tumor necrosis factor alpha (TNF-alpha)-induced insulin resistance. Topotecan 22-31 insulin Homo sapiens 42-49 11309308-5 2001 Both monoclonal antibodies show specific BCRP plasma membrane staining on cytospins obtained from topotecan- or mitoxantrone-selected cell lines, as well as from BCRP-transfected cell lines. Topotecan 98-107 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 41-45 11309308-7 2001 In the topotecan-selected T8 and mitoxantrone-selected MX3 tumor cell lines, BCRP turned out to be differentially glycosylated. Topotecan 7-16 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 77-81 11309308-16 2001 delivered BCRP substrates, e.g., topotecan or irinotecan, by using a BCRP inhibitor. Topotecan 33-42 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 10-14 11309308-16 2001 delivered BCRP substrates, e.g., topotecan or irinotecan, by using a BCRP inhibitor. Topotecan 33-42 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 69-73 11309344-7 2001 From the combined data, we conclude that the affinities of topoisomerase I drugs for BCRP are, in decreasing order: SN-38 > topotecan > 9-aminocamptothecin approximately CPT-11 > NX211 > DX8951f > BNP1350. Topotecan 127-136 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 85-89 11264156-0 2001 A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma. Topotecan 69-78 colony stimulating factor 2 Homo sapiens 43-49 11721172-1 2001 OBJECTIVES: Topotecan, a potent inhibitor of the enzyme topoisomerase I, has shown an interesting activity against several types of solid tumors, most notably small cell lung cancer (SCLC) and ovarian cancer. Topotecan 12-21 SCLC1 Homo sapiens 183-187 11162657-1 2001 Breast cancer resistance protein (BCRP), an ABC half-transporter, is overexpressed in cancer cell lines selected with doxorubicin/verapamil, topotecan, or mitoxantrone. Topotecan 141-150 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-32 11162657-1 2001 Breast cancer resistance protein (BCRP), an ABC half-transporter, is overexpressed in cancer cell lines selected with doxorubicin/verapamil, topotecan, or mitoxantrone. Topotecan 141-150 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 34-38 11162657-2 2001 BCRP-overexpressing cells show cross-resistance to camptothecin derivatives such as irinotecan, SN-38 (the active metabolite of irinotecan), and topotecan. Topotecan 145-154 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-4 11166732-4 2001 High p53 protein levels, but not genetic or functional p53 status, were associated with increased topotecan-induced DNA/topoisomerase I complex formation. Topotecan 98-107 tumor protein p53 Homo sapiens 5-8 11251005-1 2001 PURPOSE: Topotecan, administered intravenously, is active in small-cell lung cancer (SCLC). Topotecan 9-18 SCLC1 Homo sapiens 85-89 11251005-12 2001 CONCLUSION: This study found oral topotecan to be similar in efficacy to IV topotecan in the treatment of patients with relapsed SCLC, sensitive to first-line chemotherapy, with less grade 4 neutropenia and greater convenience of administration. Topotecan 34-43 SCLC1 Homo sapiens 129-133 11280753-3 2001 The RC0.1 and RC1 cells have high cross-resistance to CPT derivatives including SN-38 and topotecan, but are not cross-resistant to the non-top1 inhibitors etoposide, doxorubicin, and vincristine. Topotecan 90-99 chromobox 8 Homo sapiens 14-17 11398512-4 2001 The aim of our study was the attempt to assess the quality of life of patients with advanced colorectal cancer (IV stage in TNM scale), treated by topotecan. Topotecan 147-156 teneurin transmembrane protein 1 Homo sapiens 124-127 11212277-0 2001 The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Topotecan 101-110 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 125-157 11212277-10 2001 Moreover, CI1033 enhanced the uptake and cytotoxicity of SN-38 and TPT in cells transfected with BCRP but not empty vector. Topotecan 67-70 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 97-101 11269740-20 2001 HPRT mutational frequency may correlate with plasma steady-state topotecan lactone levels. Topotecan 65-82 hypoxanthine phosphoribosyltransferase 1 Homo sapiens 0-4 11016662-0 2000 Prevention of phosphatidylinositol 3"-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Topotecan 83-92 AKT serine/threonine kinase 1 Homo sapiens 45-48 11142692-5 2000 Three cell lines (C-33, Ca Ski and CAL-39) were highly sensitive to TPT, but one cell line (A-431) was less sensitive. Topotecan 68-71 CD82 molecule Homo sapiens 18-22 11142692-6 2000 Furthermore, the cytotoxic activity of TPT was superior to that of cisplatin in Ca Ski and C-33 cells, but inferior in CAL-39 and A-431. Topotecan 39-42 SKI proto-oncogene Homo sapiens 83-86 11142692-6 2000 Furthermore, the cytotoxic activity of TPT was superior to that of cisplatin in Ca Ski and C-33 cells, but inferior in CAL-39 and A-431. Topotecan 39-42 CD82 molecule Homo sapiens 91-95 11142692-7 2000 TPT was also more active than VP-16 in CAL-39 and Ca Ski. Topotecan 0-3 SKI proto-oncogene Homo sapiens 53-56 11142692-8 2000 On the other hand, the cytotoxic activity of TPT was weaker than PTX in C-33, CAL-39 and A-431. Topotecan 45-48 CD82 molecule Homo sapiens 72-76 11142692-9 2000 TPT increased the cytotoxic activity of cisplatin and VP-16 in C-33, Ca Ski and A-431. Topotecan 0-3 host cell factor C1 Homo sapiens 54-59 11142692-9 2000 TPT increased the cytotoxic activity of cisplatin and VP-16 in C-33, Ca Ski and A-431. Topotecan 0-3 CD82 molecule Homo sapiens 63-67 11142692-9 2000 TPT increased the cytotoxic activity of cisplatin and VP-16 in C-33, Ca Ski and A-431. Topotecan 0-3 SKI proto-oncogene Homo sapiens 72-75 11142692-11 2000 TPT also enhanced the cytotoxic activity of PTX in A-431 and Ca Ski. Topotecan 0-3 SKI proto-oncogene Homo sapiens 64-67 10930538-0 2000 BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Topotecan 28-37 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-4 10930538-0 2000 BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Topotecan 28-37 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 5-8 10930538-0 2000 BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Topotecan 28-37 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 9-13 10930538-9 2000 Our data suggest that enhanced topotecan efflux contributes partly to topotecan resistance in MCF7/TPT300 cells, possibly mediated by BCRP/MXR/ABCP. Topotecan 31-40 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 134-138 10930538-9 2000 Our data suggest that enhanced topotecan efflux contributes partly to topotecan resistance in MCF7/TPT300 cells, possibly mediated by BCRP/MXR/ABCP. Topotecan 31-40 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 139-142 10930538-9 2000 Our data suggest that enhanced topotecan efflux contributes partly to topotecan resistance in MCF7/TPT300 cells, possibly mediated by BCRP/MXR/ABCP. Topotecan 31-40 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 143-147 10930538-9 2000 Our data suggest that enhanced topotecan efflux contributes partly to topotecan resistance in MCF7/TPT300 cells, possibly mediated by BCRP/MXR/ABCP. Topotecan 70-79 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 134-138 10930538-9 2000 Our data suggest that enhanced topotecan efflux contributes partly to topotecan resistance in MCF7/TPT300 cells, possibly mediated by BCRP/MXR/ABCP. Topotecan 70-79 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 139-142 10930538-9 2000 Our data suggest that enhanced topotecan efflux contributes partly to topotecan resistance in MCF7/TPT300 cells, possibly mediated by BCRP/MXR/ABCP. Topotecan 70-79 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 143-147 11139287-0 2000 Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan. Topotecan 101-110 TNF superfamily member 10 Homo sapiens 15-27 11139287-6 2000 Topotecan, a novel topoisomerase I inhibitor, induced upregulation of TRAIL-R2 as well as downregulation of TRAIL. Topotecan 0-9 TNF receptor superfamily member 10b Homo sapiens 70-78 11139287-6 2000 Topotecan, a novel topoisomerase I inhibitor, induced upregulation of TRAIL-R2 as well as downregulation of TRAIL. Topotecan 0-9 TNF superfamily member 10 Homo sapiens 70-75 11139287-8 2000 However, exposure to topotecan resulted in an enhancement of TRAIL-induced apoptosis in all primarily TRAIL-resistant RCC cell lines. Topotecan 21-30 TNF superfamily member 10 Homo sapiens 61-66 11139287-8 2000 However, exposure to topotecan resulted in an enhancement of TRAIL-induced apoptosis in all primarily TRAIL-resistant RCC cell lines. Topotecan 21-30 TNF superfamily member 10 Homo sapiens 102-107 11036110-2 2000 BCRP can render tumor cells resistant to the anticancer drugs topotecan, mitoxantrone, doxorubicin, and daunorubicin. Topotecan 62-71 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 0-4 11036110-5 2000 Bcrp1, the murine homologue of BCRP, was expressed in the polarized mammalian cell lines LLC-PK1 and MDCK-II, and the direction of Bcrp1-mediated transport of topotecan and mitoxantrone was determined. Topotecan 159-168 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 0-5 11036110-5 2000 Bcrp1, the murine homologue of BCRP, was expressed in the polarized mammalian cell lines LLC-PK1 and MDCK-II, and the direction of Bcrp1-mediated transport of topotecan and mitoxantrone was determined. Topotecan 159-168 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 31-35 11036110-5 2000 Bcrp1, the murine homologue of BCRP, was expressed in the polarized mammalian cell lines LLC-PK1 and MDCK-II, and the direction of Bcrp1-mediated transport of topotecan and mitoxantrone was determined. Topotecan 159-168 BCR pseudogene 1 Homo sapiens 131-136 11036110-6 2000 To avoid the confounding drug transport provided by P-glycoprotein (P-gp), the roles of Bcrp1 in the bioavailability of topotecan and the effect of GF120918 were studied in both wild-type and P-gp-deficient mice and their fetuses. Topotecan 120-129 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 88-93 11036110-8 2000 When both topotecan and GF120918 were administered orally, the bioavailability (i.e., the extent to which a drug becomes available to a target tissue after administration) of topotecan in plasma was dramatically increased in P-gp-deficient mice (greater than sixfold) and wild-type mice (greater than ninefold), compared with the control (i.e., vehicle-treated) mice. Topotecan 10-19 phosphoglycolate phosphatase Mus musculus 225-229 11036110-8 2000 When both topotecan and GF120918 were administered orally, the bioavailability (i.e., the extent to which a drug becomes available to a target tissue after administration) of topotecan in plasma was dramatically increased in P-gp-deficient mice (greater than sixfold) and wild-type mice (greater than ninefold), compared with the control (i.e., vehicle-treated) mice. Topotecan 175-184 phosphoglycolate phosphatase Mus musculus 225-229 11036110-10 2000 In pregnant GF120918-treated, P-gp-deficient mice, relative fetal penetration of topotecan was twofold higher than that in pregnant vehicle-treated mice, suggesting a function for BCRP in the maternal-fetal barrier of the placenta. Topotecan 81-90 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 180-184 11036110-12 2000 We propose that strategic application of BCRP inhibitors may thus lead to more effective oral chemotherapy with topotecan or other BCRP substrate drugs. Topotecan 112-121 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 41-45 11016662-2 2000 In the course of examining the target molecules of the topoisomerase I inhibitor topotecan, we found that topotecan treatment promoted Akt dephosphorylation that led to the inactivation of Akt in human lung cancer A549 cells. Topotecan 81-90 AKT serine/threonine kinase 1 Homo sapiens 135-138 11016662-2 2000 In the course of examining the target molecules of the topoisomerase I inhibitor topotecan, we found that topotecan treatment promoted Akt dephosphorylation that led to the inactivation of Akt in human lung cancer A549 cells. Topotecan 81-90 AKT serine/threonine kinase 1 Homo sapiens 189-192 11016662-2 2000 In the course of examining the target molecules of the topoisomerase I inhibitor topotecan, we found that topotecan treatment promoted Akt dephosphorylation that led to the inactivation of Akt in human lung cancer A549 cells. Topotecan 106-115 AKT serine/threonine kinase 1 Homo sapiens 135-138 11016662-2 2000 In the course of examining the target molecules of the topoisomerase I inhibitor topotecan, we found that topotecan treatment promoted Akt dephosphorylation that led to the inactivation of Akt in human lung cancer A549 cells. Topotecan 106-115 AKT serine/threonine kinase 1 Homo sapiens 189-192 11016662-3 2000 Transfection of the constitutively active akt cDNA into A549 cells resulted in the reduction of the cytotoxic effect of topotecan, indicating that inhibition of the Akt pathway played an important role in exhibition of topotecan-mediated cytotoxic effects. Topotecan 120-129 AKT serine/threonine kinase 1 Homo sapiens 42-45 11016662-3 2000 Transfection of the constitutively active akt cDNA into A549 cells resulted in the reduction of the cytotoxic effect of topotecan, indicating that inhibition of the Akt pathway played an important role in exhibition of topotecan-mediated cytotoxic effects. Topotecan 120-129 AKT serine/threonine kinase 1 Homo sapiens 165-168 11016662-3 2000 Transfection of the constitutively active akt cDNA into A549 cells resulted in the reduction of the cytotoxic effect of topotecan, indicating that inhibition of the Akt pathway played an important role in exhibition of topotecan-mediated cytotoxic effects. Topotecan 219-228 AKT serine/threonine kinase 1 Homo sapiens 42-45 11016662-3 2000 Transfection of the constitutively active akt cDNA into A549 cells resulted in the reduction of the cytotoxic effect of topotecan, indicating that inhibition of the Akt pathway played an important role in exhibition of topotecan-mediated cytotoxic effects. Topotecan 219-228 AKT serine/threonine kinase 1 Homo sapiens 165-168 11016662-4 2000 Further analysis of Akt dephosphorylation revealed that topotecan treatment suppressed upstream kinases of Akt, 3-phosphoinositide-dependent protein kinase 1, and PI(3)K. Overall, the results demonstrate that topotecan exhibited its cytotoxic effects by down-regulating the PI(3)K-Akt survival signaling pathway in addition to inhibiting topoisomerase I. Topotecan 56-65 AKT serine/threonine kinase 1 Homo sapiens 20-23 11016662-4 2000 Further analysis of Akt dephosphorylation revealed that topotecan treatment suppressed upstream kinases of Akt, 3-phosphoinositide-dependent protein kinase 1, and PI(3)K. Overall, the results demonstrate that topotecan exhibited its cytotoxic effects by down-regulating the PI(3)K-Akt survival signaling pathway in addition to inhibiting topoisomerase I. Topotecan 56-65 AKT serine/threonine kinase 1 Homo sapiens 107-110 11016662-4 2000 Further analysis of Akt dephosphorylation revealed that topotecan treatment suppressed upstream kinases of Akt, 3-phosphoinositide-dependent protein kinase 1, and PI(3)K. Overall, the results demonstrate that topotecan exhibited its cytotoxic effects by down-regulating the PI(3)K-Akt survival signaling pathway in addition to inhibiting topoisomerase I. Topotecan 56-65 AKT serine/threonine kinase 1 Homo sapiens 107-110 11016662-4 2000 Further analysis of Akt dephosphorylation revealed that topotecan treatment suppressed upstream kinases of Akt, 3-phosphoinositide-dependent protein kinase 1, and PI(3)K. Overall, the results demonstrate that topotecan exhibited its cytotoxic effects by down-regulating the PI(3)K-Akt survival signaling pathway in addition to inhibiting topoisomerase I. Topotecan 209-218 AKT serine/threonine kinase 1 Homo sapiens 20-23 11016662-4 2000 Further analysis of Akt dephosphorylation revealed that topotecan treatment suppressed upstream kinases of Akt, 3-phosphoinositide-dependent protein kinase 1, and PI(3)K. Overall, the results demonstrate that topotecan exhibited its cytotoxic effects by down-regulating the PI(3)K-Akt survival signaling pathway in addition to inhibiting topoisomerase I. Topotecan 209-218 AKT serine/threonine kinase 1 Homo sapiens 107-110 11016662-4 2000 Further analysis of Akt dephosphorylation revealed that topotecan treatment suppressed upstream kinases of Akt, 3-phosphoinositide-dependent protein kinase 1, and PI(3)K. Overall, the results demonstrate that topotecan exhibited its cytotoxic effects by down-regulating the PI(3)K-Akt survival signaling pathway in addition to inhibiting topoisomerase I. Topotecan 209-218 AKT serine/threonine kinase 1 Homo sapiens 107-110 10997810-1 2000 BACKGROUND: The aim was to define the MTD of topotecan (TPT) given before cisplatin in patients with previously untreated SCLC. Topotecan 45-54 metallothionein 1E Homo sapiens 38-41 10891476-2 2000 Transfection and enforced expression of BCRP in drug-sensitive cells confer resistance to mitoxantrone, doxorubicin, daunorubicin, and topotecan. Topotecan 135-144 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 40-44 10997810-1 2000 BACKGROUND: The aim was to define the MTD of topotecan (TPT) given before cisplatin in patients with previously untreated SCLC. Topotecan 56-59 metallothionein 1E Homo sapiens 38-41 10839301-7 2000 Additionally, augmentation of CD95 receptor expression was found in three RCC cell lines, including one p53-mutated cell line, whereas another p53-mutated cell line showed no or only a weak CD95 receptor upregulation after exposure to topotecan or bleomycin, respectively. Topotecan 235-244 Fas cell surface death receptor Homo sapiens 30-34 10912947-7 2000 Sample pretreatment procedures of the CPT analogs topotecan, irinotecan, 9-aminocamptothecin and lurtotecan are summarized and discussed in this review. Topotecan 50-59 choline phosphotransferase 1 Homo sapiens 38-41 10912951-4 2000 The etoposide-resistant line with the highest P-gp level was cross-resistant also to SN-38, CPT-11 and topotecan (TPT), but not to 9-aminocamptothecin (9-AC), CPT and DX-8951f. Topotecan 103-112 ATP binding cassette subfamily B member 1 Homo sapiens 46-50 10912951-4 2000 The etoposide-resistant line with the highest P-gp level was cross-resistant also to SN-38, CPT-11 and topotecan (TPT), but not to 9-aminocamptothecin (9-AC), CPT and DX-8951f. Topotecan 114-117 ATP binding cassette subfamily B member 1 Homo sapiens 46-50 10839301-9 2000 Thus, although a functionally intact CD95 signalling cascade is present in most RCC cell lines, the anticancer drugs topotecan and bleomycin that induce upregulation of CD95 receptor and ligand fail to effectively activate CD95-mediated apoptosis. Topotecan 117-126 Fas cell surface death receptor Homo sapiens 169-173 10839301-9 2000 Thus, although a functionally intact CD95 signalling cascade is present in most RCC cell lines, the anticancer drugs topotecan and bleomycin that induce upregulation of CD95 receptor and ligand fail to effectively activate CD95-mediated apoptosis. Topotecan 117-126 Fas cell surface death receptor Homo sapiens 169-173 10831346-0 2000 Effect of topotecan on serum CA-125 in patients with advanced epithelial ovarian cancer. Topotecan 10-19 mucin 16, cell surface associated Homo sapiens 29-35 10806112-7 2000 Reduced levels of mitoxantrone, daunorubicin, bisantrene, topotecan, rhodamine 123 and prazosin were observed in the two sublines with high MXR expression. Topotecan 58-67 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 140-143 10806112-10 2000 Further, cells that overexpress the MXR protein seem to be more resistant to mitoxantrone and topotecan than cells with P-glycoprotein-mediated multidrug resistance. Topotecan 94-103 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 36-39 10831346-1 2000 The effect of topotecan on CA-125 serum levels was evaluated in 30 patients with advanced epithelial ovarian cancer. Topotecan 14-23 mucin 16, cell surface associated Homo sapiens 27-33 10831346-9 2000 The rate of change in CA-125 (s, slope of the exponential regression curve) during treatment with topotecan was compared with s over a period before treatment. Topotecan 98-107 mucin 16, cell surface associated Homo sapiens 22-28 10831346-11 2000 Comparing the mean values of s before and during topotecan, a significant (P = 0.005) decrease was seen in the CA-125 serum levels. Topotecan 49-58 mucin 16, cell surface associated Homo sapiens 111-117 10831346-17 2000 In conclusion, at the given dose intensity topotecan shows activity in advanced paclitaxel- and platinum-resistant ovarian cancer based on CA-125 measurements. Topotecan 43-52 mucin 16, cell surface associated Homo sapiens 139-145 10825126-0 2000 Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Topotecan 90-99 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-32 10825126-4 2000 BCRP was detected in BCRP-transfected cells and in several mitoxantrone- and topotecan-selected tumor cell sublines. Topotecan 77-86 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-4 10825136-5 2000 A close correlation was found between acute induction of apoptosis (24 h) and up-regulated expression of FasL at high concentrations of each of the three agents (0.3-3 microM doxorubicin, 0.3-3 microM topotecan, and 10-90 microM VP-16), which was caspase dependent but Fas independent. Topotecan 201-210 Fas ligand Homo sapiens 105-109 10857993-6 2000 Our results show that: 1) Sequential TPT --> G2/M-active drugs are synergistic when administration overlapped the maximum percentage of TPT-induced G2/M-phase cell arrest interval in all three mutated p53 cell lines; 2) the reverse sequential schedule (G2/M-active drug --> TPT) was antagonistic, and being only additive for Etoposide --> TPT association. Topotecan 37-40 tumor protein p53 Homo sapiens 204-207 10857993-6 2000 Our results show that: 1) Sequential TPT --> G2/M-active drugs are synergistic when administration overlapped the maximum percentage of TPT-induced G2/M-phase cell arrest interval in all three mutated p53 cell lines; 2) the reverse sequential schedule (G2/M-active drug --> TPT) was antagonistic, and being only additive for Etoposide --> TPT association. Topotecan 139-142 tumor protein p53 Homo sapiens 204-207 10857993-6 2000 Our results show that: 1) Sequential TPT --> G2/M-active drugs are synergistic when administration overlapped the maximum percentage of TPT-induced G2/M-phase cell arrest interval in all three mutated p53 cell lines; 2) the reverse sequential schedule (G2/M-active drug --> TPT) was antagonistic, and being only additive for Etoposide --> TPT association. Topotecan 139-142 tumor protein p53 Homo sapiens 204-207 10857993-6 2000 Our results show that: 1) Sequential TPT --> G2/M-active drugs are synergistic when administration overlapped the maximum percentage of TPT-induced G2/M-phase cell arrest interval in all three mutated p53 cell lines; 2) the reverse sequential schedule (G2/M-active drug --> TPT) was antagonistic, and being only additive for Etoposide --> TPT association. Topotecan 139-142 tumor protein p53 Homo sapiens 204-207 10604726-0 1999 Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines. Topotecan 42-51 ATP binding cassette subfamily B member 1 Homo sapiens 12-16 11193894-7 2000 BCRP is a very efficient transporter of topotecan. Topotecan 40-49 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 0-4 10656451-4 2000 In the present work, the involvement of the Fas/FasL system in drug-induced apoptosis in lung cancer cells was investigated upon exposure to four cytotoxic drugs (cisplatin, gemcitabine, topotecan, and paclitaxel). Topotecan 187-196 Fas ligand Homo sapiens 48-52 10777678-3 2000 Recently, an ABC half-transporter, the ABCG2 gene product Breast Cancer/Mitoxantrone Resistance Protein (BCRP/MXR), has been shown to cause mitoxantrone and topotecan resistance. Topotecan 157-166 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 39-44 10777678-3 2000 Recently, an ABC half-transporter, the ABCG2 gene product Breast Cancer/Mitoxantrone Resistance Protein (BCRP/MXR), has been shown to cause mitoxantrone and topotecan resistance. Topotecan 157-166 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 105-109 10777678-3 2000 Recently, an ABC half-transporter, the ABCG2 gene product Breast Cancer/Mitoxantrone Resistance Protein (BCRP/MXR), has been shown to cause mitoxantrone and topotecan resistance. Topotecan 157-166 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 110-113 10604726-1 1999 Recent data suggest that expression of the membrane P170-glycoprotein (P-gp) may confer resistance to the topoisomerase-I-interactive agent topotecan. Topotecan 140-149 phosphoglycolate phosphatase Homo sapiens 52-69 10604726-1 1999 Recent data suggest that expression of the membrane P170-glycoprotein (P-gp) may confer resistance to the topoisomerase-I-interactive agent topotecan. Topotecan 140-149 phosphoglycolate phosphatase Homo sapiens 71-75 10604726-2 1999 The present study describes the cellular effects of a new dihydropyridine analogue, PAK-200S, on P-gp-mediated resistance to topotecan in human breast and ovarian tumour cells. Topotecan 125-134 phosphoglycolate phosphatase Homo sapiens 97-101 10604726-3 1999 PAK-200S at a non-cytotoxic concentration of 2.0 microM completely reversed resistance to topotecan in P-gp-expressing MCF-7/adr (breast) and A2780/Dx5 (ovarian) tumour cells, respectively, with no effects on parental cells. Topotecan 90-99 phosphoglycolate phosphatase Homo sapiens 103-107 10604726-8 1999 These results suggest that reversal of P-gp-mediated resistance to topotecan by PAK-200S was related to the restoration of cellular drug concentrations of the active lactone form of topotecan rather than a direct effect on topoisomerase-I function. Topotecan 67-76 phosphoglycolate phosphatase Homo sapiens 39-43 10604726-8 1999 These results suggest that reversal of P-gp-mediated resistance to topotecan by PAK-200S was related to the restoration of cellular drug concentrations of the active lactone form of topotecan rather than a direct effect on topoisomerase-I function. Topotecan 182-191 phosphoglycolate phosphatase Homo sapiens 39-43 10493966-7 1999 On day +10 (range +9 to +11) after the last dose of Topotecan, the median WBC count and the CD34+ cell peak were 8.2 x 10(3) microl (range 4.9-13.9) and 55 microl (range 28-75), respectively. Topotecan 52-61 CD34 molecule Homo sapiens 92-96 10786197-18 1999 Furthermore, topotecan demonstrated to be an effective drug to mobilize CD34+ cells for autografting. Topotecan 13-22 CD34 molecule Homo sapiens 72-76 10569939-1 1999 Homocamptothecin (hCPT) contains a seven-membered beta-hydroxylactone in place of the conventional six-membered alpha-hydroxylactone ring found in camptothecin and its tumor active analogues, including topotecan and irinotecan. Topotecan 202-211 choline phosphotransferase 1 Homo sapiens 18-22 10493963-7 1999 In particular, topotecan and cis-platin were more active in squamous cell carcinoma than in adenocarcinoma cell lines (p=0.006 and 0.001 respectively at 0.1 microM concentration), while paclitaxel was more active in ADK than in SCC cell lines (p=0.004 at 0.01 microM concentration). Topotecan 15-24 adenosine kinase Homo sapiens 216-219 10493507-5 1999 Pharmacodynamic analysis demonstrated that BCRP/MXR/ABCP is a very efficient transporter of topotecan; in vitro, 70% of the intracellular topotecan pool was transported out of the T8 or MX3 cells within 30 s. In conclusion, we report for the first time that BCRP/MXR/ABCP can also be up-regulated upon exposure of tumor cells to the clinically important drug topotecan, and that BCRP-mediated efflux of topotecan is very efficient. Topotecan 138-147 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 43-47 10493507-5 1999 Pharmacodynamic analysis demonstrated that BCRP/MXR/ABCP is a very efficient transporter of topotecan; in vitro, 70% of the intracellular topotecan pool was transported out of the T8 or MX3 cells within 30 s. In conclusion, we report for the first time that BCRP/MXR/ABCP can also be up-regulated upon exposure of tumor cells to the clinically important drug topotecan, and that BCRP-mediated efflux of topotecan is very efficient. Topotecan 138-147 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 48-51 10493507-0 1999 Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Topotecan 46-55 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 22-26 10493507-5 1999 Pharmacodynamic analysis demonstrated that BCRP/MXR/ABCP is a very efficient transporter of topotecan; in vitro, 70% of the intracellular topotecan pool was transported out of the T8 or MX3 cells within 30 s. In conclusion, we report for the first time that BCRP/MXR/ABCP can also be up-regulated upon exposure of tumor cells to the clinically important drug topotecan, and that BCRP-mediated efflux of topotecan is very efficient. Topotecan 138-147 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 52-56 10493507-0 1999 Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Topotecan 46-55 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 27-30 10493507-6 1999 This highly efficient efflux of topotecan by BCRP/MXR/ABCP may have clinical relevance for patients being treated with topotecan. Topotecan 32-41 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 45-49 10493507-0 1999 Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Topotecan 46-55 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 31-35 10493507-6 1999 This highly efficient efflux of topotecan by BCRP/MXR/ABCP may have clinical relevance for patients being treated with topotecan. Topotecan 32-41 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 50-53 10493507-4 1999 Furthermore, BCRP/MXR/ABCP expression levels in various partially revertant T8 cells correlated with the levels of resistance to topotecan, SN-38, and mitoxantrone, strongly suggesting BCRP/MXR/ABCP to be the transporter responsible for the enhanced efflux. Topotecan 129-138 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 13-17 10493507-4 1999 Furthermore, BCRP/MXR/ABCP expression levels in various partially revertant T8 cells correlated with the levels of resistance to topotecan, SN-38, and mitoxantrone, strongly suggesting BCRP/MXR/ABCP to be the transporter responsible for the enhanced efflux. Topotecan 129-138 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 18-21 10493507-4 1999 Furthermore, BCRP/MXR/ABCP expression levels in various partially revertant T8 cells correlated with the levels of resistance to topotecan, SN-38, and mitoxantrone, strongly suggesting BCRP/MXR/ABCP to be the transporter responsible for the enhanced efflux. Topotecan 129-138 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 22-26 10493507-4 1999 Furthermore, BCRP/MXR/ABCP expression levels in various partially revertant T8 cells correlated with the levels of resistance to topotecan, SN-38, and mitoxantrone, strongly suggesting BCRP/MXR/ABCP to be the transporter responsible for the enhanced efflux. Topotecan 129-138 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 185-189 10493507-4 1999 Furthermore, BCRP/MXR/ABCP expression levels in various partially revertant T8 cells correlated with the levels of resistance to topotecan, SN-38, and mitoxantrone, strongly suggesting BCRP/MXR/ABCP to be the transporter responsible for the enhanced efflux. Topotecan 129-138 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 190-193 10493507-6 1999 This highly efficient efflux of topotecan by BCRP/MXR/ABCP may have clinical relevance for patients being treated with topotecan. Topotecan 32-41 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 54-58 10493507-6 1999 This highly efficient efflux of topotecan by BCRP/MXR/ABCP may have clinical relevance for patients being treated with topotecan. Topotecan 119-128 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 45-49 10493507-6 1999 This highly efficient efflux of topotecan by BCRP/MXR/ABCP may have clinical relevance for patients being treated with topotecan. Topotecan 119-128 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 50-53 10493507-6 1999 This highly efficient efflux of topotecan by BCRP/MXR/ABCP may have clinical relevance for patients being treated with topotecan. Topotecan 119-128 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 54-58 10235474-0 1999 Subnuclear distribution of DNA topoisomerase I and Bax protein in normal and xeroderma pigmentosum fibroblasts after irradiation with UV light and gamma rays or treatment with topotecan. Topotecan 176-185 BCL2 associated X, apoptosis regulator Homo sapiens 51-54 10493507-4 1999 Furthermore, BCRP/MXR/ABCP expression levels in various partially revertant T8 cells correlated with the levels of resistance to topotecan, SN-38, and mitoxantrone, strongly suggesting BCRP/MXR/ABCP to be the transporter responsible for the enhanced efflux. Topotecan 129-138 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 194-198 10493507-5 1999 Pharmacodynamic analysis demonstrated that BCRP/MXR/ABCP is a very efficient transporter of topotecan; in vitro, 70% of the intracellular topotecan pool was transported out of the T8 or MX3 cells within 30 s. In conclusion, we report for the first time that BCRP/MXR/ABCP can also be up-regulated upon exposure of tumor cells to the clinically important drug topotecan, and that BCRP-mediated efflux of topotecan is very efficient. Topotecan 92-101 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 43-47 10493507-5 1999 Pharmacodynamic analysis demonstrated that BCRP/MXR/ABCP is a very efficient transporter of topotecan; in vitro, 70% of the intracellular topotecan pool was transported out of the T8 or MX3 cells within 30 s. In conclusion, we report for the first time that BCRP/MXR/ABCP can also be up-regulated upon exposure of tumor cells to the clinically important drug topotecan, and that BCRP-mediated efflux of topotecan is very efficient. Topotecan 92-101 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 48-51 10493507-5 1999 Pharmacodynamic analysis demonstrated that BCRP/MXR/ABCP is a very efficient transporter of topotecan; in vitro, 70% of the intracellular topotecan pool was transported out of the T8 or MX3 cells within 30 s. In conclusion, we report for the first time that BCRP/MXR/ABCP can also be up-regulated upon exposure of tumor cells to the clinically important drug topotecan, and that BCRP-mediated efflux of topotecan is very efficient. Topotecan 92-101 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 52-56 10493507-5 1999 Pharmacodynamic analysis demonstrated that BCRP/MXR/ABCP is a very efficient transporter of topotecan; in vitro, 70% of the intracellular topotecan pool was transported out of the T8 or MX3 cells within 30 s. In conclusion, we report for the first time that BCRP/MXR/ABCP can also be up-regulated upon exposure of tumor cells to the clinically important drug topotecan, and that BCRP-mediated efflux of topotecan is very efficient. Topotecan 92-101 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 258-262 10493507-5 1999 Pharmacodynamic analysis demonstrated that BCRP/MXR/ABCP is a very efficient transporter of topotecan; in vitro, 70% of the intracellular topotecan pool was transported out of the T8 or MX3 cells within 30 s. In conclusion, we report for the first time that BCRP/MXR/ABCP can also be up-regulated upon exposure of tumor cells to the clinically important drug topotecan, and that BCRP-mediated efflux of topotecan is very efficient. Topotecan 92-101 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 263-266 10493507-5 1999 Pharmacodynamic analysis demonstrated that BCRP/MXR/ABCP is a very efficient transporter of topotecan; in vitro, 70% of the intracellular topotecan pool was transported out of the T8 or MX3 cells within 30 s. In conclusion, we report for the first time that BCRP/MXR/ABCP can also be up-regulated upon exposure of tumor cells to the clinically important drug topotecan, and that BCRP-mediated efflux of topotecan is very efficient. Topotecan 92-101 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 267-271 10493507-5 1999 Pharmacodynamic analysis demonstrated that BCRP/MXR/ABCP is a very efficient transporter of topotecan; in vitro, 70% of the intracellular topotecan pool was transported out of the T8 or MX3 cells within 30 s. In conclusion, we report for the first time that BCRP/MXR/ABCP can also be up-regulated upon exposure of tumor cells to the clinically important drug topotecan, and that BCRP-mediated efflux of topotecan is very efficient. Topotecan 92-101 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 258-262 10493507-5 1999 Pharmacodynamic analysis demonstrated that BCRP/MXR/ABCP is a very efficient transporter of topotecan; in vitro, 70% of the intracellular topotecan pool was transported out of the T8 or MX3 cells within 30 s. In conclusion, we report for the first time that BCRP/MXR/ABCP can also be up-regulated upon exposure of tumor cells to the clinically important drug topotecan, and that BCRP-mediated efflux of topotecan is very efficient. Topotecan 138-147 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 43-47 10493507-5 1999 Pharmacodynamic analysis demonstrated that BCRP/MXR/ABCP is a very efficient transporter of topotecan; in vitro, 70% of the intracellular topotecan pool was transported out of the T8 or MX3 cells within 30 s. In conclusion, we report for the first time that BCRP/MXR/ABCP can also be up-regulated upon exposure of tumor cells to the clinically important drug topotecan, and that BCRP-mediated efflux of topotecan is very efficient. Topotecan 138-147 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 48-51 10493507-5 1999 Pharmacodynamic analysis demonstrated that BCRP/MXR/ABCP is a very efficient transporter of topotecan; in vitro, 70% of the intracellular topotecan pool was transported out of the T8 or MX3 cells within 30 s. In conclusion, we report for the first time that BCRP/MXR/ABCP can also be up-regulated upon exposure of tumor cells to the clinically important drug topotecan, and that BCRP-mediated efflux of topotecan is very efficient. Topotecan 138-147 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 52-56 10493507-5 1999 Pharmacodynamic analysis demonstrated that BCRP/MXR/ABCP is a very efficient transporter of topotecan; in vitro, 70% of the intracellular topotecan pool was transported out of the T8 or MX3 cells within 30 s. In conclusion, we report for the first time that BCRP/MXR/ABCP can also be up-regulated upon exposure of tumor cells to the clinically important drug topotecan, and that BCRP-mediated efflux of topotecan is very efficient. Topotecan 138-147 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 43-47 10493507-5 1999 Pharmacodynamic analysis demonstrated that BCRP/MXR/ABCP is a very efficient transporter of topotecan; in vitro, 70% of the intracellular topotecan pool was transported out of the T8 or MX3 cells within 30 s. In conclusion, we report for the first time that BCRP/MXR/ABCP can also be up-regulated upon exposure of tumor cells to the clinically important drug topotecan, and that BCRP-mediated efflux of topotecan is very efficient. Topotecan 138-147 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 48-51 10493507-5 1999 Pharmacodynamic analysis demonstrated that BCRP/MXR/ABCP is a very efficient transporter of topotecan; in vitro, 70% of the intracellular topotecan pool was transported out of the T8 or MX3 cells within 30 s. In conclusion, we report for the first time that BCRP/MXR/ABCP can also be up-regulated upon exposure of tumor cells to the clinically important drug topotecan, and that BCRP-mediated efflux of topotecan is very efficient. Topotecan 138-147 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 52-56 10485464-0 1999 The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Topotecan 105-114 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 10-15 10485464-0 1999 The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Topotecan 105-114 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 20-24 10485464-6 1999 Our data argue strongly that mouse Bcrp1 is functionally comparable with human BCRP, conferring multidrug resistance to topotecan, mitoxantrone, doxorubicin, and related compounds. Topotecan 120-129 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 35-40 10485464-6 1999 Our data argue strongly that mouse Bcrp1 is functionally comparable with human BCRP, conferring multidrug resistance to topotecan, mitoxantrone, doxorubicin, and related compounds. Topotecan 120-129 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 79-83 20654516-7 1999 Further, camptothecin and topotecan (TPT) were compared for their effect on bax mRNA expression. Topotecan 26-35 BCL2 associated X, apoptosis regulator Rattus norvegicus 76-79 20654516-7 1999 Further, camptothecin and topotecan (TPT) were compared for their effect on bax mRNA expression. Topotecan 37-40 BCL2 associated X, apoptosis regulator Rattus norvegicus 76-79 20654516-8 1999 Whereas camptothecin induced a continuous increase in bax transcription from 0.1 mum to 10 mum, only the highest concentration of topotecan (10 mum) led to a comparable increase of bax transcription. Topotecan 130-139 BCL2 associated X, apoptosis regulator Rattus norvegicus 181-184 10505042-4 1999 The cytotoxicities of topotecan and gemcitabine on the human lung cancer cell lines H460 (wild-type-p53) and H322 (mutant p53 were determined after 72 h drug exposure employing the MTT assay. Topotecan 22-31 tumor protein p53 Homo sapiens 100-103 10505042-4 1999 The cytotoxicities of topotecan and gemcitabine on the human lung cancer cell lines H460 (wild-type-p53) and H322 (mutant p53 were determined after 72 h drug exposure employing the MTT assay. Topotecan 22-31 tumor protein p53 Homo sapiens 122-125 10355583-0 1999 Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study. Topotecan 10-19 colony stimulating factor 3 Homo sapiens 58-63 10435585-9 1999 Activation of Chk2 might not only delay mitotic entry, but also increase the capacity of cultured cells to survive after treatment with gamma-radiation or with the topoisomerase-I inhibitor topotecan. Topotecan 190-199 checkpoint kinase 2 Homo sapiens 14-18 10071262-8 1999 G-CSF support permitted further dose escalation of cisplatin and topotecan. Topotecan 65-74 colony stimulating factor 3 Homo sapiens 0-5 10235474-1 1999 Immunohistochemical methods were used to determine abundance and subnuclear distribution of DNA topoisomerase I and the Bax protein in normal and excision-repair-deficient xeroderma pigmentosum (XP) fibroblasts after irradiation of cells with gamma rays or UV light, or exposure to the topoisomerase I inhibitor topotecan. Topotecan 312-321 BCL2 associated X, apoptosis regulator Homo sapiens 120-123 10235474-10 1999 In separate assays using normal and XP cells, a dose-dependent increase in protein reacting with Bax antibody was observed in nuclei, following treatment with gamma rays or topotecan. Topotecan 173-182 BCL2 associated X, apoptosis regulator Homo sapiens 97-100 10235474-11 1999 In addition, topotecan induced a netlike arrangement of this Bax protein in nuclei. Topotecan 13-22 BCL2 associated X, apoptosis regulator Homo sapiens 61-64 10235474-14 1999 Upon further incubation with topotecan, cells showing the netlike Bax arrangement eventually died. Topotecan 29-38 BCL2 associated X, apoptosis regulator Homo sapiens 66-69 10235474-15 1999 We conclude that topotecan-induced changes made visible by nuclear Bax protein are associated with apoptosis. Topotecan 17-26 BCL2 associated X, apoptosis regulator Homo sapiens 67-70 10235474-16 1999 XP cells, when treated with topotecan, responded more readily than normal cells with both an increase in nuclear Bax protein and rearrangement of Bax, indicating that UV repair functions may be required to process DNA damage inflicted by topotecan. Topotecan 28-37 BCL2 associated X, apoptosis regulator Homo sapiens 113-116 10235474-16 1999 XP cells, when treated with topotecan, responded more readily than normal cells with both an increase in nuclear Bax protein and rearrangement of Bax, indicating that UV repair functions may be required to process DNA damage inflicted by topotecan. Topotecan 28-37 BCL2 associated X, apoptosis regulator Homo sapiens 146-149 10728907-4 1999 BDNF increases the EC50 values in survival assays for cisplatin, doxorubicin, and topotecan by two to three fold. Topotecan 82-91 brain derived neurotrophic factor Homo sapiens 0-4 10555127-9 1999 Consequently, in subsequent patients, the topotecan dose was lower in the topotecan --> VP-16 than in the other 2 arms (1.0 vs 1.25 mg/m2 daily x 5) and the VP-16 dose was lower in the topotecan --> VP-16 arm (200 vs 250 mg/m2 twice daily x 2). Topotecan 42-51 host cell factor C1 Homo sapiens 91-96 10555127-9 1999 Consequently, in subsequent patients, the topotecan dose was lower in the topotecan --> VP-16 than in the other 2 arms (1.0 vs 1.25 mg/m2 daily x 5) and the VP-16 dose was lower in the topotecan --> VP-16 arm (200 vs 250 mg/m2 twice daily x 2). Topotecan 74-83 host cell factor C1 Homo sapiens 91-96 10555127-9 1999 Consequently, in subsequent patients, the topotecan dose was lower in the topotecan --> VP-16 than in the other 2 arms (1.0 vs 1.25 mg/m2 daily x 5) and the VP-16 dose was lower in the topotecan --> VP-16 arm (200 vs 250 mg/m2 twice daily x 2). Topotecan 74-83 host cell factor C1 Homo sapiens 91-96 9732400-0 1998 Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression. Topotecan 75-84 Fas ligand Homo sapiens 16-21 9732400-6 1998 Transfer of a mutant p53 gene enhanced topotecan sensitivity in wild-type p53 LN-229 but not mutant p53 LN-18 cells. Topotecan 39-48 tumor protein p53 Homo sapiens 74-77 9732400-7 1998 CD95 ligand (CD95L)-induced apoptosis was synergistically enhanced by short-term/high concentration but not long-term/low concentration exposure to topotecan, suggesting that topotecan sensitizes human malignant glioma cells to CD95L-induced apoptosis via inhibition of RNA synthesis. Topotecan 148-157 Fas ligand Homo sapiens 0-11 9732400-7 1998 CD95 ligand (CD95L)-induced apoptosis was synergistically enhanced by short-term/high concentration but not long-term/low concentration exposure to topotecan, suggesting that topotecan sensitizes human malignant glioma cells to CD95L-induced apoptosis via inhibition of RNA synthesis. Topotecan 175-184 Fas ligand Homo sapiens 0-11 9732400-7 1998 CD95 ligand (CD95L)-induced apoptosis was synergistically enhanced by short-term/high concentration but not long-term/low concentration exposure to topotecan, suggesting that topotecan sensitizes human malignant glioma cells to CD95L-induced apoptosis via inhibition of RNA synthesis. Topotecan 175-184 Fas ligand Homo sapiens 13-18 9732400-8 1998 These data suggest that topotecan needs to be administered in high concentrations, such as an intratumoral polymer, to limit glioma cell growth in synergy with CD95L in vivo. Topotecan 24-33 Fas ligand Homo sapiens 160-165 9829730-14 1998 In contrast, low expression of the apoptosis inhibitor Bcl-2 was associated with response to TPT therapy. Topotecan 93-96 BCL2 apoptosis regulator Homo sapiens 55-60 9743293-8 1998 Thus, although p53-dependent apoptosis is induced by camptothecin, topotecan and SN-38 in this human ovarian carcinoma cell line, these drugs induce p53-independent death, as measured by clonogenic assay. Topotecan 67-76 tumor protein p53 Homo sapiens 15-18 9732400-0 1998 Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression. Topotecan 75-84 Fas cell surface death receptor Homo sapiens 16-20 9732400-3 1998 High micromolar concentrations of topotecan, which are unlikely to be achieved in plasma in human patients in vivo, were cytotoxic within 48 hr, induced DNA fragmentation, did not induce major cell cycle changes, failed to consistently alter BCL-2 or BAX protein levels but inhibited RNA synthesis and induced cleavable DNA/topoisomerase I complex formation. Topotecan 34-43 BCL2 associated X, apoptosis regulator Homo sapiens 251-254 9732400-4 1998 Prolonged exposure for 72 hr to high nanomolar to low micromolar concentrations of topotecan augmented p21 protein levels and induced G2/M arrest but failed to consistently alter BCL-2 and BAX protein levels, did not induce significant DNA/topoisomerase I complex formation and did not inhibit RNA synthesis. Topotecan 83-92 H3 histone pseudogene 16 Homo sapiens 103-106 9732400-6 1998 Transfer of a mutant p53 gene enhanced topotecan sensitivity in wild-type p53 LN-229 but not mutant p53 LN-18 cells. Topotecan 39-48 tumor protein p53 Homo sapiens 21-24 9732400-6 1998 Transfer of a mutant p53 gene enhanced topotecan sensitivity in wild-type p53 LN-229 but not mutant p53 LN-18 cells. Topotecan 39-48 tumor protein p53 Homo sapiens 74-77 9773809-2 1998 Tumor cells were exposed to CPT or TPT alone or in combination with cisplatin, 4-hydroperoxycyclophosphamide (4-HC), BCNU or etoposide (VP-16). Topotecan 35-38 host cell factor C1 Homo sapiens 136-141 9472109-0 1998 Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy. Topotecan 100-109 cyclin dependent kinase inhibitor 2A Homo sapiens 20-23 9660538-19 1998 Serum aspartate aminotransferase and albumin levels were predictive of topotecan pharmacokinetics. Topotecan 71-80 albumin Homo sapiens 37-44 9635842-10 1998 Importantly, the efflux rates of TPT in the IGROV-1 and IGROV(T100r) cell lines were not significantly different and were shown to be independent on P-glycoprotein (P-gp) or multidrug resistance-associated protein (MRP). Topotecan 33-36 ATP binding cassette subfamily B member 1 Homo sapiens 149-163 9635842-10 1998 Importantly, the efflux rates of TPT in the IGROV-1 and IGROV(T100r) cell lines were not significantly different and were shown to be independent on P-glycoprotein (P-gp) or multidrug resistance-associated protein (MRP). Topotecan 33-36 ATP binding cassette subfamily B member 1 Homo sapiens 165-169 9635842-10 1998 Importantly, the efflux rates of TPT in the IGROV-1 and IGROV(T100r) cell lines were not significantly different and were shown to be independent on P-glycoprotein (P-gp) or multidrug resistance-associated protein (MRP). Topotecan 33-36 ATP binding cassette subfamily C member 3 Homo sapiens 174-213 9635842-10 1998 Importantly, the efflux rates of TPT in the IGROV-1 and IGROV(T100r) cell lines were not significantly different and were shown to be independent on P-glycoprotein (P-gp) or multidrug resistance-associated protein (MRP). Topotecan 33-36 ATP binding cassette subfamily C member 3 Homo sapiens 215-218 9703938-0 1998 Formation of a novel topotecan metabolite in the hormone-independent human prostate carcinoma cell lines DU-145 and PC-3. Topotecan 21-30 chromobox 8 Homo sapiens 116-120 9703938-3 1998 Incubation of PC-3 cells, however, revealed a more than 2-fold higher level of cytoplasmatic TPT (25.3 +/- 4.8 pmol/10(6) cells). Topotecan 93-96 chromobox 8 Homo sapiens 14-18 9703938-7 1998 In accordance with the elevated formation of the TPT-metabolite in DU-145 cells, the expression of cytochrome P450 (CYP) isoenzymes CYP3A, CYP2B, CYP2D and CYP2E as measured by Western blot analysis was also higher in this cancer cell line. Topotecan 49-52 cytochrome P450 family 2 subfamily E member 1 Homo sapiens 156-161 9472109-4 1998 Treatment of the p16-null glioma cells, U-251 MG and D-54 MG, with paclitaxel and topotecan, resulted in cell death within 4 days. Topotecan 82-91 cyclin dependent kinase inhibitor 2A Homo sapiens 17-20 9472109-5 1998 However, overexpression of exogenous wild-type p16 protein using an adenovirus vector resulted in G1 arrest of glioma cells and resistance to the anticancer effect of paclitaxel or topotecan. Topotecan 181-190 cyclin dependent kinase inhibitor 2A Homo sapiens 47-50 9472109-6 1998 Specifically, the p16-expressing cells showed a 30-fold increase in the ID50 of topotecan and a more than 40-fold increase in the ID50 of paclitaxel. Topotecan 80-89 cyclin dependent kinase inhibitor 2A Homo sapiens 18-21 9553662-0 1998 High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study. Topotecan 10-19 colony stimulating factor 3 Homo sapiens 25-62 9553662-1 1998 PURPOSE: The premise for this study was that topotecan (TPT) resistance in preclinical studies is associated with low level expression of the p-glycoprotein (Pgp) multi-drug transporter conferred by the multi-drug resistant (MDR) phenotype, which might be overcome in clinical practice by administering moderately (2.3-fold) higher doses of TPT that have shown to be feasible with granulocyte colony-stimulating factor (G-CSF) support. Topotecan 45-54 ATP binding cassette subfamily B member 1 Homo sapiens 142-156 9553662-1 1998 PURPOSE: The premise for this study was that topotecan (TPT) resistance in preclinical studies is associated with low level expression of the p-glycoprotein (Pgp) multi-drug transporter conferred by the multi-drug resistant (MDR) phenotype, which might be overcome in clinical practice by administering moderately (2.3-fold) higher doses of TPT that have shown to be feasible with granulocyte colony-stimulating factor (G-CSF) support. Topotecan 45-54 ATP binding cassette subfamily B member 1 Homo sapiens 158-161 9553662-1 1998 PURPOSE: The premise for this study was that topotecan (TPT) resistance in preclinical studies is associated with low level expression of the p-glycoprotein (Pgp) multi-drug transporter conferred by the multi-drug resistant (MDR) phenotype, which might be overcome in clinical practice by administering moderately (2.3-fold) higher doses of TPT that have shown to be feasible with granulocyte colony-stimulating factor (G-CSF) support. Topotecan 45-54 colony stimulating factor 3 Homo sapiens 381-418 9553662-1 1998 PURPOSE: The premise for this study was that topotecan (TPT) resistance in preclinical studies is associated with low level expression of the p-glycoprotein (Pgp) multi-drug transporter conferred by the multi-drug resistant (MDR) phenotype, which might be overcome in clinical practice by administering moderately (2.3-fold) higher doses of TPT that have shown to be feasible with granulocyte colony-stimulating factor (G-CSF) support. Topotecan 45-54 colony stimulating factor 3 Homo sapiens 420-425 9553662-1 1998 PURPOSE: The premise for this study was that topotecan (TPT) resistance in preclinical studies is associated with low level expression of the p-glycoprotein (Pgp) multi-drug transporter conferred by the multi-drug resistant (MDR) phenotype, which might be overcome in clinical practice by administering moderately (2.3-fold) higher doses of TPT that have shown to be feasible with granulocyte colony-stimulating factor (G-CSF) support. Topotecan 56-59 ATP binding cassette subfamily B member 1 Homo sapiens 142-156 9553662-1 1998 PURPOSE: The premise for this study was that topotecan (TPT) resistance in preclinical studies is associated with low level expression of the p-glycoprotein (Pgp) multi-drug transporter conferred by the multi-drug resistant (MDR) phenotype, which might be overcome in clinical practice by administering moderately (2.3-fold) higher doses of TPT that have shown to be feasible with granulocyte colony-stimulating factor (G-CSF) support. Topotecan 56-59 ATP binding cassette subfamily B member 1 Homo sapiens 158-161 9553662-1 1998 PURPOSE: The premise for this study was that topotecan (TPT) resistance in preclinical studies is associated with low level expression of the p-glycoprotein (Pgp) multi-drug transporter conferred by the multi-drug resistant (MDR) phenotype, which might be overcome in clinical practice by administering moderately (2.3-fold) higher doses of TPT that have shown to be feasible with granulocyte colony-stimulating factor (G-CSF) support. Topotecan 56-59 colony stimulating factor 3 Homo sapiens 381-418 9553662-1 1998 PURPOSE: The premise for this study was that topotecan (TPT) resistance in preclinical studies is associated with low level expression of the p-glycoprotein (Pgp) multi-drug transporter conferred by the multi-drug resistant (MDR) phenotype, which might be overcome in clinical practice by administering moderately (2.3-fold) higher doses of TPT that have shown to be feasible with granulocyte colony-stimulating factor (G-CSF) support. Topotecan 56-59 colony stimulating factor 3 Homo sapiens 420-425 9553662-1 1998 PURPOSE: The premise for this study was that topotecan (TPT) resistance in preclinical studies is associated with low level expression of the p-glycoprotein (Pgp) multi-drug transporter conferred by the multi-drug resistant (MDR) phenotype, which might be overcome in clinical practice by administering moderately (2.3-fold) higher doses of TPT that have shown to be feasible with granulocyte colony-stimulating factor (G-CSF) support. Topotecan 341-344 ATP binding cassette subfamily B member 1 Homo sapiens 142-156 9553662-1 1998 PURPOSE: The premise for this study was that topotecan (TPT) resistance in preclinical studies is associated with low level expression of the p-glycoprotein (Pgp) multi-drug transporter conferred by the multi-drug resistant (MDR) phenotype, which might be overcome in clinical practice by administering moderately (2.3-fold) higher doses of TPT that have shown to be feasible with granulocyte colony-stimulating factor (G-CSF) support. Topotecan 341-344 ATP binding cassette subfamily B member 1 Homo sapiens 158-161 9553662-5 1998 This dose of TPT was previously determined to be the maximal tolerated dose (MTD) with G-CSF support in a phase I study involving solid tumor patients with similar risk factors for myelosuppression. Topotecan 13-16 colony stimulating factor 3 Homo sapiens 87-92 9553662-16 1998 Total TPT exposure was significantly higher than drug exposure achieved in similar patients at an identical dose in a previous phase I study of TPT and G-CSF, which may explain why more severe myelosuppressive effects occurred in the present study. Topotecan 6-9 colony stimulating factor 3 Homo sapiens 152-157 9259410-4 1997 PC-6/SN2-5 cells were resistant to SN-38 (32-fold) and SK&F 104864 (topotecan; 14-fold), but barely resistant to CPT-11 (3-fold) and DX-8951f (2-fold). Topotecan 72-81 proprotein convertase subtilisin/kexin type 5 Homo sapiens 0-4 9259410-6 1997 Determination of the cellular drug concentration by either flow cytometric analysis or the high-performance liquid chromatography method confirmed that the cellular accumulation of SN-38 and topotecan was significantly reduced in PC-6/SN2-5 cells, whereas that of DX-8951f was only slightly reduced. Topotecan 191-200 proprotein convertase subtilisin/kexin type 5 Homo sapiens 230-234 9815771-9 1997 Indeed, only in the subline refractory to topotecan in vivo, IGROV-1/Pt1, did we observe a persistent arrest of the cells in the S-phase, resulting in a cytostatic and not a cytotoxic effect, since a low level of apoptosis was induced by the drug. Topotecan 42-51 zinc finger protein 77 Homo sapiens 61-72 9187115-0 1997 Factors affecting topotecan-induced programmed cell death: adhesion protects cells from apoptosis and impairs cleavage of poly(ADP-ribose)polymerase. Topotecan 18-27 poly(ADP-ribose) polymerase 1 Homo sapiens 122-148 9187115-1 1997 We have evaluated the influence of anchorage status together with endogenous levels of bcl-2 family members on the ability of the topoisomerase I inhibitor, topotecan (TPT), to induce programmed cell death (PCD) in human colon, breast, lymphoid, and cervical cancer cell lines. Topotecan 157-166 BCL2 apoptosis regulator Homo sapiens 87-92 9187115-1 1997 We have evaluated the influence of anchorage status together with endogenous levels of bcl-2 family members on the ability of the topoisomerase I inhibitor, topotecan (TPT), to induce programmed cell death (PCD) in human colon, breast, lymphoid, and cervical cancer cell lines. Topotecan 168-171 BCL2 apoptosis regulator Homo sapiens 87-92 9815746-14 1997 In 7 of 10 patients, there was an increase (16.6 +/- 2.9% to 25.0 +/- 3.5%; P < 0.02) in the proportion of CD34+ cells in S-phase 24 h after the topotecan infusion and prior to doxorubicin compared to the pretreatment values, whereas 1 patient had a decrease in the proportion of CD34+ cells in S phase and 2 patients had no change. Topotecan 148-157 CD34 molecule Homo sapiens 110-114 9187115-7 1997 Although cell attachment to ProNectin F confers protection against TPT-induced chromatin condensation and cleavage of PARP, cell detachment by poly(2-hydroxyethyl methacrylate) stimulates TPT-induced PCD and PARP cleavage. Topotecan 188-191 poly(ADP-ribose) polymerase 1 Homo sapiens 208-212 9145855-5 1997 The antiviral effects of TPT were observed not only in the topoisomerase-mutated CPT-K5 line but also in peripheral blood mononuclear cells (PBMC) acutely infected with clinical isolates and in OM10.1 cells latently infected with HIV and activated by tumor necrosis factor alpha. Topotecan 25-28 tumor necrosis factor Homo sapiens 251-278 9400949-7 1997 At doses of topotecan-etoposide 1.25/40 (mg m-2)/(mg bid) two out of six patients developed neutropenia grade IV that lasted more than 7 days. Topotecan 12-21 BH3 interacting domain death agonist Homo sapiens 53-56 8688318-0 1996 Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy. Topotecan 40-49 heat shock protein family A (Hsp70) member 4 Homo sapiens 75-80 8996136-15 1997 CONCLUSION: For previously treated patients, the recommended dose of topotecan in this schedule is 0.75 mg/m2/d without growth factor support and 1.0 mg/ m2/d if it is administered with G-CSF. Topotecan 69-78 colony stimulating factor 3 Homo sapiens 186-191 8996140-11 1997 CONCLUSION: The recommended doses of TPT on a daily times-five schedule combined with PTX-24 in these patients were 0.75 mg/m2/d and 135 mg/m2, respectively, with G-CSF support. Topotecan 37-40 colony stimulating factor 3 Homo sapiens 163-168 8888741-17 1996 CONCLUSIONS: In heavily pretreated children, the MTD for topotecan given by intermittent 30-min infusion for 5 days is 1.4 mg/m2 without GCSF and 2.0 mg/m2/day with GCSF. Topotecan 57-66 colony stimulating factor 3 Homo sapiens 137-141 8888741-17 1996 CONCLUSIONS: In heavily pretreated children, the MTD for topotecan given by intermittent 30-min infusion for 5 days is 1.4 mg/m2 without GCSF and 2.0 mg/m2/day with GCSF. Topotecan 57-66 colony stimulating factor 3 Homo sapiens 165-169 9816112-7 1996 We also find that induction of wild-type p53 potentiates the cytotoxicity of topotecan, a member of the camptothecin family of drugs that also has clinical activity against colon cancer. Topotecan 77-86 tumor protein p53 Homo sapiens 41-44 9062409-20 1997 Similarly, camptothecin and topotecan were correlated to cisplatin but inversely correlated to VP-16 and other topo II poisons. Topotecan 28-37 host cell factor C1 Homo sapiens 95-100 8996136-5 1997 Once the MTD was defined, granulocyte colony-stimulating factor (G-CSF) was added to the regimen in an attempt to escalate further the dose of topotecan. Topotecan 143-152 colony stimulating factor 3 Homo sapiens 26-63 8996136-5 1997 Once the MTD was defined, granulocyte colony-stimulating factor (G-CSF) was added to the regimen in an attempt to escalate further the dose of topotecan. Topotecan 143-152 colony stimulating factor 3 Homo sapiens 65-70 9816325-14 1996 For Phase II studies of minimally treated adults with solid tumors, the recommended topotecan starting dose administered by 24-h continuous infusion is 10 mg/m2 without G-CSF. Topotecan 84-93 colony stimulating factor 3 Homo sapiens 169-174 8688318-2 1996 We investigated the impact of hsp70 overexpression on the efficacy of two new anti-cancer drugs, topotecan and gemcitabine. Topotecan 97-106 heat shock protein family A (Hsp70) member 4 Homo sapiens 30-35 8688318-4 1996 After topotecan and gemcitabine treatment hsp70-overexpressing cells showed a marked elevation in cell survival, suggesting that hsp70 overexpression was sufficient to confer resistance to the drugs. Topotecan 6-15 heat shock protein family A (Hsp70) member 4 Homo sapiens 42-47 1348448-0 1992 Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Topotecan 76-85 ATP binding cassette subfamily B member 1 Homo sapiens 10-24 8648378-0 1996 Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. Topotecan 79-88 colony stimulating factor 3 Homo sapiens 94-131 8648378-1 1996 PURPOSE: To evaluate the feasibility of escalating doses of the topoisomerase I (topo I) inhibitor topotecan (TPT) with granulocyte colony-stimulating factor (G-CSF) in minimally pretreated adults with solid tumors and to study whether G-CSF scheduling variably affects the ability to escalate TPT doses. Topotecan 99-108 colony stimulating factor 3 Homo sapiens 120-157 8648378-1 1996 PURPOSE: To evaluate the feasibility of escalating doses of the topoisomerase I (topo I) inhibitor topotecan (TPT) with granulocyte colony-stimulating factor (G-CSF) in minimally pretreated adults with solid tumors and to study whether G-CSF scheduling variably affects the ability to escalate TPT doses. Topotecan 99-108 colony stimulating factor 3 Homo sapiens 159-164 8648378-1 1996 PURPOSE: To evaluate the feasibility of escalating doses of the topoisomerase I (topo I) inhibitor topotecan (TPT) with granulocyte colony-stimulating factor (G-CSF) in minimally pretreated adults with solid tumors and to study whether G-CSF scheduling variably affects the ability to escalate TPT doses. Topotecan 99-108 colony stimulating factor 3 Homo sapiens 236-241 8648378-7 1996 However, dose escalation of TPT with G-CSF on a posttreatment schedule proceeded to 4.2 mg/m2/d. Topotecan 28-31 colony stimulating factor 3 Homo sapiens 37-42 8648378-13 1996 CONCLUSION: G-CSF administered after 5 daily 30-minute infusions of TPT permits a 2.3-fold dose escalation of TPT above the MTD in solid-tumor patients, whereas concurrent therapy with G-CSF and TPT results in severe myelosuppression. Topotecan 68-71 colony stimulating factor 3 Homo sapiens 12-17 8648378-13 1996 CONCLUSION: G-CSF administered after 5 daily 30-minute infusions of TPT permits a 2.3-fold dose escalation of TPT above the MTD in solid-tumor patients, whereas concurrent therapy with G-CSF and TPT results in severe myelosuppression. Topotecan 110-113 colony stimulating factor 3 Homo sapiens 12-17 8648378-13 1996 CONCLUSION: G-CSF administered after 5 daily 30-minute infusions of TPT permits a 2.3-fold dose escalation of TPT above the MTD in solid-tumor patients, whereas concurrent therapy with G-CSF and TPT results in severe myelosuppression. Topotecan 110-113 colony stimulating factor 3 Homo sapiens 12-17 7742543-2 1995 Here we show that topotecan stabilizes topoisomerase I/DNA cleavable complexes in radiation-resistant human B-lineage acute lymphoblastic leukemia (ALL) cells, causes rapid apoptotic cell death despite high-level expression of bcl-2 protein, and inhibits ALL cell in vitro clonogenic growth in a dose-dependent fashion. Topotecan 18-27 BCL2 apoptosis regulator Homo sapiens 227-232 8402636-6 1993 When added simultaneously with CAM or TPT, CAF prevented both effects. Topotecan 38-41 lysine acetyltransferase 2B Homo sapiens 43-46 8402636-8 1993 The bathochromic and hypochromic shift in the absorption spectrum of the water soluble compound TPT upon addition of CAF indicated that CAF and TPT interact (stack) in a fashion similar to that previously observed for CAF and DNA intercalators. Topotecan 96-99 lysine acetyltransferase 2B Homo sapiens 117-120 8402636-8 1993 The bathochromic and hypochromic shift in the absorption spectrum of the water soluble compound TPT upon addition of CAF indicated that CAF and TPT interact (stack) in a fashion similar to that previously observed for CAF and DNA intercalators. Topotecan 96-99 lysine acetyltransferase 2B Homo sapiens 136-139 8402636-8 1993 The bathochromic and hypochromic shift in the absorption spectrum of the water soluble compound TPT upon addition of CAF indicated that CAF and TPT interact (stack) in a fashion similar to that previously observed for CAF and DNA intercalators. Topotecan 96-99 lysine acetyltransferase 2B Homo sapiens 136-139 8402636-8 1993 The bathochromic and hypochromic shift in the absorption spectrum of the water soluble compound TPT upon addition of CAF indicated that CAF and TPT interact (stack) in a fashion similar to that previously observed for CAF and DNA intercalators. Topotecan 144-147 lysine acetyltransferase 2B Homo sapiens 117-120 8402636-9 1993 Microcalorimetric measurements of TPT titration with CAF indicate an exothermic reaction between these compounds (the enthalpy change was delta H degree = -4.2 kcal/mol), which is consistent with a stacking model of CAF-TPT interaction. Topotecan 34-37 lysine acetyltransferase 2B Homo sapiens 53-56 8402636-9 1993 Microcalorimetric measurements of TPT titration with CAF indicate an exothermic reaction between these compounds (the enthalpy change was delta H degree = -4.2 kcal/mol), which is consistent with a stacking model of CAF-TPT interaction. Topotecan 34-37 lysine acetyltransferase 2B Homo sapiens 216-219 8402636-10 1993 Thus, the ability of CAF to protect HL-60 cells against the cell kinetic effects of CAM or TPT, as in the case of DNA intercalating topoisomerase II inhibitors, is most likely due to formation of complexes between CAF and these aromatic molecules, which result in reducing the effective concentration of the free form of these drugs available to the cells. Topotecan 91-94 lysine acetyltransferase 2B Homo sapiens 21-24 8402636-10 1993 Thus, the ability of CAF to protect HL-60 cells against the cell kinetic effects of CAM or TPT, as in the case of DNA intercalating topoisomerase II inhibitors, is most likely due to formation of complexes between CAF and these aromatic molecules, which result in reducing the effective concentration of the free form of these drugs available to the cells. Topotecan 91-94 lysine acetyltransferase 2B Homo sapiens 214-217 1332623-1 1992 CPT-11 and Topotecan are a new semisynthetic derivative of CPT, and have been shown to inhibit DNA topoisomerase I and to have a strong antitumor activity with low toxicity against murine tumor. Topotecan 11-20 topoisomerase (DNA) I Mus musculus 95-114 11362319-0 1995 Topotecan now available for HIV, PML research. Topotecan 0-9 PML nuclear body scaffold Homo sapiens 33-36 7931489-10 1994 In 10 of 11 samples, the multi-drug resistance (Mdr) modulator quinidine altered nuclear daunorubicin (DNR) accumulation and whole-cell TPT accumulation by less than 15%, which suggests that Pgp-mediated effects on drug efflux are insufficient to explain the fourfold range of TPT sensitivities in the colony-forming assays. Topotecan 277-280 ATP binding cassette subfamily B member 1 Homo sapiens 191-194 8012971-0 1994 Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. Topotecan 173-182 DNA polymerase alpha 1, catalytic subunit Homo sapiens 9-29 1348448-10 1992 These results suggest that Pgp overexpression diminishes TPT accumulation and TPT cytotoxicity in hamster and human cells. Topotecan 57-60 ATP binding cassette subfamily B member 1 Homo sapiens 27-30 1348448-10 1992 These results suggest that Pgp overexpression diminishes TPT accumulation and TPT cytotoxicity in hamster and human cells. Topotecan 78-81 ATP binding cassette subfamily B member 1 Homo sapiens 27-30 34893686-3 2021 In the present study we investigated how SLFN11 expression regulated the sensitivity of small cell lung cancer to topotecan. Topotecan 114-123 schlafen family member 11 Homo sapiens 41-47 33972235-0 2022 Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study. Topotecan 27-36 RB transcriptional corepressor 1 Homo sapiens 76-90 33804018-7 2021 Moreover, the absorption rate of topotecan, a BCRP substrate, in wild-type mice pretreated with LY335979 was similar to that in mdr1a/1b knockout mice but significantly lower than that in bcrp knockout mice. Topotecan 33-42 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 46-50 33804018-7 2021 Moreover, the absorption rate of topotecan, a BCRP substrate, in wild-type mice pretreated with LY335979 was similar to that in mdr1a/1b knockout mice but significantly lower than that in bcrp knockout mice. Topotecan 33-42 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 188-192 34608736-7 2022 RESULTS: We showed that ovarian cancer cells express PDPN and release PDPN-rich extracellular vesicles (EVs) and that cisplatin and topotecan (chemotherapies commonly used in ovarian cancer) increase the expression of podoplanin in cancer cells. Topotecan 132-141 podoplanin Mus musculus 218-228 34893686-0 2021 FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11. Topotecan 18-27 schlafen family member 11 Homo sapiens 91-97 1310495-0 1992 Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Topotecan 104-113 topoisomerase (DNA) I Mus musculus 131-150 1682041-5 1991 In contrast to the uncharged camptothecin derivatives, such as 9-amino-camptothecin and 10,11-methylenedioxy-camptothecin, the charged camptothecin derivative, topotecan, showed reduced cytotoxicity against MDR1-overexpressing KB V1 cells. Topotecan 160-169 ATP binding cassette subfamily B member 1 Homo sapiens 207-211 1682041-6 1991 The reduced cytotoxicity of topotecan in KB V1 cells was due to the overexpression of MDR1 in KB V1 cells since verapamil restored both topotecan accumulation and cytotoxicity. Topotecan 28-37 ATP binding cassette subfamily B member 1 Homo sapiens 86-90 1682041-6 1991 The reduced cytotoxicity of topotecan in KB V1 cells was due to the overexpression of MDR1 in KB V1 cells since verapamil restored both topotecan accumulation and cytotoxicity. Topotecan 136-145 ATP binding cassette subfamily B member 1 Homo sapiens 86-90 34893686-4 2021 We showed that SLFN11 expression levels were positively associated with the sensitivity to topotecan in a panel of seven SCLC cell lines. Topotecan 91-100 schlafen family member 11 Homo sapiens 15-21 34893686-5 2021 Topotecan treatment induced different patterns of the DNA response network in SCLC cells: DNA damage response (DDR) was more prominently activated in SLFN11-deficient SCLC cell line H82 than in SLFN11-plentiful SCLC cell line DMS273, whereas topotecan induced significant accumulation of p-Chk1, p-RPA2 and Rad51 in H82 cells, but not in DMS273 cells. Topotecan 0-9 schlafen family member 11 Homo sapiens 194-200 34893686-5 2021 Topotecan treatment induced different patterns of the DNA response network in SCLC cells: DNA damage response (DDR) was more prominently activated in SLFN11-deficient SCLC cell line H82 than in SLFN11-plentiful SCLC cell line DMS273, whereas topotecan induced significant accumulation of p-Chk1, p-RPA2 and Rad51 in H82 cells, but not in DMS273 cells. Topotecan 0-9 checkpoint kinase 1 Homo sapiens 290-294 34893686-5 2021 Topotecan treatment induced different patterns of the DNA response network in SCLC cells: DNA damage response (DDR) was more prominently activated in SLFN11-deficient SCLC cell line H82 than in SLFN11-plentiful SCLC cell line DMS273, whereas topotecan induced significant accumulation of p-Chk1, p-RPA2 and Rad51 in H82 cells, but not in DMS273 cells. Topotecan 0-9 replication protein A2 Homo sapiens 298-302 34893686-5 2021 Topotecan treatment induced different patterns of the DNA response network in SCLC cells: DNA damage response (DDR) was more prominently activated in SLFN11-deficient SCLC cell line H82 than in SLFN11-plentiful SCLC cell line DMS273, whereas topotecan induced significant accumulation of p-Chk1, p-RPA2 and Rad51 in H82 cells, but not in DMS273 cells. Topotecan 0-9 RAD51 recombinase Homo sapiens 307-312 34893686-5 2021 Topotecan treatment induced different patterns of the DNA response network in SCLC cells: DNA damage response (DDR) was more prominently activated in SLFN11-deficient SCLC cell line H82 than in SLFN11-plentiful SCLC cell line DMS273, whereas topotecan induced significant accumulation of p-Chk1, p-RPA2 and Rad51 in H82 cells, but not in DMS273 cells. Topotecan 242-251 checkpoint kinase 1 Homo sapiens 290-294 34893686-5 2021 Topotecan treatment induced different patterns of the DNA response network in SCLC cells: DNA damage response (DDR) was more prominently activated in SLFN11-deficient SCLC cell line H82 than in SLFN11-plentiful SCLC cell line DMS273, whereas topotecan induced significant accumulation of p-Chk1, p-RPA2 and Rad51 in H82 cells, but not in DMS273 cells. Topotecan 242-251 replication protein A2 Homo sapiens 298-302 34893686-5 2021 Topotecan treatment induced different patterns of the DNA response network in SCLC cells: DNA damage response (DDR) was more prominently activated in SLFN11-deficient SCLC cell line H82 than in SLFN11-plentiful SCLC cell line DMS273, whereas topotecan induced significant accumulation of p-Chk1, p-RPA2 and Rad51 in H82 cells, but not in DMS273 cells. Topotecan 242-251 RAD51 recombinase Homo sapiens 307-312 34893686-7 2021 HDAC inhibitors FK228 and SAHA dose-dependently increased SLFN11 expression through suppressing DNA methylation at the SLFN11 promoter, thereby sensitizing SCLC cells to topotecan. Topotecan 170-179 histone deacetylase 9 Homo sapiens 0-4 34893686-7 2021 HDAC inhibitors FK228 and SAHA dose-dependently increased SLFN11 expression through suppressing DNA methylation at the SLFN11 promoter, thereby sensitizing SCLC cells to topotecan. Topotecan 170-179 schlafen family member 11 Homo sapiens 58-64 34159519-2 2021 We have a long-standing interest in developing and validating inhibitors of the DNA repair enzyme tyrosyl-DNA phosphodiesterase 1 (TDP1) as chemosensitizers for topoisomerase I poisons such as topotecan. Topotecan 193-202 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 98-129 34159519-2 2021 We have a long-standing interest in developing and validating inhibitors of the DNA repair enzyme tyrosyl-DNA phosphodiesterase 1 (TDP1) as chemosensitizers for topoisomerase I poisons such as topotecan. Topotecan 193-202 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 131-135 34159519-3 2021 Herein, by using thieno(2,3-b)pyridines, a class of TDP1 inhibitors, we showed that the inhibition of TDP1 can restore sensitivity to topotecan, results that are supported by TDP1 knockout cell experiments using CRISPR/Cas9. Topotecan 134-143 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 52-56 34159519-3 2021 Herein, by using thieno(2,3-b)pyridines, a class of TDP1 inhibitors, we showed that the inhibition of TDP1 can restore sensitivity to topotecan, results that are supported by TDP1 knockout cell experiments using CRISPR/Cas9. Topotecan 134-143 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 102-106 34159519-3 2021 Herein, by using thieno(2,3-b)pyridines, a class of TDP1 inhibitors, we showed that the inhibition of TDP1 can restore sensitivity to topotecan, results that are supported by TDP1 knockout cell experiments using CRISPR/Cas9. Topotecan 134-143 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 175-179 34370156-0 2021 The influence of an enamine usnic acid derivative (a tyrosyl-DNA phosphodiesterase 1 inhibitor) on the therapeutic effect of topotecan against transplanted tumors in vivo. Topotecan 125-134 tyrosyl-DNA phosphodiesterase 1 Mus musculus 53-84 34224797-3 2021 We observed that topotecan-conditioned TC-1 tumors were occupied by a vast number of monocytic cells that highly express CD11c, CD64, and costimulatory molecules are responsible for the favorable changes in the tumor microenvironment. Topotecan 17-26 integrin subunit alpha X Homo sapiens 121-126 34224797-4 2021 Ly6C+MHC-II + CD11chiCD64hi cells, referred to as topotecan-induced monocyte-derived dendritic cells (moDCs), proliferate and activate antigen-specific CD8+ T cells to levels equivalent to those of conventional DCs. Topotecan 50-59 Fc gamma receptor Ia Homo sapiens 14-25 34224797-6 2021 Notably, anti-M-CSFR reversed the acquisition of DC-like properties of topotecan-induced moDCs, leading to the abolition of the antitumor effect of topotecan combined with a cancer vaccine. Topotecan 71-80 colony stimulating factor 1 receptor Homo sapiens 16-20 34224797-6 2021 Notably, anti-M-CSFR reversed the acquisition of DC-like properties of topotecan-induced moDCs, leading to the abolition of the antitumor effect of topotecan combined with a cancer vaccine. Topotecan 148-157 colony stimulating factor 1 receptor Homo sapiens 16-20 34681681-8 2021 A combination of BIRC2-inhibitor LCL161 and topotecan exerted synergistic effects on cancer cells and animal tumor models. Topotecan 44-53 baculoviral IAP repeat containing 2 Homo sapiens 17-22 34454340-13 2021 The results demonstrated that iodine-131, in combination with A-966492 and TPT, had marked effects on radio-sensitizing and can be used as a targeted radionuclide for targeting radiotherapy in combination with topoisomerase I and PARP inhibitors to enhance radiotherapy in clinics. Topotecan 75-78 poly(ADP-ribose) polymerase 1 Homo sapiens 230-234 34768766-2 2021 TDP1 promotes the cleavage of the stable DNA-TOP1 complexes with the TOP1 inhibitor topotecan, which is a clinically used anticancer drug. Topotecan 84-93 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 0-4 34768766-2 2021 TDP1 promotes the cleavage of the stable DNA-TOP1 complexes with the TOP1 inhibitor topotecan, which is a clinically used anticancer drug. Topotecan 84-93 DNA topoisomerase I Homo sapiens 45-49 34768766-2 2021 TDP1 promotes the cleavage of the stable DNA-TOP1 complexes with the TOP1 inhibitor topotecan, which is a clinically used anticancer drug. Topotecan 84-93 DNA topoisomerase I Homo sapiens 69-73 34768766-10 2021 Leader compound 10a showed promising synergy on HeLa cells in conjunction with the TOP1 inhibitor topotecan. Topotecan 98-107 DNA topoisomerase I Homo sapiens 83-87 34370156-4 2021 In the present work, we showed a sensitizing effect of an enamine derivative of usnic acid (when administered intragastrically) on Lewis lung carcinoma in mice in combination with topotecan (TPT, Top1 poison used in the clinic). Topotecan 180-189 topoisomerase (DNA) I Mus musculus 196-200 34370156-4 2021 In the present work, we showed a sensitizing effect of an enamine derivative of usnic acid (when administered intragastrically) on Lewis lung carcinoma in mice in combination with topotecan (TPT, Top1 poison used in the clinic). Topotecan 191-194 topoisomerase (DNA) I Mus musculus 196-200 34282134-3 2021 Here we present cryo-EM structures of ABCG2 under turnover conditions containing either the endogenous substrate estrone-3-sulfate or the exogenous substrate topotecan. Topotecan 158-167 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 38-43 34465337-2 2021 The aim of this study was to investigate the role of hypoxia-inducible transcription factor (HIF)-1alpha and its inhibitor topotecan in the pathogenesis of myocarditis. Topotecan 123-132 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 53-104 34465337-15 2021 Consistently, HIF-1alpha gain-of-function significantly promoted the production of inflammatory cytokines and cell apoptosis, which was partially counteracted by topotecan administration. Topotecan 162-171 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 14-24 34465337-16 2021 CONCLUSION: To conclude, these findings demonstrated that HIF-1alpha inhibition by topotecan ameliorates LPS-induced myocarditis in vitro, providing a new approach in the treatment of myocarditis. Topotecan 83-92 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 58-68 34502348-4 2021 In this study, we discovered that by attenuating the drug transport function of ABCG2, TP-3654 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic ABCG2 substrate drugs topotecan, SN-38 and mitoxantrone. Topotecan 197-206 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 80-85 34502348-4 2021 In this study, we discovered that by attenuating the drug transport function of ABCG2, TP-3654 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic ABCG2 substrate drugs topotecan, SN-38 and mitoxantrone. Topotecan 197-206 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 108-113 34502348-4 2021 In this study, we discovered that by attenuating the drug transport function of ABCG2, TP-3654 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic ABCG2 substrate drugs topotecan, SN-38 and mitoxantrone. Topotecan 197-206 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 175-180 34285920-0 2021 Development, Characterization, and Evaluation of SLN-Loaded Thermoresponsive Hydrogel System of Topotecan as Biological Macromolecule for Colorectal Delivery. Topotecan 96-105 sarcolipin Rattus norvegicus 49-52 34356597-3 2021 It can remove covalent complex DNA-topoisomerase 1 (TOP1) stabilized by the TOP1 inhibitor topotecan, neutralizing the effect of the drugs. Topotecan 91-100 DNA topoisomerase I Homo sapiens 31-50 34356597-3 2021 It can remove covalent complex DNA-topoisomerase 1 (TOP1) stabilized by the TOP1 inhibitor topotecan, neutralizing the effect of the drugs. Topotecan 91-100 DNA topoisomerase I Homo sapiens 52-56 34356597-3 2021 It can remove covalent complex DNA-topoisomerase 1 (TOP1) stabilized by the TOP1 inhibitor topotecan, neutralizing the effect of the drugs. Topotecan 91-100 DNA topoisomerase I Homo sapiens 76-80 34356597-5 2021 Thus, TDP1 is a promising therapeutic target for the development of drug combinations with topotecan, as well as other drugs for cancer treatment. Topotecan 91-100 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 6-10 34073771-1 2021 Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is a promising target for anticancer therapy due to its ability to counter the effects topoisomerase 1 (Top1) poison, such as topotecan, thus, decreasing their efficacy. Topotecan 165-174 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 0-31 34073771-1 2021 Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is a promising target for anticancer therapy due to its ability to counter the effects topoisomerase 1 (Top1) poison, such as topotecan, thus, decreasing their efficacy. Topotecan 165-174 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 33-37 34073771-1 2021 Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is a promising target for anticancer therapy due to its ability to counter the effects topoisomerase 1 (Top1) poison, such as topotecan, thus, decreasing their efficacy. Topotecan 165-174 DNA topoisomerase I Homo sapiens 126-141 34073771-1 2021 Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is a promising target for anticancer therapy due to its ability to counter the effects topoisomerase 1 (Top1) poison, such as topotecan, thus, decreasing their efficacy. Topotecan 165-174 DNA topoisomerase I Homo sapiens 143-147 35514783-0 2022 Topotecan reduces sepsis-induced acute lung injury and decreases the inflammatory response via the inhibition of the NF-kappaB signaling pathway. Topotecan 0-9 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 117-126 34515066-7 2021 Subgroup analysis of subsistence showed that EP had prominent benefit in the following subgroups: Asian, median age > 60, first-line treatment, ECOG 0-2, intravenous topotecan, and cisplatin. Topotecan 166-175 epiregulin Homo sapiens 45-47 35429714-4 2022 The most potent TDP1 inhibitor 14 (IC50 = 1.7 +- 0.24 muM) induces cellular TDP1cc formation and shows synergistic effect with topotecan in four human cancer cell lines MCF-7, A549, H460 and HepG2. Topotecan 127-136 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 16-20 34969753-5 2022 Silencing of MUC1 increased chemosensitivity of an SCLC line to topotecan. Topotecan 64-73 mucin 1, cell surface associated Homo sapiens 13-17 35330134-3 2022 In this study, we utilize homology modelling and molecular docking analysis to determine the binding affinity and the potential interaction sites of MRP1 with Carboplatin, Gemcitabine, Doxorubicin, Paclitaxel, and Topotecan. Topotecan 214-223 ATP binding cassette subfamily B member 1 Homo sapiens 149-153 35330134-7 2022 Interestingly, our data showed that Carboplatin, Paclitaxel, and Topotecan bind specifically to Asn510 residue in the transmembrane domains 1 of the MRP1. Topotecan 65-74 ATP binding cassette subfamily B member 1 Homo sapiens 149-153 35328460-0 2022 Effect of ALDH1A1 Gene Knockout on Drug Resistance in Paclitaxel and Topotecan Resistant Human Ovarian Cancer Cell Lines in 2D and 3D Model. Topotecan 69-78 aldehyde dehydrogenase 1 family member A1 Homo sapiens 10-17 35328460-3 2022 The goal of our study was to examine the role of aldehyde dehydrogenase 1A1 (ALDH1A1) expression in paclitaxel (PAC) and topotecan (TOP) resistant ovarian cancer cell lines. Topotecan 121-130 aldehyde dehydrogenase 1 family member A1 Homo sapiens 49-75 35328460-3 2022 The goal of our study was to examine the role of aldehyde dehydrogenase 1A1 (ALDH1A1) expression in paclitaxel (PAC) and topotecan (TOP) resistant ovarian cancer cell lines. Topotecan 121-130 aldehyde dehydrogenase 1 family member A1 Homo sapiens 77-84 35345325-1 2022 BACKGROUND: Inhibition of human topoisomerase I (TOP1) by camptothecin and topotecan has been shown to reduce excessive transcription of PAMP (Pathogen-Associated Molecular Pattern)-induced genes in prior studies, preventing death from sepsis in animal models of bacterial and SARS-CoV-2 infections. Topotecan 75-84 DNA topoisomerase I Homo sapiens 49-53 33838147-3 2021 Here we present three cryo-EM structures of nanodisc-reconstituted, human ABCG2 bound to anticancer drugs tariquidar, topotecan and mitoxantrone. Topotecan 118-127 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 74-79 35154442-0 2022 The Role of DAPK1 in the Cell Cycle Regulation of Cervical Cancer Cells and in Response to Topotecan. Topotecan 91-100 death associated protein kinase 1 Homo sapiens 12-17 35154442-13 2022 Therefore, the current study examined the role of DAPK1 in topotecan-induced cervical cancer cell death, and it was identified that RNA interference-based silencing of DAPK1 decreased the apoptotic effect of topotecan. Topotecan 59-68 death associated protein kinase 1 Homo sapiens 168-173 35154442-13 2022 Therefore, the current study examined the role of DAPK1 in topotecan-induced cervical cancer cell death, and it was identified that RNA interference-based silencing of DAPK1 decreased the apoptotic effect of topotecan. Topotecan 208-217 death associated protein kinase 1 Homo sapiens 50-55 35154442-13 2022 Therefore, the current study examined the role of DAPK1 in topotecan-induced cervical cancer cell death, and it was identified that RNA interference-based silencing of DAPK1 decreased the apoptotic effect of topotecan. Topotecan 208-217 death associated protein kinase 1 Homo sapiens 168-173 35154442-14 2022 Thus, these findings suggested that DAPK1 could be a biomarker and a potential target for the response to topotecan during the therapy of patients with cervical cancer. Topotecan 106-115 death associated protein kinase 1 Homo sapiens 36-41 33921129-0 2021 Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents. Topotecan 47-56 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 19-23 33836156-4 2021 Therapeutic treatment with two doses of topotecan (TPT), an FDA-approved TOP1 inhibitor, suppresses infection-induced inflammation in hamsters. Topotecan 40-49 DNA topoisomerase I Homo sapiens 73-77 33836156-4 2021 Therapeutic treatment with two doses of topotecan (TPT), an FDA-approved TOP1 inhibitor, suppresses infection-induced inflammation in hamsters. Topotecan 51-54 DNA topoisomerase I Homo sapiens 73-77 33921129-4 2021 P-gp inhibitors increased the accumulation of the anticancer drug, topotecan (TPT)-a substrate of P-gp and BCRP, albeit with higher affinity for BCRP-in BCRP-overexpressing cells, resulting in cell death. Topotecan 67-76 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-4 33921129-4 2021 P-gp inhibitors increased the accumulation of the anticancer drug, topotecan (TPT)-a substrate of P-gp and BCRP, albeit with higher affinity for BCRP-in BCRP-overexpressing cells, resulting in cell death. Topotecan 67-76 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 98-102 33921129-4 2021 P-gp inhibitors increased the accumulation of the anticancer drug, topotecan (TPT)-a substrate of P-gp and BCRP, albeit with higher affinity for BCRP-in BCRP-overexpressing cells, resulting in cell death. Topotecan 78-81 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-4 33921129-4 2021 P-gp inhibitors increased the accumulation of the anticancer drug, topotecan (TPT)-a substrate of P-gp and BCRP, albeit with higher affinity for BCRP-in BCRP-overexpressing cells, resulting in cell death. Topotecan 78-81 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 98-102 33829017-6 2021 In addition, the increased cytotoxicity by co-administration of CBZ and TPT may be contributed by the synergistic effect on downregulating ABCG2 expression in NCI-H460/TPT10 cells. Topotecan 72-75 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 139-144 33848478-3 2021 In a proof-of-concept study, we combined M6620 (berzosertib), first-in-class ATR inhibitor, and TOP1 inhibitor topotecan in patients with relapsed SCNCs. Topotecan 111-120 DNA topoisomerase I Homo sapiens 96-100 33918289-6 2021 In this study, we have used cytotoxicity and molecular docking studies to show that NCX4040, a nitric oxide donor related to aspirin, inhibited the functions of ATPase which resulted in significant reversal of resistance to both adriamycin and topotecan in P-gp- and BCRP-expressing human cancer cell lines, respectively. Topotecan 244-253 dynein axonemal heavy chain 8 Homo sapiens 161-167 32981006-1 2021 Camptothecin (CPT) and its derivatives, irinotecan and topotecan are specific topoisomerase I (Top1) inhibitors and potent anticancer drugs. Topotecan 55-64 DNA topoisomerase I Homo sapiens 95-99 33536335-4 2021 Accordingly, we validate that clinical inhibitors of ATR (M4344 and M6620) and CHK1 (SRA737) resensitize SLFN11-KO cells to topotecan, indotecan, etoposide, cisplatin, and talazoparib. Topotecan 124-133 ATR serine/threonine kinase Homo sapiens 53-56 33871444-3 2021 Suppression of TDP1 activity may enhance the effects of topotecan. Topotecan 56-65 tyrosyl-DNA phosphodiesterase 1 Mus musculus 15-19 33536335-4 2021 Accordingly, we validate that clinical inhibitors of ATR (M4344 and M6620) and CHK1 (SRA737) resensitize SLFN11-KO cells to topotecan, indotecan, etoposide, cisplatin, and talazoparib. Topotecan 124-133 checkpoint kinase 1 Homo sapiens 79-83 33536335-4 2021 Accordingly, we validate that clinical inhibitors of ATR (M4344 and M6620) and CHK1 (SRA737) resensitize SLFN11-KO cells to topotecan, indotecan, etoposide, cisplatin, and talazoparib. Topotecan 124-133 schlafen family member 11 Homo sapiens 105-111 33425914-5 2020 Overexpression of ABCG2 localized on the cell membrane, but not ABCB1 or ABCC1, was found in NCI-H460/TPT10 cells, indicating that ABCG2 was likely to be involved in topotecan-resistance. Topotecan 166-175 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 18-23 33559345-0 2021 Camptothecin and topotecan, inhibitors of transcription factor Fli-1 and topoisomerase, markedly ameliorate lupus nephritis in NZBWF1 mice and reduce the production of inflammatory mediators in human renal cells. Topotecan 17-26 Friend leukemia integration 1 Mus musculus 63-68 33559345-0 2021 Camptothecin and topotecan, inhibitors of transcription factor Fli-1 and topoisomerase, markedly ameliorate lupus nephritis in NZBWF1 mice and reduce the production of inflammatory mediators in human renal cells. Topotecan 17-26 WD repeat and FYVE domain containing 3 Mus musculus 127-133 33559345-1 2021 OBJECTIVE: To examine the therapeutic effects of camptothecin (CPT) and topotecan (TPT), inhibitors of transcription factor Fli-1 and topoisomerase, on lupus nephritis in NZBWF1 mice and their effects on inflammatory mediators in human renal cells. Topotecan 72-81 WD repeat and FYVE domain containing 3 Mus musculus 171-177 33559345-1 2021 OBJECTIVE: To examine the therapeutic effects of camptothecin (CPT) and topotecan (TPT), inhibitors of transcription factor Fli-1 and topoisomerase, on lupus nephritis in NZBWF1 mice and their effects on inflammatory mediators in human renal cells. Topotecan 83-86 WD repeat and FYVE domain containing 3 Mus musculus 171-177 33559345-9 2021 Human renal cells treated with CPT or TPT had reduced expression of Fli-1 and decreased MCP1 following stimulation with IFN-alpha or IFN-gamma. Topotecan 38-41 Fli-1 proto-oncogene, ETS transcription factor Homo sapiens 68-73 33559345-9 2021 Human renal cells treated with CPT or TPT had reduced expression of Fli-1 and decreased MCP1 following stimulation with IFN-alpha or IFN-gamma. Topotecan 38-41 C-C motif chemokine ligand 2 Homo sapiens 88-92 33559345-9 2021 Human renal cells treated with CPT or TPT had reduced expression of Fli-1 and decreased MCP1 following stimulation with IFN-alpha or IFN-gamma. Topotecan 38-41 interferon alpha 1 Homo sapiens 120-129 33559345-9 2021 Human renal cells treated with CPT or TPT had reduced expression of Fli-1 and decreased MCP1 following stimulation with IFN-alpha or IFN-gamma. Topotecan 38-41 interferon gamma Homo sapiens 133-142 33173151-7 2021 Combining the clinically used TOP1 inhibitor topotecan with CX-5461 potentiates a G2/M cell cycle checkpoint arrest in multiple HR-proficient HGSC cell lines. Topotecan 45-54 DNA topoisomerase I Homo sapiens 30-34 33039171-0 2021 Topotecan induces hepatocellular injury via ASCT2 mediated oxidative stress. Topotecan 0-9 solute carrier family 1 member 5 Homo sapiens 44-49 33039171-10 2021 Topotecan inhibited the expression of glutamine transporter ASCT2 and the uptake of glutamine in both L02 and HepG2 cell lines. Topotecan 0-9 solute carrier family 1 member 5 Homo sapiens 60-65 33039171-12 2021 The ROS level was inhibited by ASCT2 overexpression upon topotecan treatment in both L02 and HepG2 cell lines. Topotecan 57-66 solute carrier family 1 member 5 Homo sapiens 31-36 33039171-13 2021 Topotecan-induced hepatocellular apoptosis and proliferation inhibition were attenuated by ASCT2 overexpression in both L02 and HepG2 cell lines. Topotecan 0-9 solute carrier family 1 member 5 Homo sapiens 91-96 33039171-14 2021 CONCLUSION: Topotecan-induced hepatocytes death is dependent on ASCT2 down-regulation, which causes oxidative stress via inhibiting GSH production. Topotecan 12-21 solute carrier family 1 member 5 Homo sapiens 64-69 33425914-5 2020 Overexpression of ABCG2 localized on the cell membrane, but not ABCB1 or ABCC1, was found in NCI-H460/TPT10 cells, indicating that ABCG2 was likely to be involved in topotecan-resistance. Topotecan 166-175 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 131-136 33375004-9 2020 In contrast, mMate2 did not transport TCl but showed MPP+ transport with Km of 60.0 microM that was inhibited by the drugs topotecan, acyclovir, and levofloxacin. Topotecan 123-132 solute carrier family 47, member 2 Mus musculus 13-19 33299999-4 2020 Therapeutic treatment with two doses of Topotecan (TPT), a FDA-approved Top1 inhibitor, suppresses infection-induced inflammation in hamsters. Topotecan 40-49 DNA topoisomerase I Homo sapiens 72-76 33263997-1 2020 Tyrosyl-DNA phosphodiesterase 1 (TDP1) is a molecular target for the sensitization of cancer cells to the FDA-approved topoisomerase inhibitors topotecan and irinotecan. Topotecan 144-153 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 0-31 33263997-1 2020 Tyrosyl-DNA phosphodiesterase 1 (TDP1) is a molecular target for the sensitization of cancer cells to the FDA-approved topoisomerase inhibitors topotecan and irinotecan. Topotecan 144-153 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 33-37 33299999-4 2020 Therapeutic treatment with two doses of Topotecan (TPT), a FDA-approved Top1 inhibitor, suppresses infection-induced inflammation in hamsters. Topotecan 51-54 DNA topoisomerase I Homo sapiens 72-76 33218116-0 2020 Transferrin-Conjugated pH-Responsive gamma-Cyclodextrin Nanoparticles for Antitumoral Topotecan Delivery. Topotecan 86-95 transferrin Homo sapiens 0-11 33218116-3 2020 These gammaCDP-(DMA/PEG-Tf) NPs are effective in entrapping topotecan (TPT, as a model antitumor drug) resulting from the ionic interaction between pH-responsive DMA and TPT or the host-guest interaction between gammaCDP and TPT. Topotecan 60-69 transferrin Homo sapiens 24-26 32765594-5 2020 We show here that topotecan treatment significantly down-regulated estrogen receptor alpha (ERalpha/ESR1) and antiapoptotic BCL2 genes in addition to many other p53-regulated genes. Topotecan 18-27 estrogen receptor 1 Homo sapiens 67-90 33218116-3 2020 These gammaCDP-(DMA/PEG-Tf) NPs are effective in entrapping topotecan (TPT, as a model antitumor drug) resulting from the ionic interaction between pH-responsive DMA and TPT or the host-guest interaction between gammaCDP and TPT. Topotecan 71-74 transferrin Homo sapiens 24-26 33218116-3 2020 These gammaCDP-(DMA/PEG-Tf) NPs are effective in entrapping topotecan (TPT, as a model antitumor drug) resulting from the ionic interaction between pH-responsive DMA and TPT or the host-guest interaction between gammaCDP and TPT. Topotecan 170-173 transferrin Homo sapiens 24-26 33218116-3 2020 These gammaCDP-(DMA/PEG-Tf) NPs are effective in entrapping topotecan (TPT, as a model antitumor drug) resulting from the ionic interaction between pH-responsive DMA and TPT or the host-guest interaction between gammaCDP and TPT. Topotecan 170-173 transferrin Homo sapiens 24-26 33218116-6 2020 In vivo animal studies using an MDA-MB-231 tumor xenografted mice model supported the finding that gammaCDP-(DMA/PEG-Tf) NPs are effective carriers of TPT to Tf receptor-positive MDA-MB-231 tumor cells, promoting drug uptake into the tumors through the Tf ligand-mediated endocytic pathway and increasing their toxicity due to DMA-mediated cytosolic TPT delivery. Topotecan 151-154 inositol 1,4,5-triphosphate receptor 3 Mus musculus 117-119 33218116-6 2020 In vivo animal studies using an MDA-MB-231 tumor xenografted mice model supported the finding that gammaCDP-(DMA/PEG-Tf) NPs are effective carriers of TPT to Tf receptor-positive MDA-MB-231 tumor cells, promoting drug uptake into the tumors through the Tf ligand-mediated endocytic pathway and increasing their toxicity due to DMA-mediated cytosolic TPT delivery. Topotecan 151-154 inositol 1,4,5-triphosphate receptor 3 Mus musculus 158-160 33218116-6 2020 In vivo animal studies using an MDA-MB-231 tumor xenografted mice model supported the finding that gammaCDP-(DMA/PEG-Tf) NPs are effective carriers of TPT to Tf receptor-positive MDA-MB-231 tumor cells, promoting drug uptake into the tumors through the Tf ligand-mediated endocytic pathway and increasing their toxicity due to DMA-mediated cytosolic TPT delivery. Topotecan 151-154 transferrin Homo sapiens 158-160 32899268-6 2020 As shown by the cytotoxicity assay results, BMS-599626, at noncytotoxic concentrations, sensitizes ABCG2-overexpressing cells to topotecan and mitoxantrone, two well-known substrates of ABCG2. Topotecan 129-138 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 99-104 32786885-7 2020 Some synthesized derivatives showed low cytotoxicity against HeLa cells and increased the effect of the Top1 inhibitor topotecan in vitro by three to seven times. Topotecan 119-128 DNA topoisomerase I Homo sapiens 104-108 32777141-8 2020 When tested with standard-of-care cytotoxics at human Cmax -equivalent concentrations, MYCN-amplified and non-MYCN-amplified PDCs showed a differential response to cyclophosphamide and topotecan, which mirrored the corresponding patients" responses, and correlated with gene signatures of chemosensitivity. Topotecan 185-194 MYCN proto-oncogene, bHLH transcription factor Homo sapiens 87-91 32777141-8 2020 When tested with standard-of-care cytotoxics at human Cmax -equivalent concentrations, MYCN-amplified and non-MYCN-amplified PDCs showed a differential response to cyclophosphamide and topotecan, which mirrored the corresponding patients" responses, and correlated with gene signatures of chemosensitivity. Topotecan 185-194 MYCN proto-oncogene, bHLH transcription factor Homo sapiens 110-114 32787273-8 2020 Finally, in addition to cytotoxic effects, TPT can also down-regulate the expression of HIF-1alpha and so prolong the vascular normalization time. Topotecan 43-46 hypoxia inducible factor 1 subunit alpha Homo sapiens 88-98 32765594-5 2020 We show here that topotecan treatment significantly down-regulated estrogen receptor alpha (ERalpha/ESR1) and antiapoptotic BCL2 genes in addition to many other p53-regulated genes. Topotecan 18-27 estrogen receptor 1 Homo sapiens 92-99 32765594-5 2020 We show here that topotecan treatment significantly down-regulated estrogen receptor alpha (ERalpha/ESR1) and antiapoptotic BCL2 genes in addition to many other p53-regulated genes. Topotecan 18-27 estrogen receptor 1 Homo sapiens 100-104 32765594-5 2020 We show here that topotecan treatment significantly down-regulated estrogen receptor alpha (ERalpha/ESR1) and antiapoptotic BCL2 genes in addition to many other p53-regulated genes. Topotecan 18-27 BCL2 apoptosis regulator Homo sapiens 124-128 32765594-5 2020 We show here that topotecan treatment significantly down-regulated estrogen receptor alpha (ERalpha/ESR1) and antiapoptotic BCL2 genes in addition to many other p53-regulated genes. Topotecan 18-27 tumor protein p53 Homo sapiens 161-164 32765594-7 2020 The differential expression of these genes was observed in a wild-type p53-containing breast ZR-75-1 tumor cell line following topotecan treatment. Topotecan 127-136 tumor protein p53 Homo sapiens 71-74 32765594-8 2020 The involvement of reactive oxygen free radical sensor genes, the oxidative DNA damage (OGG1) repair gene and induction of pro-apoptotic genes suggest that reactive free radical species play a role in topotecan-induced tumor cell death. Topotecan 201-210 8-oxoguanine DNA glycosylase Homo sapiens 88-92 31397978-0 2019 Synergistic combination of DT-13 and Topotecan inhibits aerobic glycolysis in human gastric carcinoma BGC-823 cells via NM IIA/EGFR/HK II axis. Topotecan 37-46 epidermal growth factor receptor Homo sapiens 127-131 32193356-10 2020 In contrast, topotecan, SN-38, and sulfasalazine had low P AB values (0.81, 1.13, and 0.19 x 10-6 cm/sec, respectively), and each AQ BCRP was above 0.6, indicating that BCRP significantly contributes to the transport of these compounds in Caco-2 cells. Topotecan 13-22 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 133-137 32193356-10 2020 In contrast, topotecan, SN-38, and sulfasalazine had low P AB values (0.81, 1.13, and 0.19 x 10-6 cm/sec, respectively), and each AQ BCRP was above 0.6, indicating that BCRP significantly contributes to the transport of these compounds in Caco-2 cells. Topotecan 13-22 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 169-173 32109764-4 2020 We demonstrate that "RADAR-MS" can quantify induction of TOP1- or TOP2-DNA adducts in cells treated with topotecan or etoposide, respectively, and also identify intermediates in physiological adduct repair. Topotecan 105-114 DNA topoisomerase I Homo sapiens 57-61 31878088-1 2019 Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is an important DNA repair enzyme in humans, and a current and promising inhibition target for the development of new chemosensitizing agents due to its ability to remove DNA damage caused by topoisomerase 1 (Top1) poisons such as topotecan and irinotecan. Topotecan 270-279 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 0-31 31878088-1 2019 Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is an important DNA repair enzyme in humans, and a current and promising inhibition target for the development of new chemosensitizing agents due to its ability to remove DNA damage caused by topoisomerase 1 (Top1) poisons such as topotecan and irinotecan. Topotecan 270-279 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 33-37 31878088-1 2019 Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is an important DNA repair enzyme in humans, and a current and promising inhibition target for the development of new chemosensitizing agents due to its ability to remove DNA damage caused by topoisomerase 1 (Top1) poisons such as topotecan and irinotecan. Topotecan 270-279 DNA topoisomerase I Homo sapiens 231-246 32572160-9 2020 B02 further synergized with clinically relevant topotecan (TPT) to engage this pathway, activating p53-BAX mediated killing of RB but not human retinal progenitor cells. Topotecan 48-57 tumor protein p53 Homo sapiens 99-102 32572160-9 2020 B02 further synergized with clinically relevant topotecan (TPT) to engage this pathway, activating p53-BAX mediated killing of RB but not human retinal progenitor cells. Topotecan 48-57 BCL2 associated X, apoptosis regulator Homo sapiens 103-106 31479512-7 2020 Based on concurrent biomarker expression, combinations of immunotherapy with platinum (ERCC1 negativity) or with doxorubicin, epirubicin, or etoposide (TOP2A positivity), have a higher probability of response while combinations with irinotecan or topotecan (TOPO1 positivity), with gemcitabine (RRM1 negativity), and fluorouracil, pemetrexed, or capecitabine (TS negativity) may be of less benefit. Topotecan 247-256 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 87-92 31479512-7 2020 Based on concurrent biomarker expression, combinations of immunotherapy with platinum (ERCC1 negativity) or with doxorubicin, epirubicin, or etoposide (TOP2A positivity), have a higher probability of response while combinations with irinotecan or topotecan (TOPO1 positivity), with gemcitabine (RRM1 negativity), and fluorouracil, pemetrexed, or capecitabine (TS negativity) may be of less benefit. Topotecan 247-256 DNA topoisomerase II alpha Homo sapiens 152-157 32243271-12 2020 Topotecan treated murine ovarian (MOSEC), colorectal (CT26), and lung (LLC) cancer cell lines displayed upregulated CDKN1A encoding p21 and downregulated Ezh2. Topotecan 0-9 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 116-122 32243271-12 2020 Topotecan treated murine ovarian (MOSEC), colorectal (CT26), and lung (LLC) cancer cell lines displayed upregulated CDKN1A encoding p21 and downregulated Ezh2. Topotecan 0-9 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 132-135 32243271-12 2020 Topotecan treated murine ovarian (MOSEC), colorectal (CT26), and lung (LLC) cancer cell lines displayed upregulated CDKN1A encoding p21 and downregulated Ezh2. Topotecan 0-9 enhancer of zeste 2 polycomb repressive complex 2 subunit Mus musculus 154-158 31352632-2 2019 This study aims to evaluate the outcome of HDC/auto-SCT with topotecan-thiotepa-carboplatin and melphalan-etoposide-carboplatin (TTC/MEC) regimens in pediatric brain tumors. Topotecan 61-70 C-C motif chemokine ligand 28 Homo sapiens 133-136 31397978-4 2019 Mechanistic studies revealed that the combination treatment promoted epidermal growth factor receptor (EGFR) degradation through non-muscle myosin IIA (NM IIA)-induced endocytosis of EGFR, further inhibited the activity of hexokinase II (HK II), and eventually promoted the aerobic glycolysis inhibition activity more efficiently compared with TPT or DT-13 monotherapy. Topotecan 344-347 epidermal growth factor receptor Homo sapiens 103-107 31397978-4 2019 Mechanistic studies revealed that the combination treatment promoted epidermal growth factor receptor (EGFR) degradation through non-muscle myosin IIA (NM IIA)-induced endocytosis of EGFR, further inhibited the activity of hexokinase II (HK II), and eventually promoted the aerobic glycolysis inhibition activity more efficiently compared with TPT or DT-13 monotherapy. Topotecan 344-347 epidermal growth factor receptor Homo sapiens 183-187 31397978-4 2019 Mechanistic studies revealed that the combination treatment promoted epidermal growth factor receptor (EGFR) degradation through non-muscle myosin IIA (NM IIA)-induced endocytosis of EGFR, further inhibited the activity of hexokinase II (HK II), and eventually promoted the aerobic glycolysis inhibition activity more efficiently compared with TPT or DT-13 monotherapy. Topotecan 344-347 hexokinase 2 Homo sapiens 223-236 31397978-6 2019 When using the NM II inhibitor (-)002Dblebbistatin or MYH-9 shRNA, the synergistic inhibition effect of DT-13 and TPT on aerobic glycolysis was eliminated in BGC-823 cells. Topotecan 114-117 myosin heavy chain 9 Homo sapiens 54-59 31397978-0 2019 Synergistic combination of DT-13 and Topotecan inhibits aerobic glycolysis in human gastric carcinoma BGC-823 cells via NM IIA/EGFR/HK II axis. Topotecan 37-46 hexokinase 2 Homo sapiens 132-137 31397978-4 2019 Mechanistic studies revealed that the combination treatment promoted epidermal growth factor receptor (EGFR) degradation through non-muscle myosin IIA (NM IIA)-induced endocytosis of EGFR, further inhibited the activity of hexokinase II (HK II), and eventually promoted the aerobic glycolysis inhibition activity more efficiently compared with TPT or DT-13 monotherapy. Topotecan 344-347 epidermal growth factor receptor Homo sapiens 69-101 31242600-2 2019 As torsional stress is generated during transcription by progression of RNA polymerase II through the transcribed gene, we tested the effects of camptothecin and of the approved TOP1 inhibitors Topotecan and SN-38 on TNFalpha-induced gene expression. Topotecan 194-203 tumor necrosis factor Homo sapiens 217-225 31408695-4 2019 In addition, the resistance of MCF7/ADR cells to TPT was reversed (the resistance index decreased from 7.17 to 0.77) by inhibiting the expression of ERalpha and BCRP to increase TPT accumulation intracellularly. Topotecan 49-52 estrogen receptor 1 Homo sapiens 149-156 31408695-4 2019 In addition, the resistance of MCF7/ADR cells to TPT was reversed (the resistance index decreased from 7.17 to 0.77) by inhibiting the expression of ERalpha and BCRP to increase TPT accumulation intracellularly. Topotecan 49-52 BCR pseudogene 1 Homo sapiens 161-165 31408695-4 2019 In addition, the resistance of MCF7/ADR cells to TPT was reversed (the resistance index decreased from 7.17 to 0.77) by inhibiting the expression of ERalpha and BCRP to increase TPT accumulation intracellularly. Topotecan 178-181 estrogen receptor 1 Homo sapiens 149-156 31408695-4 2019 In addition, the resistance of MCF7/ADR cells to TPT was reversed (the resistance index decreased from 7.17 to 0.77) by inhibiting the expression of ERalpha and BCRP to increase TPT accumulation intracellularly. Topotecan 178-181 BCR pseudogene 1 Homo sapiens 161-165 31534347-0 2019 A temperature-sensitive phase-change hydrogel of topotecan achieves a long-term sustained antitumor effect on retinoblastoma cells. Topotecan 49-58 RB transcriptional corepressor 1 Homo sapiens 110-124 31534347-11 2019 Topo-Gel, a temperature-sensitive phase-change hydrogel, is a slow-release system that prolongs the presence of topotecan in Rb tissues, and preserves the efficacy of topotecan in the long term. Topotecan 112-121 RB transcriptional corepressor 1 Homo sapiens 125-127 31534347-12 2019 Conclusion: Preparation of topotecan into a temperature-sensitive phase-change hydrogel achieves a long-term sustained antitumor effect on Rb cells, and may be a useful strategy for the treatment of intraocular Rb. Topotecan 27-36 RB transcriptional corepressor 1 Homo sapiens 139-141 31534347-12 2019 Conclusion: Preparation of topotecan into a temperature-sensitive phase-change hydrogel achieves a long-term sustained antitumor effect on Rb cells, and may be a useful strategy for the treatment of intraocular Rb. Topotecan 27-36 RB transcriptional corepressor 1 Homo sapiens 211-213 31088908-0 2019 HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity. Topotecan 61-70 tumor protein p53 Homo sapiens 20-23 31088908-4 2019 Topotecan (TPT), used in the treatment of ovarian cancer, inhibits HIF1alpha translation via a topoisomerase-1 (TOPO1)-dependent mechanism. Topotecan 0-9 hypoxia inducible factor 1 subunit alpha Homo sapiens 67-76 31088908-4 2019 Topotecan (TPT), used in the treatment of ovarian cancer, inhibits HIF1alpha translation via a topoisomerase-1 (TOPO1)-dependent mechanism. Topotecan 11-14 hypoxia inducible factor 1 subunit alpha Homo sapiens 67-76 31088908-9 2019 We determined if sublethal doses of TPT, used to knockdown HIF1alpha, reversed hypoxia-related cisplatin and paclitaxel resistance (XTT assay). Topotecan 36-39 hypoxia inducible factor 1 subunit alpha Homo sapiens 59-68 31088908-12 2019 TPT-mediated downregulation of HIF1alpha in hypoxic cells required TOPO1 resident on HIF1alpha mRNA, restored p53 transcriptional activity, downregulated ABCB1/ABCB5 cell surface expression, and reversed hypoxia-related cisplatin and paclitaxel resistance. Topotecan 0-3 hypoxia inducible factor 1 subunit alpha Homo sapiens 31-40 31088908-12 2019 TPT-mediated downregulation of HIF1alpha in hypoxic cells required TOPO1 resident on HIF1alpha mRNA, restored p53 transcriptional activity, downregulated ABCB1/ABCB5 cell surface expression, and reversed hypoxia-related cisplatin and paclitaxel resistance. Topotecan 0-3 hypoxia inducible factor 1 subunit alpha Homo sapiens 85-94 31088908-12 2019 TPT-mediated downregulation of HIF1alpha in hypoxic cells required TOPO1 resident on HIF1alpha mRNA, restored p53 transcriptional activity, downregulated ABCB1/ABCB5 cell surface expression, and reversed hypoxia-related cisplatin and paclitaxel resistance. Topotecan 0-3 tumor protein p53 Homo sapiens 110-113 31088908-12 2019 TPT-mediated downregulation of HIF1alpha in hypoxic cells required TOPO1 resident on HIF1alpha mRNA, restored p53 transcriptional activity, downregulated ABCB1/ABCB5 cell surface expression, and reversed hypoxia-related cisplatin and paclitaxel resistance. Topotecan 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 154-159 31088908-12 2019 TPT-mediated downregulation of HIF1alpha in hypoxic cells required TOPO1 resident on HIF1alpha mRNA, restored p53 transcriptional activity, downregulated ABCB1/ABCB5 cell surface expression, and reversed hypoxia-related cisplatin and paclitaxel resistance. Topotecan 0-3 ATP binding cassette subfamily B member 5 Homo sapiens 160-165 31088908-13 2019 IMPLICATIONS: TPT-mediated reduction of HIF1alpha accumulation in hypoxic ovarian cancer cell lines restores p53 tumor-suppressor function, offering a novel approach to reverse chemoresistance. Topotecan 14-17 hypoxia inducible factor 1 subunit alpha Homo sapiens 40-49 31088908-13 2019 IMPLICATIONS: TPT-mediated reduction of HIF1alpha accumulation in hypoxic ovarian cancer cell lines restores p53 tumor-suppressor function, offering a novel approach to reverse chemoresistance. Topotecan 14-17 tumor protein p53 Homo sapiens 109-112 31195594-8 2019 Four genes (EPB41L2, HLA-DQB1, LTF and SFRP1) were consistently overexpressed across multiple PFS cutoff times in initial tumor samples of patients with disease progression following topotecan treatment. Topotecan 183-192 erythrocyte membrane protein band 4.1 like 2 Homo sapiens 12-19 31195594-8 2019 Four genes (EPB41L2, HLA-DQB1, LTF and SFRP1) were consistently overexpressed across multiple PFS cutoff times in initial tumor samples of patients with disease progression following topotecan treatment. Topotecan 183-192 major histocompatibility complex, class II, DQ beta 1 Homo sapiens 21-29 31195594-8 2019 Four genes (EPB41L2, HLA-DQB1, LTF and SFRP1) were consistently overexpressed across multiple PFS cutoff times in initial tumor samples of patients with disease progression following topotecan treatment. Topotecan 183-192 lactotransferrin Homo sapiens 31-34 31195594-8 2019 Four genes (EPB41L2, HLA-DQB1, LTF and SFRP1) were consistently overexpressed across multiple PFS cutoff times in initial tumor samples of patients with disease progression following topotecan treatment. Topotecan 183-192 secreted frizzled related protein 1 Homo sapiens 39-44 30668314-0 2019 Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer. Topotecan 0-9 solute carrier family 1 member 5 Homo sapiens 32-37 31027318-7 2019 Results: The results showed a decreased level of PTPRK expression in ovarian cancer cell lines resistant to cisplatin (CIS), paclitaxel (PAC), doxorubicin (DOX), topotecan (TOP), vincristine (VIN) and methotrexate (MTX). Topotecan 162-171 protein tyrosine phosphatase receptor type K Homo sapiens 49-54 30668314-10 2019 TPT promoted glucose uptake possibly via up-regulation of hexokinase 2 (HK2) or glucose transporter 1 (GLUT1) expression, while decreased glutamine uptake by down-regulation of ASCT2 expression. Topotecan 0-3 hexokinase 2 Homo sapiens 58-70 30668314-10 2019 TPT promoted glucose uptake possibly via up-regulation of hexokinase 2 (HK2) or glucose transporter 1 (GLUT1) expression, while decreased glutamine uptake by down-regulation of ASCT2 expression. Topotecan 0-3 hexokinase 2 Homo sapiens 72-75 30668314-10 2019 TPT promoted glucose uptake possibly via up-regulation of hexokinase 2 (HK2) or glucose transporter 1 (GLUT1) expression, while decreased glutamine uptake by down-regulation of ASCT2 expression. Topotecan 0-3 solute carrier family 2 member 1 Homo sapiens 80-101 30668314-10 2019 TPT promoted glucose uptake possibly via up-regulation of hexokinase 2 (HK2) or glucose transporter 1 (GLUT1) expression, while decreased glutamine uptake by down-regulation of ASCT2 expression. Topotecan 0-3 solute carrier family 2 member 1 Homo sapiens 103-108 30668314-10 2019 TPT promoted glucose uptake possibly via up-regulation of hexokinase 2 (HK2) or glucose transporter 1 (GLUT1) expression, while decreased glutamine uptake by down-regulation of ASCT2 expression. Topotecan 0-3 solute carrier family 1 member 5 Homo sapiens 177-182 30668314-13 2019 ASCT2 knockdown induced apoptosis via the mitochondrial pathway and weakened anti-cancer effect of TPT. Topotecan 99-102 solute carrier family 1 member 5 Homo sapiens 0-5 30668314-14 2019 CONCLUSION: TPT inhibits glutamine uptake via down-regulation of ASCT2 which causes oxidative stress and induces apoptosis through the mitochondrial pathway. Topotecan 12-15 solute carrier family 1 member 5 Homo sapiens 65-70 30668314-15 2019 Moreover, TPT inhibits proliferation partially via ASCT2. Topotecan 10-13 solute carrier family 1 member 5 Homo sapiens 51-56 30389568-0 2019 Modulation of Intestinal Transport and Absorption of Topotecan, a BCRP Substrate, by Various Pharmaceutical Excipients and Their Inhibitory Mechanisms of BCRP Transporter. Topotecan 53-62 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 66-70 30691855-10 2019 RESULTS: TPT significantly decreased the expression of TNF-alpha and IL-1beta induced by LPS in THP-1 cells. Topotecan 9-12 tumor necrosis factor Homo sapiens 55-64 30691855-10 2019 RESULTS: TPT significantly decreased the expression of TNF-alpha and IL-1beta induced by LPS in THP-1 cells. Topotecan 9-12 interleukin 1 alpha Homo sapiens 69-77 30691855-14 2019 The downstream gene of NF-kappaB, including c-IAP1/2, c-FLIP, Bcl-2, IL-8, and VCAM-1, and the phosphorylation of NF-kappaB p105, p65, and IkappaB-alpha were significantly decreased after TPT administration in THP-1 cells. Topotecan 188-191 nuclear factor kappa B subunit 1 Homo sapiens 23-32 30691855-15 2019 CONCLUSIONS: In conclusion, TPT attenuates LPS-induced ALI through inhibiting the NF-kappaB signaling pathway, suggesting that TPT might serve as a useful therapeutic for ALI. Topotecan 28-31 nuclear factor kappa B subunit 1 Homo sapiens 82-91 29884612-10 2019 Finally, EAC cell lines showed subtype-specific responses to topotecan, SN-38 and palbociclib treatment. Topotecan 61-70 CYLD lysine 63 deubiquitinase Homo sapiens 9-12 30389568-0 2019 Modulation of Intestinal Transport and Absorption of Topotecan, a BCRP Substrate, by Various Pharmaceutical Excipients and Their Inhibitory Mechanisms of BCRP Transporter. Topotecan 53-62 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 154-158 30389568-1 2019 Breast cancer resistance protein transporter (ABCG2/BCRP) is highly expressed on the intestinal epithelial membrane and has a significant impact on the oral absorption of topotecan. Topotecan 171-180 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 46-51 30389568-1 2019 Breast cancer resistance protein transporter (ABCG2/BCRP) is highly expressed on the intestinal epithelial membrane and has a significant impact on the oral absorption of topotecan. Topotecan 171-180 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 52-56 30472223-0 2019 Pifithrin-alpha enhancing anticancer effect of topotecan on p53-expressing cancer cells. Topotecan 47-56 tumor protein p53 Homo sapiens 60-63 30622252-3 2019 Thus, we here establish that inactivating terminal components of the non-homologous end-joining (NHEJ) machinery or of the BRCA1-A complex specifically confer topotecan resistance to ATM-deficient cells. Topotecan 159-168 BRCA1 DNA repair associated Homo sapiens 123-128 30622252-3 2019 Thus, we here establish that inactivating terminal components of the non-homologous end-joining (NHEJ) machinery or of the BRCA1-A complex specifically confer topotecan resistance to ATM-deficient cells. Topotecan 159-168 ATM serine/threonine kinase Homo sapiens 183-186 30622252-4 2019 We show that hypersensitivity of ATM-mutant cells to topotecan or the poly-(ADP-ribose) polymerase (PARP) inhibitor olaparib reflects delayed engagement of homologous recombination at DNA-replication-fork associated single-ended double-strand breaks (DSBs), allowing some to be subject to toxic NHEJ. Topotecan 53-62 ATM serine/threonine kinase Homo sapiens 33-36 30396105-5 2019 The most effective Tdp1 inhibitor, 20d, was ton-toxic and increased the effect of topotecan both in vitro and in vivo in the Lewis lung carcinoma model. Topotecan 82-91 tyrosyl-DNA phosphodiesterase 1 Mus musculus 19-23 30396915-5 2019 Under these suppression conditions, cER values for irinotecan and topotecan (dual substrates of ABCB1 and ABCG2) were elevated by more than 4-fold and 2-fold, respectively, compared with cER values without the suppression. Topotecan 66-75 ATP binding cassette subfamily B member 1 Canis lupus familiaris 96-101 30396915-5 2019 Under these suppression conditions, cER values for irinotecan and topotecan (dual substrates of ABCB1 and ABCG2) were elevated by more than 4-fold and 2-fold, respectively, compared with cER values without the suppression. Topotecan 66-75 ATP binding cassette subfamily G member 2 Canis lupus familiaris 106-111 30191738-2 2018 TDP1 plays an essential role in the resistance of cancer cells to currently used antitumour drugs based on Top1 inhibitors such as topotecan and irinotecan. Topotecan 131-140 tyrosyl-DNA phosphodiesterase 1 Homo sapiens 0-4 30061364-1 2018 PURPOSE: Only one chemical class of topoisomerase I (TOP1) inhibitors is FDA approved, the camptothecins with irinotecan and topotecan widely used. Topotecan 125-134 DNA topoisomerase I Canis lupus familiaris 53-57 30266526-0 2018 Topotecan prevents hypoxia-induced pulmonary arterial hypertension and inhibits hypoxia-inducible factor-1alpha and TRPC channels. Topotecan 0-9 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 80-111 30266526-3 2018 RESULTS: TPT significantly suppressed the hypoxia-induced upregulation of HIF-1alpha and TRPC1/4/6 expression both in pulmonary arterial smooth muscle cells (PASMCs) from normal rats and in pulmonary arteries from PAH model rats. Topotecan 9-12 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 74-84 30266526-3 2018 RESULTS: TPT significantly suppressed the hypoxia-induced upregulation of HIF-1alpha and TRPC1/4/6 expression both in pulmonary arterial smooth muscle cells (PASMCs) from normal rats and in pulmonary arteries from PAH model rats. Topotecan 9-12 transient receptor potential cation channel, subfamily C, member 1 Rattus norvegicus 89-94 30266526-5 2018 Importantly, TPT treatment significantly inhibited the hypoxia-induced proliferation, migration and a contractile-to-synthetic phenotypic switching of normal rat PASMCs in vitro, where the effect was abrogated by overexpression of TRPC1/4/6. Topotecan 13-16 transient receptor potential cation channel, subfamily C, member 1 Rattus norvegicus 231-240 30266526-7 2018 CONCLUSION: TPT ameliorates the hypoxia-induced pulmonary vascular remodeling in PAH, and the mechanism is associated with TPT-mediated inhibition of hypoxia-induced upregulation of HIF-1alpha and TRPC1/4/6 expression, Ca2+ influx, and PASMCs proliferation. Topotecan 12-15 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 182-192 30266526-7 2018 CONCLUSION: TPT ameliorates the hypoxia-induced pulmonary vascular remodeling in PAH, and the mechanism is associated with TPT-mediated inhibition of hypoxia-induced upregulation of HIF-1alpha and TRPC1/4/6 expression, Ca2+ influx, and PASMCs proliferation. Topotecan 123-126 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 182-192 30266526-7 2018 CONCLUSION: TPT ameliorates the hypoxia-induced pulmonary vascular remodeling in PAH, and the mechanism is associated with TPT-mediated inhibition of hypoxia-induced upregulation of HIF-1alpha and TRPC1/4/6 expression, Ca2+ influx, and PASMCs proliferation. Topotecan 123-126 transient receptor potential cation channel, subfamily C, member 1 Rattus norvegicus 197-206 29803659-4 2018 RESULTS: Compared to PBS treatment, topotecan significantly decreased the ALI score, myeloperoxidase (MPO) content, total protein concentration, and presence of inflammatory cells and inflammatory cytokines in bronchoalveolar lavage fluid. Topotecan 36-45 myeloperoxidase Mus musculus 85-100 30519347-0 2018 Myotilin, a New Topotecan Resistant Protein in Ovarian Cancer Cell Lines. Topotecan 16-25 myotilin Homo sapiens 0-8 29803659-4 2018 RESULTS: Compared to PBS treatment, topotecan significantly decreased the ALI score, myeloperoxidase (MPO) content, total protein concentration, and presence of inflammatory cells and inflammatory cytokines in bronchoalveolar lavage fluid. Topotecan 36-45 myeloperoxidase Mus musculus 102-105 29803659-5 2018 Topotecan also reduced caspase-3 activation and type II alveolar epithelial cell apoptosis. Topotecan 0-9 caspase 3 Mus musculus 23-32 30257426-0 2018 The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines. Topotecan 66-75 matrix Gla protein Homo sapiens 12-30 30257426-0 2018 The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines. Topotecan 66-75 matrix Gla protein Homo sapiens 32-35 30257426-9 2018 MGP is an important factor that might contribute to cancer resistance mechanism by augmenting the interaction of cells with ECM components leading to increased resistance of ovarian cancer cells to paclitaxel and topotecan. Topotecan 213-222 matrix Gla protein Homo sapiens 0-3 30140420-4 2018 We also previously showed that one such Top1 inhibitor, topotecan, could unsilence paternal UBE3A in induced pluripotent stem cell-derived neurons from individuals with AS. Topotecan 56-65 ubiquitin protein ligase E3A Mus musculus 92-97